

NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FVIII THERAPEUTICS

RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63/079,349, filed on September 16, 2020, and U.S. Provisional Application No. 63/132,838, filed on December 31, 2020, the contents of each of which are hereby incorporated by reference in their entireties.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on September 16, 2021, is named 131698-08220_SL.txt and is 1,915,851 bytes in size.

TECHNICAL FIELD

[0003] The present disclosure relates to the field of gene therapy, including non-viral vectors for expressing a transgene or isolated polynucleotides in a subject or cell. The disclosure also relates to nucleic acid constructs, promoters, vectors, and host cells including the polynucleotides as well as methods of delivering exogenous DNA sequences to a target cell, tissue, organ or organism. For example, the present disclosure provides methods for using non-viral ceDNA vectors to express FVIII, from a cell, *e.g.*, expressing the FVIII therapeutic protein for the treatment of a subject with a hemophilia A. The methods and compositions can be used *e.g.*, for treating disease by expressing the FVIII in a cell or tissue of a subject in need thereof.

BACKGROUND

[0004] Gene therapy aims to improve clinical outcomes for patients suffering from either genetic mutations or acquired diseases caused by an aberration in the gene expression profile. Gene therapy includes the treatment or prevention of medical conditions resulting from defective genes or abnormal regulation or expression, *e.g.*, underexpression or overexpression, that can result in a disorder, disease, malignancy, *etc.* For example, a disease or disorder caused by a defective gene might be treated, prevented or ameliorated by delivery of a corrective genetic material to a patient, or might be treated, prevented or ameliorated by altering or silencing a defective gene, *e.g.*, with a corrective genetic material to a patient resulting in the therapeutic expression of the genetic material within the patient.

[0005] The basis of gene therapy is to supply a transcription cassette with an active gene product (a transgene), *e.g.*, that can result in a positive gain-of-function effect, a negative loss-of-function effect, or another outcome. Such outcomes can be attributed to expression of a therapeutic protein such as an antibody, a functional enzyme, or a fusion protein. Gene therapy can also be used to treat a disease or

malignancy caused by other factors. Human monogenic disorders can be treated by the delivery and expression of a normal gene to the target cells. Delivery and expression of a corrective gene in the patient's target cells can be carried out via numerous methods, including the use of engineered viruses and viral gene delivery vectors. Among the many virus-derived vectors available (*e.g.*, recombinant retrovirus, recombinant lentivirus, recombinant adenovirus, and the like), recombinant adeno-associated virus (rAAV) is gaining popularity as a versatile vector in gene therapy.

[0006] Adeno-associated viruses (AAV) belong to the *Parvoviridae* family and more specifically constitute the *dependoparvovirus* genus. Vectors derived from AAV (*i.e.*, recombinant AAV (rAAV) or AAV vectors) are attractive for delivering genetic material because (i) they are able to infect (transduce) a wide variety of non-dividing and dividing cell types including myocytes and neurons; (ii) they are devoid of the virus structural genes, thereby diminishing the host cell responses to virus infection, *e.g.*, interferon-mediated responses; (iii) wild-type viruses are considered non-pathogenic in humans; (iv) in contrast to wild-type AAV, which are capable of integrating into the host cell genome, replication-deficient AAV vectors lack the *rep* gene and generally persist as episomes, thus limiting the risk of insertional mutagenesis or genotoxicity; and (v) in comparison to other vector systems, AAV vectors are generally considered to be relatively poor immunogens and therefore do not trigger a significant immune response (see ii), thus gaining persistence of the vector DNA and potentially, long-term expression of the therapeutic transgenes.

[0007] However, there are several major deficiencies in using AAV particles as a gene delivery vector. One major drawback associated with rAAV is its limited viral packaging capacity of about 4.5 kb of heterologous DNA (Dong *et al.*, 1996; Athanasopoulos *et al.*, 2004; Lai *et al.*, 2010), and as a result, use of AAV vectors has been limited to less than 150,000 Da protein coding capacity. The second drawback is that as a result of the prevalence of wild-type AAV infection in the population, candidates for rAAV gene therapy have to be screened for the presence of neutralizing antibodies that eliminate the vector from the patient. A third drawback is related to the capsid immunogenicity that prevents re-administration to patients that were not excluded from an initial treatment. The immune system in the patient can respond to the vector which effectively acts as a “booster” shot to stimulate the immune system generating high titer anti-AAV antibodies that preclude future treatments. Some recent reports indicate concerns with immunogenicity in high dose situations. Another notable drawback is that the onset of AAV-mediated gene expression is relatively slow, given that single-stranded AAV DNA must be converted to double-stranded DNA prior to heterologous gene expression.

[0008] Additionally, conventional AAV virions with capsids are produced by introducing a plasmid or plasmids containing the AAV genome, *rep* genes, and *cap* genes (Grimm *et al.*, 1998). However, such encapsidated AAV virus vectors were found to inefficiently transduce certain cell and tissue types and the capsids also induce an immune response.

[0009] Accordingly, use of adeno-associated virus (AAV) vectors for gene therapy is limited due to the single administration to patients (owing to the patient immune response), the limited range of transgene genetic material suitable for delivery in AAV vectors due to minimal viral packaging capacity (about 4.5kb), and slow AAV-mediated gene expression.

[0010] There is large unmet need for disease-modifying therapies in hemophilia A. Current therapies are burdensome and require, *e.g.*, slow drip intravenous (IV) administrations. First, these Factor VIII injectables do not provide continuous delivery of factors, with trough levels allowing bleeding episodes. Second, there are no approved gene therapies for hemophilia A, and AAV based therapies cannot be used by 25% to 40% of patients due to pre-existing antibodies. AAV can only be administered once, and the resulting Factor VIII levels might not reach clinical significance, or may be supranormal, as dose levels cannot be titrated. Third, many hemophilia A patients cannot utilize these therapies because of the development of neutralizing antibodies to these exogenous, artificial clotting factors.

[0011] Accordingly, there is need in the field for a technology that permits expression of a therapeutic FVIII protein in a cell, tissue or subject for the treatment of hemophilia A.

BRIEF DESCRIPTION

[0012] The technology described herein relates to methods and compositions for treatment of hemophilia A by expression of Factor VIII (FVIII) protein from a capsid-free (*e.g.*, non-viral) DNA vector with covalently-closed ends (referred to herein as a “closed-ended DNA vector” or a “ceDNA vector”), where the ceDNA vector comprises a FVIII nucleic acid sequence or codon optimized versions thereof. These ceDNA vector can be used to produce FVIII proteins for treatment, monitoring, and diagnosis. The application of ceDNA vectors expressing FVIII to the subject for the treatment of hemophilia A is useful to: (i) provide disease modifying levels of FVIII enzyme, (ii) be minimally invasive in delivery, (iii) be repeatable and dosed-to-effect, (iv) have rapid onset of therapeutic effect, (v) result in sustained expression of corrective FVIII enzyme in the liver, (vi) restore urea cycle function, and/or (vii) be titratable to achieve the appropriate pharmacologic levels of the defective enzyme.

[0013] In embodiments, a ceDNA-vector expressing FVIII is optionally present in a liposome nanoparticle formulation (LNP) for the treatment of hemophilia A. The ceDNA vectors described herein can provide one or more benefits including, but not limited to providing disease modifying levels of FVIII, being minimally invasive in delivery, being repeatable and dosed-to-effect, providing a rapid onset of therapeutic effect, *e.g.*, in some embodiments, within days of therapeutic intervention, providing sustained expression of corrective Factor VIII levels in the circulation, being titratable to achieve the appropriate pharmacologic levels of the defective coagulation factor, and/or providing treatments for other types of hemophilia, including but not limited to Factor VIII deficiency (hemophilia A) or Factor IX deficiency (hemophilia B) or Factor XI deficiency (hemophilia C).

[0014] Accordingly, the disclosure described herein relates to a capsid-free (*e.g.*, non-viral) DNA vector with covalently-closed ends (referred to herein as a “closed-ended DNA vector” or a “ceDNA vector”) comprising a heterogeneous gene encoding FVIII, to permit expression of the FVIII therapeutic protein in a cell (*e.g.*, hepatocytes of a human patient suffering from hemophilia A).

[0015] According to one aspect, the disclosure provides a capsid-free close-ended DNA (ceDNA) vector comprising at least one nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, between flanking inverted terminal repeats (ITRs), wherein at least one heterologous nucleic acid sequence encodes at least one FVIII protein, wherein the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from any of the sequences in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633).

[0016] In a first aspect, the disclosure provides a capsid-free close-ended DNA (ceDNA) vector comprising at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs), wherein the at least one nucleic acid sequence encodes at least one FVIII protein, wherein the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from a sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any sequence in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633). According to some embodiments, the at least one nucleic acid sequence that encodes at least one FVIII protein is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identical to SEQ ID NO: 556. According to some embodiments, the at least one nucleic acid sequence that encodes at least one FVIII protein consists of SEQ ID NO: 556. According to some embodiments, the at least one nucleic acid that encodes at least one FVIII protein comprises SEQ ID NO: 556, wherein SEQ ID NO: 556 further comprises one or more modifications. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 627. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 628. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 628. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 630. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 631. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 632. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of SEQ ID NO: 633.

[0017] In some embodiments, the ceDNA vector comprises a promoter or promoter set operatively linked to the least one nucleic acid sequence that encodes at least one FVIII protein. According to some embodiments, the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from any of the sequences in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633). In some embodiments, the ceDNA vector comprises a promoter selected from the group consisting of human a1 antitrypsin (hAAT) promoter, minimal transthyretin promoter (TTRm), hAAT_core_C06, hAAT_core_C07, hAAT_core_08, hAAT_core_C09, hAAT_core_C10, and hAAT_core_truncated. In some embodiments, the ceDNA vector comprises a promoter selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 210-217. In some embodiments, the promoter set comprises a synthetic liver specific promoter set including enhancers and a core promoter, without a 5pUTR. In some embodiments, the promoter set is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 184-197, 400, 401, 484, and 617-624.

[0018] According to some embodiments, the at least one nucleic acid sequence that encodes the at least one FVIII protein is selected from any of the sequences in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633) and the promoter set is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 184-197, 400, 401, 484, and 617-624. According to some embodiments, the at least one nucleic acid sequence that encodes the at least one FVIII protein is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 556 or 626-633 and the promoter set is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 184-197, 400, 401, 484, and 617-624.

[0019] In some embodiments, the ceDNA vector comprises an enhancer. In some embodiments, the enhancer is selected from the group consisting of: a Serpin enhancer (SerpEnh), the transthyretin (TTRe) gene enhancer (TTRe), the Hepatic Nuclear Factor 1 binding site (HNF1), Hepatic Nuclear Factor 4 binding site (HNF4), Human apolipoprotein E/C-I liver specific enhancer (ApoE_Enh), the enhancer region from Pro-albumin gene (ProEnh), a CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer) (ApoE_Enh_C03, ApoE_Enh_C04, ApoE_Enh_C09, and ApoE_Enh_C10), and Hepatic nuclear factor enhancer array embedded in GE-856 (Embedded_enhancer_HNF_array). In some embodiments, the Serpin enhancer comprises a nucleic acid sequence at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identical to SEQ ID NO: 198. In some embodiments, the enhancer is selected from a nucleic acid sequence set forth in **Table 7** (SEQ ID NOs: 198-209, 485 and 557-616). In some embodiments, the enhancer is selected from a nucleic acid sequence having at least 85%, at least 90%,

at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any sequence in **Table 7** (SEQ ID NOs: 198-209, 485 and 557-616).

[0020] According to some embodiments, the at least one nucleic acid sequence that encodes the at least one FVIII protein is selected from any of the sequences in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633) and the enhancer is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 198-209, 485 and 557-616. According to some embodiments, the at least one nucleic acid sequence that encodes the at least one FVIII protein is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 556 or 626-633 and the enhancer is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any one of SEQ ID NOs: 557-616.

[0021] In some embodiments, the ceDNA vector comprises a 5' UTR sequence. In some embodiments, the 5' UTR sequence is selected from a sequence having at least 85% identity to any sequence in **Table 10**. In some embodiments, the ceDNA vector comprises an intron sequence. In some embodiments, the intron sequence is selected from a sequence having at least 85% identity to any sequence in **Table 11**. In some embodiments, the ceDNA vector comprises an exon sequence. In some embodiments, the exon sequence is selected from a sequence having at least 85% identity to any sequence in **Table 12**. In some embodiments, the ceDNA vector comprises a 3' UTR sequence. In some embodiments, the exon sequence is selected from a sequence having at least 85% identity to any sequence in **Table 13**. In some embodiments, the ceDNA vector comprises at least one poly A sequence. In some embodiments, the ceDNA vector comprises one or more DNA nuclear targeting sequences (DTS). In some embodiments, the DTS is selected from a sequence having at least 85% identity to any sequence in **Table 14**. In some embodiments, the ceDNA vector comprises one or more of the following Ubiquitous Chromatin-opening Elements (UCOE), Kozak sequences, spacer sequences or leader sequences.

[0022] In one embodiment of any of the foregoing aspects of embodiments, at least one nucleic acid sequence is cDNA.

[0023] In one embodiment of any of the foregoing aspects of embodiments, at least one ITR comprises a functional terminal resolution site and a Rep binding site.

[0024] In one embodiment of any of the foregoing aspects of embodiments, one or both of the ITRs are from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV). In some embodiments, the flanking ITRs are symmetric or asymmetric. In some embodiments, the flanking ITRs are symmetrical or substantially symmetrical. In some embodiments, the flanking ITRs are asymmetric. In some embodiments, one or both of the ITRs are wild-type, or wherein both of the ITRs are wild-type. In some embodiments, the flanking ITRs are from different viral serotypes. In

some embodiments, the flanking ITRs are from the same viral serotypes. In some embodiments, the flanking ITRs are from a pair of viral serotypes shown in Table 6 of International Publication No. WO/2019/161059 (incorporated by reference in its entirety herein). In some embodiments, one or both of the ITRs comprises a sequence selected from the sequences in **Table 2, Table 4A, Table 4B, or Table 5**. In some embodiments, at least one of the ITRs is altered from a wild-type AAV ITR sequence by a deletion, addition, or substitution that affects the overall three-dimensional conformation of the ITR. In some embodiments, one or both of the ITRs are derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. In some embodiments, one or both of the ITRs are synthetic. In some embodiments, one or both of the ITRs is not a wild-type ITR, or wherein both of the ITRs are not wild-type. In some embodiments, one or both of the ITRs is modified by a deletion, insertion, and/or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D, and D'. In some embodiments, the deletion, insertion, and/or substitution results in the deletion of all or part of a stem-loop structure normally formed by the A, A', B, B', C, or C' regions. In some embodiments, one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of all or part of a stem-loop structure normally formed by the B and B' regions. In some embodiments, one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of all or part of a stem-loop structure normally formed by the C and C' regions. In some embodiments, one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of part of a stem-loop structure normally formed by the B and B' regions and/or part of a stem-loop structure normally formed by the C and C' regions. In some embodiments, one or both of the ITRs comprise a single stem-loop structure in the region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. In some embodiments, one or both of the ITRs comprise a single stem and two loops in the region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. In some embodiments, one or both of the ITRs comprise a single stem and a single loop in the region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. In some embodiments, both ITRs are altered in a manner that results in an overall three-dimensional symmetry when the ITRs are inverted relative to each other. In some embodiments, one or both of the ITRs comprises a nucleic acid sequence selected from the sequences in **Tables 2, 4A, 4B, and 5**.

[0025] In some embodiments of any of the above aspects or embodiments, the ceDNA vector comprises a nucleic acid sequence selected from a sequence having at least 85% identity, at least 90% identity, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,

at least 98%, at least 99% or at least 100% identity with a sequence in **Table 18** (e.g., any one of SEQ ID NOs: 1-70, 442-483, or 642-646).

[0026] In another aspect, the disclosure provides a method of expressing an FVIII protein in a cell comprising contacting the cell with the ceDNA vector of any one of the aspects or embodiments herein. In some embodiments, the cell is a photoreceptor or a RPE cell. In some embodiments, the cell is *in vitro* or *in vivo*. In some embodiments of any of the above aspects or embodiments, the at least one nucleic acid sequence is codon optimized for expression in the eukaryotic cell. In some embodiments of any of the above aspects or embodiments, the at least one nucleic acid sequence is a sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any sequence set forth in **Table 1A** (e.g., any one of SEQ ID NOs: 71-183, 556 and 626-633).

[0027] In another aspect, the disclosure provides a method of treating a subject with hemophilia A, comprising administering to the subject a ceDNA vector of any one of the aspects or embodiments herein, wherein at least one nucleic acid sequence encodes at least one FVIII protein.

[0028] In another aspect, the disclosure provides a method of treating a subject with hemophilia A, comprising administering to the subject a nucleic acid sequence selected from a sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity with a sequence in **Table 18** (e.g., any one of SEQ ID NOs: 1-70, 442-483, or 642-646). According to one embodiment, the nucleic acid sequence is at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 96% identical, at least 97% identical, at least 98% identical or at least 99% identical to SEQ ID NO: 5. In one embodiment, the nucleic acid sequence comprises SEQ ID NO: 5. In another embodiment, the nucleic acid sequence consists of SEQ ID NO: 5. In some embodiments of any of the above aspects or embodiments, the ceDNA vector comprises a nucleic acid sequence selected from a sequence having at least 85% identity, at least 90% identity, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity with SEQ ID NO: 42. In some embodiments, the ceDNA comprises a nucleic acid sequence consisting of SEQ ID NO: 42.

[0029] In another aspect, the disclosure provides a method of treating a subject with hemophilia B, comprising administering to the subject a nucleic acid sequence selected from a sequence having at least 85% identity, at least 90% identity, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% identity with a sequence in **Table 18** (e.g., any one of SEQ ID NOs: 1-70, 442-483, or 642-646).

[0030] In some embodiments of any of the above aspects or embodiments, levels of FVIII in the serum of the subject are increased in subjects administered the ceDNA vector compared to a control. In some embodiments, the increase in levels of FVIII is greater than about 40% compared to the

control. In some embodiments, the at least one nucleic acid sequence is a sequence having at least 85% identity, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% to any sequence set forth in **Table 1A** (e.g., any one of SEQ ID NOs: 71-183, 556 and 626-633) or **Table 18** (e.g., any one of SEQ ID NOs: 1-70, 442-483, or 642-646). According to one embodiment, the nucleic acid sequence is at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 96% identical, at least 97% identical, at least 98% identical or at least 99% identical to SEQ ID NO: 5. According to one embodiment, the nucleic acid sequence comprises SEQ ID NO:5 or consists of SEQ ID NO: 5.

[0031] In some embodiments of the foregoing aspect or embodiments, a level of FVIII in the plasma of the subject is increased in the subject after administration. In some embodiments, the level of FVIII in the plasma of the subject is increased by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, or 100-fold after administration. In some embodiments, a level of FVIII in the serum of the subject is increased in the subject administered the ceDNA vector as compared to a control. In some embodiments, the increase in the level of FVIII in the serum of the subject is greater than about 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, or 100-fold compared to the control. In some embodiments, the control is a level of FVIII in the serum of the subject prior to administration, or wherein the control is a level of FVIII in the serum of a subject having hemophilia A who did not receive the administration.

[0032] In some embodiments, the ceDNA vector is administered at a dose of about 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.1 mg/kg to about 20 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.1 mg/kg to about 15 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.1 mg/kg to about 10 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.1 mg/kg to about 5 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.1 mg/kg to about 0.5 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.5 mg/kg to about 20 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.5 mg/kg to about 15 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.5 mg/kg to about 10 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.5 mg/kg to about 5 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 1 mg/kg to about 20 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 1 mg/kg to about 15 mg/kg. In some embodiments, the ceDNA vector

is administered at a dose of about 1 mg/kg to about 10 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 1 mg/kg to about 5 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 5 mg/kg to about 20 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 5 mg/kg to about 15 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 5 mg/kg to about 10 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 10 mg/kg to about 20 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 10 mg/kg to about 15 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 15 mg/kg to about 20 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, or 5 mg/kg. In some embodiments, the ceDNA vector is administered at a dose of about 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, or 5 mg/kg.

[0033] In some embodiments, the administration restores at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 10% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 15% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 20% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 25% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 30% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 35% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 40% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 45% of FVIII plasma levels of normal individuals not affected by hemophilia A. In some embodiments, the administration restores at least about 50% of FVIII plasma levels of normal individuals not affected by hemophilia A.

[0034] In some embodiments of any of the above aspects or embodiments, the ceDNA vector is administered to a photoreceptor cell, or an RPE cell, or both.

[0035] In some embodiments of any of the above aspects or embodiments, the ceDNA vector expresses the FVIII protein in a photoreceptor cell, or an RPE cell, or both.

[0036] In some embodiments of any of the above aspects or embodiments, the ceDNA vector is administered by any one or more of subretinal injection, suprachoroidal injection or intravitreal injection.

[0037] In another aspect, the disclosure provides a pharmaceutical composition comprising the ceDNA vector of any one of the aspects or embodiments herein.

[0038] In another aspect, the disclosure provides a cell containing a ceDNA vector of any of the aspects or embodiments herein. In some embodiments, the cell is a photoreceptor cell, or a RPE cell, or both.

[0039] In another aspect, the disclosure provides a composition comprising a ceDNA vector of any of the aspects or embodiments herein, and a lipid. In some embodiments, the lipid is a lipid nanoparticle (LNP). In another aspect, the disclosure provides a composition comprising a ceDNA vector, wherein the ceDNA vector comprises a nucleic acid sequence at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 96% identical, at least 97% identical, at least 98% identical or at least 99% identical to, comprises, or consists of SEQ ID NO: 5, and a lipid. In another aspect, the disclosure provides a composition comprising a ceDNA vector, wherein the ceDNA vector comprises a nucleic acid sequence at least 85% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 96% identical, at least 97% identical, at least 98% identical or at least 99% identical to, comprises, or consists of SEQ ID NO: 42, and a lipid. In some embodiments, the lipid is an LNP.

[0040] In another aspect, the disclosure provides a kit comprising the ceDNA vector of any of the aspects or embodiments herein, the pharmaceutical composition of any of the aspects or embodiments herein, the cell of any of the aspects or embodiments herein, or the composition of any of the aspects or embodiments herein.

[0041] In another aspect, the disclosure provides capsid-free close-ended DNA (ceDNA) vector comprising at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs), wherein at least one nucleic acid sequence encodes at least one protein, wherein the ceDNA vector comprises a promoter or promoter set operatively linked to the least one nucleic acid sequence that encodes the at least one protein, and wherein the promoter is selected from the group consisting of human $\alpha 1$ antitrypsin (hAAT) promoter, minimal transthyretin promoter (TTRm), hAAT_core_C06, hAAT_core_C07, hAAT_core_08, hAAT_core_C09, hAAT_core_C10, and hAAT_core_truncated. In some embodiments, the promoter is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 210-217. In some embodiments, the promoter set comprises a synthetic liver specific promoter set including enhancers and core promoter, without 5pUTR. In some embodiments, the promoter set is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100% identity to, comprises, or consists of any one of SEQ ID NOs: 184-197, 400, 401, 484, and 617-624.

[0042] In some embodiments of any of the aspects or embodiments herein, the ceDNA vector comprises an enhancer. In some embodiments, the enhancer is selected from the group consisting of: a Serpin enhancer (SerpEnh), the transthyretin (TTR) gene enhancer (TTRe), the Hepatic Nuclear Factor 1 binding site (HNF1), Hepatic Nuclear Factor 4 binding site (HNF4), Human apolipoprotein E/C-I liver specific enhancer (ApoE_Enh), the enhancer region from Pro-albumin gene (ProEnh), a CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer) (ApoE_Enh_C03, ApoE_Enh_C04, ApoE_Enh_C09, and ApoE_Enh_C10), and Hepatic nuclear factor enhancer array embedded in GE-856 (Embedded_enhancer_HNF_array). In some embodiments, the Serpin enhancer comprises a nucleic acid sequence at least 85% identical to SEQ ID NO: 198. In some embodiments, the enhancer is selected from a nucleic acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100% identity to, comprises, or consists of any one of SEQ ID NOs: 198-209, 485 and 557-616.

[0043] In another aspect, the disclosure provides a method of expressing a protein in a cell comprising contacting the cell with the ceDNA vector of any of the aspects or embodiments herein. In some embodiments, the cell is a photoreceptor or a RPE cell. In some embodiments, the cell is *in vitro* or *in vivo*. In some embodiments of any of the aspects or embodiments herein, the at least one nucleic acid sequence is codon optimized for expression in the eukaryotic cell.

[0044] In some embodiments of any of the aspects or embodiments herein, the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 556 and 626-633, and wherein the ceDNA vector comprises an enhancer, wherein the enhancer is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 557-616.

[0045] In another aspect, the disclosure provides a DNA vector comprising a nucleic acid sequence at least 85% identical to SEQ ID NOs: 71-183, 556 and 626-633. In some embodiments, the DNA vector comprises an enhancer sequence having at least 95% identity to any one of SEQ ID NOs: 198-209, 485, 557-616. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 198 and 557-616. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 557-616. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 557-568. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 569 and 570.

[0046] In some embodiments, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 571. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 572. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one

of SEQ ID NO: 611. In some embodiments, the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 603.

[0047] In some embodiments of the aspects and embodiments herein, the DNA vector comprises a TTRe sequence. In some embodiments, the TTRe sequence is set forth in SEQ ID NO: 199 or a sequence having at least 95% identity thereof. In some embodiments, the DNA vector comprises a TTR promoter. In some embodiments, the TTR promoter is set forth in SEQ ID NO: 211 or a sequence having 95% identity thereof. In some embodiments, the DNA vector comprises a 5' untranslated region (5' UTR) sequence selected from the group consisting of SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, and SEQ ID NO: 436. In some embodiments, the DNA vector comprises an intron sequence selected from the group consisting of SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, and SEQ ID NO: 248. In some embodiments, the DNA vector further comprises an intron sequence having at least 95% identity to SEQ ID NO: 235. In some embodiments, the DNA vector comprises a 3'UTR sequence. In some embodiments, the 3'UTR sequence comprises a WPRE element and/or bGH poly A signal sequence or a sequence having at least 95% identity to any one of SEQ ID NOs: 283-291 and 634. In some embodiments, the DNA vector comprises a microRNA (mir) sequence set forth in SEQ ID NO: 543 or a sequence having at least 95% identity thereof. In some embodiments, the DNA vector comprises a spacer sequence selected from a sequence having at least 85% identity to any sequence set forth in Table 15 (SEQ ID NOs: 318-332 and 635-641). In some embodiments, the DNA vector comprises at least one ITR flanking 5' and/or 3' end of the nucleic acid sequence at least 95% identical to SEQ ID NO: 556. In some embodiments, the at least one ITR flanking 5' and/or 3' is a wild-type AAV ITR(s). In some embodiments, the DNA vector is a closed-ended DNA (ceDNA). In some embodiments, the DNA vector is a plasmid. In some embodiments, the DNA vector comprises a nucleic acid sequence encoding a single chain (SC) FVIII. In some embodiments, the nucleic acid sequence is set forth in SEQ ID NO: 556 or a sequence having at least 99% identity thereto.

[0048] In another aspect, the disclosure provides a ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 42 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 42.

[0049] In another aspect, the disclosure provides a ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 642 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 642.

[0050] In another aspect, the disclosure provides a ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 643 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 643.

[0051] In another aspect, the disclosure provides a ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 644 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 644.

[0052] In another aspect, the disclosure provides a ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 645 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 645.

[0053] In another aspect, the disclosure provides a ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 646 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 646.

[0054] These and other aspects of the disclosure are described in further detail below.

DESCRIPTION OF DRAWINGS

[0055] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0056] Embodiments of the present disclosure, briefly summarized above and discussed in greater detail below, can be understood by reference to the illustrative embodiments of the disclosure depicted in the appended drawings. However, the appended drawings illustrate only typical embodiments of the disclosure and are therefore not to be considered limiting of scope, for the disclosure may admit to other equally effective embodiments.

[0057] **FIG. 1A** provides the T-shaped stem-loop structure of a wild-type left ITR of AAV2 (SEQ ID NO: 52) with identification of A-A' arm, B-B' arm, C-C' arm, two Rep binding sites (RBE and RBE') and also shows the terminal resolution site (*TRS*). The RBE contains a series of 4 duplex tetramers that are believed to interact with either Rep 78 or Rep 68. In addition, the RBE' is also believed to interact with Rep complex assembled on the wild-type ITR or mutated ITR in the construct. The D and D' regions contain transcription factor binding sites and other conserved structure. **FIG. 1A** discloses SEQ ID NO: 544. **FIG. 1B** shows proposed Rep-catalyzed nicking and ligating activities in a wild-type left ITR, including the T-shaped stem-loop structure of the wild-type left ITR of AAV2 with identification of A-A' arm, B-B' arm, C-C' arm, two Rep Binding sites (RBE and RBE') and also shows the terminal resolution site (*TRS*), and the D and D' region comprising several transcription factor binding sites and other conserved structure. **FIG. 1B** discloses SEQ ID NO: 545.

[0058] **FIG. 2A** provides the primary structure (polynucleotide sequence) (left) (SEQ ID NO: 547) and the secondary structure (right) (SEQ ID NO: 547) of the RBE-containing portions of the A-A' arm, and the C-C' and B-B' arm of the wild-type left AAV2 ITR. **FIG. 2B** shows an exemplary mutated ITR (also referred to as a modified ITR) sequence for the left ITR. Shown is the primary structure (left) (SEQ ID NO: 549) and the predicted secondary structure (right) (SEQ ID NO: 549) of the RBE portion of the A-A' arm, the C arm and B-B' arm of an exemplary mutated left ITR (ITR-1, left). **FIG. 2C** shows the primary structure (left) (SEQ ID NO: 550) and the secondary structure (right) (SEQ ID NO: 550) of the RBE-containing portion of the A-A' loop, and the B-B' and C-C' arms of wild-type right AAV2 ITR. **FIG. 2D** shows an exemplary right modified ITR. Shown is the primary structure (left) (SEQ ID NO: 551) and the predicted secondary structure (right) (SEQ ID NO: 551) of the RBE containing portion of the A-A' arm, the B-B' and the C arm of an exemplary mutant right ITR (ITR-1, right). Any combination of left and right ITR (*e.g.*, AAV2 ITRs or other viral serotype or synthetic ITRs) can be used as taught herein. Each of **FIGS. 2A-2D** polynucleotide sequences refer to the sequence used in the plasmid or bacmid/baculovirus genome used to produce the ceDNA as described herein. Also included in each of **FIGS. 2A-2D** are corresponding ceDNA secondary structures inferred from the ceDNA vector configurations in the plasmid or bacmid/baculovirus genome and the predicted Gibbs free energy values.

[0059] **FIG. 3A** is a schematic illustrating an upstream process for making baculovirus infected insect cells (BIICs) that are useful in the production of a ceDNA vector for expression of the FVIII as disclosed herein in the process described in the schematic in **FIG. 4B**. **FIG. 3B** is a schematic of an exemplary method of ceDNA production and **FIG. 3C** illustrates a biochemical method and process to confirm ceDNA vector production. **FIG. 3D** and **FIG. 3E** are schematic illustrations describing a process for identifying the presence of ceDNA in DNA harvested from cell pellets obtained during the ceDNA production processes in **FIG. 3B**. **FIG. 3D** shows schematic expected bands for an exemplary ceDNA either left uncut or digested with a restriction endonuclease and then subjected to electrophoresis on either a native gel or a denaturing gel. The leftmost schematic is a native gel, and shows multiple bands suggesting that in its duplex and uncut form ceDNA exists in at least monomeric and dimeric states, visible as a faster-migrating smaller monomer and a slower-migrating dimer that is twice the size of the monomer. The schematic second from the left shows that when ceDNA is cut with a restriction endonuclease, the original bands are gone and faster-migrating (*e.g.*, smaller) bands appear, corresponding to the expected fragment sizes remaining after the cleavage. Under denaturing conditions, the original duplex DNA is single-stranded and migrates as a species twice as large as observed on native gel because the complementary strands are covalently linked. Thus, in the second schematic from the right, the digested ceDNA shows a similar banding distribution to that observed on native gel, but the bands migrate as fragments twice the size of their native gel counterparts. The rightmost schematic shows that uncut ceDNA under denaturing conditions migrates as a single-

stranded open circle, and thus the observed bands are twice the size of those observed under native conditions where the circle is not open. In this figure “kb” is used to indicate relative size of nucleotide molecules based, depending on context, on either nucleotide chain length (*e.g.*, for the single stranded molecules observed in denaturing conditions) or number of base pairs (*e.g.*, for the double-stranded molecules observed in native conditions). **FIG. 3E** shows DNA having a non-continuous structure. The ceDNA can be cut by a restriction endonuclease, having a single recognition site on the ceDNA vector, and generate two DNA fragments with different sizes (1kb and 2kb) in both neutral and denaturing conditions. **FIG. 3E** also shows a ceDNA having a linear and continuous structure. The ceDNA vector can be cut by the restriction endonuclease and generate two DNA fragments that migrate as 1kb and 2kb in neutral conditions, but in denaturing conditions, the strands remain connected and produce single strands that migrate as 2kb and 4kb.

[0060] **FIG. 4** is an exemplary picture of a denaturing gel running examples of ceDNA vectors with (+) or without (-) digestion with endonucleases (EcoRI for ceDNA construct 1 and 2; BamHI for ceDNA construct 3 and 4; SpeI for ceDNA construct 5 and 6; and XhoI for ceDNA construct 7 and 8) Constructs 1-8 are described in Example 1 of International Application PCT PCT/US18/49996, which is incorporated herein in its entirety by reference. Sizes of bands highlighted with an asterisk were determined and provided on the bottom of the picture.

[0061] **FIG. 5** is an annotated schematic of the ceDNA1368 construct (6007 bp). **FIG. 5** discloses SEQ ID NOS: 8 and 552, respectively, in order of appearance.

[0062] **FIG. 6** is an annotated schematic of the ceDNA1652 construct (6250 bp). **FIG. 6** discloses SEQ ID NOS: 43 and 552, respectively, in order of appearance.

[0063] **FIG. 7** is an annotated schematic of the ceDNA1923 construct (5996 bp). **FIG. 7** discloses SEQ ID NO: 68.

[0064] **FIG. 8** is an annotated schematic of the ceDNA1373 having an intron inbetween Exon 1 and Exon 2 (*i.e.*, GE-857 “miniF8_500/500” which is a mini Factor VIII intron 1 chimera, 500 nucleotides from 5’-end of intron, 500 nucleotides from 3’-end of intron) and another intron located 5’-UTR between a promoter (TTRm) and the ATG start site (*i.e.*, GE-023 “MVM_intron”). **FIG. 8** discloses SEQ ID NO: 51.

[0065] **FIG. 9** shows a schematic of FVIII and its domains, as processed to active FVIIIa.

[0066] **FIG. 10A** and **FIG. 10B** are schematics detailing insertion of an intron (miniF8_50/100 intron) into FVIII ORF of ceDNA1367. **FIG. 10A** depicts Chimeric FVIII intron with functional splice donor and acceptor sites is inserted at native position of intron 1 into codon optimized FVIII ORF. **FIG. 10B** depicts intron flanking regions (33bp) derived from FVIII Wt cDNA sequence were substituted for codon optimized sequence in FVIII CDS. **FIG. 10B** discloses SEQ ID NO: 553.

[0067] **FIG. 11A** and **FIG. 11B** are schematics detailing insertion of introns into a FVIII ORF.

FIG. 11A depicts a chimeric FVIII intron (miniF8_200_5p and miniF8_200_3p) with functional splice donor and acceptor sites inserted at native position of intron 1 into a codon optimized FVIII ORF.

FIG. 11B depicts an enhancer element (Embedded_enhancer_HNF_array) inserted inbetween 5p and 3p regions of the chimeric intron. FIG. 11B discloses SEQ ID NO: 554.

[0068] FIG. 12 is a schematic detailing substitution of heterologous secretion signal sequences (N-terminal sequences) for the native FVIII signal sequence. Substitution of the native FVIII signal sequence for a signal sequence from chymotrypsinogen (CHY-SSv1) ORF. FVIII mature peptide is shown at the top. The sequence of FVIII N-terminus signal sequence and mature peptide cleavage site are shown at the bottom. FIG. 12 discloses SEQ ID NOS: 487-490, respectively, in order of appearance.

[0069] FIG. 13 shows a schematic of B-domain selection for the constructs described herein, ranging from a complete B domain deletion (commonly known as BDD-SQ); a B domain having V3 peptide only (known as BDD V3; McIntosh *et al.*, 2013, Blood, 121:3335-3344); a B domain having 226 amino acid with 6 N-linked glycosylation sites (266BD; 226a/N6; see Miao *et al.*, Blood (2004); and a complete B domain deletion in a single chain (SC) in which A2 domain is linked to A3 domain having a slight deletion (4 amino acid of “EITR” (SEQ ID NO: 486)) in its N-terminus of the native A3, known as “Afstyla” style (BDD-SC). FIG. 13 discloses SEQ ID NOS: 491 and 491, respectively, in order of appearance.

[0070] FIG. 14 is a graph that shows a comparison between the chromogenic activity assay versus ELISA to validate the assay method to determine FVIII activity. Various constructs were tested for FVIII activity with the chromogenic assay and the FVIII protein quantity using ELISA. The constructs tested were ceDNA692 (BBD-SQ), ceDNA704 (BDD-V3), ceDNA1270 (226/F309S), ceDNA1368 (SC) and ceDNA1373 (SC/F309S)).

[0071] FIG. 15 depicts FVIII activity *in vitro* ceDNA (ceDNA692 (BBD-SQ)); ceDNA693 (BBD-SQ); ceDNA694 (BBD-SQ); ceDNA1391 (226/F309S); ceDNA1270 (226/F309S); ceDNA1367 (SC/F309S); ceDNA1373 (SC/F309S); ceDNA1368 (SC); and ceDNA1374 (SC)) and *in vivo* hydrodynamic injection Study 1 and Study 2 at Day 3 (ceDNA692 (BBD-SQ); ceDNA694 (BBD-SQ); ceDNA933 (226BD/F309S); ceDNA1265; ceDNA1270 (226/F309S); ceDNA1270 repeat (rep); ceDNA1367 (SC/F309S); ceDNA1373 (SC/F309S); ceDNA1368 (SC); and ceDNA1374 (SC)).

[0072] FIG. 16 depicts the results of an *in vivo* study on FVIII activity at day 11 using constructs ceDNA933 (226BD/F309S), ceDNA1270 (226/F309S), ceDNA1367 (SC/F309S), and ceDNA1368 (SC) formulated in LNP.

[0073] FIG. 17 shows the results of codon optimization on FVIII activity. The FVIII activity was measure from *in vivo* and *in vitro* studies using various ceDNA of FVIII SC, codon optimized FVIII sequences (ceDNA1362; ceDNA1368; ceDNA1374; ceDNA1838; ceDNA1840; ceDNA1918; ceDNA1919; ceDNA1920; ceDNA1921; ceDNA1922; and ceDNA1923). Hydrodynamic (HD)

[0074] FIG. 18 shows that codon optimized constructs without F309S mutation: *i.e.*, ceDNA1368 and its variants such as ceDNA1923, ceDNA1823, ceDNA1840 which shows improvements on plasma FVIII concentration (IU/ml). Hydrodynamic (HD)

[0075] FIG. 19 depicts optimization of 3' untranslated regions (UTR) and their effect on FVIII activity and plasma FVIII.

[0076] FIG. 20 depicts the effect of different promoters and enhancers on FVIII activity.

[0077] FIG. 21 depicts results from *in vitro* studies showing the effect of different introns on expression of ceDNA FVIII as measured by chromogenic FVIII activity.

[0078] FIG. 22 shows plasma FVIII chromogenic activity (IU/mL) at 11 days after administration of ceDNAFVIII formulated in LNPs *in vivo*, as measured by the chromogenic assays for FVIII activity (see, Example 12).

[0079] FIG. 23 depicts the effect of different DNA nuclear targeting sequences (DTS) on FVIII activity *in vitro* and *in vivo*.

[0080] FIG. 24 depicts the effects of leader sequences on FVIII activity *in vitro* and *in vivo*.

[0081] FIG. 25 shows the results from *in vivo* studies in mice and non-human primates (NHP) using various ceDNA vectors to express FVIII protein, as described in Examples 10, 15 and 16. Results show plasma FVIII concentration (IU/ml). Mouse vehicle: Example 10, PBS, day 5, n=5; Mouse DP#1: Example 10, ceDNA1270 in LNP formulation 1 (Ionizable lipid: DSPC : Cholesterol : PEG-Lipid + DSPE-PEG-GalNAc4 (47.5 : 10.0 : 39.2 : 3.3), 1mpk, day 5, n=4; Mouse DP#2: Example 10, ceDNA1270, LNP formulation 2 (Ionizable lipid : DSPC : Cholesterol : PEG-Lipid + DSPE-PEG2000-GalNAc4 (47.3 : 10.0 : 40.5 : 2.3), 2mpk, day 5, n=5; NHP vehicle: Example 14, saline, day 5, n=2; NHP DP#1: Example 14, ceDNA1270 in LNP formulation 1 (Ionizable lipid: DSPC : Cholesterol : PEG-Lipid + DSPE-PEG-GalNAc4 (47.5 : 10.0 : 39.2 : 3.3), 1mpk, day 5, n=2; NHP DP#2: Example 15, ceDNA 1270 in LNP formulation 2 (Ionizable lipid : DSPC : Cholesterol : PEG-Lipid + DSPE-PEG2000-GalNAc4 (47.3 : 10.0 : 40.5 : 2.3), 2mpk, day 5, n=2.

[0082] FIG. 26 shows the results from *in vivo* studies in FVIII knockout mice, as described in Example 11. Results show plasma FVIII concentration (IU/ml) at day 10. The following ceDNA constructs were tested at the indicated doses (mg/kg) ceDNA1270, ceDNA1368, ceDNA1923, ceDNA1651. As shown in FIG. 26, after 10 days, mice administered these ceDNA constructs at all of the doses tested showed increases in plasma FVIII concentration. Overall, the increase in FVIII plasma concentration was dose dependent. ceDNA1270 showed a dramatic increase in plasma FVIII concentration from the 0.5 mg/kg dose to the 2.0 mg/kg dose.

[0083] FIG. 27 depicts a chart showing the result of FVIII expression using various spacer variants of 3x hSerpEnh (2-mer and 11-mer) and Serpin enhancer sequence variants (*e.g.*, bushbaby Serpin enhancer, Chinese tree shrew Serpin enhancer). One dose of 50ng plasmid containing FVIII ceDNA

sequence was hydrodynamically injected into the tail vein of Rag2 mice on day 0 with a single blood collection at day 3 (~72hr post dose) for FVIII activity.

[0084] **FIG. 28** depicts a chart showing the results from an *in vivo* study in which C57BL/6J mice were hydrodynamically injected with FVIII-ceDNA, and FVIII activity was measured at Day 3 from the serum of the treated mice. The ceDNA constructs were: (1) ceDNA construct 10 (wild-type left ITR : left ITR spacer : 3x hSerpEnh VD promoter set : Mouse TTR 5'UTR : MVM Intron: hFVIII-F309S_BD226seq124-BDD-F309 ORF which is identical to the ORF sequence of ceDNA 1651) : WPRE_3pUTR : bGH : Right ITR Spacer : wild-type right ITR; (2) ceDNA construct 60 which has the identical sequence to ceDNA construct 10 except it contains 3x_hSerpEnh-2mer spacer v17; (3) ceDNA construct 61 which has the identical sequence to ceDNA construct 10 except it contains 3x_SerpEnh_11-mer_spacers_v3; (4) ceDNA construct 62 which has the identical sequence to ceDNA construct 10 except it has 3x_Bushbaby SerpEnh with adenine (A) spacers ("Aspacers") located at 5' upstream of the TTR promoter); (5) and ceDNA construct 39 which has the similar sequence to ceDNA construct 10 except that it contains a truncated right ITR).

DETAILED DESCRIPTION

[0085] Provided herein is a method for treating hemophilia A using a ceDNA vector comprising one or more nucleic acids that encode an FVIII therapeutic protein or fragment thereof. Also provided herein are ceDNA vectors for expression of FVIII protein as described herein comprising one or more nucleic acids, *e.g.*, heterologous nucleic acids that encode for the FVIII protein. In some embodiments, the expression of FVIII protein can comprise secretion of the therapeutic protein out of the cell in which it is expressed. Alternatively, in some embodiments, the expressed FVIII protein can act or function (*e.g.*, exert its effect) within the cell in which it is expressed. In some embodiments, the ceDNA vector expresses FVIII protein in the liver, in a muscle (*e.g.*, a skeletal muscle) of a subject, or in another body part, which can act as a depot for FVIII therapeutic protein production and secretion to many systemic compartments.

I. Definitions

[0086] Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this disclosure belongs. It should be understood that this disclosure is not limited to the particular methodology, protocols, and reagents, *etc.*, described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present disclosure, which is defined solely by the claims. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th Edition, published by Merck Sharp & Dohme Corp., 2011 (ISBN 978-0-911910-19-3); Robert S. Porter *et al.* (eds.), Fields Virology, 6th Edition, published by Lippincott Williams & Wilkins, Philadelphia, PA, USA (2013), Knipe, D.M. and Howley, P.M. (ed.), The

Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor & Francis Limited, 2014 (ISBN 0815345305, 9780815345305); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis *et al.*, Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated by reference herein in their entireties.

[0087] As used herein, the terms, “administration,” “administering” and variants thereof refers to introducing a composition or agent (*e.g.*, a therapeutic nucleic acid or an immunosuppressant as described herein) into a subject and includes concurrent and sequential introduction of one or more compositions or agents. “Administration” can refer, *e.g.*, to therapeutic, pharmacokinetic, diagnostic, research, placebo, and experimental methods. “Administration” also encompasses *in vitro* and *ex vivo* treatments. The introduction of a composition or agent into a subject is by any suitable route, including orally, pulmonarily, intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or subcutaneously), rectally, intralymphatically, intratumorally, or topically. The introduction of a composition or agent into a subject is by electroporation. Administration includes self-administration and the administration by another. Administration can be carried out by any suitable route. A suitable route of administration allows the composition or the agent to perform its intended function. For example, if a suitable route is intravenous, the composition is administered by introducing the composition or agent into a vein of the subject.

[0088] As used herein, the phrases “nucleic acid therapeutic”, “therapeutic nucleic acid” and “TNA” are used interchangeably and refer to any modality of therapeutic using nucleic acids as an active component of therapeutic agent to treat a disease or disorder. As used herein, these phrases refer to RNA-based therapeutics and DNA-based therapeutics. Non-limiting examples of RNA-based therapeutics include mRNA, antisense RNA and oligonucleotides, ribozymes, aptamers, interfering RNAs (RNAi), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA

(aiRNA), microRNA (miRNA). Non-limiting examples of DNA-based therapeutics include minicircle DNA, minigene, viral DNA (*e.g.*, Lentiviral or AAV genome) or non-viral synthetic DNA vectors, closed-ended linear duplex DNA (ceDNA / CELiD), plasmids, bacmids, doggybone (dbDNA™) DNA vectors, minimalistic immunological-defined gene expression (MIDGE)-vector, nonviral ministring DNA vector (linear-covalently closed DNA vector), or dumbbell-shaped DNA minimal vector (“dumbbell DNA”).

[0089] As used herein, an “effective amount” or “therapeutically effective amount” of a therapeutic agent, such as a FVIII therapeutic protein or fragment thereof, is an amount sufficient to produce the desired effect, *e.g.*, treatment or prevention of hemophilia A. Suitable assays for measuring expression of a target gene or target sequence include, *e.g.*, examination of protein or RNA levels using techniques known to those of skill in the art such as dot blots, northern blots, *in situ* hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art. However, dosage levels are based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular active agent employed. Thus, the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods. Additionally, the terms “therapeutic amount”, “therapeutically effective amounts” and “pharmaceutically effective amounts” include prophylactic or preventative amounts of the compositions of the described disclosure. In prophylactic or preventative applications of the described disclosure, pharmaceutical compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of, a disease, disorder or condition in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the onset of the disease, disorder or condition, including biochemical, histologic and/or behavioral symptoms of the disease, disorder or condition, its complications, and intermediate pathological phenotypes presenting during development of the disease, disorder or condition. It is generally preferred that a maximum dose be used, that is, the highest safe dose according to some medical judgment. According to some embodiments, the disease, disorder or condition is hemophilia A. The terms “dose” and “dosage” are used interchangeably herein.

[0090] As used herein the term “therapeutic effect” refers to a consequence of treatment, the results of which are judged to be desirable and beneficial. A therapeutic effect can include, directly or indirectly, the arrest, reduction, or elimination of a disease manifestation. A therapeutic effect can also include, directly or indirectly, the arrest reduction or elimination of the progression of a disease manifestation.

[0091] For any therapeutic agent described herein therapeutically effective amount may be initially determined from preliminary *in vitro* studies and/or animal models. A therapeutically effective dose may also be determined from human data. The applied dose may be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal

efficacy based on the methods described above and other well-known methods is within the capabilities of the ordinarily skilled artisan. General principles for determining therapeutic effectiveness, which may be found in Chapter 1 of Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 10th Edition, McGraw-Hill (New York) (2001), incorporated herein by reference, are summarized below.

[0092] Pharmacokinetic principles provide a basis for modifying a dosage regimen to obtain a desired degree of therapeutic efficacy with a minimum of unacceptable adverse effects. In situations where the drug's plasma concentration can be measured and related to therapeutic window, additional guidance for dosage modification can be obtained.

[0093] As used herein, the terms "heterologous nucleic acid sequence" and "transgene" are used interchangeably and refer to a nucleic acid of interest (other than a nucleic acid encoding a capsid polypeptide) that is incorporated into and may be delivered and expressed by a ceDNA vector as disclosed herein. In one embodiment, a nucleic acid sequence may be a heterologous nucleic acid sequence. According to some embodiments, the term "heterologous nucleic acid" is meant to refer to a nucleic acid (or transgene) that is not present in, expressed by, or derived from the cell or subject to which it is contacted.

[0094] As used herein, the terms "expression cassette" and "transcription cassette" are used interchangeably and refer to a linear stretch of nucleic acids that includes a transgene that is operably linked to one or more promoters or other regulatory sequences sufficient to direct transcription of the transgene, but which does not comprise capsid-encoding sequences, other vector sequences or inverted terminal repeat regions. An expression cassette may additionally comprise one or more *cis*-acting sequences (*e.g.*, promoters, enhancers, or repressors), one or more introns, and one or more post-transcriptional regulatory elements.

[0095] The terms "polynucleotide" and "nucleic acid," used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes single, double, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer including purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. "Oligonucleotide" generally refers to polynucleotides of between about 5 and about 100 nucleotides of single- or double-stranded DNA. However, for the purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides are also known as "oligomers" or "oligos" and may be isolated from genes, or chemically synthesized by methods known in the art. The terms "polynucleotide" and "nucleic acid" should be understood to include, as applicable to the embodiments being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides. DNA may be in the form of, *e.g.*, antisense molecules, plasmid DNA, DNA-DNA duplexes, pre-condensed DNA, PCR products, vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric

sequences, chromosomal DNA, or derivatives and combinations of these groups. DNA may be in the form of minicircle, plasmid, bacmid, minigene, ministring DNA (linear covalently closed DNA vector), closed-ended linear duplex DNA (CELiD or ceDNA), doggybone (dbDNA™) DNA, dumbbell shaped DNA, minimalistic immunological-defined gene expression (MIDGE)-vector, viral vector or nonviral vectors. RNA may be in the form of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), mRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs and/or modified residues include, without limitation, phosphorothioates, phosphorodiamidate morpholino oligomer (morpholino), phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2'-O-methyl ribonucleotides, locked nucleic acid (LNA™), and peptide nucleic acids (PNAs). Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (*e.g.*, degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated.

[0096] “Nucleotides” contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups.

[0097] “Bases” include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.

[0098] The term “nucleic acid construct” as used herein refers to a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic. The term nucleic acid construct is synonymous with the term “expression cassette” when the nucleic acid construct contains the control sequences required for expression of a coding sequence of the present disclosure. An “expression cassette” includes a DNA coding sequence operably linked to a promoter.

[0099] By “hybridizable” or “complementary” or “substantially complementary” it is meant that a nucleic acid (*e.g.*, RNA) includes a sequence of nucleotides that enables it to non-covalently bind, *i.e.* form Watson-Crick base pairs and/or G/U base pairs, “anneal”, or “hybridize,” to another nucleic acid in a sequence-specific, antiparallel, manner (*i.e.*, a nucleic acid specifically binds to a complementary nucleic acid) under the appropriate *in vitro* and/or *in vivo* conditions of temperature and solution ionic

strength. As is known in the art, standard Watson-Crick base-pairing includes: adenine (A) pairing with thymidine (T), adenine (A) pairing with uracil (U), and guanine (G) pairing with cytosine (C). In addition, it is also known in the art that for hybridization between two RNA molecules (*e.g.*, dsRNA), guanine (G) base pairs with uracil (U). For example, G/U base-pairing is partially responsible for the degeneracy (*i.e.*, redundancy) of the genetic code in the context of tRNA anti-codon base-pairing with codons in mRNA. In the context of this disclosure, a guanine (G) of a protein-binding segment (dsRNA duplex) of a subject DNA-targeting RNA molecule is considered complementary to an uracil (U), and *vice versa*. As such, when a G/U base-pair can be made at a given nucleotide position a protein-binding segment (dsRNA duplex) of a subject DNA-targeting RNA molecule, the position is not considered to be non-complementary, but is instead considered to be complementary.

[00100] The terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein, and refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.

[00101] A DNA sequence that “encodes” a particular FVIII protein is a DNA nucleic acid sequence that is transcribed into the particular RNA and/or protein. A DNA polynucleotide may encode an RNA (mRNA) that is translated into protein, or a DNA polynucleotide may encode an RNA that is not translated into protein (*e.g.*, tRNA, rRNA, or a DNA-targeting RNA; also called “non-coding” RNA or ncRNA”).

[0001] As used herein, the term “fusion protein” as used herein refers to a polypeptide which comprises protein domains from at least two different proteins. For example, a fusion protein may comprise (i) FVIII or fragment thereof and (ii) at least one non-GOI protein. Fusion proteins encompassed herein include, but are not limited to, an antibody, or Fc or antigen-binding fragment of an antibody fused to a FVIII protein, *e.g.*, an extracellular domain of a receptor, ligand, enzyme or peptide. The FVIII protein or fragment thereof that is part of a fusion protein can be a monospecific antibody or a bispecific or multispecific antibody.

[00102] As used herein, the term “genomic safe harbor gene” or “safe harbor gene” refers to a gene or loci that a nucleic acid sequence can be inserted such that the sequence can integrate and function in a predictable manner (*e.g.*, express a protein of interest) without significant negative consequences to endogenous gene activity, or the promotion of cancer. In some embodiments, a safe harbor gene is also a loci or gene where an inserted nucleic acid sequence can be expressed efficiently and at higher levels than a non-safe harbor site.

[00103] As used herein, the term “gene delivery” means a process by which foreign DNA is transferred to host cells for applications of gene therapy.

[00104] As used herein, the term “terminal repeat” or “TR” includes any viral terminal repeat or synthetic sequence that comprises at least one minimal required origin of replication and a region

comprising a palindrome hairpin structure. A Rep-binding sequence (“RBS”) (also referred to as RBE (Rep-binding element)) and a terminal resolution site (“TRS”) together constitute a “minimal required origin of replication” and thus the TR comprises at least one RBS and at least one TRS. TRs that are the inverse complement of one another within a given stretch of polynucleotide sequence are typically each referred to as an “inverted terminal repeat” or “ITR”. In the context of a virus, ITRs mediate replication, virus packaging, integration and provirus rescue. As was unexpectedly found in the disclosure herein, TRs that are not inverse complements across their full length can still perform the traditional functions of ITRs, and thus the term ITR is used herein to refer to a TR in a ceDNA genome or ceDNA vector that is capable of mediating replication of ceDNA vector. It will be understood by one of ordinary skill in the art that in complex ceDNA vector configurations more than two ITRs or asymmetric ITR pairs may be present. The ITR can be an AAV ITR or a non-AAV ITR, or can be derived from an AAV ITR or a non-AAV ITR. For example, the ITR can be derived from the family *Parvoviridae*, which encompasses parvoviruses and dependoviruses (*e.g.*, canine parvovirus, bovine parvovirus, mouse parvovirus, porcine parvovirus, human parvovirus B-19), or the SV40 hairpin that serves as the origin of SV40 replication can be used as an ITR, which can further be modified by truncation, substitution, deletion, insertion and/or addition. *Parvoviridae* family viruses consist of two subfamilies: *Parvovirinae*, which infect vertebrates, and *Densovirinae*, which infect invertebrates. Dependoparvoviruses include the viral family of the adeno-associated viruses (AAV) which are capable of replication in vertebrate hosts including, but not limited to, human, primate, bovine, canine, equine and ovine species. For convenience herein, an ITR located 5’ to (upstream of) an expression cassette in a ceDNA vector is referred to as a “5’ ITR” or a “left ITR”, and an ITR located 3’ to (downstream of) an expression cassette in a ceDNA vector is referred to as a “3’ ITR” or a “right ITR”.

[00105] A “wild-type ITR” or “WT-ITR” refers to the sequence of a naturally occurring ITR sequence in an AAV or other dependovirus that retains, *e.g.*, Rep binding activity and Rep nicking ability. The nucleic acid sequence of a WT-ITR from any AAV serotype may slightly vary from the canonical naturally occurring sequence due to degeneracy of the genetic code or drift, and therefore WT-ITR sequences encompassed for use herein include WT-ITR sequences as result of naturally occurring changes taking place during the production process (*e.g.*, a replication error).

[00106] As used herein, the term “substantially symmetrical WT-ITRs” or a “substantially symmetrical WT-ITR pair” refers to a pair of WT-ITRs within a single ceDNA genome or ceDNA vector that are both wild-type ITRs that have an inverse complement sequence across their entire length. For example, an ITR can be considered to be a wild-type sequence, even if it has one or more nucleotides that deviate from the canonical naturally occurring sequence, so long as the changes do not affect the properties and overall three-dimensional structure of the sequence. In some aspects, the deviating nucleotides represent conservative sequence changes. As one non-limiting example, a

sequence that has at least 95%, 96%, 97%, 98%, or 99% sequence identity to the canonical sequence (as measured, *e.g.*, using BLAST at default settings), and also has a symmetrical three-dimensional spatial organization to the other WT-ITR such that their 3D structures are the same shape in geometrical space. The substantially symmetrical WT-ITR has the same A, C-C' and B-B' loops in 3D space. A substantially symmetrical WT-ITR can be functionally confirmed as WT by determining that it has an operable Rep binding site (RBE or RBE') and terminal resolution site (TRS) that pairs with the appropriate Rep protein. One can optionally test other functions, including transgene expression under permissive conditions.

[00107] As used herein, the phrases of “modified ITR” or “mod-ITR” or “mutant ITR” are used interchangeably herein and refer to an ITR that has a mutation in at least one or more nucleotides as compared to the WT-ITR from the same serotype. The mutation can result in a change in one or more of A, C, C', B, B' regions in the ITR, and can result in a change in the three-dimensional spatial organization (*i.e.* its 3D structure in geometric space) as compared to the 3D spatial organization of a WT-ITR of the same serotype.

[00108] As used herein, the term “asymmetric ITRs” also referred to as “asymmetric ITR pairs” refers to a pair of ITRs within a single ceDNA genome or ceDNA vector that are not inverse complements across their full length. As one non-limiting example, an asymmetric ITR pair does not have a symmetrical three-dimensional spatial organization to their cognate ITR such that their 3D structures are different shapes in geometrical space. Stated differently, an asymmetrical ITR pair have the different overall geometric structure, *i.e.*, they have different organization of their A, C-C' and B-B' loops in 3D space (*e.g.*, one ITR may have a short C-C' arm and/or short B-B' arm as compared to the cognate ITR). The difference in sequence between the two ITRs may be due to one or more nucleotide addition, deletion, truncation, or point mutation. In one embodiment, one ITR of the asymmetric ITR pair may be a wild-type AAV ITR sequence and the other ITR a modified ITR as defined herein (*e.g.*, a non-wild-type or synthetic ITR sequence). In another embodiment, neither ITRs of the asymmetric ITR pair is a wild-type AAV sequence and the two ITRs are modified ITRs that have different shapes in geometrical space (*i.e.*, a different overall geometric structure). In some embodiments, one mod-ITRs of an asymmetric ITR pair can have a short C-C' arm and the other ITR can have a different modification (*e.g.*, a single arm, or a short B-B' arm etc.) such that they have different three-dimensional spatial organization as compared to the cognate asymmetric mod-ITR.

[00109] As used herein, the term “symmetric ITRs” refers to a pair of ITRs within a single ceDNA genome or ceDNA vector that are wild-type or mutated (*e.g.*, modified relative to wild-type) dependoviral ITR sequences and are inverse complements across their full length. In one non-limiting example, both ITRs are wild-type ITRs sequences from AAV2. In another example, neither ITRs are wild-type ITR AAV2 sequences (*i.e.*, they are a modified ITR, also referred to as a mutant ITR), and can have a difference in sequence from the wild-type ITR due to nucleotide addition, deletion,

substitution, truncation, or point mutation. For convenience herein, an ITR located 5' to (upstream of) an expression cassette in a ceDNA vector is referred to as a "5' ITR" or a "left ITR", and an ITR located 3' to (downstream of) an expression cassette in a ceDNA vector is referred to as a "3' ITR" or a "right ITR".

[00110] As used herein, the terms "substantially symmetrical modified-ITRs" or a "substantially symmetrical mod-ITR pair" refers to a pair of modified-ITRs within a single ceDNA genome or ceDNA vector that are both that have an inverse complement sequence across their entire length. For example, the modified ITR can be considered substantially symmetrical, even if it has some nucleic acid sequences that deviate from the inverse complement sequence so long as the changes do not affect the properties and overall shape. As one non-limiting example, a sequence that has at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the canonical sequence (as measured using BLAST at default settings), and also has a symmetrical three-dimensional spatial organization to their cognate modified ITR such that their 3D structures are the same shape in geometrical space. Stated differently, a substantially symmetrical modified-ITR pair have the same A, C-C' and B-B' loops organized in 3D space. In some embodiments, the ITRs from a mod-ITR pair may have different reverse complement nucleic acid sequences but still have the same symmetrical three-dimensional spatial organization – that is both ITRs have mutations that result in the same overall 3D shape. For example, one ITR (*e.g.*, 5' ITR) in a mod-ITR pair can be from one serotype, and the other ITR (*e.g.*, 3' ITR) can be from a different serotype, however, both can have the same corresponding mutation (*e.g.*, if the 5' ITR has a deletion in the C region, the cognate modified 3' ITR from a different serotype has a deletion at the corresponding position in the C' region), such that the modified ITR pair has the same symmetrical three-dimensional spatial organization. In such embodiments, each ITR in a modified ITR pair can be from different serotypes (*e.g.*, AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) such as the combination of AAV2 and AAV6, with the modification in one ITR reflected in the corresponding position in the cognate ITR from a different serotype. In one embodiment, a substantially symmetrical modified ITR pair refers to a pair of modified ITRs (mod-ITRs) so long as the difference in nucleic acid sequences between the ITRs does not affect the properties or overall shape and they have substantially the same shape in 3D space. As a non-limiting example, a mod-ITR that has at least 95%, 96%, 97%, 98% or 99% sequence identity to the canonical mod-ITR as determined by standard means well known in the art such as BLAST (Basic Local Alignment Search Tool), or BLASTN at default settings, and also has a symmetrical three-dimensional spatial organization such that their 3D structure is the same shape in geometric space. A substantially symmetrical mod-ITR pair has the same A, C-C' and B-B' loops in 3D space, *e.g.*, if a modified ITR in a substantially symmetrical mod-ITR pair has a deletion of a C-C' arm, then the cognate mod-ITR has the corresponding deletion of the C-C' loop and also has a similar 3D structure of the remaining A and B-B' loops in the same shape in geometric space of its cognate mod-ITR.

[00111] The term “flanking” refers to a relative position of one nucleic acid sequence with respect to another nucleic acid sequence. Generally, in the sequence ABC, B is flanked by A and C. The same is true for the arrangement AxBxC. Thus, a flanking sequence precedes or follows a flanked sequence but need not be contiguous with, or immediately adjacent to the flanked sequence. In one embodiment, the term flanking refers to terminal repeats at each end of the linear duplex ceDNA vector.

[00112] As used herein, the terms “treat,” “treating,” and/or “treatment” include abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical symptoms of a condition, or substantially preventing the appearance of clinical symptoms of a condition, obtaining beneficial or desired clinical results. According to some embodiments, the condition is hemophilia A. Treating further refers to accomplishing one or more of the following: (a) reducing the severity of the disorder; (b) limiting development of symptoms characteristic of the disorder(s) being treated; (c) limiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting recurrence of symptoms in patients that were previously asymptomatic for the disorder(s). Beneficial or desired clinical results, such as pharmacologic and/or physiologic effects include, but are not limited to, preventing the disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder or condition but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), alleviation of symptoms of the disease, disorder or condition, diminishment of extent of the disease, disorder or condition, stabilization (*i.e.*, not worsening) of the disease, disorder or condition, preventing spread of the disease, disorder or condition, delaying or slowing of the disease, disorder or condition progression, amelioration or palliation of the disease, disorder or condition, and combinations thereof, as well as prolonging survival as compared to expected survival if not receiving treatment.

[00113] As used herein, the term “increase,” “enhance,” “raise” (and like terms) generally refers to the act of increasing, either directly or indirectly, a concentration, level, function, activity, or behavior relative to the natural, expected, or average, or relative to a control condition.

[00114] As used herein, the term “minimize,” “reduce,” “decrease,” and/or “inhibit” (and like terms) generally refers to the act of reducing, either directly or indirectly, a concentration, level, function, activity, or behavior relative to the natural, expected, or average, or relative to a control condition.

[00115] As used herein, the term “ceDNA genome” refers to an expression cassette that further incorporates at least one inverted terminal repeat region. A ceDNA genome may further comprise one or more spacer regions. In some embodiments the ceDNA genome is incorporated as an intermolecular duplex polynucleotide of DNA into a plasmid or viral genome.

[00116] As used herein, the term “ceDNA spacer region” refers to an intervening sequence that separates functional elements in the ceDNA vector or ceDNA genome. In some embodiments, ceDNA spacer regions keep two functional elements at a desired distance for optimal functionality. In some

embodiments, ceDNA spacer regions provide or add to the genetic stability of the ceDNA genome within *e.g.*, a plasmid or baculovirus. In some embodiments, ceDNA spacer regions facilitate ready genetic manipulation of the ceDNA genome by providing a convenient location for cloning sites and the like. For example, in certain aspects, an oligonucleotide “polylinker” containing several restriction endonuclease sites, or a non-open reading frame sequence designed to have no known protein (*e.g.*, transcription factor) binding sites can be positioned in the ceDNA genome to separate the *cis* – acting factors, *e.g.*, inserting a 6mer, 12mer, 18mer, 24mer, 48mer, 86mer, 176mer, etc. between the terminal resolution site and the upstream transcriptional regulatory element. Similarly, the spacer may be incorporated between the polyadenylation signal sequence and the 3'-terminal resolution site.

[00117] As used herein, the terms “Rep binding site,” “Rep binding element,” “RBE” and “RBS” are used interchangeably and refer to a binding site for Rep protein (*e.g.*, AAV Rep 78 or AAV Rep 68) which upon binding by a Rep protein permits the Rep protein to perform its site-specific endonuclease activity on the sequence incorporating the RBS. An RBS sequence and its inverse complement together form a single RBS. RBS sequences are known in the art, and include, for example, 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437), an RBS sequence identified in AAV2. Any known RBS sequence may be used in the embodiments of the disclosure, including other known AAV RBS sequences and other naturally known or synthetic RBS sequences. Without being bound by theory it is thought that the nuclease domain of a Rep protein binds to the duplex nucleic acid sequence GCTC, and thus the two known AAV Rep proteins bind directly to and stably assemble on the duplex oligonucleotide, 5'-(GCGC)(GCTC)(GCTC)(GCTC)-3' (SEQ ID NO: 437). In addition, soluble aggregated conformers (*i.e.*, undefined number of inter-associated Rep proteins) dissociate and bind to oligonucleotides that contain Rep binding sites. Each Rep protein interacts with both the nitrogenous bases and phosphodiester backbone on each strand. The interactions with the nitrogenous bases provide sequence specificity whereas the interactions with the phosphodiester backbone are non- or less- sequence specific and stabilize the protein-DNA complex.

[00118] As used herein, the terms “terminal resolution site” and “TRS” are used interchangeably herein and refer to a region at which Rep forms a tyrosine-phosphodiester bond with the 5' thymidine generating a 3' OH that serves as a substrate for DNA extension via a cellular DNA polymerase, *e.g.*, DNA pol delta or DNA pol epsilon. Alternatively, the Rep-thymidine complex may participate in a coordinated ligation reaction. In some embodiments, a TRS minimally encompasses a non-base-paired thymidine. In some embodiments, the nicking efficiency of the TRS can be controlled at least in part by its distance within the same molecule from the RBS. When the acceptor substrate is the complementary ITR, then the resulting product is an intramolecular duplex. TRS sequences are known in the art, and include, for example, 5'-GGTTGA-3', the hexanucleotide sequence identified in AAV2. Any known TRS sequence may be used in the embodiments of the disclosure, including other known

AAV TRS sequences and other naturally known or synthetic TRS sequences such as AGTT (SEQ ID NO: 438), GGTTGG, AGTTGG, AGTTGA, and other motifs such as RRTTRR.

[00119] As used herein, the term “ceDNA-plasmid” refers to a plasmid that comprises a ceDNA genome as an intermolecular duplex.

[00120] As used herein, the term “ceDNA-bacmid” refers to an infectious baculovirus genome comprising a ceDNA genome as an intermolecular duplex that is capable of propagating in *E. coli* as a plasmid, and so can operate as a shuttle vector for baculovirus.

[00121] As used herein, the term “ceDNA-baculovirus” refers to a baculovirus that comprises a ceDNA genome as an intermolecular duplex within the baculovirus genome.

[00122] As used herein, the terms “ceDNA-baculovirus infected insect cell” and “ceDNA-BIIC” are used interchangeably, and refer to an invertebrate host cell (including, but not limited to an insect cell (*e.g.*, an Sf9 cell)) infected with a ceDNA-baculovirus.

[00123] As used herein, the term “ceDNA” refers to capsid-free closed-ended linear double stranded (*ds*) duplex DNA for non-viral gene transfer, synthetic or otherwise. Detailed description of ceDNA is described in International application of PCT/US2017/020828, filed March 3, 2017, the entire contents of which are expressly incorporated herein by reference. Certain methods for the production of ceDNA comprising various inverted terminal repeat (ITR) sequences and configurations using cell-based methods are described in Example 1 of International applications PCT/US18/49996, filed September 7, 2018, and PCT/US2018/064242, filed December 6, 2018 each of which is incorporated herein in its entirety by reference. Certain methods for the production of synthetic ceDNA vectors comprising various ITR sequences and configurations are described, *e.g.*, in International application PCT/US2019/14122, filed January 18, 2019, the entire content of which is incorporated herein by reference.

[00124] As used herein, the term “closed-ended DNA vector” refers to a capsid-free DNA vector with at least one covalently closed end and where at least part of the vector has an intramolecular duplex structure.

[00125] As used herein, the terms “ceDNA vector” and “ceDNA” are used interchangeably and refer to a closed-ended DNA vector comprising at least one terminal palindrome. In some embodiments, the ceDNA comprises two covalently-closed ends.

[00126] As used herein, the term “neDNA” or “nicked ceDNA” refers to a closed-ended DNA having a nick or a gap of 1-100 base pairs in a stem region or spacer region 5' upstream of an open reading frame (*e.g.*, a promoter and transgene to be expressed).

[00127] As used herein, the terms “gap” refers to a discontinued portion of synthetic DNA vector of the present disclosure, creating a stretch of single stranded DNA portion in otherwise double stranded ceDNA. The gap can be 1 base-pair to 100 base-pair long in length in one strand of a duplex DNA. Typical gaps, designed and created by the methods described herein and synthetic vectors generated by

the methods can be, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60 bp long in length. Exemplified gaps in the present disclosure can be 1 bp to 10 bp long, 1 to 20 bp long, 1 to 30 bp long in length.

[00128] As defined herein, “reporters” refer to proteins that can be used to provide detectable read-outs. Reporters generally produce a measurable signal such as fluorescence, color, or luminescence. Reporter protein coding sequences encode proteins whose presence in the cell or organism is readily observed. For example, fluorescent proteins cause a cell to fluoresce when excited with light of a particular wavelength, luciferases cause a cell to catalyze a reaction that produces light, and enzymes such as β -galactosidase convert a substrate to a colored product. Exemplary reporter polypeptides useful for experimental or diagnostic purposes include, but are not limited to β -lactamase, β -galactosidase (LacZ), alkaline phosphatase (AP), thymidine kinase (TK), green fluorescent protein (GFP) and other fluorescent proteins, chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.

[00129] As used herein, the terms “sense” and “antisense” refer to the orientation of the structural element on the polynucleotide. The sense and antisense versions of an element are the reverse complement of each other.

[00130] As used herein, the term “synthetic AAV vector” and “synthetic production of AAV vector” refers to an AAV vector and synthetic production methods thereof in an entirely cell-free environment.

[00131] As used herein, “reporters” refer to proteins that can be used to provide detectable read-outs. Reporters generally produce a measurable signal such as fluorescence, color, or luminescence. Reporter protein coding sequences encode proteins whose presence in the cell or organism is readily observed. For example, fluorescent proteins cause a cell to fluoresce when excited with light of a particular wavelength, luciferases cause a cell to catalyze a reaction that produces light, and enzymes such as β -galactosidase convert a substrate to a colored product. Exemplary reporter polypeptides useful for experimental or diagnostic purposes include, but are not limited to β -lactamase, β -galactosidase (LacZ), alkaline phosphatase (AP), thymidine kinase (TK), green fluorescent protein (GFP) and other fluorescent proteins, chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.

[00132] As used herein, the term “effector protein” refers to a polypeptide that provides a detectable read-out, either as, for example, a reporter polypeptide, or more appropriately, as a polypeptide that kills a cell, *e.g.*, a toxin, or an agent that renders a cell susceptible to killing with a chosen agent or lack thereof. Effector proteins include any protein or peptide that directly targets or damages the host cell’s DNA and/or RNA. For example, effector proteins can include, but are not limited to, a restriction endonuclease that targets a host cell DNA sequence (whether genomic or on an extrachromosomal element), a protease that degrades a polypeptide target necessary for cell survival, a

DNA gyrase inhibitor, and a ribonuclease-type toxin. In some embodiments, the expression of an effector protein controlled by a synthetic biological circuit as described herein can participate as a factor in another synthetic biological circuit to thereby expand the range and complexity of a biological circuit system's responsiveness.

[00133] Transcriptional regulators refer to transcriptional activators and repressors that either activate or repress transcription of a gene of interest, such as FVIII. Promoters are regions of nucleic acid that initiate transcription of a particular gene. Transcriptional activators typically bind nearby to transcriptional promoters and recruit RNA polymerase to directly initiate transcription. Repressors bind to transcriptional promoters and sterically hinder transcriptional initiation by RNA polymerase. Other transcriptional regulators may serve as either an activator or a repressor depending on where they bind and cellular and environmental conditions. Non-limiting examples of transcriptional regulator classes include, but are not limited to homeodomain proteins, zinc-finger proteins, winged-helix (forkhead) proteins, and leucine-zipper proteins.

[00134] As used herein, a "repressor protein" or "inducer protein" is a protein that binds to a regulatory sequence element and represses or activates, respectively, the transcription of sequences operatively linked to the regulatory sequence element. Preferred repressor and inducer proteins as described herein are sensitive to the presence or absence of at least one input agent or environmental input. Preferred proteins as described herein are modular in form, comprising, for example, separable DNA-binding and input agent-binding or responsive elements or domains.

[00135] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active ingredients can also be incorporated into the compositions. The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce a toxic, an allergic, or similar untoward reaction when administered to a host.

[00136] As used herein, an "input agent responsive domain" is a domain of a transcription factor that binds to or otherwise responds to a condition or input agent in a manner that renders a linked DNA binding fusion domain responsive to the presence of that condition or input. In one embodiment, the presence of the condition or input results in a conformational change in the input agent responsive domain, or in a protein to which it is fused, that modifies the transcription-modulating activity of the transcription factor.

[00137] The term "*in vivo*" refers to assays or processes that occur in or within an organism, such as a multicellular animal. In some of the aspects described herein, a method or use can be said to occur "*in vivo*" when a unicellular organism, such as a bacterium, is used. The term "*ex vivo*" refers to methods and uses that are performed using a living cell with an intact membrane that is outside of the

body of a multicellular animal or plant, *e.g.*, explants, cultured cells, including primary cells and cell lines, transformed cell lines, and extracted tissue or cells, including blood cells, among others. The term “*in vitro*” refers to assays and methods that do not require the presence of a cell with an intact membrane, such as cellular extracts, and can refer to the introducing of a programmable synthetic biological circuit in a non-cellular system, such as a medium not comprising cells or cellular systems, such as cellular extracts.

[00138] The term “promoter,” as used herein, refers to any nucleic acid sequence that regulates the expression of another nucleic acid sequence by driving transcription of the nucleic acid sequence, which can be a target gene, *e.g.*, heterologous target gene, encoding a protein or an RNA. Promoters can be constitutive, inducible, repressible, tissue-specific, or any combination thereof. A promoter is a control region of a nucleic acid sequence at which initiation and rate of transcription of the remainder of a nucleic acid sequence are controlled. A promoter can also contain genetic elements at which regulatory proteins and molecules can bind, such as RNA polymerase and other transcription factors. In some embodiments of the aspects described herein, a promoter can drive the expression of a transcription factor that regulates the expression of the promoter itself. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain “TATA” boxes and “CAT” boxes. Various promoters, including inducible promoters, may be used to drive the expression of transgenes in the ccdNA vectors disclosed herein. A promoter sequence may be bounded at its 3’ terminus by the transcription initiation site and extends upstream (5’ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.

[00139] The term “enhancer” as used herein refers to a cis-acting regulatory sequence (*e.g.*, 50-1,500 base pairs) that binds one or more proteins (*e.g.*, activator proteins, or transcription factor) to increase transcriptional activation of a nucleic acid sequence. Enhancers can be positioned up to 1,000,000 base pairs upstream of the gene start site or downstream of the gene start site that they regulate. An enhancer can be positioned within an intronic region, or in the exonic region of an unrelated gene. An enhancer can be one naturally associated with a promoter, a gene or a sequence.

[00140] A promoter can be said to drive expression or drive transcription of the nucleic acid sequence that it regulates. The phrases “operably linked,” “operatively positioned,” “operatively linked,” “under control,” and “under transcriptional control” indicate that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence it regulates to control transcriptional initiation and/or expression of that sequence. An “inverted promoter,” as used herein, refers to a promoter in which the nucleic acid sequence is in the reverse orientation, such that what was the coding strand is now the non-coding strand, and vice versa. Inverted promoter sequences can be

used in various embodiments to regulate the state of a switch. In addition, in various embodiments, a promoter can be used in conjunction with an enhancer.

[00141] A promoter can be one naturally associated with a gene or sequence, as can be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon of a given gene or sequence. Such a promoter can be referred to as "endogenous." Similarly, in some embodiments, an enhancer can be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence.

[00142] In some embodiments, a coding nucleic acid segment is positioned under the control of a "recombinant promoter" or "heterologous promoter," both of which refer to a promoter that is not normally associated with the encoded nucleic acid sequence it is operably linked to in its natural environment. A recombinant or heterologous enhancer refers to an enhancer not normally associated with a given nucleic acid sequence in its natural environment. Such promoters or enhancers can include promoters or enhancers of other genes; promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell; and synthetic promoters or enhancers that are not "naturally occurring," *i.e.*, comprise different elements of different transcriptional regulatory regions, and/or mutations that alter expression through methods of genetic engineering that are known in the art. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, promoter sequences can be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR, in connection with the synthetic biological circuits and modules disclosed herein (see, *e.g.*, U.S. Pat. No. 4,683,202, U.S. Pat. No. 5,928,906, each incorporated herein by reference). Furthermore, it is contemplated that control sequences that direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.

[00143] As described herein, an "inducible promoter" is one that is characterized by initiating or enhancing transcriptional activity when in the presence of, influenced by, or contacted by an inducer or inducing agent. An "inducer" or "inducing agent," as defined herein, can be endogenous, or a normally exogenous compound or protein that is administered in such a way as to be active in inducing transcriptional activity from the inducible promoter. In some embodiments, the inducer or inducing agent, *i.e.*, a chemical, a compound or a protein, can itself be the result of transcription or expression of a nucleic acid sequence (*i.e.*, an inducer can be an inducer protein expressed by another component or module), which itself can be under the control of an inducible promoter. In some embodiments, an inducible promoter is induced in the absence of certain agents, such as a repressor. Examples of inducible promoters include but are not limited to, tetracycline, metallothionine, ecdysone, mammalian viruses (*e.g.*, the adenovirus late promoter; and the mouse mammary tumor virus long terminal repeat (MMTV-LTR)) and other steroid-responsive promoters, rapamycin responsive promoters and the like.

[00144] The terms “DNA regulatory sequences,” “control elements,” and “regulatory elements,” used interchangeably herein, refer to transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, protein degradation signals, and the like, that provide for and/or regulate transcription of a non-coding sequence (*e.g.*, DNA-targeting RNA) or a coding sequence (*e.g.*, site-directed modifying polypeptide, or Cas9/Csn1 polypeptide) and/or regulate translation of an encoded polypeptide.

[00145] “Operably linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. An “expression cassette” includes a DNA sequence, *e.g.*, heterologous DNA sequence, that is operably linked to a promoter or other regulatory sequence sufficient to direct transcription of the transgene in the ceDNA vector. Suitable promoters include, for example, tissue specific promoters or promoters of AAV origin.

[00146] The term “subject” as used herein refers to a human or animal, to whom treatment, including prophylactic treatment, with the ceDNA vector according to the present disclosure, is provided.

Usually, the animal is a vertebrate such as, but not limited to a primate, rodent, domestic animal or game animal. Primates include but are not limited to, chimpanzees, cynomolgous monkeys, spider monkeys, and macaques, *e.g.*, Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include, but are not limited to, cows, horses, pigs, deer, bison, buffalo, feline species, *e.g.*, domestic cat, canine species, *e.g.*, dog, fox, wolf, avian species, *e.g.*, chicken, emu, ostrich, and fish, *e.g.*, trout, catfish and salmon. In certain embodiments of the aspects described herein, the subject is a mammal, *e.g.*, a primate or a human. A subject can be male or female. Additionally, a subject can be an infant or a child. In some embodiments, the subject can be a neonate or an unborn subject, *e.g.*, the subject is *in utero*. Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of diseases and disorders. In addition, the methods and compositions described herein can be used for domesticated animals and/or pets. A human subject can be of any age, gender, race or ethnic group, *e.g.*, Caucasian (white), Asian, African, black, African American, African European, Hispanic, Mideastern, etc. In some embodiments, the subject can be a patient or other subject in a clinical setting. In some embodiments, the subject is already undergoing treatment. In some embodiments, the subject is an embryo, a fetus, neonate, infant, child, adolescent, or adult. In some embodiments, the subject is a human fetus, human neonate, human infant, human child, human adolescent, or human adult. In some embodiments, the subject is an animal embryo, or non-human embryo or non-human primate embryo. In some embodiments, the subject is a human embryo.

[00147] As used herein, the term “host cell”, includes any cell type that is susceptible to transformation, transfection, transduction, and the like with a nucleic acid construct or ceDNA

expression vector of the present disclosure. As non-limiting examples, a host cell can be an isolated primary cell, pluripotent stem cells, CD34⁺ cells), induced pluripotent stem cells, or any of a number of immortalized cell lines (*e.g.*, HepG2 cells). Alternatively, a host cell can be an *in situ* or *in vivo* cell in a tissue, organ or organism.

[00148] The term “exogenous” refers to a substance present in a cell other than its native source. The term “exogenous” when used herein can refer to a nucleic acid (*e.g.*, a nucleic acid encoding a polypeptide) or a polypeptide that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is not normally found and one wishes to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, “exogenous” can refer to a nucleic acid or a polypeptide that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is found in relatively low amounts and one wishes to increase the amount of the nucleic acid or polypeptide in the cell or organism, *e.g.*, to create ectopic expression or levels. In contrast, the term “endogenous” refers to a substance that is native to the biological system or cell.

[00149] The term “sequence identity” refers to the relatedness between two nucleic acid sequences. For purposes of the present disclosure, the degree of sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *supra*) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *supra*), preferably version 3.0.0 or later. The optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled “longest identity” (obtained using the -nobrief option) is used as the percent identity and is calculated as follows: (Identical Deoxyribonucleotides.times.100)/(Length of Alignment-Total Number of Gaps in Alignment). The length of the alignment is preferably at least 10 nucleotides, preferably at least 25 nucleotides more preferred at least 50 nucleotides and most preferred at least 100 nucleotides.

[00150] The term “homology” or “homologous” as used herein is defined as the percentage of nucleotide residues that are identical to the nucleotide residues in the corresponding sequence on the target chromosome, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleotide sequence homology can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ClustalW2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. In some embodiments, a nucleic acid sequence (*e.g.*, DNA sequence), for example of a homology arm, is considered “homologous” when the sequence is at least

70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to the corresponding native or unedited nucleic acid sequence (*e.g.*, genomic sequence) of the host cell.

[00151] The term “heterologous,” as used herein, means a nucleotide or polypeptide sequence that is not found in the native nucleic acid or protein, respectively. A heterologous nucleic acid sequence may be linked to a naturally-occurring nucleic acid sequence (or a variant thereof) (*e.g.*, by genetic engineering) to generate a chimeric nucleotide sequence encoding a chimeric polypeptide. A heterologous nucleic acid sequence may be linked to a variant polypeptide (*e.g.*, by genetic engineering) to generate a nucleotide sequence encoding a fusion variant polypeptide.

[00152] A “vector” or “expression vector” is a replicon, such as plasmid, bacmid, phage, virus, virion, or cosmid, to which another DNA segment, *i.e.*, an “insert”, may be attached so as to bring about the replication of the attached segment in a cell. A vector can be a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral in origin and/or in final form, however for the purpose of the present disclosure, a “vector” generally refers to a cDNA vector, as that term is used herein. The term “vector” encompasses any genetic element that is capable of replication when associated with the proper control elements and that can transfer gene sequences to cells. In some embodiments, a vector can be an expression vector or recombinant vector.

[00153] As used herein, the term “expression vector” refers to a vector that directs expression of an RNA or polypeptide from sequences linked to transcriptional regulatory sequences on the vector. The sequences expressed will often, but not necessarily, be heterologous to the cell. An expression vector may comprise additional elements, for example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in human cells for expression and in a prokaryotic host for cloning and amplification. The term “expression” refers to the cellular processes involved in producing RNA and proteins and as appropriate, secreting proteins, including where applicable, but not limited to, for example, transcription, transcript processing, translation and protein folding, modification and processing. “Expression products” include RNA transcribed from a gene, and polypeptides obtained by translation of mRNA transcribed from a gene. The term “gene” means the nucleic acid sequence which is transcribed (DNA) to RNA *in vitro* or *in vivo* when operably linked to appropriate regulatory sequences. The gene may or may not include regions preceding and following the coding region, *e.g.*, 5’ untranslated (5’UTR) or “leader” sequences and 3’ UTR or “trailer” sequences, as well as intervening sequences (introns) between individual coding segments (exons).

[00154] By “recombinant vector” is meant a vector that includes a nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, or “transgene” that is capable of expression *in vivo*. It should be understood that the vectors described herein can, in some embodiments, be combined with other

suitable compositions and therapies. In some embodiments, the vector is episomal. The use of a suitable episomal vector provides a means of maintaining the nucleotide of interest in the subject in high copy number extra chromosomal DNA thereby eliminating potential effects of chromosomal integration.

[00155] The phrase “genetic disease” as used herein refers to a disease, partially or completely, directly or indirectly, caused by one or more abnormalities in the genome, especially a condition that is present from birth. The abnormality may be a mutation, an insertion or a deletion. The abnormality may affect the coding sequence of the gene or its regulatory sequence. The genetic disease may be, but not limited to DMD, hemophilia, cystic fibrosis, Huntington's chorea, familial hypercholesterolemia (LDL receptor defect), hepatoblastoma, Wilson's disease, congenital hepatic porphyria, inherited disorders of hepatic metabolism, Lesch Nyhan syndrome, sickle cell anemia, thalassemia, xeroderma pigmentosum, Fanconi's anemia, retinitis pigmentosa, ataxia telangiectasia, Bloom's syndrome, retinoblastoma, and Tay-Sachs disease.

[00156] As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are essential to the method or composition, yet open to the inclusion of unspecified elements, whether essential or not.

[00157] As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment. The use of “comprising” indicates inclusion rather than limitation.

[00158] The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.

[00159] As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the disclosure.

[00160] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The abbreviation, “*e.g.*” is derived from the Latin *exempli gratia* and is used herein to indicate a non-limiting example. Thus, the abbreviation “*e.g.*” is synonymous with the term “for example.”

[00161] Groupings of alternative elements or embodiments of the disclosure disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[00162] In some embodiments of any of the aspects, the disclosure described herein does not concern a process for cloning human beings, processes for modifying the germ line genetic identity of human beings, uses of human embryos for industrial or commercial purposes or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes.

[00163] Other terms are defined herein within the description of the various aspects of the disclosure.

[00164] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior disclosure or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

[00165] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. Moreover, due to biological functional equivalency considerations, some changes can be made in protein structure without affecting the biological or chemical action in kind or amount.

These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.

[00166] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

II. Expression of a FVIII Protein from a ceDNA vector

[00167] The technology described herein is directed in general to the expression and/or production of FVIII protein in a cell from a non-viral DNA vector, *e.g.*, a ceDNA vector as described herein. ceDNA vectors for expression of FVIII protein are described in the section entitled “ceDNA vectors in general”. In particular, ceDNA vectors for expression of FVIII protein comprise a pair of ITRs (*e.g.*, symmetric or asymmetric as described herein) and between the ITR pair, a nucleic acid encoding an FVIII protein operatively linked to a promoter or regulatory sequence. A distinct advantage of ceDNA vectors for expression of FVIII protein over traditional AAV vectors, and even lentiviral vectors, is that there is no size constraint for the nucleic acid sequences, *e.g.*, heterologous nucleic acid sequences, encoding a desired protein. Even a full length 6.8kb FVIII protein can be expressed from a single ceDNA vector. Thus, the ceDNA vectors described herein can be used to express a therapeutic FVIII protein in a subject in need thereof, *e.g.*, a subject with hemophilia A.

[00168] As one will appreciate, the ceDNA vector technologies can be adapted to any level of complexity or can be used in a modular fashion, where expression of different components of a FVIII protein can be controlled in an independent manner. For example, it is specifically contemplated that the ceDNA vector technologies described here can be as simple as using a single ceDNA vector to express a single gene sequence (*e.g.*, a FVIII protein) or can be as complex as using multiple ceDNA vectors, where each vector expresses multiple FVIII proteins or associated co-factors or accessory proteins that are each independently controlled by different promoters. The following embodiments are specifically contemplated and can adapted by one of skill in the art as desired.

[00169] In one embodiment, a single ceDNA vector can be used to express a single component of an FVIII protein. Alternatively, a single ceDNA vector can be used to express multiple components (*e.g.*, at least 2) of a FVIII protein under the control of a single promoter (*e.g.*, a strong promoter), optionally using an IRES sequence(s) to ensure appropriate expression of each of the components, *e.g.*, co-factors or accessory proteins.

[00170] As one of skill in the art will appreciate, it is often desirable to express components of a FVIII protein at different expression levels, thus controlling the stoichiometry of the individual components expressed to ensure efficient FVIII protein folding and combination in the cell. Additional

variations of ceDNA vector technologies can be envisioned by one of skill in the art or can be adapted from protein production methods using conventional vectors.

A. Nucleic Acids

[00171] The characterization and development of nucleic acid molecules for potential therapeutic use are provided herein. According to some embodiments, the nucleic acids for therapeutic use encode a FVIII protein. In some embodiments, chemical modification of oligonucleotides for the purpose of altered and improved *in vivo* properties (delivery, stability, lifetime, folding, target specificity), as well as their biological function and mechanism that directly correlate with therapeutic application, are described where appropriate.

[00172] The therapeutic nucleic acid described herein is a closed ended double stranded DNA, *e.g.*, ceDNA. A distinct advantage of ceDNA vectors for expression of a therapeutic protein over traditional AAV vectors, and even lentiviral vectors, is that there is no size constraint for the nucleic acid sequences, *e.g.*, heterologous nucleic acid sequences, encoding a desired protein. Thus, ceDNA vectors can be used to express a FVIII protein in a subject in need thereof.

[00173] In general, a ceDNA vector for expression of a FVIII as disclosed herein, comprises in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleic acid sequence of interest (for example an expression cassette as described herein) and a second AAV ITR. The ITR sequences selected from any of: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (mod-ITR) (*e.g.*, asymmetric modified ITRs); (ii) two modified ITRs where the mod-ITR pair have a different three-dimensional spatial organization with respect to each other (*e.g.*, asymmetric modified ITRs), or (iii) symmetrical or substantially symmetrical WT-WT ITR pair, where each WT-ITR has the same three-dimensional spatial organization, or (iv) symmetrical or substantially symmetrical modified ITR pair, where each mod-ITR has the same three-dimensional spatial organization.

[00174] In some embodiments, a transgene encoding the FVIII protein can also encode a secretory sequence so that the FVIII protein is directed to the Golgi Apparatus and Endoplasmic Reticulum where the FVIII protein is folded into the correct conformation by chaperone molecules as it passes through the ER and out of the cell. Exemplary secretory sequences include, but are not limited to VH-02 (SEQ ID NO: 88) and VK-A26 (SEQ ID NO: 89) and Igκ Kβ signal sequence (SEQ ID NO: 548), as well as a Gluc secretory signal that allows the tagged protein to be secreted out of the cytosol, TMD-ST secretory sequence, that directs the tagged protein to the Golgi.

[00175] Regulatory switches can also be used to fine tune the expression of the FVIII protein so that the FVIII protein is expressed as desired, including but not limited to, expression of the FVIII protein at a desired expression level or amount, or alternatively, when there is the presence or absence of particular signal, including a cellular signaling event. For instance, as described herein, expression of

the FVIII protein from the ceDNA vector can be turned on or turned off when a particular condition occurs, as described herein in the section entitled Regulatory Switches.

[00176] For example, and for illustration purposes only, FVIII proteins can be used to turn off undesired reaction, such as too high a level of production of the FVIII protein. The FVIII gene can contain a signal peptide marker to bring the FVIII protein to the desired cell. However, in either situation it can be desirable to regulate the expression of the FVIII protein. ceDNA vectors readily accommodate the use of regulatory switches.

[00177] A distinct advantage of ceDNA vectors over traditional AAV vectors, and even lentiviral vectors, is that there is no size constraint for the nucleic acid sequence encoding the FVIII protein. Thus, even a full-length FVIII, as well as optionally any co-factors or assessor proteins can be expressed from a single ceDNA vector. In addition, depending on the necessary stoichiometry one can express multiple segments of the same FVIII protein, and can use same or different promoters, and can also use regulatory switches to fine tune expression of each region. For example, a ceDNA vector that comprises a dual promoter system can be used, so that a different promoter is used for each domain of the FVIII protein. Use of a ceDNA plasmid to produce the FVIII protein can include a unique combination of promoters for expression of the domains of the FVIII protein that results in the proper ratios of each domain for the formation of functional FVIII protein. Accordingly, in some embodiments, a ceDNA vector can be used to express different regions of FVIII protein separately (*e.g.*, under control of a different promoter).

[00178] In another embodiment, the FVIII protein expressed from the ceDNA vectors further comprises an additional functionality, such as fluorescence, enzyme activity, secretion signal or immune cell activator.

[00179] In some embodiments, the ceDNA encoding the FVIII protein can further comprise a linker domain, for example. As used herein “linker domain” refers to an oligo- or polypeptide region from about 2 to 100 amino acids in length, which links together any of the domains/regions of the FVIII protein as described herein. In some embodiment, linkers can include or be composed of flexible residues such as glycine and serine so that the adjacent protein domains are free to move relative to one another. Longer linkers may be used when it is desirable to ensure that two adjacent domains do not sterically interfere with one another. Linkers may be cleavable or non-cleavable. Examples of cleavable linkers include 2A linkers (for example T2A), 2A-like linkers or functional equivalents thereof and combinations thereof. The linker can be a linker region is T2A derived from *Thosea asigna* virus.

[00180] In some embodiments, a transgene encoding the FVIII protein can also include a signal sequence. In some embodiments, a transgene encoding the FVIII protein can have
It is well within the abilities of one of skill in the art to take a known and/or publically available protein sequence of FVIII, and reverse engineer a cDNA sequence to encode such a protein. The

cDNA can then be codon optimized to match the intended host cell and inserted into a ceDNA vector as described herein.

B. *ceDNA vectors expressing FVIII Protein*

[00181] A ceDNA vector for expression of FVIII protein having one or more sequences encoding a desired FVIII can comprise regulatory sequences such as promoters, secretion signals, polyA regions, and enhancers. At a minimum, a ceDNA vector comprises one or more nucleic acid sequences, *e.g.*, heterologous nucleic acid sequences, encoding a FVIII protein.

[00182] In order to achieve highly efficient and accurate FVIII protein assembly, it is specifically contemplated in some embodiments that the FVIII protein comprise an endoplasmic reticulum ER leader sequence to direct it to the ER, where protein folding occurs. For example, a sequence that directs the expressed protein(s) to the ER for folding.

[00183] In some embodiments, a cellular or extracellular localization signal (*e.g.*, secretory signal, nuclear localization signal, mitochondrial localization signal, *etc.*) is comprised in the ceDNA vector to direct the secretion or desired subcellular localization of FVIII such that the FVIII protein can bind to intracellular target(s) (*e.g.*, an intrabody) or extracellular target(s). In some embodiments, a FVIII sequence may contain a mutation that enhances FVIII secretion out of the ER. For example, FVIII secretion requires high levels of intracellular ATP, consistent with an ATP-dependent release from BiP. Mutation of Phe at position 309 to Ser or Ala (F309S) enhances the secretion of functional FVIII and reduced its ATP dependence. (Swaroop *et al.*, *J. Biol. Chem* (1997) 272:27428-34).

[00184] In some embodiments, a ceDNA vector for expression of FVIII protein as described herein permits the assembly and expression of any desired FVIII protein in a modular fashion. As used herein, the term “modular” refers to elements in a ceDNA expressing plasmid that can be readily removed from the construct. For example, modular elements in a ceDNA-generating plasmid comprise unique pairs of restriction sites flanking each element within the construct, enabling the exclusive manipulation of individual elements. Thus, the ceDNA vector platform can permit the expression and assembly of any desired FVIII ORF with any desired *cis*-acting elements such as enhancer(s), promoters, introns, 5'-UTR, 3'-UTR, poly-A, *etc.* Provided herein in various embodiments are ceDNA plasmid vectors that can reduce and/or minimize the amount of manipulation required to assemble a desired ceDNA vector encoding FVIII protein.

C. *Exemplary FVIII Proteins expressed by ceDNA vectors*

[00185] In particular, a ceDNA vector for expression of FVIII protein as disclosed herein can encode, for example, but is not limited to, FVIII proteins, as well as variants, and/or active fragments thereof, for use in the treatment, prophylaxis, and/or amelioration of one or more symptoms of hemophilia A. In one aspect, the hemophilia A is a human hemophilia A.

(i) *FVIII therapeutic proteins and fragments thereof*

[00186] Essentially any version of the FVIII therapeutic protein or fragment thereof (*e.g.*, functional fragment) can be encoded by and expressed in and from a ceDNA vector as described herein. One of skill in the art will understand that FVIII therapeutic protein includes all splice variants and orthologs of the FVIII protein. FVIII therapeutic protein includes intact molecules as well as fragments (*e.g.*, functional) thereof. According to embodiments of the present disclosure, nucleic acids encoding particular FVIII proteins are set forth in **Table 1A**.

Factor VIII

[00187] Factor VIII is the nonenzymatic cofactor to the activated clotting factor IX (FIXa), which, when proteolytically activated, interacts with FIXa to form a tight noncovalent complex that binds to and activates factor X (FX).

[00188] The Factor VIII gene or protein can also be referred to as F8, Coagulation Factor VIII, Procoagulant Component, Antihemophilic Factor, F8C, AHF, DXS1253E, FVIII, HEMA, or F8B. Expression of the Factor VIII gene is tissue-specific and is mostly observed in liver cells. The highest level of the mRNA and Factor VIII proteins has been detected in liver sinusoidal cells; significant amounts of Factor VIII are also present in hepatocytes and in Kupffer cells (resident macrophages of liver sinusoids). Moderate levels of Factor VIII protein are detectable in the serum and plasma. Low to moderate levels of Factor VIII protein are expressed in fetal brain, retina, kidney and testis.

[00189] Factor VIII mRNA is expressed throughout many tissues of the body, including bone marrow, whole blood, white blood cells, lymph nodes, thymus, brain, cerebral cortex, cerebellum, retina, spinal cord, tibial nerve, heart, artery, smooth muscle, skeletal muscle, small intestine, colon, adipocytes, kidney, liver, lung, spleen, stomach, esophagus, bladder, pancreas, thyroid, salivary gland, adrenal gland, pituitary gland, breast, skin, ovary, uterus, placenta, prostate, and testis. The FVIII gene localized on the long arm of the X chromosome occupies a region approximately 186 kbp long and consists of 26 exons (69–3,106 bp) and introns (from 207 bp to 32.4 kbp). The total length of the coding sequence of this gene is 9 kbp.

[00190] The mature factor VIII polypeptide comprises the A1–A2–B–A3–C1–C2 structural domains. Three acidic subdomains, which are denoted as a1–a3 – A1(a1)–A2(a2)–B–(a3)A3–C1–C2, localize at the boundaries of A domains and play a significant role in the interaction between FVIII and other proteins (in particular, with thrombin). Mutations in these subdomains reduce the level of factor VIII activation by thrombin (*see FIG. 9* for FVIII processing steps).

[00191] The factor VIII protein (Coagulation factor VIII isoform) is a preproprotein [Homo sapiens]; Accession number: NP_000123.1 (2351 aa) and has the sequence as set forth in SEQ ID NO: 492. According to some embodiments, an FVIII protein contemplated herein can be a modified FVIII protein. According to further embodiments, the FVIII protein can have the B-domain deleted and comprise the amino acid sequence set forth in SEQ ID NO: 555).

[00192] According to some embodiments, FVIII expressed by some of the FVIII-ceDNA vectors disclosed herein is AFSTYLA®; recombinant, single chain coagulation factor VIII (rFVIII-SingleChain); Ionocotocog alfa; CAS Registry Number: 1388129-63-2.

[00193] AFSTYLA® is a single chain recombinant factor VIII (FVIII) that most of the B-domain occurring in wild-type, full-length FVIII and 4 amino acids of the adjacent acidic A3 domain are removed (*e.g.*, amino acids 765 to 1652 of full-length FVIII).

[00194] It is to be understood that the amino acid D (aspartic acid) at position 56 in SEQ ID NO: 555 above can be freely substituted with V (valine) as a wild-type variant and that any nucleotide sequence disclosed herein for FVIII-ceDNA ORF is to be contemplated to include corresponding nucleic acid sequence(s) for the valine variant at position 56.

[00195] Expression of FVIII therapeutic protein or fragment thereof from a ceDNA vector can be achieved both spatially and temporally using one or more inducible or repressible promoters, or tissue specific promoters (*e.g.*, synthetic liver specific promoters like TTR promoters (TTRm), CpG minimized hAAT promoters described herein), as known in the art or described herein, including regulatory switches as described herein.

[00196] In one embodiment, FVIII therapeutic protein can be a “therapeutic protein variant,” which refers to the FVIII therapeutic protein having an altered amino acid sequence, composition or structure as compared to its corresponding native FVIII therapeutic protein. In one embodiment, FVIII is a functional version (*e.g.*, wild-type FVIII protein for D56V variant described above). It may also be useful to express a mutant version of FVIII protein such as a point mutation (F309 mutation) or deletion mutation (*e.g.*, B domain deleted and/or single chain recombinant FVIII) as described in many examples herein. FVIII therapeutic protein expressed from the ceDNA vectors may further comprise a sequence/moiety that confers an additional functionality, such as fluorescence, enzyme activity, or secretion signal. In one embodiment, an FVIII therapeutic protein variant comprises a non-native tag sequence for identification (*e.g.*, an immunotag) to allow it to be distinguished from endogenous FVIII therapeutic protein in a recipient host cell.

[00197] According to some embodiments, open reading frames (ORF) of the FVIII ceDNA vectors disclosed herein are codon optimized.

[00198] According to some other embodiments, the FVIII ceDNA vector is CpG minimized. For example, enhancers, promoters, 5'UTR, spacers, introns, 3'UTR, and WPRE sequences in the FVIII ceDNA vectors can be modified to have minimized level of CpG to ensure the robust expression of the vector.

[00199] In one embodiment, the FVIII therapeutic protein encoding sequence can be derived from an existing host cell or cell line, for example, by reverse transcribing mRNA obtained from the host and amplifying the sequence using PCR.

(ii) *ceDNA vectors expressing FVIII therapeutic protein*

[00200] A ceDNA vector having one or more sequences encoding a desired FVIII therapeutic protein can comprise regulatory sequences such as promoters, secretion signals, introns, polyA regions, and enhancers to maximize expression of the FVIII therapeutic protein when delivered to a desired cell or tissue. At a minimum, a ceDNA vector comprises one or more nucleic acid sequences encoding the FVIII therapeutic protein or functional fragment thereof. In one embodiment, the ceDNA vector comprises an FVIII sequence set forth in any one of SEQ ID NOs: 71-183, 556 and 626-633.

[00201] According to some aspects, the disclosure provides a ceDNA vector comprising at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs), wherein at least one nucleic acid sequence encodes at least one FVIII protein, wherein the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from a sequence having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identity to any sequence in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633). According to some embodiments, the at least one nucleic acid sequence that encodes at least one FVIII protein is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or least 99% identical to SEQ ID NO: 556. According to some embodiments, the at least one nucleic acid sequence that encodes at least one FVIII protein consists of SEQ ID NO: 556. According to some embodiments, the at least one nucleic acid that encodes at least one FVIII protein comprises SEQ ID NO: 556, wherein SEQ ID NO: 556 further comprises one or more modifications. According to some embodiments, the at least one nucleic acid comprising SEQ ID NO: 556, further comprising one or more modifications comprises or consists of a sequence selected from any one of SEQ ID NOs: 627- 633.

[00202] **Table 1A** provides sequence identifiers, descriptions of the codon optimized FVIII ORFs and the names used herein. **Table 1B** provides the corresponding GE numbers used herein for the names of FVIII ORFs.

Table 1A: Description of exemplary codon optimized FVIII ORF sequences, sequence identifiers and names used herein

SEQ ID NO	Description	Name
71	Codon optimized hFVIII with 226aa/N6 B-domain as found in ceDNA933	hFVIII-226variant-F309S_CpGmin-codop_ORF
72	Codon optimized hFVIII with 226aa/N6 B-domain as found in ceDNA1265	hFVIII-F309S-BD226-Codop-run4-seq102
73	Codon optimized hFVIII with 226aa/N6 B-domain as found in ceDNA1270	hFVIII-F309S-BD226seq124
74	Codon optimized hFVIII with SC B-domain as found in ceDNA1368	hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309
75	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1367	hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD
76	Codon optimized hFVIII with SC B-domain as found in ceDNA1374	hFVIII-F309S-BD226seq124 Afstyla-BDD-F309

77	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1373	hFVIII-F309S-BD226seq 124-Afstyla-BDD
78	Codon optimized hFVIII with SC B-domain as found in ceDNA1918	FVIII-SC_0CpG_1_ORF
79	Codon optimized hFVIII with SC B-domain as found in ceDNA1919	FVIII-SC_0CpG_6_ORF
80	Codon optimized hFVIII with SC B-domain as found in ceDNA1920	FVIII-SC_0CpG_8_ORF
81	Codon optimized hFVIII with SC B-domain as found in ceDNA1921	FVIII-SC_5_ORF
82	Codon optimized hFVIII with SC B-domain as found in ceDNA1922	FVIII-SC_5k_wt3_3_ORF
83	Codon optimized hFVIII with SC B-domain as found in ceDNA1923	FVIII-SC_5k_wt3_5_ORF
84	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1927	FVIII-SC_0CpG_1_F309S
85	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1928	FVIII-SC_0CpG_6_F309S
86	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1929	FVIII-SC_0CpG_8_F309S
87	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1930	FVIII-SC_5_F309S
88	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1931	FVIII-SC_5k_wt3_3_F309S
89	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1932	FVIII-SC_5k_wt3_5_F309S
90	Codon optimized hFVIII with SC B-domain and F309S encoding mutation as found in ceDNA1933	FVIII-SC_5k_wt3_5- 0CpG_6_ F309S hybrid
91	Sequence of Factor VIII ORF (GE-707) with signal sequence removed	FVIII_1368_ORF_ mat_peptide
92	Sequence of Factor VIII ORF (GE-715) with signal sequence removed	FVIII_1374_ ORF_mat_peptide
93	hFVIII ORF with SC B-domain	hFVIII-Wt-Afstyla BDD
94	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_miniF8_ 50/100
95	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_miniF8_ 50/200
96	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_miniF8_ 200/200
97	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_miniF8_ 500/500
98	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_HBB_ intron1
99	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_ Embedded_HCR1_ footprint123

100	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_ Embedded_ProEnh
101	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_ Embedded_enhancer_ HNF_array
102	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_F8_intron8
103	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_F8_intron16
104	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1367_ MVM_intron
105	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1367::33bpFlanks_miniF 8_50/100
106	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1367::33bpFlanks_miniF 8_200/200
107	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1367::33bpFlanks_HBB_ intron1
108	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1367::33bpFlanks_F8_in tron8
109	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1367::33bpFlanks_no intron
110	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_miniF8_ 50/100
111	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_miniF8_ 50/200
112	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_miniF8_ 200/200
113	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_miniF8_ 500/500
114	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ HBB_intron1
115	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ Embedded_HCR1_ footprint123
116	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ Embedded_ProEnh

117	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ Embedded_enhancer_ HNF_array
118	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ F8_intron8
119	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ F8_intron16
120	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII-SC_1373_ MVM_intron
121	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1373::33bpFlanks_miniF 8_50/100
122	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1373::33bpFlanks_miniF 8_200/200
123	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1373::33bpFlanks_HBB_ intron1
124	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1373::33bpFlanks_F8_in tron8
125	Codon optimized hFVIII with SC B-domain and F309S encoding mutation. Intron engineered into between Exon1 and Exon2	FVIII- SC_1373::33bpFlanks_no intron
126	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ GeneD_v4
127	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_ GeneD_v4
128	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ codop_3b
129	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_ codop_3b
130	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ GeneD_v3
131	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ GeneD_v2
132	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ codop_7b
133	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ codop_6b
134	Codon optimized hFVIII with SC B-domain and F309S encoding mutation	FVIII_SC_F309S_ codop_1b
135	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_ GeneD_v3
136	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_ GeneD_v2
137	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_ codop_7b
138	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_ codop_6b

139	Codon optimized hFVIII with SC B-domain	FVIII_SC_F309_codop_1b
140	FVIII ORF from 1368 (Afstyla BDD) with heterologous A1AT leader sequence	FVIII_1368ORF_A1AT-SSv3
141	FVIII ORF from 1374 (Afstyla BDD) with heterologous trypsinogen leader sequence	FVIII_1374ORF_TRYP-SSv2
142	FVIII ORF from 1374 (Afstyla BDD) with heterologous trans-Plasminogen Activator leader sequence	FVIII_1374ORF_tPA-SSv1
143	FVIII ORF from 1374 (Afstyla BDD) with synthetic leader sequence	FVIII_1374ORF_Secrecon-SSv2
144	FVIII ORF from 1374 (Afstyla BDD) with synthetic leader sequence	FVIII_1374ORF_Secrecon-SSv1
145	FVIII ORF from 1374 (Afstyla BDD) with heterologous Fibroin-L leader sequence	FVIII_1374ORF_Lonz-SSv2
146	FVIII ORF from 1374 (Afstyla BDD) with heterologous IL2 leader sequence	FVIII_1374ORF_IL2-SSv1
147	FVIII ORF from 1374 (Afstyla BDD) with heterologous Gaussia leader sequence	FVIII_1374ORF_Gaus-SSv1
148	FVIII ORF from 1374 (Afstyla BDD) with heterologous Chymotrypsinogen leader sequence	FVIII_1374ORF_CHY-SSv1
149	FVIII ORF from 1374 (Afstyla BDD) with heterologous Albumin leader sequence	FVIII_1374ORF_ALB-SSv1
150	FVIII ORF from 1374 (Afstyla BDD) with heterologous A1AT leader sequence	FVIII_1374ORF_A1AT-SSv3
151	FVIII ORF from 1368 (Afstyla BDD) with heterologous Trypsinogen leader sequence	FVIII_1368ORF_TRYP-NS-struct-v2
152	FVIII ORF from 1368 (Afstyla BDD) with heterologous Trypsinogen leader sequence	FVIII_1368ORF_TRYP-NS-CAI-v2
153	FVIII ORF from 1368 (Afstyla BDD) with heterologous trans-Plasminogen Activator leader sequence	FVIII_1368ORF_tPA-NS-struct
154	FVIII ORF from 1368 (Afstyla BDD) with heterologous trans-Plasminogen Activator leader sequence	FVIII_1368ORF_tPA-NS-CAI-v2
155	FVIII ORF from 1368 (Afstyla BDD) with synthetic leader sequence	FVIII_1368ORF_Secrecon-v1-NS-struct-v1
156	FVIII ORF from 1368 (Afstyla BDD) with synthetic leader sequence	FVIII_1368ORF_Secrecon-v1-NS-CAI-v2
157	FVIII ORF from 1368 (Afstyla BDD) with heterologous Fibroin-L leader sequence	FVIII_1368ORF_Lonz-SSv2
158	FVIII ORF from 1368 (Afstyla BDD) with heterologous Fibroin-L leader sequence	FVIII_1368ORF_Lonz-NS-struct-v3
159	FVIII ORF from 1368 (Afstyla BDD) with heterologous Fibroin-L leader sequence	FVIII_1368ORF_Lonz-NS-CAI-v2
160	FVIII ORF from 1368 (Afstyla BDD) with heterologous IL2 leader sequence	FVIII_1368ORF_IL2-NS-struct-v2
161	FVIII ORF from 1368 (Afstyla BDD) with heterologous IL2 leader sequence	FVIII_1368ORF_IL2-NS-CAI
162	FVIII ORF from 1368 (Afstyla BDD) with heterologous Gaussia leader sequence	FVIII_1368ORF_Gaus-NS-struct-v2
163	FVIII ORF from 1368 (Afstyla BDD) with heterologous Gaussia leader sequence	FVIII_1368ORF_Gaus-NS-CAI-v2
164	FVIII ORF from 1368 (Afstyla BDD) with heterologous Chymotrypsinogen leader sequence	FVIII_1368ORF_CHY-NS-struct

165	FVIII ORF from 1368 (Afstyla BDD) with heterologous Chymotrypsinogen leader sequence	FVIII_1368ORF_CHY-NS-CAI-v2
166	FVIII ORF from 1368 (Afstyla BDD) with heterologous A1AT leader sequence	FVIII_1368ORF_A1AT-NS-struct
167	FVIII ORF from 1368 (Afstyla BDD) with heterologous A1AT leader sequence	FVIII_1368ORF_A1AT-NS-CAI
168	FVIII ORF from 1368 (Afstyla BDD) with heterologous hCD33 leader sequence	FVIII-1368ORF_CD33-NS-struct-v2
169	FVIII ORF from 1368 (Afstyla BDD) with heterologous hCD33 leader sequence.	FVIII-1368ORF_CD33-NS-CAI-v2
170	FVIII ORF from 1368 (Afstyla BDD) with heterologous Albumin leader sequence	FVIII-1368ORF_ALB-NS-struct
171	FVIII ORF from 1368 (Afstyla BDD) with heterologous Albumin leader sequence.	FVIII-1368ORF_ALB-NS-CAI-v2
172	FVIII ORF from 1368 (Afstyla BDD) with heterologous CD33 leader sequence	FVIII_1368ORF_CD33-SSv1
173	FVIII ORF from 1374 (Afstyla BDD) with heterologous A1AT leader sequence v2	FVIII_1374ORF_A1AT-SSv2
174	FVIII ORF from 1368 (Afstyla BDD) with heterologous Trypsinogen leader sequence	FVIII_1368ORF_TRYP-SSv1
175	FVIII ORF from 1368 (Afstyla BDD) with heterologous trans plasminogen activator leader sequence	FVIII_1368ORF_tPA-SSv1
176	FVIII ORF from 1368 (Afstyla BDD) with heterologous Secrecon leader sequence	FVIII_1368ORF_Secrecon-SSv2
177	FVIII ORF from 1368 (Afstyla BDD) with heterologous Secrecon leader sequence	FVIII_1368ORF_Secrecon-SSv1
178	FVIII ORF from 1368 (Afstyla BDD) with heterologous Fibroin-L leader sequence.	FVIII_1368ORF_Lonz-SSv1
179	FVIII ORF from 1368 (Afstyla BDD) with heterologous IL-2 leader sequence	FVIII_1368ORF_IL2-SSv1
180	FVIII ORF from 1368 (Afstyla BDD) with heterologous Gaussia leader sequence	FVIII_1368ORF_Gaus-SSv1
181	FVIII ORF from 1368 (Afstyla BDD) with heterologous Chymotrypsin leader sequence	FVIII_1368ORF_CHY-SSv1
182	FVIII ORF from 1368 (Afstyla BDD) with heterologous A1AT leader sequence	FVIII_1368ORF_A1AT-SSv2
183	FVIII ORF from 1368 (Afstyla BDD) with heterologous Albumin leader sequence	FVIII-1368ORF_ALB-SSv1
556	FVIII ORF from 1651 (Afstyla BDD); reverts F309S mutation back to F309; expresss the equivalent amino acid sequence of SEQ ID NO: 555;	hFVIII-F309S-BD226seq124-BDD-F309; also referred to as hFVIII-F309S-BD226seq124-Afstyla-BDD-F309
626	Modification of FVIII ORF from ceDNA-1651 ORF (SEQ ID NO: 556). Ablation of 1st cryptic ATG start codon introduced by codon optimization	hFVIII-1651-ORF-dATG1
627	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of 1st and 2nd cryptic ATG start codon introduced by codon optimization	hFVIII-1651-ORF-dATG2
628	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of all three cryptic ATG start codons introduced by codon optimization	hFVIII-1651-ORF-dATG3

629	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of 2nd and 3rd ATG cryptic start codons introduced by codon optimization	hFVIII-1651ORF-dATG2-3
630	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of all three ATG cryptic start codons introduced by codon optimization, first three CTG cryptic start codons and first TTC cryptic start codon	hFVIII-1651ORF-dATG3_dCTG3_dTTG1
631	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of first ATG cryptic start codons introduced by codon optimization, first three CTG cryptic start codons and first TTC cryptic start codon	hFVIII-1651-ORF-dATG1_dCTG3_dTTG1
632	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of 2nd and 3rd ATG cryptic start codons, as well as first three CTG cryptic start codons and first TTG cryptic start codon	hFVIII-1651-ORF-dATG2-3_dCTG3_dTTG1
633	Modification of FVIII ORF from SEQ ID NO: 556. Ablation of 2nd and 3rd ATG cryptic start codons, as well as first three CTG cryptic start codons and first TTG cryptic start codon. Ablation of three CpGs	hFVIII-1651-ORF-dATG2-3_dCTG3_dTTG1_dCpG3

Table 1B. General Element Numbers

GE #	ORF Name	GE #	ORF Name
GE-364	hFVIII-226variant-F309S_CpGmin-codop_ORF	GE-1201	FVIII-SC_1373::33bpFlanks_miniF8_50/100
GE-721	hFVIII-F309S-BD226-Codop-run4-seq102	GE-1202	FVIII-SC_1373::33bpFlanks_miniF8_200/200
GE-776	hFVIII-F309S-BD226seq124	GE-1203	FVIII-SC_1373::33bpFlanks_HBB_intron1
GE-707	hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309	GE-1204	FVIII-SC_1373::33bpFlanks_F8_intron8
GE-706	hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD	GE-1205	FVIII-SC_1373::33bpFlanks_no intron
GE-715	hFVIII-F309S-BD226seq124-Afstyla-BDD-F309	GE-968	FVIII_SC_F309S_GeneD_v4
GE-714	hFVIII-F309S-BD226seq124-Afstyla-BDD	GE-967	FVIII_SC_F309_GeneD_v4
GE-1025	FVIII-SC_0CpG_1_ORF	GE-966	FVIII_SC_F309S_codop_3b
GE-1026	FVIII-SC_0CpG_6_ORF	GE-965	FVIII_SC_F309_codop_3b
GE-1027	FVIII-SC_0CpG_8_ORF	GE-964	FVIII_SC_F309S_GeneD_v3
GE-1028	FVIII-SC_5_ORF	GE-963	FVIII_SC_F309S_GeneD_v2
GE-1029	FVIII-SC_5k_wt3_3_ORF	GE-962	FVIII_SC_F309S_codop_7b
GE-1030	FVIII-SC_5k_wt3_5_ORF	GE-961	FVIII_SC_F309S_codop_6b
GE-1032	FVIII-SC_0CpG_1_F309S	GE-960	FVIII_SC_F309S_codop_1b
GE-1033	FVIII-SC_0CpG_6_F309S	GE-959	FVIII_SC_F309_GeneD_v3
GE-1034	FVIII-SC_0CpG_8_F309S	GE-958	FVIII_SC_F309_GeneD_v2
GE-1035	FVIII-SC_5_F309S	GE-957	FVIII_SC_F309_codop_7b
GE-1036	FVIII-SC_5k_wt3_3_F309S	GE-956	FVIII_SC_F309_codop_6b
GE-1037	FVIII-SC_5k_wt3_5_F309S	GE-955	FVIII_SC_F309_codop_1b
GE-1038	FVIII-SC_5k_wt3_5-0CpG_6_F309S hybrid	GE-848	FVIII_1368ORF_A1AT-SSv3
GE-1168	FVIII_1368_ORF_mat_peptide	GE-847	FVIII_1374ORF_TRYP-SSv2
GE-1169	FVIII_1374_ORF_mat_peptide	GE-846	FVIII_1374ORF_tPA-SSv1
GE-712	hFVIII-Wt-Afstyla BDD	GE-845	FVIII_1374ORF_Secrecon-SSv2
GE-1174	FVIII-SC_1367_miniF8_50/100	GE-844	FVIII_1374ORF_Secrecon-SSv1
GE-1175	FVIII-SC_1367_miniF8_50/200	GE-843	FVIII_1374ORF_Lonz-SSv2

GE-1176	FVIII-SC_1367_miniF8_200/200	GE-842	FVIII_1374ORF_IL2-SSv1
GE-1177	FVIII-SC_1367_miniF8_500/500	GE-841	FVIII_1374ORF_Gaus-SSv1
GE-1178	FVIII-SC_1367_HBB_intron1	GE-840	FVIII_1374ORF_CHY-SSv1
GE-1179	FVIII-SC_1367_Embedded_HCR1_footprint123	GE-839	FVIII_1374ORF_ALB-SSv1
GE-1180	FVIII-SC_1367_Embedded_ProEnh	GE-838	FVIII_1374ORF_A1AT-SSv3
GE-1181	FVIII-SC_1367_Embedded_enhancer_HNF_array	GE-837	FVIII_1368ORF_TRYP-NS-struct-v2
GE-1182	FVIII-SC_1367_F8_intron8	GE-836	FVIII_1368ORF_TRYP-NS-CAI-v2
GE-1183	FVIII-SC_1367_F8_intron16	GE-835	FVIII_1368ORF_tPA-NS-struct
GE-1184	FVIII-SC_1367_MVM_intron	GE-834	FVIII_1368ORF_tPA-NS-CAI-v2
GE-1185	FVIII-SC_1367::33bpFlanks_miniF8_50/100	GE-833	FVIII_1368ORF_Secrecon-v1-NS-struct-v1
GE-1186	FVIII-SC_1367::33bpFlanks_miniF8_200/200	GE-832	FVIII_1368ORF_Secrecon-v1-NS-CAI-v2
GE-1187	FVIII-SC_1367::33bpFlanks_HBB_intron1	GE-831	FVIII_1368ORF_Lonz-SSv2
GE-1188	FVIII-SC_1367::33bpFlanks_F8_intron8	GE-830	FVIII_1368ORF_Lonz-NS-struct-v3
GE-1189	FVIII-SC_1367::33bpFlanks_no intron	GE-829	FVIII_1368ORF_Lonz-NS-CAI-v2
GE-1190	FVIII-SC_1373_miniF8_50/100	GE-828	FVIII_1368ORF_IL2-NS-struct-v2
GE-1191	FVIII-SC_1373_miniF8_50/200	GE-827	FVIII_1368ORF_IL2-NS-CAI
GE-1192	FVIII-SC_1373_miniF8_200/200	GE-826	FVIII_1368ORF_Gaus-NS-struct-v2
GE-1193	FVIII-SC_1373_miniF8_500/500	GE-825	FVIII_1368ORF_Gaus-NS-CAI-v2
GE-1194	FVIII-SC_1373_HBB_intron1	GE-824	FVIII_1368ORF_CHY-NS-struct
GE-1195	FVIII-SC_1373_Embedded_HCR1_footprint123	GE-823	FVIII_1368ORF_CHY-NS-CAI-v2
GE-1196	FVIII-SC_1373_Embedded_ProEnh	GE-822	FVIII_1368ORF_A1AT-NS-struct
GE-1197	FVIII-SC_1373_Embedded_enhancer_HNF_array	GE-821	FVIII_1368ORF_A1AT-NS-CAI
GE-1198	FVIII-SC_1373_F8_intron8	GE-820	FVIII-1368ORF_CD33-NS-struct-v2
GE-1199	FVIII-SC_1373_F8_intron16	GE-819	FVIII-1368ORF_CD33-NS-CAI-v2
GE-1200	FVIII-SC_1373_MVM_intron	GE-818	FVIII-1368ORF_ALB-NS-struct
GE-715	hFVIII-F309S-BD226seq124-BDD-F309*	GE-817	FVIII-1368ORF_ALB-NS-CAI-v2
GE-1667	hFVIII-1651-ORF-dATG1	GE-816	FVIII_1368ORF_CD33-SSv1

GE-1669	hFVIII-1651-ORF-dATG2	GE-815	FVIII_1374ORF_A1AT-SSv2
GE-1670	hFVIII-1651-ORF-dATG3	GE-814	FVIII_1368ORF_TRYP-SSv1
GE-1674	hFVIII-1651ORF-dATG2-3	GE-813	FVIII_1368ORF_tPA-SSv1
GE-1666	hFVIII-1651ORF-dATG3_dCTG3_dTTG1	GE-812	FVIII_1368ORF_Secrecon-SSv2
GE-1668	hFVIII-1651-ORF-dATG1_dCTG3_dTTG1	GE-811	FVIII_1368ORF_Secrecon-SSv1
GE-1675	hFVIII-1651-ORF-dATG2-3_dCTG3_dTTG1	GE-810	FVIII_1368ORF_Lonz-SSv1
GE-1698	hFVIII-1651-ORF-dATG2-3_dCTG3_dTTG1_dCpG3	GE-809	FVIII_1368ORF_IL2-SSv1
		GE-808	FVIII_1368ORF_Gaus-SSv1
		GE-807	FVIII_1368ORF_CHY-SSv1
		GE-806	FVIII_1368ORF_A1AT-SSv2
		GE-805	FVIII-1368ORF_ALB-SSv1

*The two names, hFVIII-F309S-BD226seq124-Afstyla-BDD-F309 and hFVIII-F309S-BD226seq124-BDD-F309 refer to the same sequence GE-715 (SEQ ID NOs: 76 and 556).

[00203] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 71. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NOs: 71-183. In some embodiments, ceDNA vector having a nucleic acid sequence encoding FVIII (*e.g.*, Table 1A) encodes Val (V) instead of Asp (D) at the amino acid position 75 of SEQ ID NO: 492.

[00204] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 71. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 71. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 72. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 72. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 73. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 73. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 74. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[00205] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 626. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 626. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 626. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 626. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 626. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 626. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 626.

[00207] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID

[00210] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID

NO: 631. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 631. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 631. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 631. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 631. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 631. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 631.

[00211] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 632. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 632. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 632. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 632. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 632. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 632. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 632.

[00212] According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 633. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 633. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 633. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 633. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 633. According to some embodiments, nucleic acid sequence encoding a FVIII protein comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 633. According to some embodiments, the nucleic acid sequence encoding a FVIII protein comprises, or consists of, SEQ ID NO: 633.

[00213] According to some embodiments, the ceDNA construct is ceDNA933, and comprises at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs), wherein the at least one nucleic acid sequence comprises SEQ ID NO: 71.

[00214] According to some embodiments, the ceDNA construct is ceDNA1265, and comprises at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs), wherein the at least one nucleic acid sequence comprises SEQ ID NO: 72.

[00215] According to some embodiments, the ceDNA construct is ceDNA1270, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 73.

[00216] According to some embodiments, the ceDNA construct is ceDNA1368, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 74.

[00217] According to some embodiments, the ceDNA construct is ceDNA1367, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 75.

[00218] According to some embodiments, the ceDNA construct is ceDNA1374, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 76.

[00219] According to some embodiments, the ceDNA construct is ceDNA1373, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 77.

[00220] According to some embodiments, the ceDNA construct is ceDNA1918, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 78.

[00221] According to some embodiments, the ceDNA construct is ceDNA1919, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 79.

[00222] According to some embodiments, the ceDNA construct is ceDNA1920, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 80.

[00223] According to some embodiments, the ceDNA construct is ceDNA1921, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 81.

[00224] According to some embodiments, the ceDNA construct is ceDNA1922, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 82.

[00225] According to some embodiments, the ceDNA construct is ceDNA1923, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 83.

[00226] According to some embodiments, the ceDNA construct is ceDNA1927, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 84.

[00227] According to some embodiments, the ceDNA construct is ceDNA1928, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 85.

[00228] According to some embodiments, the ceDNA construct is ceDNA1929, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 86.

[00229] According to some embodiments, the ceDNA construct is ceDNA1930, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 87.

[00230] According to some embodiments, the ceDNA construct is ceDNA1931, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 88.

[00231] According to some embodiments, the ceDNA construct is ceDNA1932, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 89.

[00232] According to some embodiments, the ceDNA construct is ceDNA1933, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 90.

[00233] According to some embodiments, the ceDNA construct is ceDNA1651, and comprises at least one nucleic acid sequence between flanking ITRs, wherein the at least one nucleic acid sequence comprises SEQ ID NO: 556. According to some embodiments, the ceDNA construct is ceDNA1651, and comprises or essentially consists of SEQ ID NO:42.

[00234] In any of the above embodiments, the at least one nucleic acid sequence can be a heterologous nucleic acid sequence.

(iii) *FVIII therapeutic proteins and uses thereof for the treatment of hemophilia A*

[00235] The ceDNA vectors described herein can be used to deliver therapeutic FVIII proteins for treatment of hemophilia A associated with inappropriate expression of the FVIII protein and/or mutations within the FVIII protein.

[00236] ceDNA vectors as described herein can be used to express any desired FVIII therapeutic protein. Exemplary therapeutic FVIII therapeutic proteins include but are not limited to any FVIII

protein, or portion thereof, expressed by the sequences (*e.g.*, any one of SEQ ID NOs: 71-183, 556 and 626-633) as set forth in **Table 1A and Table 1B** herein.

[00237] In one embodiment, the expressed FVIII therapeutic protein is functional for the treatment of a hemophilia A. In some embodiments, FVIII therapeutic protein does not cause an immune system reaction.

[00238] In another embodiment, the ceDNA vectors encoding FVIII therapeutic protein or fragment thereof (*e.g.*, functional fragment) can be used to generate a chimeric protein. Thus, it is specifically contemplated herein that a ceDNA vector expressing a chimeric protein can be administered to *e.g.*, to any one or more tissues selected from: liver, kidneys, gallbladder, prostate, adrenal gland. In some embodiments, when a ceDNA vector that has been engineered to express FVIII is administered to an infant, or administered to a subject in utero, one can administer the ceDNA vector to any one or more tissues selected from: liver, adrenal gland, heart, intestine, lung, and stomach, or to a liver stem cell precursor thereof for the *in vivo* or *ex vivo* treatment of hemophilia A.

[00239] *Hemophilia*

[00240] Hemophilia A is a genetic deficiency in clotting factor VIII, which causes increased bleeding and usually affects males. In the majority of cases it is inherited as an X-linked recessive trait, though there are cases which arise from spontaneous mutations. In terms of the symptoms of hemophilia A, there are internal or external bleeding episodes. Individuals with more severe hemophilia suffer more severe and more frequent bleeding, while others with mild hemophilia typically suffer more minor symptoms except after surgery or serious trauma. Moderate hemophiliacs have variable symptoms which manifest along a spectrum between severe and mild forms.

[00241] Current treatments to prevent bleeding in people with hemophilia A involve Factor VIII medication. Most individuals with severe hemophilia require regular supplementation with intravenous recombinant or plasma concentrate Factor VIII. Recombinant blood clotting factor VIII is one of the most complex proteins for industrial manufacturing due to the low efficiency of its gene transcription, massive intracellular loss of its proprotein during post-translational processing, and the instability of the secreted protein. Mild hemophiliacs can manage their condition with desmopressin, a drug which releases stored factor VIII from blood vessel walls.

[00242] There are many complications related to treatment of hemophilia A. In children, an easily accessible intravenous port can be inserted to minimize frequent traumatic intravenous cannulation. However, these ports are associated with high infection rate and a risk of clots forming at the tip of the catheter, rendering it useless. Viral infections can be common in hemophiliacs due to frequent blood transfusions which put patients at risk of acquiring blood borne infections, such as HIV, hepatitis B and hepatitis C. Prion infections can also be transmitted by blood transfusions. Another therapeutic complication of hemophilia A is the development of inhibitor antibodies against factor VIII due to frequent infusions. These develop as the body recognizes the infused factor VIII as foreign, as the

body does not produce its own copy. In these individuals, activated factor VII, a precursor to factor VIII in the coagulation cascade, can be infused as a treatment for hemorrhage in individuals with hemophilia and antibodies against replacement factor VIII.

[00243] *Coagulation Cascade*

[00244] Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It potentially results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. The mechanism of coagulation involves activation, adhesion and aggregation of platelets along with deposition and maturation of fibrin. Disorders of coagulation are disease states which can result in bleeding (hemorrhage or bruising) or obstructive clotting (thrombosis).

[00245] Coagulation begins almost instantly after an injury to the blood vessel has damaged the endothelium lining the blood vessel. Exposure of blood to the subendothelial space initiates two processes: changes in platelets, and the exposure of subendothelial tissue factor to plasma Factor VII, which ultimately leads to fibrin formation. Platelets immediately form a plug at the site of injury; this is called primary hemostasis. Secondary hemostasis occurs simultaneously: additional coagulation factors or clotting factors beyond Factor VII (including Factor VIII) respond in a complex cascade to form fibrin strands, which strengthen the platelet plug.

[00246] The coagulation cascade of secondary hemostasis has two initial pathways which lead to fibrin formation. These are the contact activation pathway (also known as the intrinsic pathway), and the tissue factor pathway (also known as the extrinsic pathway), which both lead to the same fundamental reactions that produce fibrin. The primary pathway for the initiation of blood coagulation is the tissue factor (extrinsic) pathway. The pathways are a series of reactions, in which a zymogen (inactive enzyme precursor) of a serine protease and its glycoprotein co-factor are activated to become active components that then catalyze the next reaction in the cascade, ultimately resulting in cross-linked fibrin. Coagulation factors are generally indicated by Roman numerals, with a lowercase a appended to indicate an active form.

[00247] The coagulation factors are generally serine proteases (enzymes), which act by cleaving downstream proteins. The exceptions are tissue factor, FV, FVIII, FXIII. Tissue factor, FV and FVIII are glycoproteins, and Factor XIII is a transglutaminase. The coagulation factors circulate as inactive zymogens. The coagulation cascade is therefore classically divided into three pathways. The tissue factor and contact activation pathways both activate the “final common pathway” of factor X, thrombin and fibrin.

[00248] The main role of the tissue factor (extrinsic) pathway is to generate a “thrombin burst”, a process by which thrombin, the most important constituent of the coagulation cascade in terms of its feedback activation roles, is released very rapidly. FVIIa circulates in a higher amount than any other activated coagulation factor. The process includes the following steps:

[00249] Step 1: Following damage to the blood vessel, FVII leaves the circulation and comes into contact with tissue factor (TF) expressed on tissue-factor-bearing cells (stromal fibroblasts and leukocytes), forming an activated complex (TF-FVIIa).

[00250] Step 2: TF-FVIIa activates FIX and FX.

[00251] Step 3: FVII is itself activated by thrombin, FXIa, FXII and FXa.

[00252] Step 4: The activation of FX (to form FXa) by TF-FVIIa is almost immediately inhibited by tissue factor pathway inhibitor (TFPI).

[00253] Step 5: FXa and its co-factor FVa form the prothrombinase complex, which activates prothrombin to thrombin.

[00254] Step 6: Thrombin then activates other components of the coagulation cascade, including FV and FVIII (which forms a complex with FIX), and activates and releases FVIII from being bound to von Willebrand factor (vWF).

[00255] Step 7: FVIIIa is the co-factor of FIXa, and together they form the “tenase” complex, which activates FX; and so the cycle continues.

[00256] The contact activation (intrinsic) pathway begins with formation of the primary complex on collagen by high-molecular-weight kininogen (HMWK), prekallikrein, and FXII (Hageman factor). Prekallikrein is converted to kallikrein and FXII becomes FXIIa. FXIIa converts FXI into FXIa. Factor XIa activates FIX, which with its co-factor FVIIIa form the tenase complex, which activates FX to FXa. The minor role that the contact activation pathway has in initiating clot formation can be illustrated by the fact that patients with severe deficiencies of FXII, HMWK, and prekallikrein do not have a bleeding disorder. Instead, contact activation system is more involved in inflammation, and innate immunity.

[00257] The final common pathway shared by the intrinsic and extrinsic coagulation pathways involves the conversion of prothrombin into thrombin and fibrinogen into fibrin. Thrombin has a large array of functions, not only the conversion of fibrinogen to fibrin, the building block of a hemostatic plug. In addition, it is the most important platelet activator and on top of that it activates Factors VIII and V and their inhibitor protein C (in the presence of thrombomodulin), and it activates Factor XIII, which forms covalent bonds that crosslink the fibrin polymers that form from activated monomers.

[00258] Following activation by the contact factor or tissue factor pathways, the coagulation cascade is maintained in a prothrombotic state by the continued activation of FVIII and FIX to form the tenase complex, until it is down-regulated by the anticoagulant pathways.

[00259] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can also encode co-factors or other polypeptides, sense or antisense oligonucleotides, or RNAs (coding or non-coding; *e.g.*, siRNAs, shRNAs, micro-RNAs, and their antisense counterparts (*e.g.*, antagoMiR)) that can be used in conjunction with the FVIII protein expressed from the ceDNA. Additionally, expression cassettes comprising sequence encoding an FVIII protein can also include an

exogenous sequence that encodes a reporter protein to be used for experimental or diagnostic purposes, such as β -lactamase, β -galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.

[00260] In one embodiment, the ceDNA vector comprises a nucleic acid sequence to express the FVIII protein that is functional for the treatment of hemophilia A. In a preferred embodiment, the therapeutic FVIII protein does not cause an immune system reaction, unless so desired.

III. ceDNA vector in general for use in production of FVIII therapeutic proteins

[00261] Embodiments of the disclosure are based on methods and compositions comprising close ended linear duplexed (ceDNA) vectors that can express the FVIII transgene. In some embodiments, the transgene is a sequence encoding an FVIII protein. According to some embodiments, the transgene is a nucleic acid sequence as set forth in **Table 1A** (*e.g.*, any one of SEQ ID NOs: 71-183, 556 and 626-633). The ceDNA vectors for expression of FVIII protein as described herein are not limited by size, thereby permitting, for example, expression of all of the components necessary for expression of a transgene from a single vector. The ceDNA vector for expression of FVIII protein is preferably duplex, *e.g.*, self-complementary, over at least a portion of the molecule, such as the expression cassette (*e.g.*, ceDNA is not a double stranded circular molecule). The ceDNA vector has covalently closed ends, and thus is resistant to exonuclease digestion (*e.g.*, exonuclease I or exonuclease III), *e.g.*, for over an hour at 37°C.

[00262] In general, a ceDNA vector for expression of FVIII protein as disclosed herein, comprises in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat (ITR)(wild-type or modified), a nucleic acid sequence of interest (for example an expression cassette as described herein) and a second AAV ITR (wild-type or modified). According to some embodiments, the ITR sequences are selected from any of: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (mod-ITR) (*e.g.*, asymmetric modified ITRs); (ii) two modified ITRs where the mod-ITR pair have a different three-dimensional spatial organization with respect to each other (*e.g.*, asymmetric modified ITRs), or (iii) symmetrical or substantially symmetrical WT-WT ITR pair, where each WT-ITR has the same three-dimensional spatial organization, or (iv) symmetrical or substantially symmetrical modified ITR pair, where each mod-ITR has the same three-dimensional spatial organization.

[00263] Encompassed herein are methods and compositions comprising the ceDNA vector for FVIII protein production, which may further include a delivery system, such as but not limited to, a liposome nanoparticle delivery system. Non-limiting exemplary liposome nanoparticle systems encompassed for use are disclosed herein. In some aspects, the disclosure provides for a lipid nanoparticle comprising ceDNA and an ionizable lipid. For example, a lipid nanoparticle formulation that is made and loaded with a ceDNA vector obtained by the process is disclosed in International Application

PCT/US2018/050042, filed on September 7, 2018, which is incorporated herein by reference in its entirety.

[00264] The ceDNA vectors for expression of FVIII protein as disclosed herein have no packaging constraints imposed by the limiting space within the viral capsid. ceDNA vectors represent a viable eukaryotically-produced alternative to prokaryote-produced plasmid DNA vectors, as opposed to encapsulated AAV genomes. This permits the insertion of control elements, *e.g.*, regulatory switches as disclosed herein, large transgenes, multiple transgenes etc.

[00265] ceDNA vectors for expression of FVIII protein are capsid-free and can be obtained from a plasmid encoding in this order: a first ITR, an expression cassette comprising a transgene and a second ITR. The expression cassette may include one or more regulatory sequences that allows and/or controls the expression of the transgene, *e.g.*, where the expression cassette can comprise one or more of, in this order: an enhancer/promoter set, an ORF (transgene, *e.g.*, FVIII), a post-transcription regulatory element (*e.g.*, WPRE 3'UTR), and a polyadenylation and termination signal (*e.g.*, BGH polyA).

[00266] The expression cassette can also comprise an internal ribosome entry site (IRES) and/or a 2A element. The cis-regulatory elements include, but are not limited to, a promoter, a riboswitch, an insulator, a mir-regulatable element, a post-transcriptional regulatory element, a tissue- and cell type-specific promoter and an enhancer. In some embodiments the ITR can act as the promoter for the transgene, *e.g.*, FVIII protein. In some embodiments, the ceDNA vector comprises additional components to regulate expression of the transgene, for example, a regulatory switch, which are described herein in the section entitled "Regulatory Switches" for controlling and regulating the expression of the FVIII protein, and can include if desired, a regulatory switch which is a kill switch to enable controlled cell death of a cell comprising a ceDNA vector.

[00267] The expression cassette can comprise more than 4000 nucleotides, 5000 nucleotides, 10,000 nucleotides or 20,000 nucleotides, or 30,000 nucleotides, or 40,000 nucleotides or 50,000 nucleotides, or any range between about 4000-10,000 nucleotides or 10,000-50,000 nucleotides, or more than 50,000 nucleotides. In some embodiments, the expression cassette can comprise a transgene in the range of 500 to 50,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene in the range of 500 to 75,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene which is in the range of 500 to 10,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene which is in the range of 1000 to 10,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene which is in the range of 500 to 5,000 nucleotides in length. The ceDNA vectors do not have the size limitations of encapsidated AAV vectors, thus enable delivery of a large-size expression cassette to provide efficient transgene expression. In some embodiments, the ceDNA vector is devoid of prokaryote-specific methylation.

[00268] ceDNA expression cassette can include, for example, an expressible exogenous sequence (*e.g.*, open reading frame) or transgene that encodes a protein (*e.g.*, FVIII) that is either absent, inactive, or insufficient activity in the recipient subject or a gene that encodes a protein having a desired biological or a therapeutic effect. The transgene can encode a gene product that can function to correct the expression of a defective gene or transcript. In principle, the expression cassette can include any gene that encodes a protein, polypeptide or RNA that is either reduced or absent due to a mutation or which conveys a therapeutic benefit when overexpressed is considered to be within the scope of the disclosure.

[00269] The expression cassette can comprise any transgene (*e.g.*, encoding FVIII protein), for example, FVIII protein useful for treating hemophilia A in a subject, *i.e.*, a therapeutic FVIII protein. A ceDNA vector can be used to deliver and express any FVIII protein of interest in the subject, alone or in combination with nucleic acids encoding polypeptides, or non-coding nucleic acids (*e.g.*, RNAi, miRs etc.), as well as exogenous genes and nucleic acid sequences, including virus sequences in a subjects' genome, *e.g.*, HIV virus sequences and the like. Preferably a ceDNA vector disclosed herein is used for therapeutic purposes (*e.g.*, for medical, diagnostic, or veterinary uses) or immunogenic polypeptides. In certain embodiments, a ceDNA vector is useful to express any gene of interest in the subject, which includes one or more polypeptides, peptides, ribozymes, peptide nucleic acids, siRNAs, RNAis, antisense oligonucleotides, antisense polynucleotides, or RNAs (coding or non-coding; *e.g.*, siRNAs, shRNAs, guide RNAs (gRNAs), micro-RNAs, and their antisense counterparts (*e.g.*, antagoMiR)), antibodies, fusion proteins, or any combination thereof.

[00270] The expression cassette can also encode polypeptides, sense or antisense oligonucleotides, or RNAs (coding or non-coding; *e.g.*, siRNAs, shRNAs, micro-RNAs, and their antisense counterparts (*e.g.*, antagoMiR)). Expression cassettes can include an exogenous sequence that encodes a reporter protein to be used for experimental or diagnostic purposes, such as β -lactamase, β -galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art.

[00271] Sequences provided in the expression cassette, expression construct of a ceDNA vector for expression of FVIII protein described herein can be codon optimized for the target host cell. According to some embodiments, the sequence provided in the expression cassette is a sequence from **Table 1A** that is codon modified (*e.g.*, a sequence selected from one or more of SEQ ID NOs: 71-183, 556 and 626-633). As used herein, the term "codon optimized" or "codon optimization" refers to the process of modifying a nucleic acid sequence for enhanced expression in the cells of the vertebrate of interest, *e.g.*, mouse or human, by replacing at least one, more than one, or a significant number of codons of the native sequence (*e.g.*, a prokaryotic sequence) with codons that are more frequently or most frequently used in the genes of that vertebrate. Various species exhibit particular bias for certain codons of a particular amino acid. Typically, codon optimization does not alter the amino acid

sequence of the original translated protein. Optimized codons can be determined using *e.g.*, Aptagen's GENEFORGE® codon optimization and custom gene synthesis platform (Aptagen, Inc., 2190 Fox Mill Rd. Suite 300, Herndon, Va. 20171) or another publicly available database. In some embodiments, the nucleic acid encoding the FVIII protein is optimized for human expression, and/or is a human FVIII, or functional fragment thereof, as known in the art.

[00272] A transgene expressed by the ceDNA vector for expression of FVIII protein as disclosed herein encodes FVIII protein. There are many structural features of ceDNA vectors for expression of FVIII protein that differ from plasmid-based expression vectors. ceDNA vectors may possess one or more of the following features: the lack of original (*i.e.* not inserted) bacterial DNA, the lack of a prokaryotic origin of replication, being self-containing, *i.e.*, they do not require any sequences other than the two ITRs, including the Rep binding and terminal resolution sites (RBS and TRS), and an exogenous sequence between the ITRs, the presence of ITR sequences that form hairpins, and the absence of bacterial-type DNA methylation or indeed any other methylation considered abnormal by a mammalian host. In general, it is preferred for the present vectors not to contain any prokaryotic DNA but it is contemplated that some prokaryotic DNA may be inserted as an exogenous sequence, as a non-limiting example in a promoter or enhancer region. Another important feature distinguishing ceDNA vectors from plasmid expression vectors is that ceDNA vectors are single-strand linear DNA having closed ends, while plasmids are always double-strand DNA.

[00273] ceDNA vectors for expression of FVIII protein produced by the methods provided herein preferably have a linear and continuous structure rather than a non-continuous structure, as determined by restriction enzyme digestion assay (**FIG. 3D**). The linear and continuous structure is believed to be more stable from attack by cellular endonucleases, as well as less likely to be recombined and cause mutagenesis. Thus, a ceDNA vector in the linear and continuous structure is a preferred embodiment. The continuous, linear, single strand intramolecular duplex ceDNA vector can have covalently bound terminal ends, without sequences encoding AAV capsid proteins. These ceDNA vectors are structurally distinct from plasmids (including ceDNA plasmids described herein), which are circular duplex nucleic acid molecules of bacterial origin. The complimentary strands of plasmids may be separated following denaturation to produce two nucleic acid molecules, whereas in contrast, ceDNA vectors, while having complimentary strands, are a single DNA molecule and therefore even if denatured, remain a single molecule. In some embodiments, ceDNA vectors as described herein can be produced without DNA base methylation of prokaryotic type, unlike plasmids. Therefore, the ceDNA vectors and ceDNA-plasmids are different both in term of structure (in particular, linear versus circular) and also in view of the methods used for producing and purifying these different objects (see below), and also in view of their DNA methylation which is of prokaryotic type for ceDNA-plasmids and of eukaryotic type for the ceDNA vector.

[00274] There are several advantages of using a ceDNA vector for expression of FVIII protein as described herein over plasmid-based expression vectors, such advantages include, but are not limited to: 1) plasmids contain bacterial DNA sequences and are subjected to prokaryotic-specific methylation, *e.g.*, 6-methyl adenosine and 5-methyl cytosine methylation, whereas capsid-free AAV vector sequences are of eukaryotic origin and do not undergo prokaryotic-specific methylation; as a result, capsid-free AAV vectors are less likely to induce inflammatory and immune responses compared to plasmids; 2) while plasmids require the presence of a resistance gene during the production process, ceDNA vectors do not; 3) while a circular plasmid is not delivered to the nucleus upon introduction into a cell and requires overloading to bypass degradation by cellular nucleases, ceDNA vectors contain viral cis-elements, *i.e.*, ITRs, that confer resistance to nucleases and can be designed to be targeted and delivered to the nucleus. It is hypothesized that the minimal defining elements indispensable for ITR function are a Rep-binding site (RBS; 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437) for AAV2) and a terminal resolution site (TRS; 5'-AGTTGG-3' for AAV2) plus a variable palindromic sequence allowing for hairpin formation; and 4) ceDNA vectors do not have the over-representation of CpG dinucleotides often found in prokaryote-derived plasmids that reportedly binds a member of the Toll-like family of receptors, eliciting a T cell-mediated immune response. In contrast, transductions with capsid-free AAV vectors disclosed herein can efficiently target cell and tissue-types that are difficult to transduce with conventional AAV virions using various delivery reagent.

IV. Inverted Terminal Repeats (ITRs)

[00275] As disclosed herein, ceDNA vectors for expression of FVIII protein contain a transgene or nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, positioned between two inverted terminal repeat (ITR) sequences, where the ITR sequences can be an asymmetrical ITR pair or a symmetrical- or substantially symmetrical ITR pair, as these terms are defined herein. A ceDNA vector as disclosed herein can comprise ITR sequences that are selected from any of: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (mod-ITR) (*e.g.*, asymmetric modified ITRs); (ii) two modified ITRs where the mod-ITR pair have a different three-dimensional spatial organization with respect to each other (*e.g.*, asymmetric modified ITRs), or (iii) symmetrical or substantially symmetrical WT-WT ITR pair, where each WT-ITR has the same three-dimensional spatial organization, or (iv) symmetrical or substantially symmetrical modified ITR pair, where each mod-ITR has the same three-dimensional spatial organization, where the methods of the present disclosure may further include a delivery system, such as but not limited to a liposome nanoparticle delivery system.

[00276] In some embodiments, the ITR sequence can be from viruses of the *Parvoviridae* family, which includes two subfamilies: *Parvovirinae*, which infect vertebrates, and *Densovirinae*, which infect insects. The subfamily *Parvovirinae* (referred to as the parvoviruses) includes the genus

Dependovirus, the members of which, under most conditions, require coinfection with a helper virus such as adenovirus or herpes virus for productive infection. The genus *Dependovirus* includes adeno-associated virus (AAV), which normally infects humans (*e.g.*, serotypes 2, 3A, 3B, 5, and 6) or primates (*e.g.*, serotypes 1 and 4), and related viruses that infect other warm-blooded animals (*e.g.*, bovine, canine, equine, and ovine adeno-associated viruses). The parvoviruses and other members of the *Parvoviridae* family are generally described in Kenneth I. Berns, "Parvoviridae: The Viruses and Their Replication," Chapter 69 in *FIELDS VIROLOGY* (3d Ed. 1996).

[00277] While ITRs exemplified in the specification and Examples herein are AAV2 WT-ITRs, one of ordinary skill in the art is aware that one can as stated above use ITRs from any known parvovirus, for example a dependovirus such as AAV (*e.g.*, AAV1, AAV2, AAV3, AAV4, AAV5, AAV 5, AAV7, AAV8, AAV9, AAV10, AAV 11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genome. *E.g.*, NCBI: NC 002077; NC 001401; NC001729; NC001829; NC006152; NC 006260; NC 006261), chimeric ITRs, or ITRs from any synthetic AAV. In some embodiments, the AAV can infect warm-blooded animals, *e.g.*, avian (AAAV), bovine (BAAV), canine, equine, and ovine adeno-associated viruses. In some embodiments the ITR is from B19 parvovirus (GenBank Accession No: NC 000883), Minute Virus from Mouse (MVM) (GenBank Accession No. NC 001510); goose parvovirus (GenBank Accession No. NC 001701); snake parvovirus 1 (GenBank Accession No. NC 006148). In some embodiments, the 5' WT-ITR can be from one serotype and the 3' WT-ITR from a different serotype, as discussed herein.

[00278] An ordinarily skilled artisan is aware that ITR sequences have a common structure of a double-stranded Holliday junction, which typically is a T-shaped or Y-shaped hairpin structure, where each WT-ITR is formed by two palindromic arms or loops (B-B' and C-C') embedded in a larger palindromic arm (A-A'), and a single stranded D sequence, (where the order of these palindromic sequences defines the flip or flop orientation of the ITR). See, for example, structural analysis and sequence comparison of ITRs from different AAV serotypes (AAV1-AAV6) and described in Grimm *et al.*, J. Virology, 2006; 80(1); 426-439; Yan *et al.*, J. Virology, 2005; 364-379; Duan *et al.*, Virology 1999; 261; 8-14. One of ordinary skill in the art can readily determine WT-ITR sequences from any AAV serotype for use in a ceDNA vector or ceDNA-plasmid based on the exemplary AAV2 ITR sequences provided herein. See, for example, the sequence comparison of ITRs from different AAV serotypes (AAV1-AAV6, and avian AAV (AAAV) and bovine AAV (BAAV)) described in Grimm *et al.*, J. Virology, 2006; 80(1); 426-439; that show the % identity of the left ITR of AAV2 to the left ITR from other serotypes: AAV-1 (84%), AAV-3 (86%), AAV-4 (79%), AAV-5 (58%), AAV-6 (left ITR) (100%) and AAV-6 (right ITR) (82%).

A. *Symmetrical ITR pairs*

[00279] In some embodiments, a ceDNA vector for expression of FVIII protein as described herein comprises, in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat

(ITR), a nucleic acid sequence of interest (for example an expression cassette as described herein) and a second AAV ITR, where the first ITR (5' ITR) and the second ITR (3' ITR) are symmetric, or substantially symmetrical with respect to each other – that is, a ceDNA vector can comprise ITR sequences that have a symmetrical three-dimensional spatial organization such that their structure is the same shape in geometrical space, or have the same A, C-C' and B-B' loops in 3D space. In such an embodiment, a symmetrical ITR pair, or substantially symmetrical ITR pair can be modified ITRs (*e.g.*, mod-ITRs) that are not wild-type ITRs. A mod-ITR pair can have the same sequence which has one or more modifications from wild-type ITR and are reverse complements (inverted) of each other. In alternative embodiments, a modified ITR pair are substantially symmetrical as defined herein, that is, the modified ITR pair can have a different sequence but have corresponding or the same symmetrical three-dimensional shape.

(i) *Wildtype ITRs*

[00280] In some embodiments, the symmetrical ITRs, or substantially symmetrical ITRs are wild-type (WT-ITRs) as described herein. In some embodiments, both ITRs have a wild-type sequence, but do not necessarily have to be WT-ITRs from the same AAV serotype. In some embodiments, one WT-ITR can be from one AAV serotype, and the other WT-ITR can be from a different AAV serotype. In such an embodiment, a WT-ITR pair are substantially symmetrical as defined herein, *e.g.*, they can have one or more conservative nucleotide modification while still retaining the symmetrical three-dimensional spatial organization.

[00281] Accordingly, as disclosed herein, ceDNA vectors contain a transgene or nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, positioned between two flanking wild-type inverted terminal repeat (WT-ITR) sequences, that are either the reverse complement (inverted) of each other, or alternatively, are substantially symmetrical relative to each other, *e.g.*, a WT-ITR pair having symmetrical three-dimensional spatial organization. In some embodiments, a wild-type ITR sequence (*e.g.*, AAV WT-ITR) comprises a functional Rep binding site (RBS; *e.g.*, 5'-GCGCGCTCGCTCGCTC-3' for AAV2, SEQ ID NO: 437) and a functional terminal resolution site (TRS; *e.g.*, 5'-AGTT-3', SEQ ID NO: 438).

[00282] In one aspect, ceDNA vectors for expression of FVIII protein are obtainable from a vector polynucleotide that encodes a nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, operatively positioned between two WT inverted terminal repeat sequences (WT-ITRs) (*e.g.*, AAV WT-ITRs). In some embodiments, both ITRs have a wild-type sequence, but do not necessarily have to be WT-ITRs from the same AAV serotype. In some embodiments, one WT-ITR can be from one AAV serotype, and the other WT-ITR can be from a different AAV serotype. In such an embodiment, the WT-ITR pair are substantially symmetrical as defined herein, that is, they can have one or more conservative nucleotide modification while still retaining the symmetrical three-dimensional spatial organization. In some embodiments, the 5' WT-ITR is from one AAV serotype, and the 3' WT-ITR is

from the same or a different AAV serotype. In some embodiments, the 5' WT-ITR and the 3' WT-ITR are mirror images of each other, that is they are symmetrical. In some embodiments, the 5' WT-ITR and the 3' WT-ITR are from the same AAV serotype.

[00283] WT ITRs are well known. In one embodiment the two ITRs are from the same AAV2 serotype. In certain embodiments one can use WT from other serotypes. There are a number of serotypes that are homologous, *e.g.*, AAV2, AAV4, AAV6, AAV8. In one embodiment, closely homologous ITRs (*e.g.*, ITRs with a similar loop structure) can be used. In another embodiment, one can use AAV WT ITRs that are more diverse, *e.g.*, AAV2 and AAV5, and still another embodiment, one can use an ITR that is substantially WT - that is, it has the basic loop structure of the WT but some conservative nucleotide changes that do not alter or affect the properties. When using WT-ITRs from the same viral serotype, one or more regulatory sequences may further be used. In certain embodiments, the regulatory sequence is a regulatory switch that permits modulation of the activity of the ceDNA, *e.g.*, the expression of the encoded FVIII protein.

[00284] In some embodiments, one aspect of the technology described herein relates to a ceDNA vector for expression of FVIII protein, wherein the ceDNA vector comprises at least one nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, encoding the FVIII protein, operably positioned between two wild-type inverted terminal repeat sequences (WT-ITRs), wherein the WT-ITRs can be from the same serotype, different serotypes or substantially symmetrical with respect to each other (*i.e.*, have the symmetrical three-dimensional spatial organization such that their structure is the same shape in geometrical space, or have the same A, C-C' and B-B' loops in 3D space). In some embodiments, the symmetric WT-ITRs comprises a functional terminal resolution site and a Rep binding site. In some embodiments, the nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence, encodes a transgene, and the vector is not in a viral capsid.

[00285] In some embodiments, the WT-ITRs are the same but the reverse complement of each other. For example, the sequence AACG in the 5' ITR may be CGTT (*i.e.*, the reverse complement) in the 3' ITR at the corresponding site. In one example, the 5' WT-ITR sense strand comprises the sequence of ATCGATCG and the corresponding 3' WT-ITR sense strand comprises CGATCGAT (*i.e.*, the reverse complement of ATCGATCG). In some embodiments, the WT-ITRs ceDNA further comprises a terminal resolution site and a replication protein binding site (RPS) (sometimes referred to as a replicative protein binding site), *e.g.*, a Rep binding site.

[00286] Exemplary WT-ITR sequences for use in the ceDNA vectors for expression of FVIII protein comprising WT-ITRs are shown in **Table 2** herein, which shows pairs of WT-ITRs (5' WT-ITR and the 3' WT-ITR).

[00287] As an exemplary example, the present disclosure provides a ceDNA vector for expression of FVIII protein comprising a promoter operably linked to a transgene (*e.g.*, heterologous nucleic acid sequence), with or without the regulatory switch, where the ceDNA is devoid of capsid proteins and is:

(a) produced from a ceDNA-plasmid that encodes WT-ITRs, where each WT-ITR has the same number of intramolecularly duplexed base pairs in its hairpin secondary configuration (preferably excluding deletion of any AAA or TTT terminal loop in this configuration compared to these reference sequences), and (b) is identified as ceDNA using the assay for the identification of ceDNA by agarose gel electrophoresis under native gel and denaturing conditions in Example 1.

[00288] In some embodiments, the flanking WT-ITRs are substantially symmetrical to each other. In this embodiment the 5' WT-ITR can be from one serotype of AAV, and the 3' WT-ITR from a different serotype of AAV, such that the WT-ITRs are not identical reverse complements. For example, the 5' WT-ITR can be from AAV2, and the 3' WT-ITR from a different serotype (*e.g.*, AAV1, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12). In some embodiments, WT-ITRs can be selected from two different parvoviruses selected from any to of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (*e.g.*, royal python parvovirus), bovine parvovirus, goat parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. In some embodiments, such a combination of WT ITRs is the combination of WT-ITRs from AAV2 and AAV6. In one embodiment, the substantially symmetrical WT-ITRs are when one is inverted relative to the other ITR at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical and all points in between, and has the same symmetrical three-dimensional spatial organization. In some embodiments, a WT-ITR pair are substantially symmetrical as they have symmetrical three-dimensional spatial organization, *e.g.*, have the same 3D organization of the A, C-C', B-B' and D arms. In one embodiment, a substantially symmetrical WT-ITR pair are inverted relative to the other, and are at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical and all points in between, to each other, and one WT-ITR retains the Rep-binding site (RBS) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437) and a terminal resolution site (TRS). In some embodiments, a substantially symmetrical WT-ITR pair are inverted relative to each other, and are at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical and all points in between, to each other, and one WT-ITR retains the Rep-binding site (RBS) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437) and a terminal resolution site (TRS) and in addition to a variable palindromic sequence allowing for hairpin secondary structure formation. Homology can be determined by standard means well known in the art such as BLAST (Basic Local Alignment Search Tool), BLASTN at default setting.

[00289] In some embodiments, the structural element of the ITR can be any structural element that is involved in the functional interaction of the ITR with a large Rep protein (*e.g.*, Rep 78 or Rep 68). In certain embodiments, the structural element provides selectivity to the interaction of an ITR with a large Rep protein, *i.e.*, determines at least in part which Rep protein functionally interacts with the

ITR. In other embodiments, the structural element physically interacts with a large Rep protein when the Rep protein is bound to the ITR. Each structural element can be, *e.g.*, a secondary structure of the ITR, a nucleic acid sequence of the ITR, a spacing between two or more elements, or a combination of any of the above. In one embodiment, the structural elements are selected from the group consisting of an A and an A' arm, a B and a B' arm, a C and a C' arm, a D arm, a Rep binding site (RBE) and an RBE' (*i.e.*, complementary RBE sequence), and a terminal resolution site (TRS).

[00290] By way of example only, Table 6 of International Publication No. WO/2019/161059 (incorporated by reference in its entirety herein), indicates exemplary combinations of WT-ITRs.

[00291] By way of example only, **Table 2** sets forth the corresponding SEQ ID NOs: of the sequences of exemplary WT-ITRs from some different AAV serotypes.

Table 2

AAV serotype	5' WT-ITR (LEFT)	3' WT-ITR (RIGHT)
AAV1	SEQ ID NO: 493	SEQ ID NO: 494
AAV2	SEQ ID NO: 495	SEQ ID NO: 496
AAV3	SEQ ID NO: 497	SEQ ID NO: 498
AAV4	SEQ ID NO: 499	SEQ ID NO: 500
AAV5	SEQ ID NO: 501	SEQ ID NO: 502
AAV6	SEQ ID NO: 503	SEQ ID NO: 504

[00292] In some embodiments, the nucleic acid sequence of the WT-ITR sequence can be modified (*e.g.*, by modifying 1, 2, 3, 4 or 5, or more nucleotides or any range therein), whereby the modification is a substitution for a complementary nucleotide, *e.g.*, G for a C, and *vice versa*, and T for an A, and *vice versa*.

[00293] The ceDNA vector for expression of FVIII protein as described herein can include WT-ITR structures that retains an operable RBE, TRS and RBE' portion. **FIG. 1A** and **FIG. 1B**, using wild-type ITRs for exemplary purposes, show one possible mechanism for the operation of a TRS site within a wild-type ITR structure portion of a ceDNA vector. In some embodiments, the ceDNA vector for expression of FVIII protein contains one or more functional WT-ITR polynucleotide sequences that comprise a Rep-binding site (RBS; 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437) for AAV2) and a terminal resolution site (TRS; 5'-AGTT (SEQ ID NO: 438)). In some embodiments, at least one WT-ITR is functional. In alternative embodiments, where a ceDNA vector for expression of FVIII protein comprises two WT-ITRs that are substantially symmetrical to each other, at least one WT-ITR is functional and at least one WT-ITR is non-functional.

B. Modified ITRs (mod-ITRs) in general for ceDNA vectors comprising asymmetric ITR pairs or symmetric ITR pairs

[00294] As discussed herein, a ceDNA vector for expression of FVIII protein can comprise a symmetrical ITR pair or an asymmetrical ITR pair. In both instances, one or both of the ITRs can be modified ITRs – the difference being that in the first instance (*i.e.*, symmetric mod-ITRs), the mod-

ITRs have the same three-dimensional spatial organization (*i.e.*, have the same A-A', C-C' and B-B' arm configurations), whereas in the second instance (*i.e.*, asymmetric mod-ITRs), the mod-ITRs have a different three-dimensional spatial organization (*i.e.*, have a different configuration of A-A', C-C' and B-B' arms).

[00295] In some embodiments, a modified ITR is an ITRs that is modified by deletion, insertion, and/or substitution as compared to a wild-type ITR sequence (*e.g.*, AAV ITR). In some embodiments, at least one of the ITRs in the ceDNA vector comprises a functional Rep binding site (RBS; *e.g.*, 5'-GCGCGCTCGCTCGCTC-3' for AAV2, SEQ ID NO: 437) and a functional terminal resolution site (TRS; *e.g.*, 5'-AGTT-3', SEQ ID NO: 438.) In one embodiment, at least one of the ITRs is a non-functional ITR. In one embodiment, the different or modified ITRs are not each wild-type ITRs from different serotypes.

[00296] Specific alterations and mutations in the ITRs are described in detail herein, but in the context of ITRs, "altered" or "mutated" or "modified", it indicates that nucleotides have been inserted, deleted, and/or substituted relative to the wild-type, reference, or original ITR sequence. The altered or mutated ITR can be an engineered ITR. As used herein, "engineered" refers to the aspect of having been manipulated by the hand of man. For example, a polypeptide is considered to be "engineered" when at least one aspect of the polypeptide, *e.g.*, its sequence, has been manipulated by the hand of man to differ from the aspect as it exists in nature.

[00297] In some embodiments, a mod-ITR may be synthetic. In one embodiment, a synthetic ITR is based on ITR sequences from more than one AAV serotype. In another embodiment, a synthetic ITR includes no AAV-based sequence. In yet another embodiment, a synthetic ITR preserves the ITR structure described above although having only some or no AAV-sourced sequence. In some aspects, a synthetic ITR may interact preferentially with a wild-type Rep or a Rep of a specific serotype, or in some instances will not be recognized by a wild-type Rep and be recognized only by a mutated Rep.

[00298] The skilled artisan can determine the corresponding sequence in other serotypes by known means. For example, determining if the change is in the A, A', B, B', C, C' or D region and determine the corresponding region in another serotype. One can use BLAST® (Basic Local Alignment Search Tool) or other homology alignment programs at default status to determine the corresponding sequence. The disclosure further provides populations and pluralities of ceDNA vectors comprising mod-ITRs from a combination of different AAV serotypes – that is, one mod-ITR can be from one AAV serotype and the other mod-ITR can be from a different serotype. Without wishing to be bound by theory, in one embodiment one ITR can be from or based on an AAV2 ITR sequence and the other ITR of the ceDNA vector can be from or be based on any one or more ITR sequence of AAV serotype 1 (AAV1), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12).

[00299] Any parvovirus ITR can be used as an ITR or as a base ITR for modification. Preferably, the parvovirus is a dependovirus. More preferably AAV. The serotype chosen can be based upon the tissue tropism of the serotype. AAV2 has a broad tissue tropism, AAV1 preferentially targets to neuronal and skeletal muscle, and AAV5 preferentially targets neuronal, retinal pigmented epithelia, and photoreceptors. AAV6 preferentially targets skeletal muscle and lung. AAV8 preferentially targets liver, skeletal muscle, heart, and pancreatic tissues. AAV9 preferentially targets liver, skeletal and lung tissue. In one embodiment, the modified ITR is based on an AAV2 ITR.

[00300] More specifically, the ability of a structural element to functionally interact with a particular large Rep protein can be altered by modifying the structural element. For example, the nucleic acid sequence of the structural element can be modified as compared to the wild-type sequence of the ITR. In one embodiment, the structural element (*e.g.*, A arm, A' arm, B arm, B' arm, C arm, C' arm, D arm, RBE, RBE', and TRS) of an ITR can be removed and replaced with a wild-type structural element from a different parvovirus. For example, the replacement structure can be from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (*e.g.*, royal python parvovirus), bovine parvovirus, goat parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. For example, the ITR can be an AAV2 ITR and the A or A' arm or RBE can be replaced with a structural element from AAV5. In another example, the ITR can be an AAV5 ITR and the C or C' arms, the RBE, and the TRS can be replaced with a structural element from AAV2. In another example, the AAV ITR can be an AAV5 ITR with the B and B' arms replaced with the AAV2 ITR B and B' arms.

[00301] By way of example only, **Table 3** indicates exemplary modifications of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in regions of a modified ITR, where X is indicative of a modification of at least one nucleic acid (*e.g.*, a deletion, insertion and/ or substitution) in that section relative to the corresponding wild-type ITR. In some embodiments, any modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in any of the regions of C and/or C' and/or B and/or B' retains three sequential T nucleotides (*i.e.*, TTT) in at least one terminal loop. For example, if the modification results in any of: a single arm ITR (*e.g.*, single C-C' arm, or a single B-B' arm), or a modified C-B' arm or C'-B arm, or a two arm ITR with at least one truncated arm (*e.g.*, a truncated C-C' arm and/or truncated B-B' arm), at least the single arm, or at least one of the arms of a two arm ITR (where one arm can be truncated) retains three sequential T nucleotides (*i.e.*, TTT) in at least one terminal loop. In some embodiments, a truncated C-C' arm and/or a truncated B-B' arm has three sequential T nucleotides (*i.e.*, TTT) in the terminal loop.

[00302] **Table 3:** Exemplary combinations of modifications of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) to different B-B' and C-C' regions or arms of ITRs (X indicates a nucleotide modification, *e.g.*, addition, deletion or substitution of at least one nucleotide in the region).

B region	B' region	C region	C' region
X			
	X		
X	X		
		X	
			X
		X	X
X		X	
X			X
	X	X	
	X		X
X	X	X	
X	X		X
X		X	X
	X	X	X
X	X	X	X

[00303] In some embodiments, mod-ITR for use in a ceDNA vector for expression of FVIII protein comprises an asymmetric ITR pair, or a symmetric mod-ITR pair as disclosed herein, can comprise any one of the combinations of modifications shown in **Table 3**, and also a modification of at least one nucleotide in any one or more of the regions selected from: between A' and C, between C and C', between C' and B, between B and B' and between B' and A. In some embodiments, any modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in the C or C' or B or B' regions, still preserves the terminal loop of the stem-loop. In some embodiments, any modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) between C and C' and/or B and B' retains three sequential T nucleotides (*i.e.*, TTT) in at least one terminal loop. In alternative embodiments, any modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) between C and C' and/or B and B' retains three sequential A nucleotides (*i.e.*, AAA) in at least one terminal loop. In some embodiments, a modified ITR for use herein can comprise any one of the combinations of modifications shown in **Table 3**, and also a modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in any one or more of the regions selected from: A', A and/or D. For example, in some embodiments, a modified ITR for use herein can comprise any one of the combinations of modifications shown in **Table 3**, and also a modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in the A region. In some embodiments, a modified ITR for use herein can comprise any one of the combinations of modifications shown in **Table 3**, and also a modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in the A' region. In some embodiments, a modified ITR for use herein can comprise any one of the combinations of modifications shown in **Table 3**, and also a modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in the A and/or A' region. In some embodiments, a modified ITR for use herein can comprise any one of the combinations of modifications shown in **Table 3**, and also a modification of at least one nucleotide (*e.g.*, a deletion, insertion and/ or substitution) in the D region.

[00304] In one embodiment, the nucleic acid sequence of the structural element can be modified (*e.g.*, by modifying 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides or any range therein) to produce a modified structural element. In one embodiment, the specific modifications to the ITRs are exemplified herein (*e.g.*, shown in FIG. 7A-7B of PCT/US2018/064242, filed on December 6, 2018 and incorporated by reference in its entirety herein (*e.g.*, SEQ ID NOs: 97-98, 101-103, 105-108, 111-112, 117-134, 545-54 in PCT/US2018/064242)). In some embodiments, an ITR can be modified (*e.g.*, by modifying 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides or any range therein). In other embodiments, the ITR can have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, or more sequence identity with one of the modified ITRs or the RBE-containing section of the A-A' arm and C-C' and B-B' arms of SEQ ID NO: 3, 4, 15-47, 101-116 or 165-187, or shown in Tables 2-9 (*i.e.*, SEQ ID NO: 110-112, 115-190, 200-468) of International application PCT/US18/49996, which is incorporated herein in its entirety by reference.

[00305] In some embodiments, a modified ITR can for example, comprise removal or deletion of all of a particular arm, *e.g.*, all or part of the A-A' arm, or all or part of the B-B' arm or all or part of the C-C' arm, or alternatively, the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs forming the stem of the loop so long as the final loop capping the stem (*e.g.*, single arm) is still present (*e.g.*, see ITR-21 in FIG. 7A of PCT/US2018/064242, filed December 6, 2018, incorporated by reference in its entirety herein). In some embodiments, a modified ITR can comprise the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the B-B' arm. In some embodiments, a modified ITR can comprise the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the C-C' arm (see, *e.g.*, ITR-1 in FIG. 3B, or ITR-45 in FIG. 7A of PCT/US2018/064242, filed December 6, 2018, incorporated by reference in its entirety herein). In some embodiments, a modified ITR can comprise the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the C-C' arm and the removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the B-B' arm. Any combination of removal of base pairs is envisioned, for example, 6 base pairs can be removed in the C-C' arm and 2 base pairs in the B-B' arm. As an illustrative example, **FIG. 2B** shows an exemplary modified ITR with at least 7 base pairs deleted from each of the C portion and the C' portion, a substitution of a nucleotide in the loop between C and C' region, and at least one base pair deletion from each of the B region and B' regions such that the modified ITR comprises two arms where at least one arm (*e.g.*, C-C') is truncated. In some embodiments, the modified ITR also comprises at least one base pair deletion from each of the B region and B' regions, such that the B-B' arm is also truncated relative to WT ITR.

[00306] In some embodiments, a modified ITR can have between 1 and 50 (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotide deletions relative to a full-length wild-type ITR sequence. In some embodiments, a modified ITR can have between 1 and 30 nucleotide

deletions relative to a full-length WT ITR sequence. In some embodiments, a modified ITR has between 2 and 20 nucleotide deletions relative to a full-length wild-type ITR sequence.

[00307] In some embodiments, a modified ITR does not contain any nucleotide deletions in the RBE-containing portion of the A or A' regions, so as not to interfere with DNA replication (*e.g.*, binding to an RBE by Rep protein, or nicking at a terminal resolution site). In some embodiments, a modified ITR encompassed for use herein has one or more deletions in the B, B', C, and/or C region as described herein.

[00308] In another embodiment, the structure of the structural element can be modified. For example, the structural element a change in the height of the stem and/or the number of nucleotides in the loop. For example, the height of the stem can be about 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or more or any range therein. In one embodiment, the stem height can be about 5 nucleotides to about 9 nucleotides and functionally interacts with Rep. In another embodiment, the stem height can be about 7 nucleotides and functionally interacts with Rep. In another example, the loop can have 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or more or any range therein.

[00309] In another embodiment, the number of GAGY binding sites or GAGY-related binding sites within the RBE or extended RBE can be increased or decreased. In one example, the RBE or extended RBE, can comprise 1, 2, 3, 4, 5, or 6 or more GAGY binding sites or any range therein. Each GAGY binding site can independently be an exact GAGY sequence or a sequence similar to GAGY as long as the sequence is sufficient to bind a Rep protein.

[00310] In another embodiment, the spacing between two elements (such as but not limited to the RBE and a hairpin) can be altered (*e.g.*, increased or decreased) to alter functional interaction with a large Rep protein. For example, the spacing can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides or more or any range therein.

[00311] The ceDNA vector for expression of FVIII protein as described herein can include an ITR structure that is modified with respect to the wild-type AAV2 ITR structure disclosed herein, but still retains an operable RBE, TRS and RBE' portion. **FIG. 1A** and **FIG. 1B** show one possible mechanism for the operation of a TRS site within a wild-type ITR structure portion of a ceDNA vector for expression of FVIII protein. In some embodiments, the ceDNA vector for expression of FVIII protein contains one or more functional ITR polynucleotide sequences that comprise a Rep-binding site (RBS; 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437) for AAV2) and a terminal resolution site (TRS; 5'-AGTT (SEQ ID NO: 438)). In some embodiments, at least one ITR (wt or modified ITR) is functional. In alternative embodiments, where a ceDNA vector for expression of FVIII protein comprises two modified ITRs that are different or asymmetrical to each other, at least one modified ITR is functional and at least one modified ITR is non-functional.

[00312] In some embodiments, the modified ITR (*e.g.*, the left or right ITR) of a ceDNA vector for expression of FVIII protein as described herein has modifications within the loop arm, the truncated

arm, or the spacer. Exemplary sequences of ITRs having modifications within the loop arm, the truncated arm, or the spacer are listed in Table 2 (*i.e.*, SEQ ID NOS: 135-190, 200-233); Table 3 (*e.g.*, SEQ ID Nos: 234-263); Table 4 (*e.g.*, SEQ ID NOS: 264-293); Table 5 (*e.g.*, SEQ ID Nos: 294-318 herein); Table 6 (*e.g.*, SEQ ID NO: 319-468; and Tables 7-9 (*e.g.*, SEQ ID Nos: 101-110, 111-112, 115-134) or Table 10A or 10B (*e.g.*, SEQ ID Nos: 9, 100, 469-483, 484-499) of International application PCT/US18/49996, which is incorporated herein in its entirety by reference.

[00313] In some embodiments, the modified ITR for use in a ceDNA vector for expression of FVIII protein comprising an asymmetric ITR pair, or symmetric mod-ITR pair is selected from any or a combination of those shown in Tables 2, 3, 4, 5, 6, 7, 8, 9 and 10A-10B of International application PCT/US18/49996 which is incorporated herein in its entirety by reference.

[00314] Additional exemplary modified ITRs for use in a ceDNA vector for expression of FVIII protein comprising an asymmetric ITR pair, or symmetric mod-ITR pair in each of the above classes are provided in **Tables 4A** and **4B**. The predicted secondary structure of the Right modified ITRs in **Table 4A** are shown in FIG. 7A of International Application PCT/US2018/064242, filed December 6, 2018, and the predicted secondary structure of the Left modified ITRs in **Table 4B** are shown in FIG. 7B of International Application PCT/US2018/064242, filed December 6, 2018, each of which is incorporated herein in its entirety by reference.

[00315] **Table 4A** and **Table 4B** show exemplary right and left modified ITRs.

Table 4A: Exemplary modified right ITRs. These exemplary modified right ITRs can further comprise the RBE of GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437), spacer of ACTGAGGC (SEQ ID NO: 439), the spacer complement GCCTCAGT (SEQ ID NO: 440) and RBE' (*i.e.*, complement to RBE) of GAGCGAGCGAGCGCGC (SEQ ID NO: 441).

ITR Construct	SEQ ID NO:		ITR Construct	SEQ ID NO:
ITR-18 Right	505		ITR-27 Right	514
ITR-19 Right	506		ITR-28 Right	515
ITR-20 Right	507		ITR-29 Right	516
ITR-21 Right	508		ITR-30 Right	517
ITR-22 Right	509		ITR-31 Right	518
ITR-23 Right	510		ITR-32 Right	519
ITR-24 Right	511		ITR-49 Right	520
ITR-25 Right	512		ITR-50 right	521
ITR-26 Right	513			

TABLE 4B: Exemplary modified left ITRs. These exemplary modified left ITRs can further comprise the RBE of GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437), spacer of ACTGAGGC (SEQ ID NO: 439), the spacer complement GCCTCAGT (SEQ ID NO: 440) and RBE complement (RBE') of GAGCGAGCGAGCGCGC (SEQ ID NO: 441).

ITR Construct	SEQ ID NO:		ITR Construct	SEQ ID NO:
---------------	------------	--	---------------	------------

ITR-33 Left	522		ITR-42 Left	531
ITR-34 Left	523		ITR-43 Left	532
ITR-35 Left	524		ITR-44 Left	533
ITR-36 Left	525		ITR-45 Left	534
ITR-37 Left	526		ITR-46 Left	535
ITR-38 Left	527		ITR-47 Left	536
ITR-39 Left	528		ITR-48 Left	537
ITR-40 Left	529		ITR-41 Left	530

[00316] In one embodiment, a ceDNA vector for expression of FVIII protein comprises, in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleic acid sequence of interest (for example an expression cassette as described herein) and a second AAV ITR, where the first ITR (5' ITR) and the second ITR (3' ITR) are asymmetric with respect to each other – that is, they have a different 3D-spatial configuration from one another. As an exemplary embodiment, the first ITR can be a wild-type ITR and the second ITR can be a mutated or modified ITR, or vice versa, where the first ITR can be a mutated or modified ITR and the second ITR a wild-type ITR. In some embodiment, the first ITR and the second ITR are both mod-ITRs, but have different sequences, or have different modifications, and thus are not the same modified ITRs, and have different 3D spatial configurations. Stated differently, a ceDNA vector with asymmetric ITRs comprises ITRs where any changes in one ITR relative to the WT-ITR are not reflected in the other ITR; or alternatively, where the asymmetric ITRs have a modified asymmetric ITR pair can have a different sequence and different three-dimensional shape with respect to each other. Exemplary asymmetric ITRs in the ceDNA vector for expression of FVIII protein and for use to generate a ceDNA-plasmid are shown in **Table 4A and 4B**.

[00317] In an alternative embodiment, a ceDNA vector for expression of FVIII protein comprises two symmetrical mod-ITRs - that is, both ITRs have the same sequence, but are reverse complements (inverted) of each other. In some embodiments, a symmetrical mod-ITR pair comprises at least one or any combination of a deletion, insertion, or substitution relative to wild-type ITR sequence from the same AAV serotype. The additions, deletions, or substitutions in the symmetrical ITR are the same but the reverse complement of each other. For example, an insertion of 3 nucleotides in the C region of the 5' ITR would be reflected in the insertion of 3 reverse complement nucleotides in the corresponding section in the C' region of the 3' ITR. Solely for illustration purposes only, if the addition is AACG in the 5' ITR, the addition is CGTT in the 3' ITR at the corresponding site. For example, if the 5' ITR sense strand is ATCGATCG with an addition of AACG between the G and A to result in the sequence ATCGAACGATCG (SEQ ID NO: 538). The corresponding 3' ITR sense strand is CGATCGAT (the reverse complement of ATCGATCG) with an addition of CGTT (*i.e.* the reverse complement of AACG) between the T and C to result in the sequence CGATCGTTCGAT (SEQ ID NO: 539) (the reverse complement of ATCGAACGATCG) (SEQ ID NO: 538).

[00318] In alternative embodiments, the modified ITR pair are substantially symmetrical as defined herein - that is, the modified ITR pair can have a different sequence but have corresponding or the same symmetrical three-dimensional shape. For example, one modified ITR can be from one serotype and the other modified ITR be from a different serotype, but they have the same mutation (*e.g.*, nucleotide insertion, deletion or substitution) in the same region. Stated differently, for illustrative purposes only, a 5' mod-ITR can be from AAV2 and have a deletion in the C region, and the 3' mod-ITR can be from AAV5 and have the corresponding deletion in the C' region, and provided the 5' mod-ITR and the 3' mod-ITR have the same or symmetrical three-dimensional spatial organization, they are encompassed for use herein as a modified ITR pair.

[00319] In some embodiments, a substantially symmetrical mod-ITR pair has the same A, C-C' and B-B' loops in 3D space, *e.g.*, if a modified ITR in a substantially symmetrical mod-ITR pair has a deletion of a C-C' arm, then the cognate mod-ITR has the corresponding deletion of the C-C' loop and also has a similar 3D structure of the remaining A and B-B' loops in the same shape in geometric space of its cognate mod-ITR. By way of example only, substantially symmetrical ITRs can have a symmetrical spatial organization such that their structure is the same shape in geometrical space. This can occur, *e.g.*, when a G-C pair is modified, for example, to a C-G pair or vice versa, or A-T pair is modified to a T-A pair, or vice versa. Therefore, using the exemplary example above of modified 5' ITR as a ATCGAACGATCG (SEQ ID NO: 538), and modified 3' ITR as CGATCGTTCGAT (SEQ ID NO: 539) (*i.e.*, the reverse complement of ATCGAACGATCG (SEQ ID NO: 538)), these modified ITRs would still be symmetrical if, for example, the 5' ITR had the sequence of ATCGAACCATCG (SEQ ID NO: 540), where G in the addition is modified to C, and the substantially symmetrical 3' ITR has the sequence of CGATCGTTCGAT (SEQ ID NO: 539), without the corresponding modification of the T in the addition to a. In some embodiments, such a modified ITR pair are substantially symmetrical as the modified ITR pair has symmetrical stereochemistry.

[00320] Table 5 shows exemplary symmetric modified ITR pairs (*i.e.* a left modified ITRs and the symmetric right modified ITR) for use in a ceDNA vector for expression of FVIII protein. The bold (red) portion of the sequences identify partial ITR sequences (*i.e.*, sequences of A-A', C-C' and B-B' loops), also shown in FIGS 31A-46B. These exemplary modified ITRs can comprise the RBE of GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 437), spacer of ACTGAGGC (SEQ ID NO: 439), the spacer complement GCCTCAGT (SEQ ID NO: 440) and RBE' (*i.e.*, complement to RBE) of GAGCGAGCGAGCGCGC (SEQ ID NO: 441).

Table 5: Exemplary symmetric modified ITR pairs (and corresponding SEQ ID NOs) in a ceDNA vector for expression of FVIII protein			
LEFT modified ITR (modified 5' ITR)		Symmetric RIGHT modified ITR (modified 3' ITR)	
ITR-33 left	SEQ ID NO: 522	ITR-18, right	SEQ ID NO: 505
ITR-34 left	SEQ ID NO: 523	ITR-51, right	SEQ ID NO: 520
ITR-35 left	SEQ ID NO: 524	ITR-19, right	SEQ ID NO: 506

ITR-36 left	SEQ ID NO: 525	ITR-20, right	SEQ ID NO: 507
ITR-37 left	SEQ ID NO: 526	ITR-21, right	SEQ ID NO: 508
ITR-38 left	SEQ ID NO: 527	ITR-22 right	SEQ ID NO: 509
ITR-39 left	SEQ ID NO: 528	ITR-23, right	SEQ ID NO: 510
ITR-40 left	SEQ ID NO: 529	ITR-24, right	SEQ ID NO: 511
ITR-41 left	SEQ ID NO: 530	ITR-25 right	SEQ ID NO: 512
ITR-42 left	SEQ ID NO: 531	ITR-26 right	SEQ ID NO: 513
ITR-43 left	SEQ ID NO: 532	ITR-27 right	SEQ ID NO: 514
ITR-44 left	SEQ ID NO: 533	ITR-28 right	SEQ ID NO: 515
ITR-45 left	SEQ ID NO: 534	ITR-29, right	SEQ ID NO: 516
ITR-46 left	SEQ ID NO: 535	ITR-30, right	SEQ ID NO: 517
ITR-47, left	SEQ ID NO: 536	ITR-31, right	SEQ ID NO: 518
ITR-48, left	SEQ ID NO: 537	ITR-32 right	SEQ ID NO: 519

[00321] In some embodiments, a ceDNA vector for expression of FVIII protein comprising an asymmetric ITR pair can comprise an ITR with a modification corresponding to any of the modifications in ITR sequences or ITR partial sequences shown in any one or more of **Tables 4A-4B** herein, or the sequences shown in FIG. 7A-7B of International Application PCT/US2018/064242, filed December 6, 2018, which is incorporated herein in its entirety, or disclosed in Tables 2, 3, 4, 5, 6, 7, 8, 9 or 10A-10B of International application PCT/US18/49996 filed September 7, 2018 which is incorporated herein in its entirety by reference.

V. Exemplary ceDNA vectors

[00322] As described above, the present disclosure relates to recombinant ceDNA expression vectors and ceDNA vectors that encode FVIII protein, comprising any one of: an asymmetrical ITR pair, a symmetrical ITR pair, or substantially symmetrical ITR pair as described above. In certain embodiments, the disclosure relates to recombinant ceDNA vectors for expression of FVIII protein having flanking ITR sequences and a transgene, where the ITR sequences are asymmetrical, symmetrical or substantially symmetrical relative to each other as defined herein, and the ceDNA further comprises a nucleic acid sequence of interest (for example an expression cassette comprising the nucleic acid of a transgene) located between the flanking ITRs, wherein said nucleic acid molecule is devoid of viral capsid protein coding sequences.

[00323] The ceDNA expression vector for expression of FVIII protein may be any ceDNA vector that can be conveniently subjected to recombinant DNA procedures including nucleic acid sequence(s) as described herein, provided at least one ITR is altered. The ceDNA vectors for expression of FVIII protein of the present disclosure are compatible with the host cell into which the ceDNA vector is to be introduced. In certain embodiments, the ceDNA vectors may be linear. In certain embodiments, the ceDNA vectors may exist as an extrachromosomal entity. In certain embodiments, the ceDNA vectors of the present disclosure may contain an element(s) that permits integration of a donor sequence into the host cell's genome. As used herein "transgene" and "heterologous nucleic acid sequence" are synonymous, and may encode a FVIII protein, as described herein.

[00324] ceDNA vectors are capsid-free and can be obtained from a plasmid encoding in this order: a first ITR, an expressible transgene cassette and a second ITR, where the first and second ITR sequences are asymmetrical, symmetrical or substantially symmetrical relative to each other as defined herein. ceDNA vectors for expression of FVIII protein are capsid-free and can be obtained from a plasmid encoding in this order: a first ITR, an expressible transgene (protein or nucleic acid) and a second ITR, where the first and second ITR sequences are asymmetrical, symmetrical or substantially symmetrical relative to each other as defined herein. In some embodiments, the expressible transgene cassette includes, as needed: an enhancer/promoter, one or more homology arms, a donor sequence, a post-transcription regulatory element (*e.g.*, WPRE, *e.g.*, SEQ ID NO: 67)), and a polyadenylation and termination signal (*e.g.*, BGH polyA, *e.g.*, SEQ ID NO: 68).

A. Regulatory elements

[00325] The ceDNA vectors for expression of FVIII protein as described herein comprising an asymmetric ITR pair or symmetric ITR pair as defined herein, can further comprise a specific combination of cis-regulatory elements. The cis-regulatory elements include, but are not limited to, a promoter, a riboswitch, an insulator, a mir-regulatable element, a post-transcriptional regulatory element, a tissue- and cell type-specific promoter and an enhancer. In some embodiments, the ITR can act as the promoter for the transgene, *e.g.*, FVIII protein. In some embodiments, the ceDNA vector for expression of FVIII protein as described herein comprises additional components to regulate expression of the transgene, for example, regulatory switches as described herein, to regulate the expression of the transgene, or a kill switch, which can kill a cell comprising the ceDNA vector encoding FVIII protein thereof. Regulatory elements, including Regulatory Switches that can be used in the present disclosure are more fully discussed in International application PCT/US18/49996, which is incorporated herein in its entirety by reference.

[00326] Described herein are ceDNA vectors that comprise a codon optimized FVII nucleic acid sequence and combined with particular *cis*-elements (*e.g.*, promoters, enhancers, specific promoter and enhancer combinations). According to some embodiments, particular codon optimized FVIII nucleic acid sequences perform better when combined with one or more specific promoter sequence and/or a specific enhancer sequence, compared to the same codon optimized FVIII nucleic acid sequence combined with another promoter sequence and/or a specific enhancer sequence.

(i) Promoters:

[00327] It will be appreciated by one of ordinary skill in the art that promoters used in the ceDNA vectors for expression of FVIII protein as disclosed herein are tailored as appropriate for the specific sequences they are promoting.

[00328] Expression cassettes of the ceDNA vector for expression of FVIII protein can contain tissue-specific eukaryotic promoters to limit transgene expression to specific cell types and reduce toxic

effects and immune responses resulting from unregulated, ectopic expression. The promoter region used may further include one or more additional regulatory sequences (*e.g.*, native), *e.g.*, enhancers.

[00329] In some embodiments, a promoter may also be a promoter from a human gene. The promoter may also be a tissue specific promoter, such as a liver specific promoter, such as human alpha 1-antitrypsin (HAAT). According to some embodiments, the promoter may be synthetic.

[00330] Non-limiting examples of suitable promoters for use in accordance with the present disclosure include any of the promoters described herein, or any of the following:

[00331] According to some embodiments, the promoter is hAAT core, the human a1 antitrypsin (hAAT) promoter (Core promoter sequence from human A1AT gene). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 210.

[00332] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 210. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 210. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 210. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 210. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 210. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 210. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 210. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 210.

[00333] According to some embodiments, the promoter is the minimal transthyretin promoter (TTRm). According to some embodiments, the TTRm promoter comprises the sequence set forth as SEQ ID NO: 211.

[00334] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 211. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 211. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 211. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 211. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 211. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 211. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 211. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 211.

[00335] According to some embodiments, the promoter is hAAT_core_C06, a CpG minimized version of the hAAT core promoter (A1AT gene promoter). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 212.

[00336] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 212. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 212. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 212. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 212. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 212. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 212. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 212. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 212.

[00337] According to some embodiments, the promoter is hAAT_core_C07, a CpG minimized version of the hAAT core promoter (A1AT gene promoter). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 213.

[00338] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 213. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 213. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 213. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 213. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 213. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 213. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 213. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 213.

[00339] According to some embodiments, the promoter is hAAT_core_C08, a CpG minimized version of the hAAT core promoter (A1AT gene promoter). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 214.

[00340] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 214. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 214. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 214. According to some embodiments, the promoter comprises a nucleic acid sequence at least

about 96% identical to SEQ ID NO: 214. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 214. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 214. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 214. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 214.

[00341] According to some embodiments, the promoter is hAAT_core_C09, a CpG minimized version of the hAAT core promoter (A1AT gene promoter). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 215.

[00342] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 215. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 215. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 215. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 215. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 215. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 215. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 215. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 215.

[00343] According to some embodiments, the promoter is hAAT_core_C10, a CpG minimized version of the hAAT core promoter (A1AT gene promoter). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 216.

[00344] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 216. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 216. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 216. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 216. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 216. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 216. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 216. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 216.

[00345] According to some embodiments, the promoter is hAAT_core_truncated, 5p truncated hAAT core promoter derived from hAAT_core (SEQ ID NO: 210). According to some embodiments, the hAAT promoter comprises the sequence set forth as SEQ ID NO: 217.

[00346] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 217. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 217. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 217. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 217. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 217. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 217. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 217. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 217.

[00347] **Table 6** lists core promoter sequences, and their corresponding SEQ ID NOs, that can be implemented in ceDNA FVIII therapeutics described herein.

Table 6. Core Promoters

	Name	Description	SEQ ID NO.
GE-015	hAAT_core	Core promoter sequence from human A1AT gene	210
GE-1121	TTRm	Core promoter sequence from mouse Transthyretin gene	211
GE-1133	hAAT_core_C06	CpG minimized version of the hAAT core promoter (A1AT gene promoter)	212
GE-1134	hAAT_core_C07	CpG minimized version of the hAAT core promoter (A1AT gene promoter)	213
GE-1135	hAAT_core_C08	CpG minimized version of the hAAT core promoter (A1AT gene promoter)	214
GE-1136	hAAT_core_C09	CpG minimized version of the hAAT core promoter (A1AT gene promoter)	215
GE-1137	hAAT_core_C10	CpG minimized version of the hAAT core promoter (A1AT gene promoter) (also referred to as hAAT(979))	216
GE-1170	hAAT_core_truncated	5p truncated hAAT core promoter derived from GE-015	217

[00348] According to particular embodiments, the promoter is selected from the group consisting of: the VandenDriessche (referred to as “VD” or “VanD”) promoter, human alpha 1-antitrypsin (hAAT) promoter (including the CpG minimized hAAT(979) promoter (CpGmin hAAT_core_C10) and other CpGmin_hAAT promoters like hAAT_core_C06; hAAT_core_C07; hAAT_core_C08; and hAAT_core_C09) and the transthyretin (TTR) liver specific promoter.

[00349] In some embodiments, the VD promoter comprises the minute virus mouse (MVM) intron, the minimal transthyretin promoter (TTRm), the serpin enhancer (72 bp) and TTRm 5' UTR. According to some embodiments, the TTRm comprises SEQ ID NO: 211. According to some embodiments, the serpin enhancer comprises tSEQ ID NO: 19. According to some embodiments, the TTRm 5'UTR comprises SEQ ID NO: 426.

[00350] According to further embodiments, the VD promoter comprises SEQ ID NO: 541.

[00351] According to some embodiments, the CpGmin_hAAT promoter comprises a sequence selected from any one of SEQ ID NOs: 212, 213, 214, 215 or 216.

(ii) *Enhancers*

[00352] In some embodiments, a ceDNA expressing FVIII comprises one or more enhancers. In some embodiments, an enhancer sequence is located 5' of the promoter sequence. In some embodiments, the enhancer sequence is located 3' of the promoter sequence. According to some embodiments, the enhancer is the enhancer region for Serpin1 gene (SerpEnh) as described by Chuah, M., *et al.* ((2014). Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates Molecular Therapy, 22(9), 1605-1613, incorporated by reference in its entirety herein).

[00353] According to some embodiments, the sequence of the serpin enhancer (SerpEnh) is set forth in SEQ ID NO: 198.

[00354] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 198.

[00355] According to some embodiments, the enhancer is the enhancer region for Transthyretin (TTRe) gene (TTRe). According to some embodiments, the sequence of the enhancer region for Transthyretin (TTRe) gene (TTRe) is set forth in SEQ ID NO: 199.

[00356] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 199. According to some embodiments, the enhancer consists of SEQ ID NO: 199. According to some embodiments, the enhancer is the Hepatic Nuclear Factor 1 binding site (HNF1). According to some embodiments, the sequence of the Hepatic Nuclear Factor 1 binding site (HNF1) is set forth in SEQ ID NO: 200.

[00357] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 200. According to some embodiments, the enhancer consists of SEQ ID NO: 200.

[00358] According to some embodiments, the enhancer is the Hepatic Nuclear Factor 4 binding site (HNF4). According to some embodiments, the sequence of the Hepatic Nuclear Factor 4 binding site (HNF4) is set forth in SEQ ID NO: 201.

[00359] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 201. According to some embodiments, the enhancer consists of SEQ ID NO: 201.

[00360] According to some embodiments, the enhancer is the Human apolipoprotein E/C-I liver specific enhancer (ApoE_Enh). According to some embodiments, the sequence of the Human apolipoprotein E/C-I liver specific enhancer (ApoE_Enh) is set forth in SEQ ID NO: 202.

[00361] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 202. According to some embodiments, the enhancer consists of SEQ ID NO: 202.

[00362] According to some embodiments, the enhancer is the Enhancer region from Pro-albumin gene (ProEnh). According to some embodiments, the sequence of the Enhancer region from Pro-albumin gene (ProEnh) is set forth in SEQ ID NO: 203.

[00363] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 203. According to some embodiments, the enhancer consists of SEQ ID NO: 203.

[00364] According to some embodiments, the enhancer is a CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer) (ApoE_Enh_C03, ApoE_Enh_C04, ApoE_Enh_C09, and ApoE_Enh_C10). According to some embodiments, the sequence of ApoE_Enh_C03, ApoE_Enh_C04, ApoE_Enh_C09 and ApoE_Enh_C10 are set forth in SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206 and SEQ ID NO: 207.

[00365] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 204. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 204.

[00366] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 205. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 205.

[00367] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 206. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 206.

According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 207. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 207.

[00368] According to some embodiments, the enhancer is the HCR1 footprint123 embedded in GE-856 (Embedded_HCR1_footprint123). According to some embodiments, the sequence of the HCR1 footprint123 embedded in GE-856 is set forth in SEQ ID NO: 208.

[00369] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 208. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 208.

[00370] According to some embodiments, the enhancer is the Hepatic nuclear factor enhancer array embedded in GE-856 (Embedded_enhancer_HNF_array). According to some embodiments, the sequence of the Hepatic nuclear factor enhancer array embedded in GE-856 is set forth in SEQ ID NO: 209.

[00371] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 209. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 209.

[00372] According to some embodiments, the enhancer is a derivative of Human apolipoprotein E/C-I liver specific enhancer (ApoE_enhancer_v2). According to some embodiments, the sequence of the ApoE_enhancer_v2 is set forth in SEQ ID NO: 485.

[00373] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 485. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 485.

[00374] According to some embodiments, the enhancer is a derivative of Serpin enhancer from bushbaby (Bushbaby SerpEnh). According to some embodiments, the bushbaby Serpin enhancer sequence is shown below as SEQ ID NO: 557:

GGGGGAAGCTACTGGTGAATATTAACCAAGGTCACCCAGTTATCAGGGAGCAAACAGGA
GCTAAGTCCAT and set forth in SEQ ID NO: 557.

[00375] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 557. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 557. According to some other embodiments, the bushbaby Serpin enhancer comprises 2x, 3x, 4x, 5x, 6x, 7x, and up to 10x repeats of the nucleic acid sequence comprising SEQ ID NO: 557, with or without a spacer sequence between each iteration of the sequence.

[00376] According to some embodiments, the enhancer is a derivative of Serpin enhancer from Chinese tree shrew (Chinese tree shrew SerpEnh). According to some embodiments, the Chinese tree shrew Serpin enhancer sequence is as follows:

GGAGGCTGTTGGTGAATATTAACCAAGGTCACCTCAGTTATCGGAGGAGCAAACAAGGG
CTAAGTCCAC and set forth in SEQ ID NO: 617.

[00377] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 617. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 617. According to some other embodiments, the

bushbaby Serpin enhancer comprises 2x, 3x, 4x, 5x, 6x, 7x, and up to 10x repeats of the nucleic acid sequence comprising SEQ ID NO: 617, with or without a spacer sequence between each iteration.

[00378] According to some embodiments, the enhancer is a derivative of Serpin enhancer from human SERPINA1 enhancer with FOXA & HNF4 consensus sites and internal CpG removed (HNF4_FOXA_v1). According to some embodiments, the HNF4_FOXA_v1 Serpin enhancer sequence is as follows:

[00379] GGGGGAGGCTGCTGGTAAACATTAACCAAGGTCACCCCAGTTATCAGAGGAGC AAACAGGGGCAAAGTCCAC and set forth in SEQ ID NO: 625.

[00380] According to some embodiments, the enhancer comprises a nucleic acid sequence at least about 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 625. According to some embodiments, the enhancer comprises, or consists of SEQ ID NO: 625. According to some other embodiments, the HNF4_FOXA_v1 Serpin enhancer comprises 2x, 3x, 4x, 5x, 6x, 7x, and up to 10x repeats of the nucleic acid sequence comprising SEQ ID NO: 625, with or without a spacer sequence between each iteration.

[00381] A summary of these enhancers that can be utilized in ceDNA FVIII constructs is listed in Table 7.

Table 7. Enhancers

GE-##	Name (Abbreviation)	Description	SEQ ID NO.
GE-1115	Human Serpin Enhancer (hSerpEnh)	Enhancer region for Serpin1 gene as reported Chuah, M., et al. (2014). Liver-Specific Transcriptional Modules Identified by Genomewide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates Molecular Therapy 22(9), 1605-1613. dx.doi.org/10.1038/mt.2014.114	198
GE-1116	TTRe	Enhancer region for Transthyretin gene	199
GE-1117	HNF1	Hepatic Nuclear Factor 1 binding site	200
GE-1118	HNF4	Hepatic Nuclear Factor 4 binding site	201
GE-1119	ApoE_Enh	Human apolipoprotein E/C-I liver specific enhancer	202
GE-1120	ProEnh	Enhancer region from Pro-albumin gene	203
GE-1129	ApoE_Enh_C03	CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer)	204
GE-1130	ApoE_Enh_C04	CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer)	205
GE-1131	ApoE_Enh_C09	CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer)	206
GE-1132	ApoE_Enh_C10	CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer)	207

GE-1127	Embedded_HCR1_footprint 123	HCR1 footprint123 embedded in GE-856 (aka between GE-859/GE-860)	208
GE-1128	Embedded_enhancer_HNF_ array	Hepatic nuclear factor enhancer array embedded in GE-856 (aka between GE- 859/GE-860)	209
GE-1237	ApoE_Enh_v2	Derivative of Human apolipoprotein E/C-I liver specific enhancer	485
	3x_HNF4_FOXA_v1	3x repeat of the Human SERPINA1 enhancer with FOXA & HNF4 consensus sites spacer in bold	558
	3x_HNF4_FOXA_v1_CpGmi n	3x repeat of HNF4_FOXA_v1 with CpG minimization	559
	3x_HNF4_FOXA_v1_Second aryStruct_min_v1	3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization v1	560
	3x_HNF4_FOXA_v1_Second aryStruct_min_v1_CpG_min	3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization and CpG minimization v1	561
	3x_HNF4_FOXA_v1_Second aryStruct_min_v2	(3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization v2 ("C" spacer))	562
	3x_HNF4_FOXA_v1_Second aryStruct_min_v2_CpG_min	(3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization and CpG minimization v2 ("A" spacer))	563
	3x_HNF4_FOXA_v1_Second aryStruct_min_v3	(3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization v3 ("C" spacer))	564
	3x_HNF4_FOXA_v1_Second aryStruct_min_v3_CpG_min	(3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization and CpG minimization v3 ("A" spacer))	565
	3x_HNF4_FOXA_v1_Second aryStruct_min_v4_Aspacers	("A" spacer inbetween the repeats) (3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization v4 (2585))	566
	3x_HNF4_FOXA_v1_Second aryStruct_min_v5_Aspacers	("A" spacer inbetween the repeats) (3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization v5)	567
	3x_HNF4_FOXA_v1_Second aryStruct_min_v6_Aspacers	("A" spacer inbetween the repeats) (3x repeat of HNF4_FOXA_v1 with poly- C/poly-G minimization v6)	568
	3x_ChineseTreeShrew	(3x repeat of the Chinese Tree Shrew SERPINA1 enhancer ("C" spancer inbetween the repeats))	569
	3x_ChineseTreeShrew_CpG min	(3x repeat of the Chinese Tree Shrew SERPINA1 enhancer with CpG minimization)	570

	3x_hSerpEnh_Aspacers	(3x repeat of the human SERPINA1 enhancer with 1 adenine between the repeats ("A" spacer))	571
	3x_Bushbaby_Aspacers	(3x repeat of the Bushbaby SERPINA1 enhancer with adenine nucleotide spacer ("A" spacer))	572
	5x_HNF4_FOXA_v1	(5x repeat of HNF4_FOXA_v1 ("C" spacer))	573
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v1 (	5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v1 ("C" spacer))	574
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v1_CpG_min	5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization and CpG minimization v1 ("AG" spacer))	575
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v2	(5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v2 ("C" spacer))	576
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v2_CpG_min	5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization and CpG minimization v2 ("A" spacer))	577
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v3	(5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v3 ("C" spacer))	578
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v3_CpG_min	5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization and CpG minimization v3)	579
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v4_Aspacers	(5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v4)	580
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v5_Aspacers)	(5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v5)	581
	5x_HNF4_FOXA_v1_SecondaryStruct_min_v6_Aspacers	(5x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v6)	582
	5x_ChineseTreeShrew	(5x repeat of the Chinese Tree Shrew SERPINA1 enhancer)	583

5x_ChineseTreeShrew_CpG_min	(5x repeat of the Chinese Tree Shrew SERPINA1 enhancer with CpG minimization)	584
5x_Bushbaby_Aspacers	(5x repeat of the Bushbaby SERPINA1 enhancer with adenine nucleotide spacer)	585
10x_HNF4_FOXA_v1	(10x repeat of HNF4_FOXA_v1)	586
10x_HNF4_FOXA_v1_SecondaryStruct_min_v1	(10x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v1)	587
10x_HNF4_FOXA_v1_SecondaryStruct_min_v1_CpG_min	(10x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization and CpG minimization v1)	588
10x_HNF4_FOXA_v1_SecondaryStruct_min_v2	(10x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v2)	589
10x_HNF4_FOXA_v1_SecondaryStruct_min_v2_CpG_min	(10x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization and CpG minimization v2)	590
10x_HNF4_FOXA_v1_SecondaryStruct_min_v3	(10x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization v3)	591
10x_HNF4_FOXA_v1_SecondaryStruct_min_v3_CpG_min	(10x repeat of HNF4_FOXA_v1 with poly-C/poly-G minimization and CpG minimization v3)	592
10x_hSerpEnh	(10x repeat of the human SERPINA1 enhancer ("C" spacer))	593
10x_Bushbaby_Aspacers	(10x repeat of the Bushbaby SERPINA1 enhancer with adenine nucleotide spacer)	594
Bushbaby_HNF4/FOXv1_HNF4mod	(Bushbaby SERPINA1 enhancer, FOXA_HNF4_v1 enhancer, HNF4 consensus binding site enhancer)	595
HNF4mod_BushbabyMod_HNF4/FOXv1	(HNF4 consensus binding site enhancer, Bushbaby SERPINA1 enhancer, FOXA_HNF4_v1 enhancer)	596

	3x_hSerpEnh_2mer_spacers_v1	(3x repeat of hSerpEnh with 2mer spacers v1 (bold underlined))	597
	3x_hSerpEnh_2mer_spacers_v4	(3x repeat of hSerpEnh with 2mer spacers v4 (bold underlined))	598
	3x_hSerpEnh_2mer_spacers_v8	(3x repeat of hSerpEnh with 2mer spacers v8 (bold underlined))	599
	3x_hSerpEnh_2mer_spacers_v9	(3x repeat of hSerpEnh with 2mer spacers v9 (bold underlined))	600
	3x_hSerpEnh_2mer_spacers_v10	(3x repeat of hSerpEnh with 2mer spacers v10 (bold underlined))	601
	3x_hSerpEnh_2mer_spacers_v12	(3x repeat of hSerpEnh with 2mer spacers v12 (bold underlined))	602
	3x_hSerpEnh_2mer_spacers_v17	(3x repeat of hSerpEnh with 2mer spacers v17 (bold underlined))	603
	3x_hSerpEnh_3mer_spacers_v1	(3x repeat of hSerpEnh with 3mer spacers v1 (bold underlined))	604
	3x_hSerpEnh_3mer_spacers_v2	(3x repeat of hSerpEnh with 3mer spacers v2 (bold underlined))	605
	3x_hSerpEnh_5mer_spacers_v1	(3x repeat of hSerpEnh with 5mer spacers v1 (bold underlined))	606
	3x_hSerpEnh_5mer_spacers_v2	(3x repeat of hSerpEnh with 5mer spacers v2 (bold underlined))	607
	3x_hSerpEnh_5mer_spacers_v3	(3x repeat of hSerpEnh with 5mer spacers v3 (bold underlined))	608
	3x_hSerpEnh_11mer_spacers_v1	(3x repeat of hSerpEnh with 11mer spacers v1 (bold underlined))	609
	3x_hSerpEnh_11mer_spacers_v2	(3x repeat of hSerpEnh with 11mer spacers v2 (bold underlined))	610

	3x_hSerpEnh_11mer_spacers_v3	(3x repeat of hSerpEnh with 11mer spacers v3 (bold underlined))	611
	3x_hSerpEnh_11mer_spacers_HNF4former_spacers_FOX Afor	(3x repeat of hSerpEnh with 11mer spacers (bold underlined) with HNF4 binding site in orientation 1 & FOXA binding site in orientation 1)	612
	3x_hSerpEnh_11mer_spacers_HNF4former_spacers_FOX Arev (3x repeat of hSerpEnh with 11mer spacers (bold underlined) with HNF4 binding site in orientation 1 & FOXA binding site in orientation 2)	11mer spacers (bold underlined) with HNF4 binding site in orientation 2 & FOXA binding site in orientation 1)	613
	3x_hSerpEnh_11mer_spacers_HNF4revmer_spacers_FOX Afor (3x repeat of hSerpEnh with	11mer spacers (bold underlined) with HNF4 binding site in orientation 2 & FOXA binding site in orientation 1)	614
	3x_hSerpEnh_11mer_spacers_HNF4revmer_spacers_FOX Arev	(3x repeat of hSerpEnh with 11mer spacers (bold underlined) with HNF4 binding site in orientation 2 & FOXA binding site in orientation 2)	615
	3x_hSerpEnh_30mer_spacers_v1	(3x repeat of hSerpEnh with 30mer spacers v1 (bold underlined))	616

[00382] In some other embodiments, the enhancers can be used in tandem.

Promoter sets

[00383] According to some embodiments, the promoter comprises a synthetic liver specific promoter set including enhancers and core promoter, without 5pUTR, referred to as a promoter set.

[00384] According to some embodiments, the 3xHNF1-4_ProEnh (Pro-albumin enhancer) enhancer fused to TTR promoter comprises the sequence set forth in SEQ ID NO:184.

According to some embodiments, the 3xHNF1-4_ProEnh (Pro-albumin enhancer) enhancer fused to 3x VanD-TTRe and TTR promoter comprises the sequence set forth in SEQ ID NO: 185.

[00385] According to some embodiments, the 5xHNF1_ProEnh_enhancer fused to TTR promoter comprises the sequence set forth in SEQ ID NO: 186. According to some embodiments, the 5xHNF1_ProEnh_enhancer fused to 3x SerpEnh VD-TTRe and TTR promoter comprises the sequence set forth in SEQ ID NO:187.

[00386] According to some embodiments, the promoter set (promoter set 1471) comprises the sequence set forth as SEQ ID NO: 184.

[00387] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 184. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 184. According to some

embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 184. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 184. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 184. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 184. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 184. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 184.

[00388] According to some embodiments, the promoter set (promoter set 1472) comprises the sequence set forth as SEQ ID NO: 185.

[00389] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 185. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 185. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 185. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 185. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 185. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 185. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 185. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 185.

[00390] According to some embodiments, the promoter set (promoter set 1473) comprises the sequence set forth as SEQ ID NO: 186.

[00391] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 186. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 186. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 186. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 186. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 186. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 186. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 186. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 186.

[00392] According to some embodiments, the promoter set (promoter set 1474) comprises the sequence set forth as SEQ ID NO: 187.

[00393] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 187. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 187. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 187. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 187. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 187. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 187. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 187. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 187.

[00394] According to some embodiments, the promoter set (promoter set 1475) comprises the sequence set forth as SEQ ID NO: 484.

[00395] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 484. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 484. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 484. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 484. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 484. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 484. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 484. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 484.

[00396] According to some embodiments, the promoter set (promoter set 1476) comprises the sequence set forth as SEQ ID NO: 189.

[00397] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 189. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 189. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 189. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 189. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 189. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 189. According to some embodiments, the promoter comprises a nucleic acid sequence at least

about 99% identical to SEQ ID NO: 189. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 189.

[00398] According to some embodiments, the promoter set (promoter set 1477) comprises the sequence set forth as SEQ ID NO: 190.

[00399] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 190. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 190. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 190. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 190. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 190. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 190. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 190. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 190.

[00400] According to some embodiments, the promoter set (promoter set 1478) comprises the sequence set forth as SEQ ID NO: 191.

[00401] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 191. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 191. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 191. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 191. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 191. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 191. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 191. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 191.

[00402] According to some embodiments, the promoter set (promoter set 1479) comprises the sequence set forth as SEQ ID NO: 192.

[00403] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 192. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 192. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 192. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 192. According to some embodiments, the promoter comprises a

nucleic acid sequence at least about 97% identical to SEQ ID NO: 192. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 192. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 192. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 192.

[00404] According to some embodiments, the promoter set (promoter set 1480) comprises the sequence set forth as SEQ ID NO: 193.

[00405] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 193. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 193. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 193. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 193. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 193. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 193. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 193. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 193.

[00406] According to some embodiments, the promoter set (promoter set 1368) comprises the sequence set forth as SEQ ID NO: 194.

[00407] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 194. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 194. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 194. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 194. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 194. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 194. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 194. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 194.

[00408] According to some embodiments, the promoter set (promoter set 1648) comprises the sequence set forth as SEQ ID NO: 195).

[00409] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 195. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 195. According to some

embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 195. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 195. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 195. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 195. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 195. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 195.

[00410] According to some embodiments, the promoter set (promoter set 1657) comprises the sequence set forth as SEQ ID NO: 196.

[00411] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 196. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 196. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 196. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 196. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 196. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 196. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 196. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 196.

[00412] According to some embodiments, the promoter set (promoter set 1622) comprises the sequence set forth as SEQ ID NO: 197.

[00413] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 197. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 197. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 197. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 197. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 197. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 197. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 197. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 197.

[00414] According to some embodiments, the promoter set (promoter set 1664) comprises the sequence set forth as SEQ ID NO: 400.

[00415] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 400. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 400. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 400. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 400. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 400. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 400. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 400. According to some embodiments, the promoter consists of the nucleic acid sequence of SEQ ID NO: 400.

[00416] According to some embodiments, the promoter set (promoter set 979) comprises the sequence set forth as SEQ ID NO: 401.

[00417] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 401. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 401.

[00418] According to some embodiments, the promoter set (promoter set 2558) comprises the sequence set forth as SEQ ID NO: 617.

[00419] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises a nucleic acid sequence at least

about 99% identical to SEQ ID NO: 617. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 617.

[00420] According to some embodiments, the promoter set (promoter set 2559) comprises the sequence set forth as SEQ ID NO: 618.

[00421] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 618. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 618.

[00422] According to some embodiments, the promoter set (promoter set 2560) comprises the sequence set forth as SEQ ID NO: 619.

[00423] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 619. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 619.

[00424] According to some embodiments, the promoter set (promoter set 2580) comprises the sequence set forth as SEQ ID NO: 620.

[00425] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises a

nucleic acid sequence at least about 97% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 620. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 620.

[00426] According to some embodiments, the promoter set (promoter set 2583) comprises the sequence set forth as SEQ ID NO: 621.

[00427] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 621. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 621.

[00428] According to some embodiments, the promoter set (promoter set 2584) comprises the sequence set forth as SEQ ID NO: 622.

[00429] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 622. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 622.

[00430] According to some embodiments, the promoter set (promoter set 2588) comprises the sequence set forth as SEQ ID NO: 623.

[00431] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 623. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 623. According to some

embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 623. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 623. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 623. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 623. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 623. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 623.

[00432] According to some embodiments, the promoter set (promoter set 2589) comprises the sequence set forth as SEQ ID NO: 624.

[00433] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises, or consists of, the nucleic acid sequence of SEQ ID NO: 624.

[00434] A summary of promoter sets that can be utilized in ceDNA FVIII constructs are shown in **Table 8** and in **Table 9**.

Table 8: Promoter Sets

GE	Name	Description	SEQ ID NO.
GE-1223	PromoterSet - 1471	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	184
GE-1224	PromoterSet - 1472	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	185
GE-1225	PromoterSet - 1473	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	186
GE-1226	PromoterSet - 1474	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	187
GE-1227	PromoterSet - 1475	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	188
GE-1228	PromoterSet - 1476	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	189

GE-1229	PromoterSet - 1477	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	190
GE-1230	PromoterSet - 1478	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	191
GE-1231	PromoterSet - 1479	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	192
GE-1232	PromoterSet - 1480	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	193
GE-1233	PromoterSet - 1368	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	194
GE-1234	PromoterSet- 1648	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	195
GE-1235	PromoterSet for ceDNA1657	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	196
GE-1236	PromoterSet- 1622	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	197
GE-1270	PromoterSet - 1664	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	400
GE-1271	PromoterSet - 979	Synthetic Liver specific PromoterSet including enhancers and core promoter (without 5pUTR)	401
GE-1690	PromoterSet- 2558	Promoter formed by contentation of 1) 3x repeat of HNF4_FOXA_v1 with reduction of poly-C/poly-G sequences and reduction of CpGs introduced by multimerization and concatenation with backbone sequences (v1). Repeats are separated by an adenine. 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	641
GE-1691	PromoterSet- 2559	Promoter formed by contentation of 1) 3x repeat of HNF4_FOXA_v1 with reduction of poly-C/poly-G sequences (v2). Repeats are separated by a cytosine. 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	618
GE-1692	PromoterSet- 2560	Promoter formed by contentation of 1) 3x repeat of HNF4_FOXA_v1 with reduction of poly-C/poly-G sequences and reduction of CpGs introduced by multimerization and concatenation with backbone sequences (v2.) Repeats are separated by an adenine. 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	619
GE-1693	PromoterSet- 2580	Promoter formed by contentation of 1) 3x repeat of the SerpEnh_Bushbaby enhancer with adenine nucleotide spacer. Repeats are separated by an adenine. 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	620

GE-1694	PromoterSet-2583	Promoter formed by contentation of 1) 3 SERPINA1 enhancer variants: a) SerpEnh_Bushbaby, b) HNF4_FOXA_v1, c) human SERPINA1 enhancer with an HNF4 consensus site, internal CpG removed, and poly-C/poly-G regions reduced 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	621
GE-1695	PromoterSet-2584	Promoter formed by contentation of 1) 3 SERPINA1 enhancer variants: a) human SERPINA1 enhancer with an HNF4 consensus site, internal CpG removed, and poly-C/poly-G regions reduced, b) SerpEnh_Bushbaby with the second G changed to A, c) FOXA_HNF4_v1, 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	622
GE-1696	PromoterSet-2588	Promoter formed by contentation of 1) 3x repeat of the Chinese Tree Shrew SERPINA1 enhancer. Repeats separated by a cytosine. 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	623
GE-1697	PromoterSet-2589	Promoter formed by contentation of 1) 3x repeat of the Chinese Tree Shrew SERPINA1 enhancer with CpG reduction. Repeats separated by an adenine. 2) KpnI site 3) enhancer region for the murine transthyretin gene 4) XbaI site and BamHI site 5) murine transthyretin promoter	624

Table 9. Promoter sets: Combinations of the hAAT CpG minimized enhancer and core promoters CpG minimized hAAT core_C10 (hAAT_979) or hAAT_core_C06); combinations of the HNF4/FOXA - TTR and TTR promoter; combinations of the bushbaby variant enhancer repeats and TTR and TTR promoter; combinations of the Chinese tree shrew enhancer repeats and TTR and TTR promoter.

Name	SEQ ID NO.
PromoterSet-970	402
PromoterSet-971	403
PromoterSet-972	404
PromoterSet-973	405
PromoterSet-974	406
PromoterSet-975	407
PromoterSet-976	408
PromoterSet-977	409
PromoterSet-978	410
PromoterSet-2558	641
PromoterSet-2559	618
PromoterSet-2560	619
PromoterSet-2580	620
PromoterSet-2583	621
PromoterSet-2584	622

PromoterSet-2588	623
PromoterSet-2589	624

[00435] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 402. According to some embodiments, the promoter comprises, or consists of the nucleic acid sequence of SEQ ID NO: 402.

[00436] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 403. According to some embodiments, the promoter comprises, or consists of the nucleic acid sequence of SEQ ID NO: 403.

[00437] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 404. According to some embodiments, the promoter comprises, or consists of the nucleic acid sequence of SEQ ID NO: 404.

[00451] According to some embodiments, the promoter comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 624. According to some embodiments, the promoter comprises, or consists of the nucleic acid sequence of SEQ ID NO: 624.

(iii) *5' UTR sequences and intron sequences*

[00452] In some embodiments, a cDNA vector comprises a 5' UTR sequence and/or an intron sequence that located 3' of the 5' ITR sequence. In some embodiments, the 5' UTR is located 5' of the transgene, *e.g.*, sequence encoding the FVIII protein. According to some embodiments, the 5' UTR sequence is selected from those listed in **Table 10** below and in International Application No. PCT/US2020/021328, for example in Table 9A, incorporated by reference in its entirety herein.

Table 10. 5' UTR

GE ##	Name	Description	SEQ ID NO.
GE-1124	TTR-MVM-PmeI-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron, 3) PmeI restriction site, and 4) consensus kozak sequence	411
GE-1125	TTR-MVM_v2-PmeI-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron_v2, 3) PmeI restriction site, and 4) consensus kozak sequence	412
GE-1126	TTR-MVM-PmeI*-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron, 3) Mutated PmeI restriction site, and 4) consensus kozak sequence	413
GE-1138	hAAT-5pUTR_v2	5pUTR region derived from SERPINA1 (A1AT) gene	414
GE-1167	TTR-MVMspliced-PmeI-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) Spliced form of Minute Virus of Mouse Intron, 3) PmeI restriction site, and 4) consensus kozak sequence	415
GE-772	5pUTR-325243	5pUTR variable region #325243	416

GE-774	5pUTR-constant	5pUTR constant region	417
GE-1208	hAAT-SV40-PmeI-Mod-5pUTR	5pUTR formed form concatenation of 1) the hAAT promoter 5pUTR, 2) SV40 intron, 3) PmeI restriction site, and 4) modified kozak sequence	418
GE-1209	hAAT-SV40-PmeI-Mod2-5pUTR	5pUTR formed form concatenation of 1) the hAAT promoter 5pUTR, 2) SV40 intron, 3) PmeI restriction site, and 4) modified kozak sequence v2	419
GE-1210	hAAT-SV40-PmeI-Con-5pUTR	5pUTR formed form concatenation of 1) the hAAT promoter 5pUTR, 2) SV40 intron, 3) PmeI restriction site, and 4) consensus kozak sequence	420
GE-1211	hAAT-SV40-PmeI-325243-5pUTR	5pUTR formed form concatenation of 1) the hAAT promoter 5pUTR, 2) SV40 intron, 3) PmeI restriction site, and 4) 325243-5pUTR	421
GE-1212	hAAT-SV40-PmeI-536-5pUTR	5pUTR formed form concatenation of 1) the hAAT promoter 5pUTR, 2) SV40 intron, 3) PmeI restriction site, and 4) 536-kozak	422
GE-1219	TTR-XbaI-MVM-PmeI-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) XbaI restriction site, 3) Minute Virus of Mouse Intron, 4) PmeI restriction site, and 5) consensus kozak sequence	423
GE-1220	TTR-XbaI-MVM_v2-PmeI-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) XbaI restriction site, 3) Minute Virus of Mouse Intron_v2, 4) PmeI restriction site, and 5) consensus kozak sequence	424
GE-1221	TTR-XbaI-MVM-PmeI*-Consensus-5pUTR	5pUTR formed form concatenation of 1) the Transthyretin promoter 5pUTR, 2) XbaI restriction site, 3) Minute Virus of Mouse Intron, 4) Mutated PmeI restriction site, and 5) consensus kozak sequence	425
GE-1122	TTR-5pUTR	5pUTR from mouse Transthyretin gene	426
GE-1260	hAAT-PmeI-Mod2-5pUTR	5pUTR formed by concatenation of 1) the hAAT promoter 5pUTR, 3) PmeI restriction site, and 4) modified kozak sequence v2	427
GE-1261	TTR-MVM_v2-PmeI-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron_v2, 3) PmeI restriction site, and 4) Mod_Minimum_Consensus_Kozak_v2	428
GE-1262	TTR-MVM-PmeI-325243-5pUTR Copy	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron, 3) PmeI restriction site, and 4) 325243-5pUTR	429
GE-1263	TTR-MVM-PmeI*-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron, 3) Mutated PmeI	430

		restriction site, and 4) Mod_Minimum_Consensus_Kozak_v2	
GE-1264	TTR-MVM-PmeI-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) Minute Virus of Mouse Intron, 3) PmeI restriction site, and 4) Mod_Minimum_Consensus_Kozak_v2	431
GE-1265	TTR-MVMspliced-PmeI-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) Spliced form of Minute Virus of Mouse Intron, 3) PmeI restriction site, and 4) Mod_Minimum_Consensus_Kozak_v2	432
GE-1266	TTR-XbaI-MVM_v2-PmeI-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) XbaI restriction site, 3) Minute Virus of Mouse Intron_v2, 4) PmeI restriction site, and 5) Mod_Minimum_Consensus_Kozak_v2	433
GE-1267	TTR-XbaI-MVM-PmeI*-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) XbaI restriction site, 3) Minute Virus of Mouse Intron, 4) Mutated PmeI restriction site, and 5) Mod_Minimum_Consensus_Kozak_v2	434
GE-1268	TTR-XbaI-MVM-PmeI-Mod2-5pUTR	5pUTR formed by concatenation of 1) the Transthyretin promoter 5pUTR, 2) XbaI restriction site, 3) Minute Virus of Mouse Intron, 4) PmeI restriction site, and 5) Mod_Minimum_Consensus_Kozak_v2	435
GE-1269	hAAT-PmeI-Con-5pUTR	5pUTR formed by concatenation of 1) the hAAT promoter 5pUTR, 3) PmeI restriction site, and 4) Consensus Kozak Sequence	436

[00453] According to some embodiments, the 5'-UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of any one of the sequences set forth as SEQ ID NOS: 411-436.

[00454] According to some embodiment, a ceDNA vector comprises an intron sequence that is located 3' of the 5' ITR sequence. According to some embodiment, a ceDNA vector comprises an intron sequence that is located within the ORF of FVIII, inbetween two exons. According to some embodiments, the intron sequence is selected from those listed in **Table 11** below, which provides the sequence identifier and a description of the intron.

Table 11. Introns

SEQ ID NO	Description
235	Intron from Minute Virus of Mouse (MVM)
236	Intron from Minute Virus of Mouse with additional 'G' residue included in Splice Acceptor flanking sequence
237	Modified intron from SV40 virus
238	mini Factor VIII intron 1 chimera, 50 nucleotides from 5'-end of intron, 100 nucleotides from 3'-end of intron

239	mini Factor VIII intron 1 chimera, 50 nucleotides from 5'-end of intron, 200 nucleotides from 3'-end of intron
240	mini Factor VIII intron 1 chimera, 200 nucleotides from 5'-end of intron, 200 nucleotides from 3'-end of intron
241	mini Factor VIII intron 1 chimera, 500 nucleotides from 5'-end of intron, 500 nucleotides from 3'-end of intron
242	human beta globin intron 1
243	Human Factor VIII intron 8
244	Human Factor VIII intron 16
245	first (5') 200 bps of Factor VIII intron 1, used for annotation of embedded enhancers
246	last (3') 200 bps of Factor VIII intron 1, used for annotation of embedded enhancers
247	Predicted Sequence of MVM intron (GE-023) post splicing
248	Intron from Minute Virus of Mouse with flanking exon regions removed

[00455] According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 235. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 235. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 236. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 236. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 237. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 237. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 238. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 238. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 239. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 239. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 240. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 240. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 241. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 241. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 242. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 242. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 243. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 243. According to some

embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 244. According to some embodiments, the intron sequence consists of SEQ ID NO: 244. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 245. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 245. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 246. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 246. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 247. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 247. According to some embodiments, the intron sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 248. According to some embodiments, the intron sequence comprises, or consists of SEQ ID NO: 248.

(iv) *Exon sequences*

[00456] According to some embodiment, a cDNA vector comprises an exon sequence. According to some embodiments, the exon sequence is selected from those listed in **Table 12** below, which provides the sequence identifier and a description of the exon.

Table 12.

SEQ ID NO	Description
293	Exon1 from FVIII ORF hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD with 33bp of WT ORF sequence upstream of the splice donor site of intron1
294	Exon2-26 from FVIII ORF hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD with 33bp of WT ORF sequence downstream of the splice acceptor site of intron1
295	Exon1 from FVIII ORF _hFVIII-F309S-BD226seq124-Afstyla-BDD with 33bp of WT ORF sequence upstream of the splice donor site of intron1
296	Exon2-26 from FVIII ORF _hFVIII-F309S-BD226seq124-Afstyla-BDD with 33bp of WT ORF sequence downstream of the splice acceptor site of intron1
297	exon1 from FVIII ORF: hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD
298	exon2-26 from FVIII ORF: hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD
299	exon1 from FVIII ORF: hFVIII-F309S-BD226seq124-Afstyla-BDD
300	exon2-26 from FVIII ORF: _hFVIII-F309S-BD226seq124-Afstyla-BDD
301	33bp of WT hFVIII ORF sequence downstream of the splice acceptor site of intron1
302	33bp of WT hFVIII ORF sequence upstream of the splice donor site of intron1

[00457] According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 293. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 293. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%,

96%, 97%, 98%, 99% identical to SEQ ID NO: 294. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 294. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 295. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 295. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 296. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 296. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 297. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 297. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 298. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 298. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 299. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 299. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 300. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 300. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 301. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 301. According to some embodiments, the exon sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 302. According to some embodiments, the exon sequence comprises, or consists of SEQ ID NO: 302.

(v) 3' UTR sequences

[00458] In some embodiments, a ceDNA vector comprises a 3' UTR sequence that located 5' of the 3' ITR sequence. In some embodiments, the 3' UTR is located 3' of the transgene, *e.g.*, sequence encoding the FVIII protein. According to some embodiments, the 3' UTR sequence is selected from those listed in **Table 13** below, which provides the sequence identifier and a description of the 3' UTR.

Table 13.

SEQ ID NO	Description (name)
283	Poly A signal derived from gene encoding bovine growth hormone (bGH)
284	Postranscriptional regularoty element derived from Woodchuck Hepatitis Virus (WPRES_3pUTR)
285	PolyA region from SV40 virus (SV40_polyA)

286	Derived from Human hemoglobin beta (HBB) gene 3pUTR (HBB_3pUTR)
287	Derived from Human hemoglobin beta (HBB) gene 3pUTR (HBBv3_3pUTR)
288	Derived from Human hemoglobin beta (HBB) gene 3pUTR (HBBv2_3pUTR)
289	Derived from Human hemoglobin beta (HBB) gene 3pUTR (HBBv3_CpGmin)
290	Derived from Human hemoglobin beta (HBB) gene 3pUTR (HBBv2_CpGmin)
291	Derived from Human hemoglobin beta (HBB) gene 3pUTR (HBB-3pUTR-CpGmin_v1)
634	Shortened WPRE3 sequence with minimal gamma and alpha element (ref: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975461/), modified to remove ATG's generating cryptic ORFs > 25 aa (WPRE_3pUTR_v3-ATG)

WPRE_3pUTR_v3-ATG

GTAAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCTTAACATGTTGCTCCTTTTACGCTGTGTGGATACGCTGCTTTATAGCCTCTGTATCTAGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTAGTTCTTGCCACGGCGGAACTCATCGCCGCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCCGTGG (SEQ ID NO: 634)

[00459] According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 283. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 283. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 284. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 284. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 285. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 285. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 286. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 286. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 287. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 287. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 288. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 288. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 289. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 289. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 290. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO:

290. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 291. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 291. According to some embodiments, the 3' UTR sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 634. According to some embodiments, the 3' UTR sequence comprises, or consists of SEQ ID NO: 634.

(v) *Polyadenylation Sequences:*

[00460] A sequence encoding a polyadenylation sequence can be included in the ceDNA vector for expression of FVIII protein to stabilize an mRNA expressed from the ceDNA vector, and to aid in nuclear export and translation. In one embodiment, the ceDNA vector does not include a polyadenylation sequence. In other embodiments, the ceDNA vector for expression of FVIII protein includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 45, at least 50 or more adenine dinucleotides. In some embodiments, the polyadenylation sequence comprises about 43 nucleotides, about 40-50 nucleotides, about 40-55 nucleotides, about 45-50 nucleotides, about 35-50 nucleotides, or any range there between. The expression cassettes can include any poly-adenylation sequence known in the art or a variation thereof. In some embodiments, a poly-adenylation (polyA) sequence is selected from any of those listed in International Application No. PCT/US2020/021328, for example in Table 10, incorporated by reference in its entirety herein. Other polyA sequences commonly known in the art can also be used, *e.g.*, including but not limited to, naturally occurring sequence isolated from bovine BGHpA (*e.g.*, SEQ ID NO: 68) or a virus SV40pA (*e.g.*, SEQ ID NO: 86), or a synthetic sequence (*e.g.*, SEQ ID NO: 87). Some expression cassettes can also include SV40 late polyA signal upstream enhancer (USE) sequence. In some embodiments, a USE sequence can be used in combination with SV40pA or heterologous poly-A signal. PolyA sequences are located 3' of the transgene encoding the FVIII protein. The expression cassettes can also include a post-transcriptional element to increase the expression of a transgene. In some embodiments, Woodchuck Hepatitis Virus (WHP) posttranscriptional regulatory element (WPRE) (*e.g.*, SEQ ID NO: 67) is used to increase the expression of a transgene. Other posttranscriptional processing elements such as the post-transcriptional element from the thymidine kinase gene of herpes simplex virus, or hepatitis B virus (HBV) can be used. Secretory sequences can be linked to the transgenes, *e.g.*, VH-02 and VK-A26 sequences, *e.g.*, SEQ ID NO: 88 and SEQ ID NO: 89.

(vi) *DNA Nuclear Targeting Sequences (DTS)*

In some embodiments, the ceDNA vector for expression of FVIII protein comprises one or more DNA nuclear targeting sequences (DTS), for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more DTSs. In some embodiments, the one or more DTSs are located at or near the amino-terminus, at or near the carboxy-terminus, or a combination of these (*e.g.*, one or more NLS at the amino-terminus and/or one or more

NLS at the carboxy terminus). When more than one DTS is present, each can be selected independently of the others, such that a single DTS is present in more than one copy and/or in combination with one or more other DTSs present in one or more copies. According to some embodiments, the DTS is selected from those listed in **Table 14** below, which provides the sequence identifier, a description of the DTS, and name.

Table 14.

SEQ ID NO	Description	Name
303	"nuclear factor kappa B (NFκB) transcription factor binding site triplet, comprising three 10-bp κB sites (GGGACTTTCC (SEQ ID NO: 546)) separated by a 5-bp optimized spacer (AGCTG)"	3NF_DTS
304	CpG-minimized spacer optimized for priming in PCR	3'DTS_primer_pad
305	CpG-minimized spacer optimized for priming in PCR	5'DTS_primer_pad
306	5X repeat of Igk κB motif 5'-GGGGACTTTCC-3' (SEQ ID NO: 548), 3 bp spacer, as described by Mesika <i>et al.</i> , 2001 Mol Ther	5x_κB_mesika_DTS
307	2X repeat of glucocorticoid response element (GRE; origin not described), SalI restriction site as spacer, as described by Dames <i>et al.</i> , 2007 J Gene Med	2x_GRE_dames_DTS
308	Single CREB binding site as described by Badding <i>et al.</i> , 2012 Gene Ther	CREB_badding_DTS
309	5x 72bp tandem repeat from SV40 genome separated by random CpG free 20 mer sequences.	SV40DNA_DTS_10merRepeat
310	High activity, high affinity GRE binding site	2x_Cgt_GRE_meijsing_DTS
311	72 base pair single repeat region from SV40 genome.	SV40DNA_DTS_72bp SingleRepeat
312	72 base pair tandem repeat region from SV40 genome.	SV40DNA_DTS_72bp TandemRepeat
313	5x Dual SV40 Enhancer elements separated by CpGfree spacer elements	10xSV40-DTS-array

B. Additional Components of ceDNA vectors

[00461] The ceDNA vectors for expression of FVIII protein of the present disclosure may contain nucleotides that encode other components for gene expression.

(i) *Ubiquitous Chromatin-opening Elements (UCOE)*

[00462] According to some embodiments, the ceDNA vectors may further comprise Ubiquitous Chromatin-opening Elements (UCOE), which structurally consist of methylation-free CpG islands encompassing single or dual divergently-transcribed housekeeping gene promoters, and are defined by their ability to consistently confer stable, site of integration-independent transgene expression that is proportional to copy number (Neville *et al.*, Volume 35, Issue 5, September 2017, Pages 557-56).

[00463] According to some embodiments, the ceDNA vector for expression of FVIII protein comprises a minimal UCOE derived from CBX3 intergenic region, which comprises mutations to

eliminate splice sites in the CBX3 intron region (CBX3(674mut1)). According to some embodiments, the minimal UCOE comprises, or consists of, SEQ ID NO: 292.

[00464] According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 85% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 90% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 95% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 96% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 97% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 98% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises a nucleic acid sequence at least about 99% identical to SEQ ID NO: 292. According to some embodiments, the UCOE comprises, or consists of the nucleic acid sequence of SEQ ID NO: 292.

(ii) *Kozak Sequences*

[00465] According to some embodiments, the ceDNA vectors may further comprise one or more Kozak sequences. According to some embodiments, the Kozak sequence is a consensus Kozak sequence. According to some embodiments, the Kozak sequence is a modified Kozak sequence. According to some embodiments, the Kozak sequence is a minimal Kozak sequence.

[00466] According to some embodiments, the consensus Kozak sequence (Consensus_Kozak) comprises GCCGCCACC (SEQ ID NO: 314). According to some embodiments, the modified consensus Kozak sequence (Mod_Minimum_Consensus_Kozak_v1) comprises AGCCACC (SEQ ID NO: 315). According to some embodiments, the modified consensus Kozak sequence (Mod_Minimum_Consensus_Kozak_v2) comprises CGCAGCCACC (SEQ ID NO: 316). According to some embodiments, the minimal consensus Kozak sequence (536_Kozak) comprises ACC (SEQ ID NO: 317).

(iii) *Spacer Sequences*

[00467] According to some embodiments, the ceDNA vectors may further comprise one or more spacer sequences. According to some embodiments, the spacer sequence is selected from one or more of those listed in **Table 15** below, which provides the sequence identifier, a description of the spacer sequence and the name.

Table 15. Spacers

SEQ ID NO	Description	Name
318	Synthetic Spacer Sequence	spacer_left-ITR_v1
319	Synthetic Spacer Sequence	spacer_left-ITR_v2.1
320	Synthetic Spacer Sequence	spacer_right-ITR_v1
321	CpG-free 20 bp spacer sequence	CpGfree20mer_1

322	CpG-free 20 bp spacer sequence	CpGfree20mer_2
323	CpG-free 20 bp spacer sequence	CpGfree20mer_3
324	CpG-free 20 bp spacer sequence	CpGfree20mer_4
325	CpG-free 20 bp spacer sequence	CpGfree20mer_5
326	CpG-free 20 bp spacer sequence	CpGfree20mer_6
327	CpG-free 20 bp spacer sequence	CpGfree20mer_6B
328	CpG-free synthetic spacer	Sp100-1
329	CpG-free synthetic spacer	Sp800-1
330	CpG-free synthetic spacer	Sp400-1
331	CpG-free synthetic spacer	Sp200-3
332	CpG-free synthetic spacer	Sp200-2
634	CpG-free Left ITR spacer with SbfI site	Spacer_Left-ITR_v7
635	Left ITR spacer with NotI site	Spacer_Left-ITR_v8
636	CpG-free Left ITR spacer with MfeI site v1	Spacer_Left-ITR_v9
637	CpG-free Left ITR spacer with MfeI site v2	Spacer_Left-ITR_v10
638	CpG-free Left ITR spacer with MfeI site v3	Spacer_Left-ITR_v11
639	CpG-free Right ITR spacer v1	Spacer_Right-ITR_v7
640	CpG-free Right ITR spacer v2	Spacer_Right-ITR_v8

[00468] According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 318. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 319. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 320. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 321. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 322. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 323. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 324. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 325. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 326. According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 327.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 328.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 329.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 330.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 331.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 332.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 634.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 635.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 636.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 637.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 638.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 639.

According to some embodiments, the spacer sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 640.

(iv) *Leader Sequences*

[00469] According to some embodiments, the ceDNA vectors may further comprise one or more leader sequences. According to some embodiments, the leader sequence is selected from one or more of those listed in **Table 16** below, which provides the sequence identifier, a description of the leader sequence and the name.

Table 16. Leader Sequences

SEQ ID NO	Description	Name
249	Albumin leader sequence codon optimization #1	ALB-NS-CAI-v2
250	Albumin leader sequence codon optimization #2	ALB-NS-struct
251	Albumin leader sequence codon optimization #3	ALB-SSv1
252	CD33 leader sequence codon optimization #1	CD33-NS-CAI-v2
253	CD33 leader sequence codon optimization #2	CD33-NS-struct
254	CD33 leader sequence codon optimization #3	CD33-SSv1

255	Chymotrypsinogen leader sequence codon optimization #1	CHY-NS-CAI-v2
256	Chymotrypsinogen leader sequence codon optimization #2	CHY-NS-struct
257	Chymotrypsinogen leader sequence codon optimization #3	CHY-SSv1
258	Gaussia leader sequence codon optimization #1	Gaus-CAI-v2
259	Gaussia leader sequence codon optimization #2	Gaus-NS-struct-v2
260	Gaussia leader sequence codon optimization #3	Gaus-SSv1
261	IL-2 leader sequence codon optimization #1	IL2-NS-CAI
262	IL-2 leader sequence codon optimization #2	IL2-NS-struct
263	IL-2 leader sequence codon optimization #3	IL2-SSv1
264	Fibroin-L leader sequence codon optimization #1	Lonz-NS-CAI-v1
265	Fibroin-L leader sequence codon optimization #2	Lonz-NS-struct-v2
266	Fibroin-L leader sequence codon optimization #3	Lonz-SSv1
267	Secrecon leader sequence v1 codon optimization #1	Secrecon-v1-NS-CAI-v2
268	Secrecon leader sequence v1 codon optimization #2	Secrecon-v1-NS-struct
269	Secrecon leader sequence v1 codon optimization #3	Secrecon-SSv1
270	Secrecon leader sequence v2 codon optimization #3	Secrecon-SSv2
271	trans plasminogen activator leader sequence codon optimization #1	tPA-NS-CAI-v2
272	trans plasminogen activator leader sequence codon optimization #2	tPA-NS-struct
273	trans plasminogen activator leader sequence codon optimization #3	tPA-SSv1
274	Trypsinogen leader sequence codon optimization #1	TRYP-NS-CAI-v2
275	Trypsinogen leader sequence codon optimization #2	TRYP-NS-struct-v2
276	Trypsinogen leader sequence codon optimization #3	TRYP-SSv2
277	Fibroin-L leader sequence codon optimization #1 truncated to remove terminal 'QV' residues	LonzB-NS-CAI-v1
278	Fibroin-L leader sequence codon optimization #2 truncated to remove terminal 'QV' residues	LonzB-NS-struct-v2
279	Fibroin-L leader sequence codon optimization #3 truncated to remove terminal 'QV' residues	LonzB-SSv1
280	A1AT leader sequence codon optimization #1	A1AT-NS-CAI-v2
281	A1AT leader sequence codon optimization #2	A1AT-NS-struct
282	A1AT leader sequence codon optimization #3	A1AT-SSv3

[00470] According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 249. According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 250. According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about

85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 269.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 270.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 271.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 272.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 273.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 274.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 275.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 276.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 277.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 278.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 279.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 280.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 281.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 282.

According to some embodiments, the leader sequence comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, comprises, or consists of SEQ ID NO: 283.

[00471] In some embodiments, the ceDNA vector for expression of FVIII protein may comprise one or more micro RNA (MIR) sequences involved in immune responses or hepato-homestasis as shown in **Table 17** below.

[00472] **Table 17.** MIR Sequences

GE#	Name	SEQ ID NO	Description
GE-699	mir122_4x	542	micro-RNA involved in regulation of immune responses

GE-020	mir-142_3pUTR	543	micro-RNA involved in liver homeostasis; Triplet repeat of mir-142 binding site
--------	---------------	-----	---

[00473] According to some embodiments, to select for specific gene targeting events, a protective shRNA may be embedded in a microRNA and inserted into a recombinant ceDNA vector designed to integrate site-specifically into the highly active locus, such as an albumin locus. Such embodiments may provide a system for *in vivo* selection and expansion of gene-modified hepatocytes in any genetic background such as described in Nygaard *et al.*, *A universal system to select gene-modified hepatocytes in vivo*, *Gene Therapy*, June 8, 2016. The ceDNA vectors of the present disclosure may contain one or more selectable markers that permit selection of transformed, transfected, transduced, or the like cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, NeoR, and the like. In certain embodiments, positive selection markers are incorporated into the donor sequences such as NeoR. Negative selections markers may be incorporated downstream the donor sequences, for example a nucleic acid sequence HSV-tk encoding a negative selection marker may be incorporated into a nucleic acid construct downstream the donor sequence.

C. *Regulatory Switches*

[00474] A molecular regulatory switch is one which generates a measurable change in state in response to a signal. Such regulatory switches can be usefully combined with the ceDNA vectors for expression of FVIII protein as described herein to control the output of expression of FVIII protein from the ceDNA vector. In some embodiments, the ceDNA vector for expression of FVIII protein comprises a regulatory switch that serves to fine tune expression of the FVIII protein. For example, it can serve as a biocontainment function of the ceDNA vector. In some embodiments, the switch is an “ON/OFF” switch that is designed to start or stop (*i.e.*, shut down) expression of FVIII protein in the ceDNA vector in a controllable and regulatable fashion. In some embodiments, the switch can include a “kill switch” that can instruct the cell comprising the ceDNA vector to undergo cell programmed death once the switch is activated. Exemplary regulatory switches encompassed for use in a ceDNA vector for expression of FVIII protein can be used to regulate the expression of a transgene, and are more fully discussed in International application PCT/US18/49996, which is incorporated herein in its entirety by reference

(i) *Binary Regulatory Switches*

[00475] In some embodiments, the ceDNA vector for expression of FVIII protein comprises a regulatory switch that can serve to controllably modulate expression of FVIII protein. For example, the expression cassette located between the ITRs of the ceDNA vector may additionally comprise a regulatory region, *e.g.*, a promoter, cis-element, repressor, enhancer etc., that is operatively linked to the nucleic acid sequence encoding FVIII protein, where the regulatory region is regulated by one or more cofactors or exogenous agents. By way of example only, regulatory regions can be modulated by

small molecule switches or inducible or repressible promoters. Non-limiting examples of inducible promoters are hormone-inducible or metal-inducible promoters. Other exemplary inducible promoters/enhancer elements include, but are not limited to, an RU486-inducible promoter, an ecdysone-inducible promoter, a rapamycin-inducible promoter, and a metallothionein promoter.

(ii) *Small molecule Regulatory Switches*

[00476] A variety of art-known small-molecule based regulatory switches are known in the art and can be combined with the ceDNA vectors for expression of FVIII protein as disclosed herein to form a regulatory-switch controlled ceDNA vector. In some embodiments, the regulatory switch can be selected from any one or a combination of: an orthogonal ligand/nuclear receptor pair, for example retinoid receptor variant/LG335 and GRQCIMFI, along with an artificial promoter controlling expression of the operatively linked transgene, such as that as disclosed in Taylor, *et al.* BMC Biotechnology 10 (2010): 15; engineered steroid receptors, *e.g.*, modified progesterone receptor with a C-terminal truncation that cannot bind progesterone but binds RU486 (mifepristone) (US Patent No. 5,364,791); an ecdysone receptor from *Drosophila* and their ecdysteroid ligands (Saez, *et al.*, PNAS, 97(26)(2000), 14512–14517; or a switch controlled by the antibiotic trimethoprim (TMP), as disclosed in Sando R 3rd; Nat Methods. 2013, 10(11):1085-8. In some embodiments, the regulatory switch to control the transgene or expressed by the ceDNA vector is a pro-drug activation switch, such as that disclosed in US patents 8,771,679, and 6,339,070, the contents of all of which are incorporated by reference in their entireties herein.

(iii) *“Passcode” Regulatory Switches*

[00477] In some embodiments the regulatory switch can be a “passcode switch” or “passcode circuit”. Passcode switches allow fine tuning of the control of the expression of the transgene from the ceDNA vector when specific conditions occur – that is, a combination of conditions need to be present for transgene expression and/or repression to occur. For example, for expression of a transgene to occur at least conditions A and B must occur. A passcode regulatory switch can be any number of conditions, *e.g.*, at least 2, or at least 3, or at least 4, or at least 5, or at least 6 or at least 7 or more conditions to be present for transgene expression to occur. In some embodiments, at least 2 conditions (*e.g.*, A, B conditions) need to occur, and in some embodiments, at least 3 conditions need to occur (*e.g.*, A, B and C, or A, B and D). By way of an example only, for gene expression from a ceDNA to occur that has a passcode “ABC” regulatory switch, conditions A, B and C must be present. Conditions A, B and C could be as follows; condition A is the presence of a condition or disease, condition B is a hormonal response, and condition C is a response to the transgene expression. For example, if the transgene edits a defective EPO gene, Condition A is the presence of Chronic Kidney Disease (CKD), Condition B occurs if the subject has hypoxic conditions in the kidney, Condition C is that Erythropoietin-producing cells (EPC) recruitment in the kidney is impaired; or alternatively, HIF-

2 activation is impaired. Once the oxygen levels increase or the desired level of EPO is reached, the transgene turns off again until 3 conditions occur, turning it back on.

[00478] In some embodiments, a passcode regulatory switch or “Passcode circuit” encompassed for use in the ceDNA vector comprises hybrid transcription factors (TFs) to expand the range and complexity of environmental signals used to define biocontainment conditions. As opposed to a deadman switch which triggers cell death in the presence of a predetermined condition, the “passcode circuit” allows cell survival or transgene expression in the presence of a particular “passcode”, and can be easily reprogrammed to allow transgene expression and/or cell survival only when the predetermined environmental condition or passcode is present.

[00479] Any and all combinations of regulatory switches disclosed herein, *e.g.*, small molecule switches, nucleic acid-based switches, small molecule-nucleic acid hybrid switches, post-transcriptional transgene regulation switches, post-translational regulation, radiation-controlled switches, hypoxia-mediated switches and other regulatory switches known by persons of ordinary skill in the art as disclosed herein can be used in a passcode regulatory switch as disclosed herein. Regulatory switches encompassed for use are also discussed in the review article Kis *et al.*, J R Soc Interface. 12: 20141000 (2015), and summarized in Table 1 of Kis, the contents of which are incorporated by reference in its entirety herein. In some embodiments, a regulatory switch for use in a passcode system can be selected from any or a combination of the switches disclosed in Table 11 of International Patent Application PCT/US18/49996, which is incorporated herein in its entirety by reference.

(iv) Nucleic acid-based regulatory switches to control transgene expression

[00480] In some embodiments, the regulatory switch to control the expression of FVIII protein by the ceDNA is based on a nucleic acid based control mechanism. Exemplary nucleic acid control mechanisms are known in the art and are envisioned for use. For example, such mechanisms include riboswitches, such as those disclosed in, *e.g.*, US2009/0305253, US2008/0269258, US2017/0204477, WO2018026762A1, US patent 9,222,093 and EP application EP288071, and disclosed in the review by Villa JK *et al.*, Microbiol Spectr. 2018 May;6(3). Also included are metabolite-responsive transcription biosensors, such as those disclosed in WO2018/075486 and WO2017/147585. Other art-known mechanisms envisioned for use include silencing of the transgene with an siRNA or RNAi molecule (*e.g.*, miR, shRNA). For example, the ceDNA vector can comprise a regulatory switch that encodes a RNAi molecule that is complementary to the two part of the transgene expressed by the ceDNA vector. When such RNAi is expressed even if the transgene (*e.g.*, FVIII protein) is expressed by the ceDNA vector, it will be silenced by the complementary RNAi molecule, and when the RNAi is not expressed when the transgene is expressed by the ceDNA vector the transgene (*e.g.*, FVIII protein) is not silenced by the RNAi.

[00481] In some embodiments, the regulatory switch is a tissue-specific self-inactivating regulatory switch, for example as disclosed in US2002/0022018, whereby the regulatory switch deliberately switches transgene (*e.g.*, FVIII protein) off at a site where transgene expression might otherwise be disadvantageous. In some embodiments, the regulatory switch is a recombinase reversible gene expression system, for example as disclosed in US2014/0127162 and US Patent 8,324,436.

(v) Post-transcriptional and post-translational regulatory switches.

[00482] In some embodiments, the regulatory switch to control the expression of FVIII protein by the ceDNA vector is a post-transcriptional modification system. For example, such a regulatory switch can be an aptazyme riboswitch that is sensitive to tetracycline or theophylline, as disclosed in US2018/0119156, GB201107768, WO2001/064956A3, EP Patent 2707487 and Beilstein *et al.*, ACS Synth. Biol., 2015, 4 (5), pp 526–534; Zhong *et al.*, Elife. 2016 Nov 2;5. pii: e18858. In some embodiments, it is envisioned that a person of ordinary skill in the art could encode both the transgene and an inhibitory siRNA which contains a ligand sensitive (OFF-switch) aptamer, the net result being a ligand sensitive ON-switch.

(vi) Other exemplary regulatory switches

[00483] Any known regulatory switch can be used in the ceDNA vector to control the expression of FVIII protein by the ceDNA vector, including those triggered by environmental changes. Additional examples include, but are not limited to; the BOC method of Suzuki *et al.*, Scientific Reports 8; 10051 (2018); genetic code expansion and a non-physiologic amino acid; radiation-controlled or ultra-sound controlled on/off switches (see, *e.g.*, Scott S *et al.*, Gene Ther. 2000 Jul;7(13):1121-5; US patents 5,612,318; 5,571,797; 5,770,581; 5,817,636; and WO1999/025385A1, the contents of each of which is incorporated by reference in its entirety herein). In some embodiments, the regulatory switch is controlled by an implantable system, *e.g.*, as disclosed in US patent 7,840,263; US2007/0190028A1 where gene expression is controlled by one or more forms of energy, including electromagnetic energy, that activates promoters operatively linked to the transgene in the ceDNA vector.

[00484] In some embodiments, a regulatory switch envisioned for use in the ceDNA vector is a hypoxia-mediated or stress-activated switch, *e.g.*, such as those disclosed in WO1999060142A2, US patent 5,834,306; 6,218,179; 6,709,858; US2015/0322410; Greco *et al.*, (2004) Targeted Cancer Therapies 9, S368, as well as FROG, TOAD and NRSE elements and conditionally inducible silence elements, including hypoxia response elements (HREs), inflammatory response elements (IREs) and shear-stress activated elements (SSAEs), *e.g.*, as disclosed in U.S. Patent 9,394,526. Such an embodiment is useful for turning on expression of the transgene from the ceDNA vector after ischemia or in ischemic tissues, and/or tumors.

(vii) Kill Switches

[00485] Other embodiments described herein relate to a ceDNA vector for expression of FVIII protein as described herein comprising a kill switch. A kill switch as disclosed herein enables a cell

comprising the ceDNA vector to be killed or undergo programmed cell death as a means to permanently remove an introduced ceDNA vector from the subject's system. It will be appreciated by one of ordinary skill in the art that use of kill switches in the ceDNA vectors for expression of FVIII protein would be typically coupled with targeting of the ceDNA vector to a limited number of cells that the subject can acceptably lose or to a cell type where apoptosis is desirable (*e.g.*, cancer cells). In all aspects, a "kill switch" as disclosed herein is designed to provide rapid and robust cell killing of the cell comprising the ceDNA vector in the absence of an input survival signal or other specified condition. Stated another way, a kill switch encoded by a ceDNA vector for expression of FVIII protein as described herein can restrict cell survival of a cell comprising a ceDNA vector to an environment defined by specific input signals. Such kill switches serve as a biological biocontainment function should it be desirable to remove the ceDNA vector e expression of FVIII protein in a subject or to ensure that it will not express the encoded FVIII protein.

[00486] Other kill switches known to a person of ordinary skill in the art are encompassed for use in the ceDNA vector for expression of FVIII protein as disclosed herein, *e.g.*, as disclosed in US2010/0175141; US2013/0009799; US2011/0172826; US2013/0109568, as well as kill switches disclosed in Jusiak *et al.*, Reviews in Cell Biology and molecular Medicine; 2014; 1-56; Kobayashi *et al.*, PNAS, 2004; 101; 8419-9; Marchisio *et al.*, Int. Journal of Biochem and Cell Biol., 2011; 43; 310-319; and in Reinshagen *et al.*, Science Translational Medicine, 2018, 11.

[00487] Accordingly, in some embodiments, the ceDNA vector for expression of FVIII protein can comprise a kill switch nucleic acid construct, which comprises the nucleic acid encoding an effector toxin or reporter protein, where the expression of the effector toxin (*e.g.*, a death protein) or reporter protein is controlled by a predetermined condition. For example, a predetermined condition can be the presence of an environmental agent, such as, *e.g.*, an exogenous agent, without which the cell will default to expression of the effector toxin (*e.g.*, a death protein) and be killed. In alternative embodiments, a predetermined condition is the presence of two or more environmental agents, *e.g.*, the cell will only survive when two or more necessary exogenous agents are supplied, and without either of which, the cell comprising the ceDNA vector is killed.

[00488] In some embodiments, the ceDNA vector for expression of FVIII protein is modified to incorporate a kill-switch to destroy the cells comprising the ceDNA vector to effectively terminate the *in vivo* expression of the transgene being expressed by the ceDNA vector (*e.g.*, expression of FVIII protein). Specifically, the ceDNA vector is further genetically engineered to express a switch-protein that is not functional in mammalian cells under normal physiological conditions. Only upon administration of a drug or environmental condition that specifically targets this switch-protein, the cells expressing the switch-protein will be destroyed thereby terminating the expression of the therapeutic protein or peptide. For instance, it was reported that cells expressing HSV-thymidine kinase can be killed upon administration of drugs, such as ganciclovir and cytosine deaminase. See, for

example, Dey and Evans, Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK), in Targets in Gene Therapy, edited by You (2011); and Beltinger *et al.*, Proc. Natl. Acad. Sci. USA 96(15):8699-8704 (1999). In some embodiments the ceDNA vector can comprise a siRNA kill switch referred to as DISE (Death Induced by Survival gene Elimination) (Murmann *et al.*, Oncotarget. 2017; 8:84643-84658. Induction of DISE in ovarian cancer cells *in vivo*).

D. Constructs

[00489] Provided herein are FVIII ceDNA constructs comprising a nucleic acid sequence as set forth in Table 1, in combination with one of more of a promoter sequence, an enhancer sequence, a 5' UTR sequence, an intron sequence, a leader sequence, a 3'UTR sequence, a UCOE sequence, an exon sequence, a DNA nuclear targeting sequences (DTS) sequence, a Kozak sequence and/or a spacer sequence. According to some embodiments, the FVIII ceDNA construct comprises a sequence as set forth in **Table 18** below.

Table 18. ceDNA FVIII constructs

SEQ ID NO	ceDNA Construct Identifier
1	692
2	693
3	694
4	933
5	1270
6	1362
7	1367
8	1368
9	1373
10	1374
11	1375
12	1377
13	1378
14	1381
15	1387
16	1391
17	1572
18	1574
19	1579
20	1582
21	1585
22	1593
23	1598
24	1602
25	1611
26	1612
27	1615

28	1616
29	1620
30	1622
31	1627
32	1628
33	1632
34	1636
35	1637
36	1638
37	1645
38	1646
39	1647
40	1648
41	1649
42	1651
43	1652
44	1655
45	1657
46	1664
47	1668
48	1695
49	1700
50	1701
51	1708
52	1712
53	1725
54	1738
55	1740
56	1741
57	1742
58	1743
59	1744
60	1838
61	1840
62	1886
63	1918
64	1919
65	1920
66	1921
67	1922
68	1923
69	1930
70	1931
442	1658

443	1666
444	1880
445	1885
446	1948
447	1949
448	1950
449	ceDNA fusion 1476:: 1923ORF
450	ceDNA fusion 1477:: 1923ORF
451	ceDNA fusion 1478:: 1923ORF
452	ceDNA fusion 1479:: 1923ORF
453	ceDNA fusion 1480::1923ORF
454	ceDNA fusion 1649:: 3xG-1923ORF
455	ceDNA fusion 1649:: 3xG-Min-Con-1923ORF
456	ceDNA fusion 1649:: 3xG-mod-Con-1923ORF
457	ceDNA fusion 1649::325243-1923ORF
458	ceDNA fusion 1649::Min-Con-1923ORF
459	ceDNA fusion 1668::3xG-Mod-Con-1923ORF
460	ceDNA fusion 1668::1923ORF
461	ceDNA fusion 1668::Mod-Con-1923ORF
462	ceDNA fusion 1471::1923ORF
463	ceDNA fusion 1471::con-1923ORF
464	ceDNA fusion 1472::1923ORF
465	ceDNA fusion 1472::Con-1923ORF
466	ceDNA fusion 1473::1923ORF
467	ceDNA fusion 1473::Con-1923ORF
468	ceDNA fusion 1474::1923ORF
469	ceDNA fusion 1474::Con-1923ORF
470	ceDNA fusion 1475::1923ORF
471	ceDNA fusion 1622::1923ORF
472	ceDNA fusion 1627::1923ORF
473	ceDNA fusion 1628::1923ORF
474	ceDNA fusion 1632::1923 ORF
475	ceDNA fusion 1636::1923ORF
476	ceDNA fusion 1637::1923ORF
477	ceDNA fusion 1637::Con-1923ORF
478	ceDNA fusion 1638::1923ORF
479	ceDNA fusion 1645::1923ORF
480	ceDNA Fusion 1646::1923ORF
481	ceDNA Fusion 1649::1923ORF
482	ceDNA Fusion 1649::mod-Con-1923ORF
483	1719
642	ceDNA construct 10 (3x hSerpEnh VD, 1651)

643	ceDNA construct 60 (w/ 3x hSerpEnh_2mer_spacers_v17)
644	ceDNA construct 61 (w/ 3x hSerpEnh_11mer_spacers_v3)
645	ceDNA construct 62(w/ 3x Bushbaby SerpEnh_Aspacers)
646	ceDNA construct 39 (wild-type left ITR and right ITR truncation)

[00490] According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 1. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 1. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 2. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 2. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 3. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 3. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 4. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 4. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 5. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 5. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 6. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 6. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 7. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 7. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 8. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 8. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 9. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 9. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 10. According to some embodiments, the ceDNA construct comprises, or consists of SEQ ID NO: 10. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 11. According to some embodiments, the ceDNA

[illegible]

[illegible]

[illegible]

[illegible]

According to some embodiments, the ceDNA construct consists of SEQ ID NO: 62. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 63. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 63. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 64. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 64. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 65. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 65. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 66. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 66. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 67. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 67. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 68. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 68. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 69. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 69. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 70. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 70. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 442. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 442. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 443. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 443. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 444. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 444. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO: 445. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 445. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises SEQ ID NO:

[illegible]

[illegible]

[illegible]

SEQ ID NO: 643. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises, SEQ ID NO: 644. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 644. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises, SEQ ID NO: 645. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 645. According to some embodiments, a ceDNA construct comprises a nucleic acid sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, or comprises, SEQ ID NO: 646. According to some embodiments, the ceDNA construct consists of SEQ ID NO: 646.

VI. Detailed method of Production of a ceDNA Vector

A. *Production in General*

[00491] Certain methods for the production of a ceDNA vector for expression of FVIII protein comprising an asymmetrical ITR pair or symmetrical ITR pair as defined herein is described in section IV of International application PCT/US18/49996 filed September 7, 2018, which is incorporated herein in its entirety by reference. In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can be produced using insect cells, as described herein. In alternative embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can be produced synthetically and in some embodiments, in a cell-free method, as disclosed on International Application PCT/US19/14122, filed January 18, 2019, which is incorporated herein in its entirety by reference.

[00492] As described herein, in one embodiment, a ceDNA vector for expression of FVIII protein can be obtained, for example, by the process comprising the steps of: a) incubating a population of host cells (*e.g.*, insect cells) harboring the polynucleotide expression construct template (*e.g.*, a ceDNA-plasmid, a ceDNA-Bacmid, and/or a ceDNA-baculovirus), which is devoid of viral capsid coding sequences, in the presence of a Rep protein under conditions effective and for a time sufficient to induce production of the ceDNA vector within the host cells, and wherein the host cells do not comprise viral capsid coding sequences; and b) harvesting and isolating the ceDNA vector from the host cells. The presence of Rep protein induces replication of the vector polynucleotide with a modified ITR to produce the ceDNA vector in a host cell. However, no viral particles (*e.g.*, AAV virions) are expressed. Thus, there is no size limitation such as that naturally imposed in AAV or other viral-based vectors.

[00493] The presence of the ceDNA vector isolated from the host cells can be confirmed by digesting DNA isolated from the host cell with a restriction enzyme having a single recognition site on the ceDNA vector and analyzing the digested DNA material on a non-denaturing gel to confirm the

presence of characteristic bands of linear and continuous DNA as compared to linear and non-continuous DNA.

[00494] In yet another aspect, the disclosure provides for use of host cell lines that have stably integrated the DNA vector polynucleotide expression template (ceDNA template) into their own genome in production of the non-viral DNA vector, *e.g.*, as described in Lee, L. *et al.* (2013) Plos One 8(8): e69879. Preferably, Rep is added to host cells at an MOI of about 3. When the host cell line is a mammalian cell line, *e.g.*, HEK293 cells, the cell lines can have polynucleotide vector template stably integrated, and a second vector such as herpes virus can be used to introduce Rep protein into cells, allowing for the excision and amplification of ceDNA in the presence of Rep and helper virus.

[00495] In one embodiment, the host cells used to make the ceDNA vectors for expression of FVIII protein as described herein are insect cells, and baculovirus is used to deliver both the polynucleotide that encodes Rep protein and the non-viral DNA vector polynucleotide expression construct template for ceDNA, *e.g.*, as described in **FIGS. 4A-4C** and Example 1. In some embodiments, the host cell is engineered to express Rep protein.

[00496] The ceDNA vector is then harvested and isolated from the host cells. The time for harvesting and collecting ceDNA vectors described herein from the cells can be selected and optimized to achieve a high-yield production of the ceDNA vectors. For example, the harvest time can be selected in view of cell viability, cell morphology, cell growth, etc. In one embodiment, cells are grown under sufficient conditions and harvested a sufficient time after baculoviral infection to produce ceDNA vectors but before a majority of cells start to die because of the baculoviral toxicity. The DNA vectors can be isolated using plasmid purification kits such as Qiagen Endo-Free Plasmid kits. Other methods developed for plasmid isolation can be also adapted for DNA vectors. Generally, any nucleic acid purification methods can be adopted.

[00497] The DNA vectors can be purified by any means known to those of skill in the art for purification of DNA. In one embodiment, ceDNA vectors are purified as DNA molecules. In another embodiment, the ceDNA vectors are purified as exosomes or microparticles.

[00498] The presence of the ceDNA vector for expression of FVIII protein can be confirmed by digesting the vector DNA isolated from the cells with a restriction enzyme having a single recognition site on the DNA vector and analyzing both digested and undigested DNA material using gel electrophoresis to confirm the presence of characteristic bands of linear and continuous DNA as compared to linear and non-continuous DNA. **FIG. 4C** and **FIG. 4D** illustrate one embodiment for identifying the presence of the closed ended ceDNA vectors produced by the processes herein.

B. ceDNA Plasmid

[00499] A ceDNA-plasmid is a plasmid used for later production of a ceDNA vector for expression of FVIII protein. In some embodiments, a ceDNA-plasmid can be constructed using known techniques to provide at least the following as operatively linked components in the direction of transcription: (1)

a modified 5' ITR sequence; (2) an expression cassette containing a cis-regulatory element, for example, a promoter, inducible promoter, regulatory switch, enhancers and the like; and (3) a modified 3' ITR sequence, where the 3' ITR sequence is symmetric relative to the 5' ITR sequence. In some embodiments, the expression cassette flanked by the ITRs comprises a cloning site for introducing an exogenous sequence. The expression cassette replaces the rep and cap coding regions of the AAV genomes.

[00500] In one aspect, a ceDNA vector for expression of FVIII protein is obtained from a plasmid, referred to herein as a "ceDNA-plasmid" encoding in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), an expression cassette comprising a transgene, and a mutated or modified AAV ITR, wherein said ceDNA-plasmid is devoid of AAV capsid protein coding sequences. In alternative embodiments, the ceDNA-plasmid encodes in this order: a first (or 5') modified or mutated AAV ITR, an expression cassette comprising a transgene, and a second (or 3') modified AAV ITR, wherein said ceDNA-plasmid is devoid of AAV capsid protein coding sequences, and wherein the 5' and 3' ITRs are symmetric relative to each other. In alternative embodiments, the ceDNA-plasmid encodes in this order: a first (or 5') modified or mutated AAV ITR, an expression cassette comprising a transgene, and a second (or 3') mutated or modified AAV ITR, wherein said ceDNA-plasmid is devoid of AAV capsid protein coding sequences, and wherein the 5' and 3' modified ITRs are have the same modifications (*i.e.*, they are inverse complement or symmetric relative to each other).

[00501] In a further embodiment, the ceDNA-plasmid system is devoid of viral capsid protein coding sequences (*i.e.* it is devoid of AAV capsid genes but also of capsid genes of other viruses). In addition, in a particular embodiment, the ceDNA-plasmid is also devoid of AAV Rep protein coding sequences. Accordingly, in a preferred embodiment, ceDNA-plasmid is devoid of functional AAV cap and AAV rep genes GG-3' for AAV2) plus a variable palindromic sequence allowing for hairpin formation.

[00502] A ceDNA-plasmid of the present disclosure can be generated using natural nucleotide sequences of the genomes of any AAV serotypes well known in the art. In one embodiment, the ceDNA-plasmid backbone is derived from the AAV1, AAV2, AAV3, AAV4, AAV5, AAV 5, AAV7, AAV8, AAV9, AAV10, AAV 11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genome. *E.g.*, NCBI: NC 002077; NC 001401; NC001729; NC001829; NC006152; NC 006260; NC 006261; Kotin and Smith, The Springer Index of Viruses, available at the URL maintained by Springer (at www.oesys.springer.de/viruses/database/mkchapter.asp?virID=42.04).(note -references to a URL or database refer to the contents of the URL or database as of the effective filing date of this application) In a particular embodiment, the ceDNA-plasmid backbone is derived from the AAV2 genome. In another particular embodiment, the ceDNA-plasmid backbone is a synthetic backbone genetically engineered to include at its 5' and 3' ITRs derived from one of these AAV genomes.

[00503] A ceDNA-plasmid can optionally include a selectable or selection marker for use in the establishment of a ceDNA vector-producing cell line. In one embodiment, the selection marker can be inserted downstream (*i.e.*, 3') of the 3' ITR sequence. In another embodiment, the selection marker can be inserted upstream (*i.e.*, 5') of the 5' ITR sequence. Appropriate selection markers include, for example, those that confer drug resistance. Selection markers can be, for example, a blasticidin S-resistance gene, kanamycin, geneticin, and the like. In a preferred embodiment, the drug selection marker is a blasticidin S-resistance gene.

[00504] An exemplary ceDNA (*e.g.*, rAAV0) vector for expression of FVIII protein is produced from an rAAV plasmid. A method for the production of a rAAV vector, can comprise: (a) providing a host cell with a rAAV plasmid as described above, wherein both the host cell and the plasmid are devoid of capsid protein encoding genes, (b) culturing the host cell under conditions allowing production of an ceDNA genome, and (c) harvesting the cells and isolating the AAV genome produced from said cells.

C. Exemplary method of making the ceDNA vectors from ceDNA plasmids

[00505] Methods for making capsid-less ceDNA vectors for expression of FVIII protein are also provided herein, notably a method with a sufficiently high yield to provide sufficient vector for *in vivo* experiments.

[00506] In some embodiments, a method for the production of a ceDNA vector for expression of FVIII protein comprises the steps of: (1) introducing the nucleic acid construct comprising an expression cassette and two symmetric ITR sequences into a host cell (*e.g.*, Sf9 cells), (2) optionally, establishing a clonal cell line, for example, by using a selection marker present on the plasmid, (3) introducing a Rep coding gene (either by transfection or infection with a baculovirus carrying said gene) into said insect cell, and (4) harvesting the cell and purifying the ceDNA vector. The nucleic acid construct comprising an expression cassette and two ITR sequences described above for the production of ceDNA vector can be in the form of a ceDNA plasmid, or Bacmid or Baculovirus generated with the ceDNA plasmid as described below. The nucleic acid construct can be introduced into a host cell by transfection, viral transduction, stable integration, or other methods known in the art.

D. Cell lines

[00507] Host cell lines used in the production of a ceDNA vector for expression of FVIII protein can include insect cell lines derived from *Spodoptera frugiperda*, such as Sf9 Sf21, or *Trichoplusia ni* cell, or other invertebrate, vertebrate, or other eukaryotic cell lines including mammalian cells. Other cell lines known to an ordinarily skilled artisan can also be used, such as HEK293, Huh-7, HeLa, HepG2, HepLA, 911, CHO, COS, MeWo, NIH3T3, A549, HT1 180, monocytes, and mature and immature dendritic cells. Host cell lines can be transfected for stable expression of the ceDNA-plasmid for high yield ceDNA vector production.

[00508] CeDNA-plasmids can be introduced into Sf9 cells by transient transfection using reagents (*e.g.*, liposomal, calcium phosphate) or physical means (*e.g.*, electroporation) known in the art. Alternatively, stable Sf9 cell lines which have stably integrated the ceDNA-plasmid into their genomes can be established. Such stable cell lines can be established by incorporating a selection marker into the ceDNA -plasmid as described above. If the ceDNA -plasmid used to transfect the cell line includes a selection marker, such as an antibiotic, cells that have been transfected with the ceDNA-plasmid and integrated the ceDNA-plasmid DNA into their genome can be selected for by addition of the antibiotic to the cell growth media. Resistant clones of the cells can then be isolated by single-cell dilution or colony transfer techniques and propagated.

E. Isolating and Purifying ceDNA vectors:

[00509] Examples of the process for obtaining and isolating ceDNA vectors are described in **FIGS. 4A-4E** and the specific examples below. ceDNA-vectors for expression of FVIII protein disclosed herein can be obtained from a producer cell expressing AAV Rep protein(s), further transformed with a ceDNA-plasmid, ceDNA-bacmid, or ceDNA-baculovirus. Plasmids useful for the production of ceDNA vectors include plasmids that encode FVIII protein, or plasmids encoding one or more REP proteins.

[00510] In one aspect, a polynucleotide encodes the AAV Rep protein (Rep 78 or 68) delivered to a producer cell in a plasmid (Rep-plasmid), a bacmid (Rep-bacmid), or a baculovirus (Rep-baculovirus). The Rep-plasmid, Rep-bacmid, and Rep-baculovirus can be generated by methods described above.

[00511] Methods to produce a ceDNA vector for expression of FVIII protein are described herein. Expression constructs used for generating a ceDNA vector for expression of FVIII protein as described herein can be a plasmid (*e.g.*, ceDNA-plasmids), a Bacmid (*e.g.*, ceDNA-bacmid), and/or a baculovirus (*e.g.*, ceDNA-baculovirus). By way of an example only, a ceDNA-vector can be generated from the cells co-infected with ceDNA-baculovirus and Rep-baculovirus. Rep proteins produced from the Rep-baculovirus can replicate the ceDNA-baculovirus to generate ceDNA-vectors. Alternatively, ceDNA vectors for expression of FVIII protein can be generated from the cells stably transfected with a construct comprising a sequence encoding the AAV Rep protein (Rep78/52) delivered in Rep-plasmids, Rep-bacmids, or Rep-baculovirus. CeDNA-Baculovirus can be transiently transfected to the cells, be replicated by Rep protein and produce ceDNA vectors.

[00512] The bacmid (*e.g.*, ceDNA-bacmid) can be transfected into permissive insect cells such as Sf9, Sf21, Tni (*Trichoplusia ni*) cell, High Five cell, and generate ceDNA-baculovirus, which is a recombinant baculovirus including the sequences comprising the symmetric ITRs and the expression cassette. ceDNA-baculovirus can be again infected into the insect cells to obtain a next generation of the recombinant baculovirus. Optionally, the step can be repeated once or multiple times to produce the recombinant baculovirus in a larger quantity.

[00513] The time for harvesting and collecting ceDNA vectors for expression of FVIII protein as described herein from the cells can be selected and optimized to achieve a high-yield production of the ceDNA vectors. For example, the harvest time can be selected in view of cell viability, cell morphology, cell growth, etc. Usually, cells can be harvested after sufficient time after baculoviral infection to produce ceDNA vectors (*e.g.*, ceDNA vectors) but before majority of cells start to die because of the viral toxicity. The ceDNA-vectors can be isolated from the Sf9 cells using plasmid purification kits such as Qiagen ENDO-FREE PLASMID® kits. Other methods developed for plasmid isolation can be also adapted for ceDNA vectors. Generally, any art-known nucleic acid purification methods can be adopted, as well as commercially available DNA extraction kits.

[00514] Alternatively, purification can be implemented by subjecting a cell pellet to an alkaline lysis process, centrifuging the resulting lysate and performing chromatographic separation. As one non-limiting example, the process can be performed by loading the supernatant on an ion exchange column (*e.g.*, SARTOBIND Q®) which retains nucleic acids, and then eluting (*e.g.*, with a 1.2 M NaCl solution) and performing a further chromatographic purification on a gel filtration column (*e.g.*, 6 fast flow GE). The capsid-free AAV vector is then recovered by, *e.g.*, precipitation.

[00515] In some embodiments, ceDNA vectors for expression of FVIII protein can also be purified in the form of exosomes, or microparticles. It is known in the art that many cell types release not only soluble proteins, but also complex protein/nucleic acid cargoes via membrane microvesicle shedding (Cocucci et al, 2009; EP 10306226.1) Such vesicles include microvesicles (also referred to as microparticles) and exosomes (also referred to as nanovesicles), both of which comprise proteins and RNA as cargo. Microvesicles are generated from the direct budding of the plasma membrane, and exosomes are released into the extracellular environment upon fusion of multivesicular endosomes with the plasma membrane. Thus, ceDNA vector-containing microvesicles and/or exosomes can be isolated from cells that have been transduced with the ceDNA-plasmid or a bacmid or baculovirus generated with the ceDNA-plasmid.

[00516] Microvesicles can be isolated by subjecting culture medium to filtration or ultracentrifugation at 20,000 x g, and exosomes at 100,000 x g. The optimal duration of ultracentrifugation can be experimentally-determined and will depend on the particular cell type from which the vesicles are isolated. Preferably, the culture medium is first cleared by low-speed centrifugation (*e.g.*, at 2000 x g for 5-20 minutes) and subjected to spin concentration using, *e.g.*, an AMICON® spin column (Millipore, Watford, UK). Microvesicles and exosomes can be further purified via FACS or MACS by using specific antibodies that recognize specific surface antigens present on the microvesicles and exosomes. Other microvesicle and exosome purification methods include, but are not limited to, immunoprecipitation, affinity chromatography, filtration, and magnetic beads coated with specific antibodies or aptamers. Upon purification, vesicles are washed with, *e.g.*, phosphate-buffered saline. One advantage of using microvesicles or exosome to deliver ceDNA-

containing vesicles is that these vesicles can be targeted to various cell types by including on their membrane proteins recognized by specific receptors on the respective cell types. (See also EP 10306226)

[00517] Another aspect of the disclosure herein relates to methods of purifying ceDNA vectors from host cell lines that have stably integrated a ceDNA construct into their own genome. In one embodiment, ceDNA vectors are purified as DNA molecules. In another embodiment, the ceDNA vectors are purified as exosomes or microparticles.

[00518] FIG. 5 of International application PCT/US18/49996 shows a gel confirming the production of ceDNA from multiple ceDNA-plasmid constructs using the method described in the Examples. The ceDNA is confirmed by a characteristic band pattern in the gel, as discussed with respect to FIG. 4D in the Examples.

VII. Pharmaceutical Compositions

[00519] In another aspect, pharmaceutical compositions are provided. The pharmaceutical composition comprises a ceDNA vector for expression of FVIII protein as described herein and a pharmaceutically acceptable carrier or diluent.

[00520] The ceDNA vectors for expression of FVIII protein as disclosed herein can be incorporated into pharmaceutical compositions suitable for administration to a subject for *in vivo* delivery to cells, tissues, or organs of the subject. Typically, the pharmaceutical composition comprises a ceDNA-vector as disclosed herein and a pharmaceutically acceptable carrier. For example, the ceDNA vectors for expression of FVIII protein as described herein can be incorporated into a pharmaceutical composition suitable for a desired route of therapeutic administration (*e.g.*, parenteral administration). Passive tissue transduction via high pressure intravenous or intra-arterial infusion, as well as intracellular injection, such as intranuclear microinjection or intracytoplasmic injection, are also contemplated. Pharmaceutical compositions for therapeutic purposes can be formulated as a solution, microemulsion, dispersion, liposomes, or other ordered structure suitable to high ceDNA vector concentration. Sterile injectable solutions can be prepared by incorporating the ceDNA vector compound in the required amount in an appropriate buffer with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization including a ceDNA vector can be formulated to deliver a transgene in the nucleic acid to the cells of a recipient, resulting in the therapeutic expression of the transgene or donor sequence therein. The composition can also include a pharmaceutically acceptable carrier.

[00521] Pharmaceutically active compositions comprising a ceDNA vector for expression of FVIII protein can be formulated to deliver a transgene for various purposes to the cell, *e.g.*, cells of a subject.

[00522] Pharmaceutical compositions for therapeutic purposes typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposomes, or other ordered structure suitable to high ceDNA vector

concentration. Sterile injectable solutions can be prepared by incorporating the ceDNA vector compound in the required amount in an appropriate buffer with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

[00523] A ceDNA vector for expression of FVIII protein as disclosed herein can be incorporated into a pharmaceutical composition suitable for topical, systemic, intra-amniotic, intrathecal, intracranial, intra-arterial, intravenous, intralymphatic, intraperitoneal, subcutaneous, tracheal, intra-tissue (*e.g.*, intramuscular, intracardiac, intrahepatic, intrarenal, intracerebral), intrathecal, intravesical, conjunctival (*e.g.*, extra-orbital, intraorbital, retroorbital, intraretinal, subretinal, choroidal, sub-choroidal, intrastromal, intracameral and intravitreal), intracochlear, and mucosal (*e.g.*, oral, rectal, nasal) administration. Passive tissue transduction via high pressure intravenous or intraarterial infusion, as well as intracellular injection, such as intranuclear microinjection or intracytoplasmic injection, are also contemplated.

[00524] In some aspects, the methods provided herein comprise delivering one or more ceDNA vectors for expression of FVIII protein as disclosed herein to a host cell. Also provided herein are cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells. Methods of delivery of nucleic acids can include lipofection, nucleofection, microinjection, biolistics, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, and agent-enhanced uptake of DNA. Lipofection is described in *e.g.*, U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355, the contents of each of which are incorporated by reference in their entireties herein) and lipofection reagents are sold commercially (*e.g.*, TRANSFECTAM™ and LIPFECTIN™). Delivery can be to cells (*e.g.*, *in vitro* or *ex vivo* administration) or target tissues (*e.g.*, *in vivo* administration).

[00525] Various techniques and methods are known in the art for delivering nucleic acids to cells. For example, nucleic acids, such as ceDNA for expression of FVIII protein can be formulated into lipid nanoparticles (LNPs), lipidoids, liposomes, lipid nanoparticles, lipoplexes, or core-shell nanoparticles. Typically, LNPs are composed of nucleic acid (*e.g.*, ceDNA) molecules, one or more ionizable or cationic lipids (or salts thereof), one or more non-ionic or neutral lipids (*e.g.*, a phospholipid), a molecule that prevents aggregation (*e.g.*, PEG or a PEG-lipid conjugate), and optionally a sterol (*e.g.*, cholesterol).

[00526] Another method for delivering nucleic acids, such as ceDNA for expression of FVIII protein to a cell is by conjugating the nucleic acid with a ligand that is internalized by the cell. For example, the ligand can bind a receptor on the cell surface and internalized via endocytosis. The ligand can be covalently linked to a nucleotide in the nucleic acid. Exemplary conjugates for delivering nucleic acids into a cell are described, example, in WO2015/006740, WO2014/025805, WO2012/037254, WO2009/082606, WO2009/073809, WO2009/018332, WO2006/112872, WO2004/090108,

WO2004/091515 and WO2017/177326, the contents of each of which are incorporated by reference in their entireties herein.

[00527] Nucleic acids, such as ceDNA vectors for expression of FVIII protein can also be delivered to a cell by transfection. Useful transfection methods include, but are not limited to, lipid-mediated transfection, cationic polymer-mediated transfection, or calcium phosphate precipitation. Transfection reagents are well known in the art and include, but are not limited to, TurboFect Transfection Reagent (Thermo Fisher Scientific), Pro-Ject Reagent (Thermo Fisher Scientific), TRANSPASS™ P Protein Transfection Reagent (New England Biolabs), CHARIOT™ Protein Delivery Reagent (Active Motif), PROTEOJUICE™ Protein Transfection Reagent (EMD Millipore), 293fectin, LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ 3000 (Thermo Fisher Scientific), LIPOFECTAMINE™ (Thermo Fisher Scientific), LIPOFECTIN™ (Thermo Fisher Scientific), DMRIE-C, CELLFECTIN™ (Thermo Fisher Scientific), OLIGOFECTAMINE™ (Thermo Fisher Scientific), LIPOFECTACE™, FUGENE™ (Roche, Basel, Switzerland), FUGENE™ HD (Roche), TRANSFECTAM™ (Transfectam, Promega, Madison, Wis.), TFX-10™ (Promega), TFX-20™ (Promega), TFX-50™ (Promega), TRANSFECTIN™ (BioRad, Hercules, Calif.), SILENTFECT™ (Bio-Rad), Effectene™ (Qiagen, Valencia, Calif.), DC-chol (Avanti Polar Lipids), GENEPORTER™ (Gene Therapy Systems, San Diego, Calif.), DHARMAFECT 1™ (Dharmacon, Lafayette, Colo.), DHARMAFECT 2™ (Dharmacon), DHARMAFECT 3™ (Dharmacon), DHARMAFECT 4™ (Dharmacon), ESCORT™ III (Sigma, St. Louis, Mo.), and ESCORT™ IV (Sigma Chemical Co.). Nucleic acids, such as ceDNA, can also be delivered to a cell via microfluidics methods known to those of skill in the art.

[00528] ceDNA vectors for expression of FVIII protein as described herein can also be administered directly to an organism for transduction of cells *in vivo*. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

[00529] Methods for introduction of a nucleic acid vector ceDNA vector for expression of FVIII protein as disclosed herein can be delivered into hematopoietic stem cells, for example, by the methods as described, for example, in U.S. Pat. No. 5,928,638, the contents of which is incorporated by reference in its entirety herein.

[00530] The ceDNA vectors for expression of FVIII protein in accordance with the present disclosure can be added to liposomes for delivery to a cell or target organ in a subject. Liposomes are vesicles that possess at least one lipid bilayer. Liposomes are typically used as carriers for drug/therapeutic delivery in the context of pharmaceutical development. They work by fusing with a cellular membrane and repositioning its lipid structure to deliver a drug or active pharmaceutical

ingredient (API). Liposome compositions for such delivery are composed of phospholipids, especially compounds having a phosphatidylcholine group, however these compositions may also include other lipids. Exemplary liposomes and liposome formulations, including but not limited to polyethylene glycol (PEG)-functional group containing compounds are disclosed in International Application PCT/US2018/050042, filed on September 7, 2018 and in International application PCT/US2018/064242, filed on December 6, 2018, *e.g.*, see the section entitled “Pharmaceutical Formulations”.

[00531] Various delivery methods known in the art or modification thereof can be used to deliver ceDNA vectors *in vitro* or *in vivo*. For example, in some embodiments, ceDNA vectors for expression of FVIII protein are delivered by making transient penetration in cell membrane by mechanical, electrical, ultrasonic, hydrodynamic, or laser-based energy so that DNA entrance into the targeted cells is facilitated. For example, a ceDNA vector can be delivered by transiently disrupting cell membrane by squeezing the cell through a size-restricted channel or by other means known in the art. In some cases, a ceDNA vector alone is directly injected as naked DNA into any one of: any one or more tissues selected from: liver, kidneys, gallbladder, prostate, adrenal gland, heart, intestine, lung, and stomach, skin, thymus, cardiac muscle or skeletal muscle. In some cases, a ceDNA vector is delivered by gene gun. Gold or tungsten spherical particles (1–3 μm diameter) coated with capsid-free AAV vectors can be accelerated to high speed by pressurized gas to penetrate into target tissue cells.

[00532] Compositions comprising a ceDNA vector for expression of FVIII protein and a pharmaceutically acceptable carrier are specifically contemplated herein. In some embodiments, the ceDNA vector is formulated with a lipid delivery system, for example, liposomes as described herein. In some embodiments, such compositions are administered by any route desired by a skilled practitioner. The compositions may be administered to a subject by different routes including orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, intrapleurally, intravenous, intra-arterial, intraperitoneal, subcutaneous, intramuscular, intranasal intrathecal, and intraarticular or combinations thereof. For veterinary use, the composition may be administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian may readily determine the dosing regimen and route of administration that is most appropriate for a particular animal. The compositions may be administered by traditional syringes, needleless injection devices, “microprojectile bombardment gene guns”, or other physical methods such as electroporation (“EP”), hydrodynamic methods, or ultrasound.

[00533] In some cases, a ceDNA vector for expression of FVIII protein is delivered by hydrodynamic injection, which is a simple and highly efficient method for direct intracellular delivery of any water-soluble compounds and particles into internal organs and skeletal muscle in an entire limb.

[00534] In some cases, ceDNA vectors for expression of FVIII protein are delivered by ultrasound by making nanoscopic pores in membrane to facilitate intracellular delivery of DNA particles into cells of internal organs or tumors, so the size and concentration of plasmid DNA have great role in efficiency of the system. In some cases, ceDNA vectors are delivered by magnetofection by using magnetic fields to concentrate particles containing nucleic acid into the target cells.

[00535] In some cases, chemical delivery systems can be used, for example, by using nanomeric complexes, which include compaction of negatively charged nucleic acid by polycationic nanomeric particles, belonging to cationic liposome/micelle or cationic polymers. Cationic lipids used for the delivery method includes, but not limited to monovalent cationic lipids, polyvalent cationic lipids, guanidine containing compounds, cholesterol derivative compounds, cationic polymers, (*e.g.*, poly(ethylenimine), poly-L-lysine, protamine, other cationic polymers), and lipid-polymer hybrid.

A. Exosomes

[00536] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is delivered by being packaged in an exosome. Exosomes are small membrane vesicles of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. Their surface consists of a lipid bilayer from the donor cell's cell membrane, they contain cytosol from the cell that produced the exosome, and exhibit membrane proteins from the parental cell on the surface. Exosomes are produced by various cell types including epithelial cells, B and T lymphocytes, mast cells (MC) as well as dendritic cells (DC). Some embodiments, exosomes with a diameter between 10nm and 1 μ m, between 20nm and 500nm, between 30nm and 250nm, between 50nm and 100nm are envisioned for use. Exosomes can be isolated for a delivery to target cells using either their donor cells or by introducing specific nucleic acids into them. Various approaches known in the art can be used to produce exosomes containing capsid-free AAV vectors of the present disclosure.

B. Microparticle/Nanoparticles

[00537] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is delivered by a lipid nanoparticle. Generally, lipid nanoparticles comprise an ionizable amino lipid (*e.g.*, heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, DLin-MC3-DMA, a phosphatidylcholine (1,2-distearoyl-sn-glycero-3-phosphocholine, DSPC), cholesterol and a coat lipid (polyethylene glycol-dimyristolglycerol, PEG-DMG), for example as disclosed by Tam *et al.* (2013). *Advances in Lipid Nanoparticles for siRNA delivery*. Pharmaceuticals 5(3): 498-507.

[00538] In some embodiments, a lipid nanoparticle has a mean diameter between about 10 and about 1000 nm. In some embodiments, a lipid nanoparticle has a diameter that is less than 300 nm. In some embodiments, a lipid nanoparticle has a diameter between about 10 and about 300 nm. In some embodiments, a lipid nanoparticle has a diameter that is less than 200 nm. In some embodiments, a lipid nanoparticle has a diameter between about 25 and about 200 nm. In some embodiments, a lipid

nanoparticle preparation (*e.g.*, composition comprising a plurality of lipid nanoparticles) has a size distribution in which the mean size (*e.g.*, diameter) is about 70 nm to about 200 nm, and more typically the mean size is about 100 nm or less.

[00539] Various lipid nanoparticles known in the art can be used to deliver ceDNA vector for expression of FVIII protein as disclosed herein. For example, various delivery methods using lipid nanoparticles are described in U.S. Patent Nos. 9,404,127, 9,006,417 and 9,518,272.

[00540] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is delivered by a gold nanoparticle. Generally, a nucleic acid can be covalently bound to a gold nanoparticle or non-covalently bound to a gold nanoparticle (*e.g.*, bound by a charge-charge interaction), for example as described by Ding *et al.* (2014). *Gold Nanoparticles for Nucleic Acid Delivery*. Mol. Ther. 22(6); 1075-1083. In some embodiments, gold nanoparticle-nucleic acid conjugates are produced using methods described, for example, in U.S. Patent No. 6,812,334.

C. Conjugates

[00541] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is conjugated (*e.g.*, covalently bound to an agent that increases cellular uptake. An “agent that increases cellular uptake” is a molecule that facilitates transport of a nucleic acid across a lipid membrane. For example, a nucleic acid can be conjugated to a lipophilic compound (*e.g.*, cholesterol, tocopherol, *etc.*), a cell penetrating peptide (CPP) (*e.g.*, penetratin, TAT, Syn1B, *etc.*), and polyamines (*e.g.*, spermine). Further examples of agents that increase cellular uptake are disclosed, for example, in Winkler (2013). *Oligonucleotide conjugates for therapeutic applications*. Ther. Deliv. 4(7); 791-809.

[00542] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is conjugated to a polymer (*e.g.*, a polymeric molecule) or a folate molecule (*e.g.*, folic acid molecule). Generally, delivery of nucleic acids conjugated to polymers is known in the art, for example as described in WO2000/34343 and WO2008/022309. In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is conjugated to a poly(amide) polymer, for example as described by U.S. Patent No. 8,987,377. In some embodiments, a nucleic acid described by the disclosure is conjugated to a folic acid molecule as described in U.S. Patent No. 8,507,455.

[00543] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is conjugated to a carbohydrate, for example as described in U.S. Patent No. 8,450,467.

D. Nanocapsule

[00544] Alternatively, nanocapsule formulations of a ceDNA vector for expression of FVIII protein as disclosed herein can be used. Nanocapsules can generally entrap substances in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use.

E. *Liposomes*

[00545] The ceDNA vectors for expression of FVIII protein in accordance with the present disclosure can be added to liposomes for delivery to a cell or target organ in a subject. Liposomes are vesicles that possess at least one lipid bilayer. Liposomes are typically used as carriers for drug/therapeutic delivery in the context of pharmaceutical development. They work by fusing with a cellular membrane and repositioning its lipid structure to deliver a drug or active pharmaceutical ingredient (API). Liposome compositions for such delivery are composed of phospholipids, especially compounds having a phosphatidylcholine group, however these compositions may also include other lipids.

[00546] The formation and use of liposomes are generally known to those of skill in the art. Liposomes have been developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been described (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).

F. *Exemplary liposome and Lipid Nanoparticle (LNP) Compositions*

[00547] The ceDNA vectors for expression of FVIII protein in accordance with the present disclosure can be added to liposomes for delivery to a cell, *e.g.*, a cell in need of expression of the transgene. Liposomes are vesicles that possess at least one lipid bilayer. Liposomes are typically used as carriers for drug/therapeutic delivery in the context of pharmaceutical development. They work by fusing with a cellular membrane and repositioning its lipid structure to deliver a drug or active pharmaceutical ingredient (API). Liposome compositions for such delivery are composed of phospholipids, especially compounds having a phosphatidylcholine group, however these compositions may also include other lipids.

[00548] Lipid nanoparticles (LNPs) comprising ceDNA vectors are disclosed in International Application PCT/US2018/050042, filed on September 7, 2018, and International Application PCT/US2018/064242, filed on December 6, 2018 which are incorporated herein in their entirety and envisioned for use in the methods and compositions for ceDNA vectors for expression of FVIII protein as disclosed herein.

[00549] In some aspects, the disclosure provides for a liposome formulation that includes one or more compounds with a polyethylene glycol (PEG) functional group (so-called “PEG-ylated compounds”) which can reduce the immunogenicity/ antigenicity of, provide hydrophilicity and hydrophobicity to the compound(s) and reduce dosage frequency. Or the liposome formulation simply includes polyethylene glycol (PEG) polymer as an additional component. In such aspects, the molecular weight of the PEG or PEG functional group can be from 62 Da to about 5,000 Da.

[00550] In some aspects, the disclosure provides for a liposome formulation that will deliver an API with extended release or controlled release profile over a period of hours to weeks. In some related

aspects, the liposome formulation may comprise aqueous chambers that are bound by lipid bilayers. In other related aspects, the liposome formulation encapsulates an API with components that undergo a physical transition at elevated temperature which releases the API over a period of hours to weeks.

[00551] In some aspects, the liposome formulation comprises sphingomyelin and one or more lipids disclosed herein. In some aspects, the liposome formulation comprises optisomes.

[00552] In some aspects, the disclosure provides for a liposome formulation that includes one or more lipids selected from: N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, (distearoyl-sn-glycero-phosphoethanolamine), MPEG (methoxy polyethylene glycol)-conjugated lipid, HSPC (hydrogenated soy phosphatidylcholine); PEG (polyethylene glycol); DSPE (distearoyl-sn-glycero-phosphoethanolamine); DSPC (distearoylphosphatidylcholine); DOPC (dioleoylphosphatidylcholine); DPPG (dipalmitoylphosphatidylglycerol); EPC (egg phosphatidylcholine); DOPS (dioleoylphosphatidylserine); POPC (palmitoyl-oleoylphosphatidylcholine); SM (sphingomyelin); MPEG (methoxy polyethylene glycol); DMPC (dimyristoyl phosphatidylcholine); DMPG (dimyristoyl phosphatidylglycerol); DSPG (distearoylphosphatidylglycerol); DEPC (dierucoylphosphatidylcholine); DOPE (dioleoyl-sn-glycero-phosphoethanolamine); cholesteryl sulphate (CS); dipalmitoylphosphatidylglycerol (DPPG); DOPC (dioleoyl-sn-glycero-phosphatidylcholine) or any combination thereof.

[00553] In some aspects, the disclosure provides for a liposome formulation comprising phospholipid, cholesterol and a PEG-ylated lipid in a molar ratio of 56:38:5. In some aspects, the liposome formulation's overall lipid content is from 2-16 mg/mL. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group, a lipid containing an ethanolamine functional group and a PEG-ylated lipid. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group, a lipid containing an ethanolamine functional group and a PEG-ylated lipid in a molar ratio of 3:0.015:2 respectively. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group, cholesterol and a PEG-ylated lipid. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group and cholesterol. In some aspects, the PEG-ylated lipid is PEG-2000-DSPE. In some aspects, the disclosure provides for a liposome formulation comprising DPPG, soy PC, MPEG-DSPE lipid conjugate and cholesterol.

[00554] In some aspects, the disclosure provides for a liposome formulation comprising one or more lipids containing a phosphatidylcholine functional group and one or more lipids containing an ethanolamine functional group. In some aspects, the disclosure provides for a liposome formulation comprising one or more: lipids containing a phosphatidylcholine functional group, lipids containing an

ethanolamine functional group, and sterols, *e.g.*, cholesterol. In some aspects, the liposome formulation comprises DOPC/ DEPC; and DOPE.

[00555] In some aspects, the disclosure provides for a liposome formulation further comprising one or more pharmaceutical excipients, *e.g.*, sucrose and/or glycine.

[00556] In some aspects, the disclosure provides for a liposome formulation that is either unilamellar or multilamellar in structure. In some aspects, the disclosure provides for a liposome formulation that comprises multi-vesicular particles and/or foam-based particles. In some aspects, the disclosure provides for a liposome formulation that are larger in relative size to common nanoparticles and about 150 to 250 nm in size. In some aspects, the liposome formulation is a lyophilized powder.

[00557] In some aspects, the disclosure provides for a liposome formulation that is made and loaded with ceDNA vectors disclosed or described herein, by adding a weak base to a mixture having the isolated ceDNA outside the liposome. This addition increases the pH outside the liposomes to approximately 7.3 and drives the API into the liposome. In some aspects, the disclosure provides for a liposome formulation having a pH that is acidic on the inside of the liposome. In such cases the inside of the liposome can be at pH 4-6.9, and more preferably pH 6.5. In other aspects, the disclosure provides for a liposome formulation made by using intra-liposomal drug stabilization technology. In such cases, polymeric or non-polymeric highly charged anions and intra-liposomal trapping agents are utilized, *e.g.*, polyphosphate or sucrose octasulfate.

[00558] In some aspects, the disclosure provides for a lipid nanoparticle comprising ceDNA and an ionizable lipid. For example, a lipid nanoparticle formulation that is made and loaded with ceDNA obtained by the process as disclosed in International Application PCT/US2018/050042, filed on September 7, 2018, which is incorporated herein. This can be accomplished by high energy mixing of ethanolic lipids with aqueous ceDNA at low pH which protonates the ionizable lipid and provides favorable energetics for ceDNA/lipid association and nucleation of particles. The particles can be further stabilized through aqueous dilution and removal of the organic solvent. The particles can be concentrated to the desired level.


[00559] Generally, the lipid particles are prepared at a total lipid to ceDNA (mass or weight) ratio of from about 10:1 to 30:1. In some embodiments, the lipid to ceDNA ratio (mass/mass ratio; w/w ratio) can be in the range of from about 1:1 to about 25:1, from about 10:1 to about 14:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. The amounts of lipids and ceDNA can be adjusted to provide a desired N/P ratio, for example, N/P ratio of 3, 4, 5, 6, 7, 8, 9, 10 or higher. Generally, the lipid particle formulation's overall lipid content can range from about 5 mg/ml to about 30 mg/mL.

[00560] The ionizable lipid is typically employed to condense the nucleic acid cargo, *e.g.*, ceDNA at low pH and to drive membrane association and fusogenicity. Generally, ionizable lipids are lipids comprising at least one amino group that is positively charged or becomes protonated under acidic

conditions, for example at pH of 6.5 or lower. Ionizable lipids are also referred to as cationic lipids herein.

[00561] Exemplary ionizable lipids are described in International PCT patent publications WO2015/095340, WO2015/199952, WO2018/011633, WO2017/049245, WO2015/061467, WO2012/040184, WO2012/000104, WO2015/074085, WO2016/081029, WO2017/004143, WO2017/075531, WO2017/117528, WO2011/022460, WO2013/148541, WO2013/116126, WO2011/153120, WO2012/044638, WO2012/054365, WO2011/090965, WO2013/016058, WO2012/162210, WO2008/042973, WO2010/129709, WO2010/144740, WO2012/099755, WO2013/049328, WO2013/086322, WO2013/086373, WO2011/071860, WO2009/132131, WO2010/048536, WO2010/088537, WO2010/054401, WO2010/054406, WO2010/054405, WO2010/054384, WO2012/016184, WO2009/086558, WO2010/042877, WO2011/000106, WO2011/000107, WO2005/120152, WO2011/141705, WO2013/126803, WO2006/007712, WO2011/038160, WO2005/121348, WO2011/066651, WO2009/127060, WO2011/141704, WO2006/069782, WO2012/031043, WO2013/006825, WO2013/033563, WO2013/089151, WO2017/099823, WO2015/095346, and WO2013/086354, and US patent publications US2016/0311759, US2015/0376115, US2016/0151284, US2017/0210697, US2015/0140070, US2013/0178541, US2013/0303587, US2015/0141678, US2015/0239926, US2016/0376224, US2017/0119904, US2012/0149894, US2015/0057373, US2013/0090372, US2013/0274523, US2013/0274504, US2013/0274504, US2009/0023673, US2012/0128760, US2010/0324120, US2014/0200257, US2015/0203446, US2018/0005363, US2014/0308304, US2013/0338210, US2012/0101148, US2012/0027796, US2012/0058144, US2013/0323269, US2011/0117125, US2011/0256175, US2012/0202871, US2011/0076335, US2006/0083780, US2013/0123338, US2015/0064242, US2006/0051405, US2013/0065939, US2006/0008910, US2003/0022649, US2010/0130588, US2013/0116307, US2010/0062967, US2013/0202684, US2014/0141070, US2014/0255472, US2014/0039032, US2018/0028664, US2016/0317458, and US2013/0195920, the contents of all of which are incorporated herein by reference in their entireties.

[00562] In some embodiments, the ionizable lipid is MC3 (6Z,9Z,28Z,31Z)-heptatriacont-6,9,28,31-tetraen-19-yl-4-(dimethylamino) butanoate (DLin-MC3-DMA or MC3) having the following structure:



DLin-M-C3-DMA ("MC3")

[00563] The lipid DLin-MC3-DMA is described in Jayaraman *et al.*, Angew. Chem. Int. Ed Engl. (2012), 51(34): 8529-8533, content of which is incorporated herein by reference in its entirety.

[00564] In some embodiments, the ionizable lipid is the lipid ATX-002 as described in WO2015/074085, content of which is incorporated herein by reference in its entirety.

[00565] In some embodiments, the ionizable lipid is (13Z,16Z)-*N,N*-dimethyl-3-nonyldocosa-13,16-dien-1-amine (Compound 32), as described in WO2012/040184, the contents of which is incorporated herein by reference in its entirety.

[00566] In some embodiments, the ionizable lipid is Compound 6 or Compound 22 as described in WO2015/199952, the contents of which is incorporated herein by reference in its entirety.

[00567] Without limitations, ionizable lipid can comprise 20-90% (mol) of the total lipid present in the lipid nanoparticle. For example, ionizable lipid molar content can be 20-70% (mol), 30-60% (mol) or 40-50% (mol) of the total lipid present in the lipid nanoparticle. In some embodiments, ionizable lipid comprises from about 50 mol % to about 90 mol % of the total lipid present in the lipid nanoparticle.

[00568] In some aspects, the lipid nanoparticle can further comprise a non-cationic lipid. Non-ionic lipids include amphipathic lipids, neutral lipids and anionic lipids. Accordingly, the non-cationic lipid can be a neutral uncharged, zwitterionic, or anionic lipid. Non-cationic lipids are typically employed to enhance fusogenicity.

[00569] Exemplary non-cationic lipids envisioned for use in the methods and compositions as disclosed herein are described in International Application PCT/US2018/050042, filed on September 7, 2018, and PCT/US2018/064242, filed on December 6, 2018 which is incorporated herein in its entirety. Exemplary non-cationic lipids are described in International Application Publication WO2017/099823 and US patent publication US2018/0028664, the contents of both of which are incorporated herein by reference in their entirety.

[00570] The non-cationic lipid can comprise 0-30% (mol) of the total lipid present in the lipid nanoparticle. For example, the non-cationic lipid content is 5-20% (mol) or 10-15% (mol) of the total lipid present in the lipid nanoparticle. In various embodiments, the molar ratio of ionizable lipid to the neutral lipid ranges from about 2:1 to about 8:1.

[00571] In some embodiments, the lipid nanoparticles do not comprise any phospholipids. In some aspects, the lipid nanoparticle can further comprise a component, such as a sterol, to provide membrane integrity.

[00572] One exemplary sterol that can be used in the lipid nanoparticle is cholesterol and derivatives thereof. Exemplary cholesterol derivatives are described in International application WO2009/127060 and US patent publication US2010/0130588, the contents of both of which are incorporated herein by reference in their entirety.

[00573] The component providing membrane integrity, such as a sterol, can comprise 0-50% (mol) of the total lipid present in the lipid nanoparticle. In some embodiments, such a component is 20-50% (mol) 30-40% (mol) of the total lipid content of the lipid nanoparticle.

[00574] In some aspects, the lipid nanoparticle can further comprise a polyethylene glycol (PEG) or a conjugated lipid molecule. Generally, these are used to inhibit aggregation of lipid nanoparticles and/or provide steric stabilization. Exemplary conjugated lipids include, but are not limited to, PEG-lipid conjugates, polyoxazoline (POZ)-lipid conjugates, polyamide-lipid conjugates (such as ATTA-lipid conjugates), cationic-polymer lipid (CPL) conjugates, and mixtures thereof. In some embodiments, the conjugated lipid molecule is a PEG-lipid conjugate, for example, a (methoxy polyethylene glycol)-conjugated lipid. Exemplary PEG-lipid conjugates include, but are not limited to, PEG-diacylglycerol (DAG) (such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG)), PEG-dialkylxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), a pegylated phosphatidylethanolamine (PEG-PE), PEG succinate diacylglycerol (PEGS-DAG) (such as 4-O-(2',3'-di(tetradecanoyloxy)propyl-1-O-(w-methoxy(polyethoxy)ethyl) butanedioate (PEG-S-DMG)), PEG dialkoxypopylcarbam, N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, or a mixture thereof. Additional exemplary PEG-lipid conjugates are described, for example, in US5,885,613, US6,287,591, US2003/0077829, US2003/0077829, US2005/0175682, US2008/0020058, US2011/0117125, US2010/0130588, US2016/0376224, and US2017/0119904, the contents of all of which are incorporated herein by reference in their entireties.

[00575] In some embodiments, a PEG-lipid is a compound as defined in US2018/0028664, the contents of which is incorporated herein by reference in its entirety. In some embodiments, a PEG-lipid is disclosed in US20150376115 or in US2016/0376224, the content of both of which is incorporated herein by reference in its entirety.

[00576] The PEG-DAA conjugate can be, for example, PEG-dilauryloxypropyl, PEG-dimyristyloxypropyl, PEG-dipalmitoyloxypropyl, or PEG-distearoyloxypropyl. The PEG-lipid can be one or more of PEG-DMG, PEG-dilaurylglycerol, PEG-dipalmitoylglycerol, PEG-disterylglycerol, PEG-dilaurylglycamide, PEG-dimyristylglycamide, PEG-dipalmitoylglycamide, PEG-disterylglycamide, PEG-cholesterol (1-[8'-(Cholest-5-en-3[beta]-oxy)carboxamido-3',6'-dioxaoctanyl] carbamoyl-[omega]-methyl-poly(ethylene glycol), PEG-DMB (3,4-Ditetradecoxybenzyl- [omega]-methyl-poly(ethylene glycol) ether), and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]. In some examples, the PEG-lipid can be selected from the group consisting of PEG-DMG, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000],

[00577] Lipids conjugated with a molecule other than a PEG can also be used in place of PEG-lipid. For example, polyoxazoline (POZ)-lipid conjugates, polyamide-lipid conjugates (such as ATTA-lipid conjugates), and cationic-polymer lipid (CPL) conjugates can be used in place of or in addition to the PEG-lipid. Exemplary conjugated lipids, *i.e.*, PEG-lipids, (POZ)-lipid conjugates, ATTA-lipid conjugates and cationic polymer-lipids are described in the International patent application

publications WO1996/010392, WO1998/051278, WO2002/087541, WO2005/026372, WO2008/147438, WO2009/086558, WO2012/000104, WO2017/117528, WO2017/099823, WO2015/199952, WO2017/004143, WO2015/095346, WO2012/000104, WO2012/000104, and WO2010/006282, US patent application publications US2003/0077829, US2005/0175682, US2008/0020058, US2011/0117125, US2013/0303587, US2018/0028664, US2015/0376115, US2016/0376224, US2016/0317458, US2013/0303587, US2013/0303587, and US20110123453, and US patents US5,885,613, US6,287,591, US6,320,017, and US6,586,559, the contents of all of which are incorporated herein by reference in their entireties.

[00578] In some embodiments, the one or more additional compound can be a therapeutic agent. The therapeutic agent can be selected from any class suitable for the therapeutic objective. In other words, the therapeutic agent can be selected from any class suitable for the therapeutic objective. In other words, the therapeutic agent can be selected according to the treatment objective and biological action desired. For example, if the ceDNA within the LNP is useful for treating hemophilia A, the additional compound can be an anti-hemophilia A agent (*e.g.*, a chemotherapeutic agent, or other hemophilia A therapy (including, but not limited to, a small molecule or an antibody)). In another example, if the LNP containing the ceDNA is useful for treating an infection, the additional compound can be an antimicrobial agent (*e.g.*, an antibiotic or antiviral compound). In yet another example, if the LNP containing the ceDNA is useful for treating an immune disease or disorder, the additional compound can be a compound that modulates an immune response (*e.g.*, an immunosuppressant, immunostimulatory compound, or compound modulating one or more specific immune pathways). In some embodiments, different cocktails of different lipid nanoparticles containing different compounds, such as a ceDNA encoding a different protein or a different compound, such as a therapeutic may be used in the compositions and methods of the disclosure.

[00579] In some embodiments, the additional compound is an immune modulating agent. For example, the additional compound is an immunosuppressant. In some embodiments, the additional compound is immune stimulatory agent. Also provided herein is a pharmaceutical composition comprising the lipid nanoparticle-encapsulated insect-cell produced, or a synthetically produced ceDNA vector for expression of FVIII protein as described herein and a pharmaceutically acceptable carrier or excipient.

[00580] In some aspects, the disclosure provides for a lipid nanoparticle formulation further comprising one or more pharmaceutical excipients. In some embodiments, the lipid nanoparticle formulation further comprises sucrose, tris, trehalose and/or glycine.

[00581] The ceDNA vector can be complexed with the lipid portion of the particle or encapsulated in the lipid position of the lipid nanoparticle. In some embodiments, the ceDNA can be fully encapsulated in the lipid position of the lipid nanoparticle, thereby protecting it from degradation by a nuclease, *e.g.*, in an aqueous solution. In some embodiments, the ceDNA in the lipid nanoparticle is

not substantially degraded after exposure of the lipid nanoparticle to a nuclease at 37°C. for at least about 20, 30, 45, or 60 minutes. In some embodiments, the ceDNA in the lipid nanoparticle is not substantially degraded after incubation of the particle in serum at 37°C. for at least about 30, 45, or 60 minutes or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 hours.

[00582] In certain embodiments, the lipid nanoparticles are substantially non-toxic to a subject, *e.g.*, to a mammal such as a human. In some aspects, the lipid nanoparticle formulation is a lyophilized powder.

[00583] In some embodiments, lipid nanoparticles are solid core particles that possess at least one lipid bilayer. In other embodiments, the lipid nanoparticles have a non-bilayer structure, *i.e.*, a non-lamellar (*i.e.*, non-bilayer) morphology. Without limitations, the non-bilayer morphology can include, for example, three dimensional tubes, rods, cubic symmetries, etc. For example, the morphology of the lipid nanoparticles (lamellar vs. non-lamellar) can readily be assessed and characterized using, *e.g.*, Cryo-TEM analysis as described in US2010/0130588, the content of which is incorporated herein by reference in its entirety.

[00584] In some further embodiments, the lipid nanoparticles having a non-lamellar morphology are electron dense. In some aspects, the disclosure provides for a lipid nanoparticle that is either unilamellar or multilamellar in structure. In some aspects, the disclosure provides for a lipid nanoparticle formulation that comprises multi-vesicular particles and/or foam-based particles.

[00585] By controlling the composition and concentration of the lipid components, one can control the rate at which the lipid conjugate exchanges out of the lipid particle and, in turn, the rate at which the lipid nanoparticle becomes fusogenic. In addition, other variables including, *e.g.*, pH, temperature, or ionic strength, can be used to vary and/or control the rate at which the lipid nanoparticle becomes fusogenic. Other methods which can be used to control the rate at which the lipid nanoparticle becomes fusogenic will be apparent to those of ordinary skill in the art based on this disclosure. It will also be apparent that by controlling the composition and concentration of the lipid conjugate, one can control the lipid particle size.

[00586] The pKa of formulated cationic lipids can be correlated with the effectiveness of the LNPs for delivery of nucleic acids (see Jayaraman *et al.*, *Angewandte Chemie, International Edition* (2012), 51(34), 8529-8533; Semple *et al.*, *Nature Biotechnology* 28, 172-176 (2010), both of which are incorporated by reference in their entirety). The preferred range of pKa is ~5 to ~7. The pKa of the cationic lipid can be determined in lipid nanoparticles using an assay based on fluorescence of 2-(p-toluidino)-6-naphthalene sulfonic acid (TNS).

VIII. Methods of Use

[00587] A ceDNA vector for expression of FVIII protein as disclosed herein can also be used in a method for the delivery of a nucleic acid sequence of interest (*e.g.*, encoding FVIII protein) to a target

cell (*e.g.*, a host cell). In some embodiments, the method comprises a method for delivering FVIII protein to a cell of a subject in need thereof and treating hemophilia A. The disclosure allows for the *in vivo* expression of FVIII protein encoded in the ceDNA vector in a cell in a subject such that therapeutic effect of the expression of FVIII protein occurs. These results are seen with both *in vivo* and *in vitro* modes of ceDNA vector delivery.

[00588] In addition, the disclosure provides a method for the delivery of FVIII protein in a cell of a subject in need thereof, comprising multiple administrations of the ceDNA vector of the disclosure encoding said FVIII protein. Since the ceDNA vector of the disclosure does not induce an immune response like that typically observed against encapsidated viral vectors, such a multiple administration strategy will likely have greater success in a ceDNA-based system. The ceDNA vector are administered in sufficient amounts to transfect the cells of a desired tissue and to provide sufficient levels of gene transfer and expression of the FVIII protein without undue adverse effects.

Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, retinal administration (*e.g.*, subretinal injection, suprachoroidal injection or intravitreal injection), intravenous (*e.g.*, in a liposome formulation), direct delivery to the selected organ (*e.g.*, any one or more tissues selected from: liver, kidneys, gallbladder, prostate, adrenal gland, heart, intestine, lung, and stomach), intramuscular, and other parental routes of administration. Routes of administration may be combined, if desired.

[00589] Delivery of a ceDNA vector for expression of FVIII protein as described herein is not limited to delivery of the expressed FVIII protein. For example, conventionally produced (*e.g.*, using a cell-based production method (*e.g.*, insect-cell production methods) or synthetically produced ceDNA vectors as described herein may be used with other delivery systems provided to provide a portion of the gene therapy. One non-limiting example of a system that may be combined with the ceDNA vectors in accordance with the present disclosure includes systems which separately deliver one or more co-factors or immune suppressors for effective gene expression of the ceDNA vector expressing the FVIII protein.

[00590] The disclosure also provides for a method of treating hemophilia A in a subject comprising introducing into a target cell in need thereof (in particular a muscle cell or tissue) of the subject a therapeutically effective amount of a ceDNA vector, optionally with a pharmaceutically acceptable carrier. While the ceDNA vector can be introduced in the presence of a carrier, such a carrier is not required. The ceDNA vector selected comprises a nucleic acid sequence encoding an FVIII protein useful for treating hemophilia A. In particular, the ceDNA vector may comprise a desired FVIII protein sequence operably linked to control elements capable of directing transcription of the desired FVIII protein encoded by the exogenous DNA sequence when introduced into the subject. The ceDNA vector can be administered via any suitable route as provided above, and elsewhere herein.

[00591] The compositions and vectors provided herein can be used to deliver an FVIII protein for various purposes. In some embodiments, the transgene encodes an FVIII protein that is intended to be used for research purposes, *e.g.*, to create a somatic transgenic animal model harboring the transgene, *e.g.*, to study the function of the FVIII protein product. In another example, the transgene encodes an FVIII protein that is intended to be used to create an animal model of hemophilia A. In some embodiments, the encoded FVIII protein is useful for the treatment or prevention of hemophilia A states in a mammalian subject. The FVIII protein can be transferred (*e.g.*, expressed in) to a patient in a sufficient amount to treat hemophilia A associated with reduced expression, lack of expression or dysfunction of the gene.

[00592] In principle, the expression cassette can include a nucleic acid or any transgene that encodes an FVIII protein that is either reduced or absent due to a mutation or which conveys a therapeutic benefit when overexpressed is considered to be within the scope of the disclosure. Preferably, noninserted bacterial DNA is not present and preferably no bacterial DNA is present in the ceDNA compositions provided herein.

[00593] A ceDNA vector is not limited to one species of ceDNA vector. As such, in another aspect, multiple ceDNA vectors expressing different proteins or the same FVIII protein but operatively linked to different promoters or cis-regulatory elements can be delivered simultaneously or sequentially to the target cell, tissue, organ, or subject. Therefore, this strategy can allow for the gene therapy or gene delivery of multiple proteins simultaneously. It is also possible to separate different portions of a FVIII protein into separate ceDNA vectors (*e.g.*, different domains and/or co-factors required for functionality of a FVIII protein) which can be administered simultaneously or at different times, and can be separately regulatable, thereby adding an additional level of control of expression of a FVIII protein. Delivery can also be performed multiple times and, importantly for gene therapy in the clinical setting, in subsequent increasing or decreasing doses, given the lack of an anti-capsid host immune response due to the absence of a viral capsid. It is anticipated that no anti-capsid response will occur as there is no capsid.

[00594] The disclosure also provides for a method of treating hemophilia A in a subject comprising introducing into a target cell in need thereof (in particular a muscle cell or tissue) of the subject a therapeutically effective amount of a ceDNA vector as disclosed herein, optionally with a pharmaceutically acceptable carrier. While the ceDNA vector can be introduced in the presence of a carrier, such a carrier is not required. The ceDNA vector implemented comprises a nucleic acid sequence of interest useful for treating the hemophilia A. In particular, the ceDNA vector may comprise a desired exogenous DNA sequence operably linked to control elements capable of directing transcription of the desired polypeptide, protein, or oligonucleotide encoded by the exogenous DNA sequence when introduced into the subject. The ceDNA vector can be administered via any suitable route as provided above, and elsewhere herein.

IX. Methods of delivering ceDNA vectors for FVIII protein production

[00595] In some embodiments, a ceDNA vector for expression of FVIII protein can be delivered to a target cell *in vitro* or *in vivo* by various suitable methods. ceDNA vectors alone can be applied or injected. According to embodiments, ceDNA vectors can be delivered to a cell without the help of a transfection reagent or other physical means. Alternatively, according to other embodiments, ceDNA vectors for expression of FVIII protein can be delivered using any art-known transfection reagent or other art-known physical means that facilitates entry of DNA into a cell, *e.g.*, liposomes, alcohols, polylysine- rich compounds, arginine-rich compounds, calcium phosphate, microvesicles, microinjection, electroporation and the like.

[00596] The ceDNA vectors for expression of FVIII protein as disclosed herein can efficiently target cell and tissue-types that are normally difficult to transduce with conventional AAV virions using various delivery reagent.

[00597] One aspect of the technology described herein relates to a method of delivering an FVIII protein to a cell. Typically, for *in vivo* and *in vitro* methods, a ceDNA vector for expression of FVIII protein as disclosed herein may be introduced into the cell using the methods as disclosed herein, as well as other methods known in the art. A ceDNA vector for expression of FVIII protein as disclosed herein are preferably administered to the cell in a biologically-effective amount. If the ceDNA vector is administered to a cell *in vivo* (*e.g.*, to a subject), a biologically-effective amount of the ceDNA vector is an amount that is sufficient to result in transduction and expression of the FVIII protein in a target cell.

[00598] Exemplary modes of administration of a ceDNA vector for expression of FVIII protein as disclosed herein includes oral, rectal, transmucosal, intranasal, inhalation (*e.g.*, via an aerosol), buccal (*e.g.*, sublingual), vaginal, intrathecal, intraocular, transdermal, intraendothelial, in utero (or in ovo), parenteral (*e.g.*, intravenous, subcutaneous, intradermal, intracranial, intramuscular [including administration to skeletal, diaphragm and/or cardiac muscle], intrapleural, intracerebral, and intraarticular). Administration can be systemically or direct delivery to the liver or elsewhere (*e.g.*, any kidneys, gallbladder, prostate, adrenal gland, heart, intestine, lung, and stomach).

[00599] Administration can be topical (*e.g.*, to both skin and mucosal surfaces, including airway surfaces, and transdermal administration), intralymphatic, and the like, as well as direct tissue or organ injection (*e.g.*, but not limited to, liver, but also to eye, muscles, including skeletal muscle, cardiac muscle, diaphragm muscle, or brain).

[00600] Administration of the ceDNA vector can be to any site in a subject, including, without limitation, a site selected from the group consisting of the liver and/or also eyes, brain, a skeletal muscle, a smooth muscle, the heart, the diaphragm, the airway epithelium, the kidney, the spleen, the pancreas, the skin.

[00601] The most suitable route in any given case will depend on the nature and severity of the condition being treated, ameliorated, and/or prevented and on the nature of the particular ceDNA vector that is being used. Additionally, ceDNA permits one to administer more than one FVIII protein in a single vector, or multiple ceDNA vectors (*e.g.*, a ceDNA cocktail).

A. Intramuscular Administration of a ceDNA vector

[00602] In some embodiments, a method of treating a disease in a subject comprises introducing into a target cell in need thereof (in particular a muscle cell or tissue) of the subject a therapeutically effective amount of a ceDNA vector encoding an FVIII protein, optionally with a pharmaceutically acceptable carrier. In some embodiments, the ceDNA vector for expression of FVIII protein is administered to a muscle tissue of a subject.

[00603] In some embodiments, administration of the ceDNA vector can be to any site in a subject, including, without limitation, a site selected from the group consisting of a skeletal muscle, a smooth muscle, the heart, the diaphragm, or muscles of the eye.

[00604] Administration of a ceDNA vector for expression of FVIII protein as disclosed herein to a skeletal muscle according to the present disclosure includes but is not limited to administration to the skeletal muscle in the limbs (*e.g.*, upper arm, lower arm, upper leg, and/or lower leg), back, neck, head (*e.g.*, tongue), thorax, abdomen, pelvis/perineum, and/or digits. The ceDNA as disclosed herein vector can be delivered to skeletal muscle by intravenous administration, intra-arterial administration, intraperitoneal administration, limb perfusion, (optionally, isolated limb perfusion of a leg and/or arm; see, *e.g.*, Arruda *et al.*, (2005) Blood 105: 3458-3464), and/or direct intramuscular injection. In particular embodiments, the ceDNA vector as disclosed herein is administered to the liver, eye, a limb (arm and/or leg) of a subject (*e.g.*, a subject with muscular dystrophy such as DMD) by limb perfusion, optionally isolated limb perfusion (*e.g.*, by intravenous or intra-articular administration. In embodiments, the ceDNA vector as disclosed herein can be administered without employing "hydrodynamic" techniques.

[00605] For instance, tissue delivery (*e.g.*, to retina) of conventional viral vectors is often enhanced by hydrodynamic techniques (*e.g.*, intravenous/intravenous administration in a large volume), which increase pressure in the vasculature and facilitate the ability of the viral vector to cross the endothelial cell barrier. In particular embodiments, the ceDNA vectors described herein can be administered in the absence of hydrodynamic techniques such as high volume infusions and/or elevated intravascular pressure (*e.g.*, greater than normal systolic pressure, for example, less than or equal to a 5%, 10%, 15%, 20%, 25% increase in intravascular pressure over normal systolic pressure). Such methods may reduce or avoid the side effects associated with hydrodynamic techniques such as edema, nerve damage and/or compartment syndrome.

[00606] Furthermore, a composition comprising a ceDNA vector for expression of FVIII protein as disclosed herein that is administered to a skeletal muscle can be administered to a skeletal muscle in

the limbs (*e.g.*, upper arm, lower arm, upper leg, and/or lower leg), back, neck, head (*e.g.*, tongue), thorax, abdomen, pelvis/perineum, and/or digits. Suitable skeletal muscles include but are not limited to abductor digiti minimi (in the hand), abductor digiti minimi (in the foot), abductor hallucis, abductor ossis metatarsi quinti, abductor pollicis brevis, abductor pollicis longus, adductor brevis, adductor hallucis, adductor longus, adductor magnus, adductor pollicis, anconeus, anterior scalene, articularis genus, biceps brachii, biceps femoris, brachialis, brachioradialis, buccinator, coracobrachialis, corrugator supercilii, deltoid, depressor anguli oris, depressor labii inferioris, digastric, dorsal interossei (in the hand), dorsal interossei (in the foot), extensor carpi radialis brevis, extensor carpi radialis longus, extensor carpi ulnaris, extensor digiti minimi, extensor digitorum, extensor digitorum brevis, extensor digitorum longus, extensor hallucis brevis, extensor hallucis longus, extensor indicis, extensor pollicis brevis, extensor pollicis longus, flexor carpi radialis, flexor carpi ulnaris, flexor digiti minimi brevis (in the hand), flexor digiti minimi brevis (in the foot), flexor digitorum brevis, flexor digitorum longus, flexor digitorum profundus, flexor digitorum superficialis, flexor hallucis brevis, flexor hallucis longus, flexor pollicis brevis, flexor pollicis longus, frontalis, gastrocnemius, geniohyoid, gluteus maximus, gluteus medius, gluteus minimus, gracilis, iliocostalis cervicis, iliocostalis lumborum, iliocostalis thoracis, iliopsoas, inferior gemellus, inferior oblique, inferior rectus, infraspinatus, interspinalis, intertransversi, lateral pterygoid, lateral rectus, latissimus dorsi, levator anguli oris, levator labii superioris, levator labii superioris alaeque nasi, levator palpebrae superioris, levator scapulae, long rotators, longissimus capitis, longissimus cervicis, longissimus thoracis, longus capitis, longus colli, lumbricals (in the hand), lumbricals (in the foot), masseter, medial pterygoid, medial rectus, middle scalene, multifidus, mylohyoid, obliquus capitis inferior, obliquus capitis superior, obturator externus, obturator internus, occipitalis, omohyoid, opponens digiti minimi, opponens pollicis, orbicularis oculi, orbicularis oris, palmar interossei, palmaris brevis, palmaris longus, pectineus, pectoralis major, pectoralis minor, peroneus brevis, peroneus longus, peroneus tertius, piriformis, plantar interossei, plantaris, platysma, popliteus, posterior scalene, pronator quadratus, pronator teres, psoas major, quadratus femoris, quadratus plantae, rectus capitis anterior, rectus capitis lateralis, rectus capitis posterior major, rectus capitis posterior minor, rectus femoris, rhomboid major, rhomboid minor, risorius, sartorius, scalenus minimus, semimembranosus, semispinalis capitis, semispinalis cervicis, semispinalis thoracis, semitendinosus, serratus anterior, short rotators, soleus, spinalis capitis, spinalis cervicis, spinalis thoracis, splenius capitis, splenius cervicis, sternocleidomastoid, sternohyoid, sternothyroid, stylohyoid, subclavius, subscapularis, superior gemellus, superior oblique, superior rectus, supinator, supraspinatus, temporalis, tensor fascia lata, teres major, teres minor, thoracis, thyrohyoid, tibialis anterior, tibialis posterior, trapezius, triceps brachii, vastus intermedius, vastus lateralis, vastus medialis, zygomaticus major, and zygomaticus minor, and any other suitable skeletal muscle as known in the art.

[00607] Administration of a ceDNA vector for expression of FVIII protein as disclosed herein to diaphragm muscle can be by any suitable method including intravenous administration, intra-arterial administration, and/or intra-peritoneal administration. In some embodiments, delivery of an expressed transgene from the ceDNA vector to a target tissue can also be achieved by delivering a synthetic depot comprising the ceDNA vector, where a depot comprising the ceDNA vector is implanted into skeletal, smooth, cardiac and/or diaphragm muscle tissue or the muscle tissue can be contacted with a film or other matrix comprising the ceDNA vector as described herein. Such implantable matrices or substrates are described in U.S. Pat. No. 7,201,898.

[00608] Administration of a ceDNA vector for expression of FVIII protein as disclosed herein to cardiac muscle includes administration to the left atrium, right atrium, left ventricle, right ventricle and/or septum. The ceDNA vector as described herein can be delivered to cardiac muscle by intravenous administration, intra-arterial administration such as intra-aortic administration, direct cardiac injection (*e.g.*, into left atrium, right atrium, left ventricle, right ventricle), and/or coronary artery perfusion.

[00609] Administration of a ceDNA vector for expression of FVIII protein as disclosed herein to smooth muscle can be by any suitable method including intravenous administration, intra-arterial administration, and/or intra-peritoneal administration. In one embodiment, administration can be to endothelial cells present in, near, and/or on smooth muscle. Non-limiting examples of smooth muscles include the iris of the eye, bronchioles of the lung, laryngeal muscles (vocal cords), muscular layers of the stomach, esophagus, small and large intestine of the gastrointestinal tract, ureter, detrusor muscle of the urinary bladder, uterine myometrium, penis, or prostate gland.

[00610] In some embodiments, of a ceDNA vector for expression of FVIII protein as disclosed herein is administered to skeletal muscle, diaphragm muscle and/or cardiac muscle. In representative embodiments, a ceDNA vector according to the present disclosure is used to treat and/or prevent disorders of skeletal, cardiac and/or diaphragm muscle.

[00611] Specifically, it is contemplated that a composition comprising a ceDNA vector for expression of FVIII protein as disclosed herein can be delivered to one or more muscles of the eye (*e.g.*, Lateral rectus, Medial rectus, Superior rectus, Inferior rectus, Superior oblique, Inferior oblique), facial muscles (*e.g.*, Occipitofrontalis muscle, Temporoparietalis muscle, Procerus muscle, Nasalis muscle, Depressor septi nasi muscle, Orbicularis oculi muscle, Corrugator supercilii muscle, Depressor supercilii muscle, Auricular muscles, Orbicularis oris muscle, Depressor anguli oris muscle, Risorius, Zygomaticus major muscle, Zygomaticus minor muscle, Levator labii superioris, Levator labii superioris alaeque nasi muscle, Depressor labii inferioris muscle, Levator anguli oris, Buccinator muscle, Mentalis) or tongue muscles (*e.g.*, genioglossus, hyoglossus, chondroglossus, styloglossus, palatoglossus, superior longitudinal muscle, inferior longitudinal muscle, the vertical muscle, and the transverse muscle).

(i) *Intramuscular injection*: In some embodiments, a composition comprising a ceDNA vector for expression of FVIII protein as disclosed herein can be injected into one or more sites of a given muscle, for example, skeletal muscle (*e.g.*, deltoid, vastus lateralis, ventrogluteal muscle of dorsogluteal muscle, or anterolateral thigh for infants) in a subject using a needle. The composition comprising ceDNA can be introduced to other subtypes of muscle cells. Non-limiting examples of muscle cell subtypes include skeletal muscle cells, cardiac muscle cells, smooth muscle cells and/or diaphragm muscle cells.

[00612] Methods for intramuscular injection are known to those of skill in the art and as such are not described in detail herein. However, when performing an intramuscular injection, an appropriate needle size should be determined based on the age and size of the patient, the viscosity of the composition, as well as the site of injection. **Table 19** provides guidelines for exemplary sites of injection and corresponding needle size:

Table 19: Guidelines for intramuscular injection in human patients

<i>Injection Site</i>	<i>Needle Gauge</i>	<i>Needle Size</i>	<i>Max. vol. of composition</i>
Ventrogluteal site (gluteus medius and gluteus minimus)	<i>Aqueous solutions</i> : 20-25 gauge <i>Viscous or oil-based solution</i> : 18-21 gauge	Thin adult: 15 to 25 mm Average adult: 25 mm Larger adult (over 150 lbs): 25 to 38 mm. Children and infants: will require a smaller needle	3mL
Vastus lateralis	<i>Aqueous solutions</i> : 20-25 gauge <i>Viscous or oil-based solution</i> : 18-21 gauge <u>Children/infants</u> : 22 to 25 gauge	Adult: 25 mm to 38 mm	3mL
Deltoid	22 to 25 gauge	Males: 130-260lbs: 25 mm Females: <130 lbs: 16 mm 130-200 lbs: 25mm >200lbs: 38mm	1mL

[00613] In certain embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is formulated in a small volume, for example, an exemplary volume as outlined in **Table 8** for a given subject. In some embodiments, the subject can be administered a general or local anesthetic prior to the injection, if desired. This is particularly desirable if multiple injections are required or if a deeper muscle is injected, rather than the common injection sites noted above.

[00614] In some embodiments, intramuscular injection can be combined with electroporation, delivery pressure or the use of transfection reagents to enhance cellular uptake of the ceDNA vector.

(ii) *Transfection Reagents*: In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is formulated in compositions comprising one or more transfection reagents to facilitate uptake of the vectors into myotubes or muscle tissue. Thus, in one embodiment, the nucleic acids described herein are administered to a muscle cell, myotube or muscle tissue by transfection using methods described elsewhere herein.

(iii) *Electroporation*: In certain embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is administered in the absence of a carrier to facilitate entry of ceDNA into the cells, or in a physiologically inert pharmaceutically acceptable carrier (*i.e.*, any carrier that does not improve or enhance uptake of the capsid free, non-viral vectors into the myotubes). In such embodiments, the uptake of the capsid free, non-viral vector can be facilitated by electroporation of the cell or tissue.

[00615] Cell membranes naturally resist the passage of extracellular into the cell cytoplasm. One method for temporarily reducing this resistance is “electroporation”, where electrical fields are used to create pores in cells without causing permanent damage to the cells. These pores are large enough to allow DNA vectors, pharmaceutical drugs, DNA, and other polar compounds to gain access to the interior of the cell. With time, the pores in the cell membrane close and the cell once again becomes impermeable.

[00616] Electroporation can be used in both *in vitro* and *in vivo* applications to introduce *e.g.*, exogenous DNA into living cells. *In vitro* applications typically mix a sample of live cells with the composition comprising *e.g.*, DNA. The cells are then placed between electrodes such as parallel plates and an electrical field is applied to the cell/composition mixture.

[00617] There are a number of methods for *in vivo* electroporation; electrodes can be provided in various configurations such as, for example, a caliper that grips the epidermis overlying a region of cells to be treated. Alternatively, needle-shaped electrodes may be inserted into the tissue, to access more deeply located cells. In either case, after the composition comprising *e.g.*, nucleic acids are injected into the treatment region, the electrodes apply an electrical field to the region. In some electroporation applications, this electric field comprises a single square wave pulse on the order of 100 to 500 V/cm. of about 10 to 60 ms duration. Such a pulse may be generated, for example, in known applications of the Electro Square Porator T820, made by the BTX Division of Genetronics, Inc.

[00618] Typically, successful uptake of *e.g.*, nucleic acids occurs only if the muscle is electrically stimulated immediately, or shortly after administration of the composition, for example, by injection into the muscle.

[00619] In certain embodiments, electroporation is achieved using pulses of electric fields or using low voltage/long pulse treatment regimens (*e.g.*, using a square wave pulse electroporation system).

Exemplary pulse generators capable of generating a pulsed electric field include, for example, the ECM600, which can generate an exponential wave form, and the ElectroSquarePorator (T820), which can generate a square wave form, both of which are available from BTX, a division of Genetronics, Inc. (San Diego, Calif.). Square wave electroporation systems deliver controlled electric pulses that rise quickly to a set voltage, stay at that level for a set length of time (pulse length), and then quickly drop to zero.

[00620] In some embodiments, a local anesthetic is administered, for example, by injection at the site of treatment to reduce pain that may be associated with electroporation of the tissue in the presence of a composition comprising a capsid free, non-viral vector as described herein. In addition, one of skill in the art will appreciate that a dose of the composition should be chosen that minimizes and/or prevents excessive tissue damage resulting in fibrosis, necrosis or inflammation of the muscle.

(iv) *Delivery Pressure*: In some embodiments, delivery of a ceDNA vector for expression of FVIII protein as disclosed herein to muscle tissue is facilitated by delivery pressure, which uses a combination of large volumes and rapid injection into an artery supplying a limb (*e.g.*, iliac artery). This mode of administration can be achieved through a variety of methods that involve infusing limb vasculature with a composition comprising a ceDNA vector, typically while the muscle is isolated from the systemic circulation using a tourniquet or vessel clamps. In one method, the composition is circulated through the limb vasculature to permit extravasation into the cells. In another method, the intravascular hydrodynamic pressure is increased to expand vascular beds and increase uptake of the ceDNA vector into the muscle cells or tissue. In one embodiment, the ceDNA composition is administered into an artery.

(v) *Lipid Nanoparticle Compositions*: In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein for intramuscular delivery are formulated in a composition comprising a liposome as described elsewhere herein.

(vi) *Systemic Administration of a ceDNA Vector targeted to Muscle Tissue*: In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is formulated to be targeted to the muscle via indirect delivery administration, where the ceDNA is transported to the muscle as opposed to the liver. Accordingly, the technology described herein encompasses indirect administration of compositions comprising a ceDNA vector for expression of FVIII protein as disclosed herein to muscle tissue, for example, by systemic administration. Such compositions can be administered topically, intravenously (by bolus or continuous infusion), intracellular injection, intratissue injection, orally, by inhalation, intraperitoneally, subcutaneously, intracavity, and can be delivered by peristaltic means, if desired, or by other means known by those skilled in the art. The agent can be administered systemically, for example, by intravenous infusion, if so desired.

[00621] In some embodiments, uptake of a ceDNA vector for expression of FVIII protein as disclosed herein into muscle cells/tissue is increased by using a targeting agent or moiety that preferentially directs the vector to muscle tissue. Thus, in some embodiments, a capsid free, ceDNA vector can be concentrated in muscle tissue as compared to the amount of capsid free ceDNA vectors present in other cells or tissues of the body.

[00622] In some embodiments, the composition comprising a ceDNA vector for expression of FVIII protein as disclosed herein further comprises a targeting moiety to muscle cells. In other embodiments, the expressed gene product comprises a targeting moiety specific to the tissue in which it is desired to act. The targeting moiety can include any molecule, or complex of molecules, which is/are capable of targeting, interacting with, coupling with, and/or binding to an intracellular, cell surface, or extracellular biomarker of a cell or tissue. The biomarker can include, for example, a cellular protease, a kinase, a protein, a cell surface receptor, a lipid, and/or fatty acid. Other examples of biomarkers that the targeting moieties can target, interact with, couple with, and/or bind to include molecules associated with a particular disease. For example, the biomarkers can include cell surface receptors implicated in cancer development, such as epidermal growth factor receptor and transferrin receptor. The targeting moieties can include, but are not limited to, synthetic compounds, natural compounds or products, macromolecular entities, bioengineered molecules (*e.g.*, polypeptides, lipids, polynucleotides, antibodies, antibody fragments), and small entities (*e.g.*, small molecules, neurotransmitters, substrates, ligands, hormones and elemental compounds) that bind to molecules expressed in the target muscle tissue.

[00623] In certain embodiments, the targeting moiety may further comprise a receptor molecule, including, for example, receptors, which naturally recognize a specific desired molecule of a target cell. Such receptor molecules include receptors that have been modified to increase their specificity of interaction with a target molecule, receptors that have been modified to interact with a desired target molecule not naturally recognized by the receptor, and fragments of such receptors (see, *e.g.*, Skerra, 2000, *J. Molecular Recognition*, 13:167-187). A preferred receptor is a chemokine receptor. Exemplary chemokine receptors have been described in, for example, Lapidot et al, 2002, *Exp Hematol*, 30:973-81 and Onuffer *et al.*, 2002, *Trends Pharmacol Sci*, 23:459-67.

[00624] In other embodiments, the additional targeting moiety may comprise a ligand molecule, including, for example, ligands which naturally recognize a specific desired receptor of a target cell, such as a Transferrin (Tf) ligand. Such ligand molecules include ligands that have been modified to increase their specificity of interaction with a target receptor, ligands that have been modified to interact with a desired receptor not naturally recognized by the ligand, and fragments of such ligands.

[00625] In still other embodiments, the targeting moiety may comprise an aptamer. Aptamers are oligonucleotides that are selected to bind specifically to a desired molecular structure of the target cell. Aptamers typically are the products of an affinity selection process similar to the affinity selection of

phage display (also known as *in vitro* molecular evolution). The process involves performing several tandem iterations of affinity separation, *e.g.*, using a solid support to which the diseased immunogen is bound, followed by polymerase chain reaction (PCR) to amplify nucleic acids that bound to the immunogens. Each round of affinity separation thus enriches the nucleic acid population for molecules that successfully bind the desired immunogen. In this manner, a random pool of nucleic acids may be “educated” to yield aptamers that specifically bind target molecules. Aptamers typically are RNA, but may be DNA or analogs or derivatives thereof, such as, without limitation, peptide nucleic acids (PNAs) and phosphorothioate nucleic acids.

[00626] In some embodiments, the targeting moiety can comprise a photo-degradable ligand (*i.e.*, a ‘caged’ ligand) that is released, for example, from a focused beam of light such that the capsid free, non-viral vectors or the gene product are targeted to a specific tissue.

[00627] It is also contemplated herein that the compositions be delivered to multiple sites in one or more muscles of the subject. That is, injections can be in at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100 injections sites. Such sites can be spread over the area of a single muscle or can be distributed among multiple muscles.

B. Administration of the ceDNA vector for expression of FVIII protein to non-muscle locations

[00628] In another embodiment, a ceDNA vector for expression of FVIII protein is administered to the liver. The ceDNA vector may also be administered to different regions of the eye such as the cornea and/or optic nerve. The ceDNA vector may also be introduced into the spinal cord, brainstem (medulla oblongata, pons), midbrain (hypothalamus, thalamus, epithalamus, pituitary gland, substantia nigra, pineal gland), cerebellum, telencephalon (corpus striatum, cerebrum including the occipital, temporal, parietal and frontal lobes, cortex, basal ganglia, hippocampus and portaamygdala), limbic system, neocortex, corpus striatum, cerebrum, and inferior colliculus.. The ceDNA vector may be delivered into the cerebrospinal fluid (*e.g.*, by lumbar puncture). The ceDNA vector for expression of FVIII protein may further be administered intravascularly to the CNS in situations in which the blood-brain barrier has been perturbed (*e.g.*, brain tumor or cerebral infarct).

[00629] In some embodiments, the ceDNA vector for expression of FVIII protein can be administered to the desired region(s) of the eye by any route known in the art, including but not limited to, intrathecal, intra-ocular, intracerebral, intraventricular, intravenous (*e.g.*, in the presence of a sugar such as mannitol), intranasal, intra-aural, intra-ocular (*e.g.*, intra-vitreous, sub-retinal, anterior chamber) and peri-ocular (*e.g.*, sub-Tenon's region) delivery as well as intramuscular delivery with retrograde delivery to motor neurons.

[00630] In some embodiments, the ceDNA vector for expression of FVIII protein is administered in a liquid formulation by direct injection (*e.g.*, stereotactic injection) to the desired region or compartment in the CNS. In other embodiments, the ceDNA vector can be provided by topical application to the desired region or by intra-nasal administration of an aerosol formulation. Administration to the eye may be by topical application of liquid droplets. As a further alternative, the ceDNA vector can be administered as a solid, slow-release formulation (see, *e.g.*, U.S. Pat. No. 7,201,898). In yet additional embodiments, the ceDNA vector can be used for retrograde transport to treat, ameliorate, and/or prevent diseases and disorders involving motor neurons (*e.g.*, amyotrophic lateral sclerosis (ALS); spinal muscular atrophy (SMA), etc.). For example, the ceDNA vector can be delivered to muscle tissue from which it can migrate into neurons.

C. Ex vivo treatment

[00631] In some embodiments, cells are removed from a subject, a ceDNA vector for expression of FVIII protein as disclosed herein is introduced therein, and the cells are then replaced back into the subject. Methods of removing cells from subject for treatment *ex vivo*, followed by introduction back into the subject are known in the art (see, *e.g.*, U.S. Pat. No. 5,399,346; the disclosure of which is incorporated herein in its entirety). Alternatively, a ceDNA vector is introduced into cells from another subject, into cultured cells, or into cells from any other suitable source, and the cells are administered to a subject in need thereof.

[00632] Cells transduced with a ceDNA vector for expression of FVIII protein as disclosed herein are preferably administered to the subject in a "therapeutically-effective amount" in combination with a pharmaceutical carrier. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

[00633] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can encode an FVIII protein as described herein (sometimes called a transgene or heterologous nucleic acid sequence) that is to be produced in a cell *in vitro*, *ex vivo*, or *in vivo*. For example, in contrast to the use of the ceDNA vectors described herein in a method of treatment as discussed herein, in some embodiments a ceDNA vector for expression of FVIII protein may be introduced into cultured cells and the expressed FVIII protein isolated from the cells, *e.g.*, for the production of antibodies and fusion proteins. In some embodiments, the cultured cells comprising a ceDNA vector for expression of FVIII protein as disclosed herein can be used for commercial production of antibodies or fusion proteins, *e.g.*, serving as a cell source for small or large scale biomanufacturing of antibodies or fusion proteins. In alternative embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein is introduced into cells in a host non-human subject, for *in vivo* production of antibodies or fusion proteins, including small scale production as well as for commercial large scale FVIII protein production.

[00634] The ceDNA vectors for expression of FVIII protein as disclosed herein can be used in both veterinary and medical applications. Suitable subjects for *ex vivo* gene delivery methods as described above include both avians (*e.g.*, chickens, ducks, geese, quail, turkeys and pheasants) and mammals (*e.g.*, humans, bovines, ovines, caprines, equines, felines, canines, and lagomorphs), with mammals being preferred. Human subjects are most preferred. Human subjects include neonates, infants, juveniles, and adults.

D. Dose ranges

[00635] Provided herein are methods of treatment comprising administering to the subject an effective amount of a composition comprising a ceDNA vector encoding an FVIII protein as described herein. As will be appreciated by a skilled practitioner, the term “effective amount” refers to the amount of the ceDNA composition administered that results in expression of the FVIII protein in a “therapeutically effective amount” for the treatment of hemophilia A.

[00636] *In vivo* and/or *in vitro* assays can optionally be employed to help identify optimal dosage ranges for use. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the condition, and should be decided according to the judgment of the person of ordinary skill in the art and each subject's circumstances. Effective doses can be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[00637] A ceDNA vectors for expression of FVIII protein as disclosed herein is administered in sufficient amounts to transfect the cells of a desired tissue and to provide sufficient levels of gene transfer and expression without undue adverse effects. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, those described above in the “Administration” section, such as direct delivery to the selected organ (*e.g.*, intraportal delivery to the liver), oral, inhalation (including intranasal and intratracheal delivery), intraocular, intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other parental routes of administration. Routes of administration can be combined, if desired.

[00638] The dose of the amount of a ceDNA vectors for expression of FVIII protein as disclosed herein required to achieve a particular “therapeutic effect,” will vary based on several factors including, but not limited to: the route of nucleic acid administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene(s), RNA product(s), or resulting expressed protein(s). One of skill in the art can readily determine a ceDNA vector dose range to treat a patient having a particular disease or disorder based on the aforementioned factors, as well as other factors that are well known in the art.

[00639] Dosage regime can be adjusted to provide the optimum therapeutic response. For example, the oligonucleotide can be repeatedly administered, *e.g.*, several doses can be administered daily, or the dose can be proportionally reduced as indicated by the exigencies of the therapeutic situation. One of ordinary skill in the art will readily be able to determine appropriate doses and schedules of

administration of the subject oligonucleotides, whether the oligonucleotides are to be administered to cells or to subjects.

[00640] A “therapeutically effective dose” will fall in a relatively broad range that can be determined through clinical trials and will depend on the particular application (neural cells will require very small amounts, while systemic injection would require large amounts). For example, for direct *in vivo* injection into skeletal or cardiac muscle of a human subject, a therapeutically effective dose will be on the order of from about 1 µg to 100 g of the ceDNA vector. If exosomes or microparticles are used to deliver the ceDNA vector, then a therapeutically effective dose can be determined experimentally, but is expected to deliver from 1 µg to about 100 g of vector. Moreover, a therapeutically effective dose is an amount ceDNA vector that expresses a sufficient amount of the transgene to have an effect on the subject that results in a reduction in one or more symptoms of the disease, but does not result in significant off-target or significant adverse side effects. In one embodiment, a “therapeutically effective amount” is an amount of an expressed FVIII protein that is sufficient to produce a statistically significant, measurable change in expression of hemophilia A biomarker or reduction of a given disease symptom. Such effective amounts can be gauged in clinical trials as well as animal studies for a given ceDNA vector composition.

[00641] Formulation of pharmaceutically acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens.

[00642] For *in vitro* transfection, an effective amount of a ceDNA vectors for expression of FVIII protein as disclosed herein to be delivered to cells (1×10^6 cells) will be on the order of 0.1 to 100 µg ceDNA vector, preferably 1 to 20 µg, and more preferably 1 to 15 µg or 8 to 10 µg. Larger ceDNA vectors will require higher doses. If exosomes or microparticles are used, an effective *in vitro* dose can be determined experimentally but would be intended to deliver generally the same amount of the ceDNA vector.

[00643] For the treatment of hemophilia A, the appropriate dosage of a ceDNA vector that expresses an FVIII protein as disclosed herein will depend on the specific type of disease to be treated, the type of a FVIII protein, the severity and course of the hemophilia A disease, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The ceDNA vector encoding a FVIII protein is suitably administered to the patient at one time or over a series of treatments. Various dosing schedules including, but not limited to, single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

[00644] Depending on the type and severity of the disease, a ceDNA vector is administered in an amount that the encoded FVIII protein is expressed at about 0.3 mg/kg to 100 mg/kg (*e.g.*, 15 mg/kg-100 mg/kg, or any dosage within that range), by one or more separate administrations, or by continuous infusion. One typical daily dosage of the ceDNA vector is sufficient to result in the

expression of the encoded FVIII protein at a range from about 15 mg/kg to 100 mg/kg or more, depending on the factors mentioned above. One exemplary dose of the ceDNA vector is an amount sufficient to result in the expression of the encoded FVIII protein as disclosed herein in a range from about 10 mg/kg to about 50 mg/kg. Thus, one or more doses of a ceDNA vector in an amount sufficient to result in the expression of the encoded FVIII protein at about 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 2.0 mg/kg, 3 mg/kg, 4.0 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, or 100 mg/kg (or any combination thereof) may be administered to the patient. In some embodiments, the ceDNA vector is an amount sufficient to result in the expression of the encoded FVIII protein for a total dose in the range of 50 mg to 2500 mg. An exemplary dose of a ceDNA vector is an amount sufficient to result in the total expression of the encoded FVIII protein at about 50 mg, about 100 mg, 200 mg, 300 mg, 400 mg, about 500 mg, about 600 mg, about 700 mg, about 720 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2050 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg (or any combination thereof). As the expression of the FVIII protein from ceDNA vector can be carefully controlled by regulatory switches herein, or alternatively multiple dose of the ceDNA vector administered to the subject, the expression of the FVIII protein from the ceDNA vector can be controlled in such a way that the doses of the expressed FVIII protein may be administered intermittently, *e.g.*, every week, every two weeks, every three weeks, every four weeks, every month, every two months, every three months, or every six months from the ceDNA vector. The progress of this therapy can be monitored by conventional techniques and assays.

[00645] In certain embodiments, a ceDNA vector is administered an amount sufficient to result in the expression of the encoded FVIII protein at a dose of 15 mg/kg, 30 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg or a flat dose, *e.g.*, 300 mg, 500 mg, 700 mg, 800 mg, or higher. In some embodiments, the expression of the FVIII protein from the ceDNA vector is controlled such that the FVIII protein is expressed every day, every other day, every week, every 2 weeks or every 4 weeks for a period of time. In some embodiments, the expression of the FVIII protein from the ceDNA vector is controlled such that the FVIII protein is expressed every 2 weeks or every 4 weeks for a period of time. In certain embodiments, the period of time is 6 months, one year, eighteen months, two years, five years, ten years, 15 years, 20 years, or the lifetime of the patient.

[00646] Treatment can involve administration of a single dose or multiple doses. In some embodiments, more than one dose can be administered to a subject; in fact, multiple doses can be administered as needed, because the ceDNA vector elicits does not elicit an anti-capsid host immune response due to the absence of a viral capsid. As such, one of skill in the art can readily determine an

appropriate number of doses. The number of doses administered can, for example, be on the order of 1-100, preferably 2-20 doses.

[00647] Without wishing to be bound by any particular theory, the lack of typical anti-viral immune response elicited by administration of a ceDNA vector as described by the disclosure (*i.e.*, the absence of capsid components) allows the ceDNA vector for expression of FVIII protein to be administered to a host on multiple occasions. In some embodiments, the number of occasions in which a nucleic acid is delivered to a subject is in a range of 2 to 10 times (*e.g.*, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times). In some embodiments, a ceDNA vector is delivered to a subject more than 10 times.

In some embodiments, a dose of a ceDNA vector for expression of FVIII protein as disclosed herein is administered to a subject no more than once per calendar day (*e.g.*, a 24-hour period). In some embodiments, a dose of a ceDNA vector is administered to a subject no more than once per 2, 3, 4, 5, 6, or 7 calendar days. In some embodiments, a dose of a ceDNA vector for expression of FVIII protein as disclosed herein is administered to a subject no more than once per calendar week (*e.g.*, 7 calendar days). In some embodiments, a dose of a ceDNA vector is administered to a subject no more than bi-weekly (*e.g.*, once in a two calendar week period). In some embodiments, a dose of a ceDNA vector is administered to a subject no more than once per calendar month (*e.g.*, once in 30 calendar days). In some embodiments, a dose of a ceDNA vector is administered to a subject no more than once per six calendar months. In some embodiments, a dose of a ceDNA vector is administered to a subject no more than once per calendar year (*e.g.*, 365 days or 366 days in a leap year). In particular embodiments, more than one administration (*e.g.*, two, three, four or more administrations) of a ceDNA vector for expression of FVIII protein as disclosed herein may be employed to achieve the desired level of gene expression over a period of various intervals, *e.g.*, daily, weekly, monthly, yearly, etc.

[00648] Administration of the ceDNA compositions described herein can be repeated for a limited period of time. In some embodiments, the doses are given periodically or by pulsed administration. In a preferred embodiment, the doses recited above are administered over several months. The duration of treatment depends upon the subject's clinical progress and responsiveness to therapy. Booster treatments over time are contemplated. Further, the level of expression can be titrated as the subject grows.

[00649] An FVIII therapeutic protein can be expressed in a subject for at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 6 months, at least 12 months/one year, at least 2 years, at least 5 years, at least 10 years, at least 15 years, at least 20 years, at least 30 years, at least 40 years, at least 50 years or more. Long-term expression can be achieved by repeated administration of the ceDNA vectors described herein at predetermined or desired intervals.

[00650] In some embodiments, a therapeutic a FVIII protein encoded by a ceDNA vector as disclosed herein can be regulated by a regulatory switch, inducible or repressible promotor so that it is

expressed in a subject for at least 1 hour, at least 2 hours, at least 5 hours, at least 10 hours, at least 12 hours, at least 18 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 72 hours, at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 6 months, at least 12 months/one year, at least 2 years, at least 5 years, at least 10 years, at least 15 years, at least 20 years, at least 30 years, at least 40 years, at least 50 years or more. In one embodiment, the expression can be achieved by repeated administration of the ceDNA vectors described herein at predetermined or desired intervals. Alternatively, a ceDNA vector for expression of FVIII protein as disclosed herein can further comprise components of a gene editing system (*e.g.*, CRISPR/Cas, TALENs, zinc finger endonucleases etc.) to permit insertion of the one or more nucleic acid sequences encoding the FVIII protein for substantially permanent treatment or “curing” the disease. Such ceDNA vectors comprising gene editing components are disclosed in International Application PCT/US18/64242, and can include the 5' and 3' homology arms (*e.g.*, SEQ ID NO: 151-154, or sequences with at least 40%, 50%, 60%, 70% or 80% homology thereto) for insertion of the nucleic acid encoding the a FVIII protein into safe harbor regions, such as, but not including albumin gene or CCR5 gene. By way of example, a ceDNA vector expressing a FVIII protein can comprise at least one genomic safe harbor (GSH)-specific homology arms for insertion of the FVIII transgene into a genomic safe harbor is disclosed in International Patent Application PCT/US2019/020225, filed on March 1, 2019, which is incorporated herein in its entirety by reference.

[00651] The duration of treatment depends upon the subject's clinical progress and responsiveness to therapy. Continuous, relatively low maintenance doses are contemplated after an initial higher therapeutic dose.

E. Unit dosage forms

[00652] In some embodiments, the pharmaceutical compositions comprising a ceDNA vector for expression of FVIII protein as disclosed herein can conveniently be presented in unit dosage form. A unit dosage form will typically be adapted to one or more specific routes of administration of the pharmaceutical composition. In some embodiments, the unit dosage form is adapted for droplets to be administered directly to the eye. In some embodiments, the unit dosage form is adapted for administration by inhalation. In some embodiments, the unit dosage form is adapted for administration by a vaporizer. In some embodiments, the unit dosage form is adapted for administration by a nebulizer. In some embodiments, the unit dosage form is adapted for administration by an aerosolizer. In some embodiments, the unit dosage form is adapted for oral administration, for buccal administration, or for sublingual administration. In some embodiments, the unit dosage form is adapted for intravenous, intramuscular, or subcutaneous administration. In some embodiments, the unit dosage form is adapted for subretinal injection, suprachoroidal injection or intravitreal injection.

[00653] In some embodiments, the unit dosage form is adapted for intrathecal or intracerebroventricular administration. In some embodiments, the pharmaceutical composition is formulated for topical administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

X. Methods of Treatment

[00654] The technology described herein also demonstrates methods for making, as well as methods of using the disclosed ceDNA vectors for expression of FVIII protein in a variety of ways, including, for example, *ex vivo*, *ex situ*, *in vitro* and *in vivo* applications, methodologies, diagnostic procedures, and/or gene therapy regimens.

[00655] In one embodiment, the expressed therapeutic FVIII protein expressed from a ceDNA vector as disclosed herein is functional for the treatment of disease. In a preferred embodiment, the therapeutic FVIII protein does not cause an immune system reaction, unless so desired.

[00656] Provided herein is a method of treating hemophilia A in a subject comprising introducing into a target cell in need thereof (for example, a muscle cell or tissue, or other affected cell type) of the subject a therapeutically effective amount of a ceDNA vector for expression of FVIII protein as disclosed herein, optionally with a pharmaceutically acceptable carrier. While the ceDNA vector can be introduced in the presence of a carrier, such a carrier is not required. The ceDNA vector implemented comprises a nucleic acid sequence encoding an FVIII protein as described herein useful for treating the disease. In particular, a ceDNA vector for expression of FVIII protein as disclosed herein may comprise a desired FVIII protein DNA sequence operably linked to control elements capable of directing transcription of the desired FVIII protein encoded by the exogenous DNA sequence when introduced into the subject. The ceDNA vector for expression of FVIII protein as disclosed herein can be administered via any suitable route as provided above, and elsewhere herein.

[00657] Disclosed herein are ceDNA vector compositions and formulations for expression of FVIII protein as disclosed herein that include one or more of the ceDNA vectors of the present disclosure together with one or more pharmaceutically-acceptable buffers, diluents, or excipients. Such compositions may be included in one or more diagnostic or therapeutic kits, for diagnosing, preventing, treating or ameliorating one or more symptoms of hemophilia A. In one aspect the disease, injury, disorder, trauma or dysfunction is a human disease, injury, disorder, trauma or dysfunction.

[00658] Another aspect of the technology described herein provides a method for providing a subject in need thereof with a diagnostically- or therapeutically-effective amount of a ceDNA vector for expression of FVIII protein as disclosed herein, the method comprising providing to a cell, tissue or organ of a subject in need thereof, an amount of the ceDNA vector as disclosed herein; and for a time effective to enable expression of the FVIII protein from the ceDNA vector thereby providing the

subject with a diagnostically- or a therapeutically-effective amount of the FVIII protein expressed by the ceDNA vector. In a further aspect, the subject is human.

[00659] Another aspect of the technology described herein provides a method for diagnosing, preventing, treating, or ameliorating at least one or more symptoms of hemophilia A, a disorder, a dysfunction, an injury, an abnormal condition, or trauma in a subject. In an overall and general sense, the method includes at least the step of administering to a subject in need thereof one or more of the disclosed ceDNA vector for FVIII protein production, in an amount and for a time sufficient to diagnose, prevent, treat or ameliorate the one or more symptoms of the disease, disorder, dysfunction, injury, abnormal condition, or trauma in the subject. In such an embodiment, the subject can be evaluated for efficacy of the FVIII protein, or alternatively, detection of the FVIII protein or tissue location (including cellular and subcellular location) of the FVIII protein in the subject. As such, the ceDNA vector for expression of FVIII protein as disclosed herein can be used as an *in vivo* diagnostic tool, *e.g.*, for the detection of cancer or other indications. In a further aspect, the subject is human.

[00660] Another aspect is use of a ceDNA vector for expression of FVIII protein as disclosed herein as a tool for treating or reducing one or more symptoms of hemophilia A or disease states. There are a number of inherited diseases in which defective genes are known, and typically fall into two classes: deficiency states, usually of enzymes, which are generally inherited in a recessive manner, and unbalanced states, which may involve regulatory or structural proteins, and which are typically but not always inherited in a dominant manner. For unbalanced disease states, a ceDNA vector for expression of FVIII protein as disclosed herein can be used to create hemophilia A state in a model system, which could then be used in efforts to counteract the disease state. Thus, the ceDNA vector for expression of FVIII protein as disclosed herein permit the treatment of genetic diseases. As used herein, hemophilia A state is treated by partially or wholly remedying the deficiency or imbalance that causes the disease or makes it more severe.

[00661] As used herein, the term “therapeutically effective amount” is an amount of an expressed FVIII therapeutic protein, or functional fragment thereof that is sufficient to produce a statistically significant, measurable change in expression of a disease biomarker or reduction in a given disease symptom (see “Efficacy Measurement” below). Such effective amounts can be gauged in clinical trials as well as animal studies for a given ceDNA composition.

[00662] The efficacy of a given treatment for hemophilia A, can be determined by the skilled clinician. However, a treatment is considered “effective treatment,” as the term is used herein, if any one or all of the signs or symptoms of the disease or disorder is/are altered in a beneficial manner, or other clinically accepted symptoms or markers of disease are improved, or ameliorated, *e.g.*, by at least 10% following treatment with a ceDNA vector encoding FVIII, or a functional fragment thereof. Efficacy can also be measured by failure of an individual to worsen as assessed by stabilization of the disease, or the need for medical interventions (*i.e.*, progression of the disease is halted or at least

slowed). Methods of measuring these indicators are known to those of skill in the art and/or described herein. Treatment includes any treatment of a disease in an individual or an animal (some non-limiting examples include a human, or a mammal) and includes: (1) inhibiting the disease, *e.g.*, arresting, or slowing progression of the disease or disorder; or (2) relieving the disease, *e.g.*, causing regression of symptoms; and (3) preventing or reducing the likelihood of the development of the disease, or preventing secondary diseases/disorders associated with the disease, such as liver or kidney failure. An effective amount for the treatment of a disease means that amount which, when administered to a mammal in need thereof, is sufficient to result in effective treatment as that term is defined herein, for that disease.

[00663] Efficacy of an agent can be determined by assessing physical indicators that are particular to hemophilia A. Standard methods of analysis of hemophilia A indicators are known in the art.

A. Host cells

[00664] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein delivers the FVIII protein transgene into a subject host cell. In some embodiments, the cells are photoreceptor cells. In some embodiments, the cells are RPE cells. In some embodiments, the subject host cell is a human host cell, including, for example blood cells, stem cells, hematopoietic cells, CD34⁺ cells, liver cells, cancer cells, vascular cells, muscle cells, pancreatic cells, neural cells, ocular or retinal cells, epithelial or endothelial cells, dendritic cells, fibroblasts, or any other cell of mammalian origin, including, without limitation, hepatic (*i.e.*, liver) cells, lung cells, cardiac cells, pancreatic cells, intestinal cells, diaphragmatic cells, renal (*i.e.*, kidney) cells, neural cells, blood cells, bone marrow cells, or any one or more selected tissues of a subject for which gene therapy is contemplated. In one aspect, the subject host cell is a human host cell.

[00665] The present disclosure also relates to recombinant host cells as mentioned above, including a ceDNA vector for expression of FVIII protein as disclosed herein. Thus, one can use multiple host cells depending on the purpose as is obvious to the skilled artisan. A construct or a ceDNA vector for expression of FVIII protein as disclosed herein including donor sequence is introduced into a host cell so that the donor sequence is maintained as a chromosomal integrant as described earlier. The term host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the donor sequence and its source.

[00666] The host cell may also be a eukaryote, such as a mammalian, insect, plant, or fungal cell. In one embodiment, the host cell is a human cell (*e.g.*, a primary cell, a stem cell, or an immortalized cell line). In some embodiments, the host cell can be administered a ceDNA vector for expression of FVIII protein as disclosed herein *ex vivo* and then delivered to the subject after the gene therapy event. A host cell can be any cell type, *e.g.*, a somatic cell or a stem cell, an induced pluripotent stem cell, or a blood cell, *e.g.*, T-cell or B-cell, or bone marrow cell. In certain embodiments, the host cell is an

allogenic cell. For example, T-cell genome engineering is useful for cancer immunotherapies, disease modulation such as HIV therapy (*e.g.*, receptor knock out, such as CXCR4 and CCR5) and immunodeficiency therapies. MHC receptors on B-cells can be targeted for immunotherapy. In some embodiments, gene modified host cells, *e.g.*, bone marrow stem cells, *e.g.*, CD34⁺ cells, or induced pluripotent stem cells can be transplanted back into a patient for expression of a therapeutic protein.

B. Additional diseases for gene therapy:

[00667] In general, a ceDNA vector for expression of FVIII protein as disclosed herein can be used to deliver any FVIII protein in accordance with the description above to treat, prevent, or ameliorate the symptoms associated with hemophilia A related to an aberrant protein expression or gene expression in a subject.

[00668] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can be used to deliver an FVIII protein to skeletal, cardiac or diaphragm muscle, for production of an FVIII protein for secretion and circulation in the blood or for systemic delivery to other tissues to treat, ameliorate, and/or prevent hemophilia A.

[00669] The a ceDNA vector for expression of FVIII protein as disclosed herein can be administered to the lungs of a subject by any suitable means, optionally by administering an aerosol suspension of respirable particles comprising the ceDNA vectors, which the subject inhales. The respirable particles can be liquid or solid. Aerosols of liquid particles comprising the ceDNA vectors may be produced by any suitable means, such as with a pressure-driven aerosol nebulizer or an ultrasonic nebulizer, as is known to those of skill in the art. See, *e.g.*, U.S. Pat. No. 4,501,729. Aerosols of solid particles comprising the ceDNA vectors may likewise be produced with any solid particulate medicament aerosol generator, by techniques known in the pharmaceutical art.

[00670] In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can be administered to tissues of the CNS (*e.g.*, brain, eye).

[00671] Ocular disorders that may be treated, ameliorated, or prevented with a ceDNA vector for expression of FVIII protein as disclosed herein include ophthalmic disorders involving the retina, posterior tract, and optic nerve (*e.g.*, retinitis pigmentosa, diabetic retinopathy and other retinal degenerative diseases, uveitis, age-related macular degeneration, glaucoma). Many ophthalmic diseases and disorders are associated with one or more of three types of indications: (1) angiogenesis, (2) inflammation, and (3) degeneration. In some embodiments, the ceDNA vector as disclosed herein can be employed to deliver anti-angiogenic factors; anti-inflammatory factors; factors that retard cell degeneration, promote cell sparing, or promote cell growth and combinations of the foregoing. Diabetic retinopathy, for example, is characterized by angiogenesis. Diabetic retinopathy can be treated by delivering one or more anti-angiogenic antibodies or fusion proteins either intraocularly (*e.g.*, in the vitreous) or periocularly (*e.g.*, in the sub-Tenon's region). Additional ocular diseases that may be treated, ameliorated, or prevented with the ceDNA vectors of the disclosure include

geographic atrophy, vascular or “wet” macular degeneration, PKU, Leber Congenital Amaurosis (LCA), Usher syndrome, pseudoxanthoma elasticum (PXE), x-linked retinitis pigmentosa (XLRP), x-linked retinoschisis (XLRs), Choroideremia, Leber hereditary optic neuropathy (LHON), Archomatsopia, cone-rod dystrophy, Fuchs endothelial corneal dystrophy, diabetic macular edema and ocular cancer and tumors.

[00672] In some embodiments, inflammatory ocular diseases or disorders (*e.g.*, uveitis) can be treated, ameliorated, or prevented by a ceDNA vector for expression of FVIII protein as disclosed herein. One or more anti-inflammatory antibodies or fusion proteins can be expressed by intraocular (*e.g.*, vitreous or anterior chamber) administration of the ceDNA vector as disclosed herein.

In some embodiments, a ceDNA vector for expression of FVIII protein as disclosed herein can encode an FVIII protein that is associated with transgene encoding a reporter polypeptide (*e.g.*, an enzyme such as Green Fluorescent Protein, or alkaline phosphatase). In some embodiments, a transgene that encodes a reporter protein useful for experimental or diagnostic purposes, is selected from any of: β -lactamase, β -galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art. In some aspects, ceDNA vectors expressing an FVIII protein linked to a reporter polypeptide may be used for diagnostic purposes, as well as to determine efficacy or as markers of the ceDNA vector's activity in the subject to which they are administered.

C. Testing for successful gene expression using a ceDNA vector

[00673] Assays well known in the art can be used to test the efficiency of gene delivery of an FVIII protein by a ceDNA vector can be performed in both *in vitro* and *in vivo* models. Levels of the expression of the FVIII protein by ceDNA can be assessed by one skilled in the art by measuring mRNA and protein levels of the FVIII protein (*e.g.*, reverse transcription PCR, western blot analysis, and enzyme-linked immunosorbent assay (ELISA)). In one embodiment, ceDNA comprises a reporter protein that can be used to assess the expression of the FVIII protein, for example by examining the expression of the reporter protein by fluorescence microscopy or a luminescence plate reader. For *in vivo* applications, protein function assays can be used to test the functionality of a given FVIII protein to determine if gene expression has successfully occurred. One skilled will be able to determine the best test for measuring functionality of an FVIII protein expressed by the ceDNA vector *in vitro* or *in vivo*.

[00674] It is contemplated herein that the effects of gene expression of an FVIII protein from the ceDNA vector in a cell or subject can last for at least 1 month, at least 2 months, at least 3 months, at least four months, at least 5 months, at least six months, at least 10 months, at least 12 months, at least 18 months, at least 2 years, at least 5 years, at least 10 years, at least 20 years, or can be permanent.

[00675] In some embodiments, an FVIII protein in the expression cassette, expression construct, or ceDNA vector described herein can be codon optimized for the host cell. As used herein, the term

“codon optimized” or “codon optimization” refers to the process of modifying a nucleic acid sequence for enhanced expression in the cells of the vertebrate of interest, *e.g.*, mouse or human (*e.g.*, humanized), by replacing at least one, more than one, or a significant number of codons of the native sequence (*e.g.*, a prokaryotic sequence) with codons that are more frequently or most frequently used in the genes of that vertebrate. Various species exhibit particular bias for certain codons of a particular amino acid. Typically, codon optimization does not alter the amino acid sequence of the original translated protein. Optimized codons can be determined using *e.g.*, Aptagen’s Gene Forge® codon optimization and custom gene synthesis platform (Aptagen, Inc.) or another publicly available database.

D. Determining Efficacy by Assessing FVIII protein Expression from the ceDNA vector

[00676] Essentially any method known in the art for determining protein expression can be used to analyze expression of a FVIII protein from a ceDNA vector. Non-limiting examples of such methods/assays include enzyme-linked immunoassay (ELISA), affinity ELISA, ELISPOT, serial dilution, flow cytometry, surface plasmon resonance analysis, kinetic exclusion assay, mass spectrometry, Western blot, immunoprecipitation, and PCR.

[00677] For assessing FVIII protein expression *in vivo*, a biological sample can be obtained from a subject for analysis. Exemplary biological samples include a biofluid sample, a body fluid sample, blood (including whole blood), serum, plasma, urine, saliva, a biopsy and/or tissue sample etc. A biological sample or tissue sample can also refer to a sample of tissue or fluid isolated from an individual including, but not limited to, tumor biopsy, stool, spinal fluid, pleural fluid, nipple aspirates, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, breast milk, cells (including, but not limited to, blood cells), tumors, organs, and also samples of *in vitro* cell culture constituent. The term also includes a mixture of the above-mentioned samples. The term “sample” also includes untreated or pretreated (or pre-processed) biological samples. In some embodiments, the sample used for the assays and methods described herein comprises a serum sample collected from a subject to be tested.

E. Determining Efficacy of the expressed FVIII protein by Clinical Parameters

[00678] The efficacy of a given FVIII protein expressed by a ceDNA vector for hemophilia A (*i.e.*, functional expression) can be determined by the skilled clinician. However, a treatment is considered “effective treatment,” as the term is used herein, if any one or all of the signs or symptoms of hemophilia A is/are altered in a beneficial manner, or other clinically accepted symptoms or markers of disease are improved, or ameliorated, *e.g.*, by at least 10% following treatment with a ceDNA vector encoding a therapeutic FVIII protein as described herein. Efficacy can also be measured by failure of an individual to worsen as assessed by stabilization of hemophilia A, or the need for medical interventions (*i.e.*, progression of the disease is halted or at least slowed). Methods of measuring these indicators are known to those of skill in the art and/or described herein. Treatment includes any

treatment of a disease in an individual or an animal (some non-limiting examples include a human, or a mammal) and includes: (1) inhibiting hemophilia A, *e.g.*, arresting, or slowing progression of hemophilia A; or (2) relieving the hemophilia A, *e.g.*, causing regression of a hemophilia A symptom; and (3) preventing or reducing the likelihood of the development of the hemophilia A disease, or preventing secondary diseases/disorders associated with hemophilia A. An effective amount for the treatment of a disease means that amount which, when administered to a mammal in need thereof, is sufficient to result in effective treatment as that term is defined herein, for that disease. Efficacy of an agent can be determined by assessing physical indicators that are particular to hemophilia A disease. A physician can assess for any one or more of clinical symptoms of hemophilia A which include: unexplained and excessive bleeding from cuts or injuries, or after surgery or dental work; many large or deep bruises; unusual bleeding after vaccinations; pain, swelling or tightness in your joints; blood in your urine or stool; nosebleeds without a known cause; in infants, unexplained irritability.

XI. Various applications of ceDNA vectors expressing antibodies or fusion proteins

[00679] As disclosed herein, the compositions and ceDNA vectors for expression of FVIII protein as described herein can be used to express an FVIII protein for a range of purposes. In one embodiment, the ceDNA vector expressing an FVIII protein can be used to create a somatic transgenic animal model harboring the transgene, *e.g.*, to study the function or disease progression of hemophilia A. In some embodiments, a ceDNA vector expressing an FVIII protein is useful for the treatment, prevention, or amelioration of hemophilia A states or disorders in a mammalian subject.

[00680] In some embodiments the FVIII protein can be expressed from the ceDNA vector in a subject in a sufficient amount to treat a disease associated with increased expression, increased activity of the gene product, or inappropriate upregulation of a gene.

[00681] In some embodiments the FVIII protein can be expressed from the ceDNA vector in a subject in a sufficient amount to treat hemophilia A with a reduced expression, lack of expression or dysfunction of a protein.

[00682] It will be appreciated by one of ordinary skill in the art that the transgene may not be an open reading frame of a gene to be transcribed itself; instead it may be a promoter region or repressor region of a target gene, and the ceDNA vector may modify such region with the outcome of so modulating the expression of the FVIII gene.

[00683] The compositions and ceDNA vectors for expression of FVIII protein as disclosed herein can be used to deliver an FVIII protein for various purposes as described above.

[00684] In some embodiments, the transgene encodes one or more FVIII proteins which are useful for the treatment, amelioration, or prevention of hemophilia A states in a mammalian subject. The FVIII protein expressed by the ceDNA vector is administered to a patient in a sufficient amount to treat hemophilia A associated with an abnormal gene sequence, which can result in any one or more of

the following: increased protein expression, over activity of the protein, reduced expression, lack of expression or dysfunction of the target gene or protein.

[00685] In some embodiments, the ceDNA vectors for expression of FVIII protein as disclosed herein are envisioned for use in diagnostic and screening methods, whereby an FVIII protein is transiently or stably expressed in a cell culture system, or alternatively, a transgenic animal model.

[00686] Another aspect of the technology described herein provides a method of transducing a population of mammalian cells with a ceDNA vector for expression of FVIII protein as disclosed herein. In an overall and general sense, the method includes at least the step of introducing into one or more cells of the population, a composition that comprises an effective amount of one or more of the ceDNA vectors for expression of FVIII protein as disclosed herein.

[00687] Additionally, the present disclosure provides compositions, as well as therapeutic and/or diagnostic kits that include one or more of the disclosed ceDNA vectors for expression of FVIII protein as disclosed herein or ceDNA compositions, formulated with one or more additional ingredients, or prepared with one or more instructions for their use.

[00688] A cell to be administered a ceDNA vector for expression of FVIII protein as disclosed herein may be of any type, including but not limited to neural cells (including cells of the peripheral and central nervous systems, in particular, brain cells), lung cells, retinal cells, epithelial cells (*e.g.*, gut and respiratory epithelial cells), muscle cells, dendritic cells, pancreatic cells (including islet cells), hepatic cells, myocardial cells, bone cells (*e.g.*, bone marrow stem cells), hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, germ cells, and the like. Alternatively, the cell may be any progenitor cell. As a further alternative, the cell can be a stem cell (*e.g.*, neural stem cell, liver stem cell). As still a further alternative, the cell may be a cancer or tumor cell. Moreover, the cells can be from any species of origin, as indicated above.

A. Production and Purification of ceDNA vectors expressing FVIII

[00689] The ceDNA vectors disclosed herein are to be used to produce FVIII protein either *in vitro* or *in vivo*. The FVIII proteins produced in this manner can be isolated, tested for a desired function, and purified for further use in research or as a therapeutic treatment. Each system of protein production has its own advantages/disadvantages. While proteins produced *in vitro* can be easily purified and can produce proteins in a short time, proteins produced *in vivo* can have post-translational modifications, such as glycosylation.

[00690] FVIII therapeutic protein produced using ceDNA vectors can be purified using any method known to those of skill in the art, for example, ion exchange chromatography, affinity chromatography, precipitation, or electrophoresis.

[00691] An FVIII therapeutic protein produced by the methods and compositions described herein can be tested for binding to the desired target protein.

[00692] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limiting. It should be understood that this disclosure is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present disclosure, which is defined solely by the claims.

EXAMPLES

[00693] The following examples are provided by way of illustration not limitation. It will be appreciated by one of ordinary skill in the art that ceDNA vectors can be constructed from any of the wild-type or modified ITRs described herein, and that the following exemplary methods can be used to construct and assess the activity of such ceDNA vectors. While the methods are exemplified with certain ceDNA vectors, they are applicable to any ceDNA vector in keeping with the description.

EXAMPLE 1: Constructing ceDNA Vectors Using an Insect Cell-Based Method

[00694] Production of the ceDNA vectors using a polynucleotide construct template is described in Example 1 of PCT/US18/49996, which is incorporated herein in its entirety by reference. For example, a polynucleotide construct template used for generating the ceDNA vectors of the present disclosure can be a ceDNA-plasmid, a ceDNA-Bacmid, and/or a ceDNA-baculovirus. Without being limited to theory, in a permissive host cell, in the presence of *e.g.*, Rep, the polynucleotide construct template having two symmetric ITRs and an expression construct, where at least one of the ITRs is modified relative to a wild-type ITR sequence, replicates to produce ceDNA vectors. ceDNA vector production undergoes two steps: first, excision (“rescue”) of template from the template backbone (*e.g.*, ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus genome etc.) via Rep proteins, and second, Rep mediated replication of the excised ceDNA vector.

[00695] *Production of ceDNA-bacmids:*

[00696] DH10Bac competent cells (MAX EFFICIENCY® DH10Bac™ Competent Cells, Thermo Fisher) were transformed with either test or control plasmids following a protocol according to the manufacturer’s instructions. Recombination between the plasmid and a baculovirus shuttle vector in the DH10Bac cells were induced to generate recombinant ceDNA-bacmids. The recombinant bacmids were selected by screening a positive selection based on blue-white screening in *E. coli* (Φ 80dlacZ Δ M15 marker provides α -complementation of the β -galactosidase gene from the bacmid vector) on a bacterial agar plate containing X-gal and IPTG with antibiotics to select for transformants and maintenance of the bacmid and transposase plasmids. White colonies caused by transposition that disrupts the β -galactoside indicator gene were picked and cultured in 10 ml of media.

[00697] The recombinant ceDNA-bacmids were isolated from the *E. coli* and transfected into Sf9 or Sf21 insect cells using EugeneHD to produce infectious baculovirus. The adherent Sf9 or Sf21 insect cells were cultured in 50 ml of media in T25 flasks at 25°C. Four days later, culture medium (containing the P0 virus) was removed from the cells, filtered through a 0.45 µm filter, separating the infectious baculovirus particles from cells or cell debris.

[00698] Optionally, the first generation of the baculovirus (P0) was amplified by infecting naïve Sf9 or Sf21 insect cells in 50 to 500 ml of media. Cells were maintained in suspension cultures in an orbital shaker incubator at 130 rpm at 25 °C, monitoring cell diameter and viability, until cells reach a diameter of 18-19 nm (from a naïve diameter of 14-15 nm), and a density of ~4.0E+6 cells/mL. Between 3 and 8 days post-infection, the P1 baculovirus particles in the medium were collected following centrifugation to remove cells and debris then filtration through a 0.45 µm filter.

[00699] The ceDNA-baculovirus comprising the test constructs were collected and the infectious activity, or titer, of the baculovirus was determined. Specifically, four x 20 ml Sf9 cell cultures at 2.5E+6 cells/ml were treated with P1 baculovirus at the following dilutions: 1/1000, 1/10,000, 1/50,000, 1/100,000, and incubated at 25-27°C. Infectivity was determined by the rate of cell diameter increase and cell cycle arrest, and change in cell viability every day for 4 to 5 days.

[00700] A “Rep-plasmid” as disclosed in FIG. 8A of PCT/US18/49996, which is incorporated herein in its entirety by reference, was produced in a pFASTBAC™-Dual expression vector (ThermoFisher) comprising both the Rep78 and Rep52 or Rep68 and Rep40. The Rep-plasmid was transformed into the DH10Bac competent cells (MAX EFFICIENCY® DH10Bac™ Competent Cells (Thermo Fisher) following a protocol provided by the manufacturer. Recombination between the Rep-plasmid and a baculovirus shuttle vector in the DH10Bac cells were induced to generate recombinant bacmids (“Rep-bacmids”). The recombinant bacmids were selected by a positive selection that included-blue-white screening in *E. coli* (Φ80dlacZΔM15 marker provides α-complementation of the β-galactosidase gene from the bacmid vector) on a bacterial agar plate containing X-gal and IPTG. Isolated white colonies were picked and inoculated in 10 ml of selection media (kanamycin, gentamicin, tetracycline in LB broth). The recombinant bacmids (Rep-bacmids) were isolated from the *E. coli* and the Rep-bacmids were transfected into Sf9 or Sf21 insect cells to produce infectious baculovirus.

[00701] The Sf9 or Sf21 insect cells were cultured in 50 ml of media for 4 days, and infectious recombinant baculovirus (“Rep-baculovirus”) were isolated from the culture. Optionally, the first generation Rep-baculovirus (P0) were amplified by infecting naïve Sf9 or Sf21 insect cells and cultured in 50 to 500 ml of media. Between 3 and 8 days post-infection, the P1 baculovirus particles in the medium were collected either by separating cells by centrifugation or filtration or another fractionation process. The Rep-baculovirus were collected and the infectious activity of the baculovirus was determined. Specifically, four x 20 mL Sf9 cell cultures at 2.5x10⁶ cells/mL were treated with P1 baculovirus at the following dilutions, 1/1000, 1/10,000, 1/50,000, 1/100,000, and

incubated. Infectivity was determined by the rate of cell diameter increase and cell cycle arrest, and change in cell viability every day for 4 to 5 days.

[00702] *ceDNA vector generation and characterization*

[00703] With reference to **FIG. 3B**, Sf9 insect cell culture media containing either (1) a sample-containing a ceDNA-bacmid or a ceDNA-baculovirus, and (2) Rep-baculovirus described above were then added to a fresh culture of Sf9 cells (2.5E+6 cells/ml, 20ml) at a ratio of 1:1000 and 1:10,000, respectively. The cells were then cultured at 130 rpm at 25°C. 4-5 days after the co-infection, cell diameter and viability are detected. When cell diameters reached 18-20nm with a viability of ~70-80%, the cell cultures were centrifuged, the medium was removed, and the cell pellets were collected. The cell pellets are first resuspended in an adequate volume of aqueous medium, either water or buffer. The ceDNA vector was isolated and purified from the cells using Qiagen MIDI PLUS™ purification protocol (Qiagen, 0.2mg of cell pellet mass processed per column).

[00704] Yields of ceDNA vectors produced and purified from the Sf9 insect cells were initially determined based on UV absorbance at 260nm.

[00705] ceDNA vectors can be assessed by identified by agarose gel electrophoresis under native or denaturing conditions as illustrated in **FIG. 3D**, where (a) the presence of characteristic bands migrating at twice the size on denaturing gels versus native gels after restriction endonuclease cleavage and gel electrophoretic analysis and (b) the presence of monomer and dimer (2x) bands on denaturing gels for uncleaved material is characteristic of the presence of ceDNA vector.

[00706] Structures of the isolated ceDNA vectors were further analyzed by digesting the DNA obtained from co-infected Sf9 cells (as described herein) with restriction endonucleases selected for a) the presence of only a single cut site within the ceDNA vectors, and b) resulting fragments that were large enough to be seen clearly when fractionated on a 0.8% denaturing agarose gel (>800 bp). As illustrated in **FIGS. 3D and 3E**, linear DNA vectors with a non-continuous structure and ceDNA vector with the linear and continuous structure can be distinguished by sizes of their reaction products—for example, a DNA vector with a non-continuous structure is expected to produce 1kb and 2kb fragments, while a non-encapsidated vector with the continuous structure is expected to produce 2kb and 4kb fragments.

[00707] Therefore, to demonstrate in a qualitative fashion that isolated ceDNA vectors are covalently closed-ended as is required by definition, the samples were digested with a restriction endonuclease identified in the context of the specific DNA vector sequence as having a single restriction site, preferably resulting in two cleavage products of unequal size (*e.g.*, 1000 bp and 2000 bp). Following digestion and electrophoresis on a denaturing gel (which separates the two complementary DNA strands), a linear, non-covalently closed DNA will resolve at sizes 1000 bp and 2000 bp, while a covalently closed DNA (*i.e.*, a ceDNA vector) will resolve at 2x sizes (2000 bp and 4000 bp), as the two DNA strands are linked and are now unfolded and twice the length (though single stranded).

Furthermore, digestion of monomeric, dimeric, and *n*-meric forms of the DNA vectors will all resolve as the same size fragments due to the end-to-end linking of the multimeric DNA vectors (see **FIG. 3D**).

[00708] As used herein, the phrase “assay for the Identification of DNA vectors by agarose gel electrophoresis under native gel and denaturing conditions” refers to an assay to assess the closedness of the ceDNA by performing restriction endonuclease digestion followed by electrophoretic assessment of the digest products. One such exemplary assay follows, though one of ordinary skill in the art will appreciate that many art-known variations on this example are possible. The restriction endonuclease is selected to be a single cut enzyme for the ceDNA vector of interest that will generate products of approximately 1/3x and 2/3x of the DNA vector length. This resolves the bands on both native and denaturing gels. Before denaturation, it is important to remove the buffer from the sample. The Qiagen PCR clean-up kit or desalting “spin columns,” *e.g.*, GE HEALTHCARE ILUSTRA™ MICROSPIN™ G-25 columns are some art-known options for the endonuclease digestion. The assay includes for example, i) digest DNA with appropriate restriction endonuclease(s), 2) apply to *e.g.*, a Qiagen PCR clean-up kit, elute with distilled water, iii) adding 10x denaturing solution (10x = 0.5 M NaOH, 10mM EDTA), add 10X dye, not buffered, and analyzing, together with DNA ladders prepared by adding 10X denaturing solution to 4x, on a 0.8 – 1.0 % gel previously incubated with 1mM EDTA and 200mM NaOH to ensure that the NaOH concentration is uniform in the gel and gel box, and running the gel in the presence of 1x denaturing solution (50 mM NaOH, 1mM EDTA). One of ordinary skill in the art will appreciate what voltage to use to run the electrophoresis based on size and desired timing of results. After electrophoresis, the gels are drained and neutralized in 1x TBE or TAE and transferred to distilled water or 1x TBE/TAE with 1x SYBR Gold. Bands can then be visualized with *e.g.*, Thermo Fisher, SYBR® Gold Nucleic Acid Gel Stain (10,000X Concentrate in DMSO) and epifluorescent light (blue) or UV (312nm).

[00709] The purity of the generated ceDNA vector can be assessed using any art-known method. As one exemplary and non-limiting method, contribution of ceDNA-plasmid to the overall UV absorbance of a sample can be estimated by comparing the fluorescent intensity of ceDNA vector to a standard. For example, if based on UV absorbance 4μg of ceDNA vector was loaded on the gel, and the ceDNA vector fluorescent intensity is equivalent to a 2kb band which is known to be 1μg, then there is 1μg of ceDNA vector, and the ceDNA vector is 25% of the total UV absorbing material. Band intensity on the gel is then plotted against the calculated input that band represents – for example, if the total ceDNA vector is 8kb, and the excised comparative band is 2kb, then the band intensity would be plotted as 25% of the total input, which in this case would be .25μg for 1.0μg input. Using the ceDNA vector plasmid titration to plot a standard curve, a regression line equation is then used to calculate the quantity of the ceDNA vector band, which can then be used to determine the percent of total input represented by the ceDNA vector, or percent purity.

[00710] For comparative purposes, Example 1 describes the production of ceDNA vectors using an insect cell based method and a polynucleotide construct template, and is also described in Example 1 of PCT/US18/49996, which is incorporated herein in its entirety by reference. For example, a polynucleotide construct template used for generating the ceDNA vectors of the present disclosure according to Example 1 can be a ceDNA-plasmid, a ceDNA-Bacmid, and/or a ceDNA-baculovirus. Without being limited to theory, in a permissive host cell, in the presence of *e.g.*, Rep, the polynucleotide construct template having two symmetric ITRs and an expression construct, where at least one of the ITRs is modified relative to a wild-type ITR sequence, replicates to produce ceDNA vectors. ceDNA vector production undergoes two steps: first, excision (“rescue”) of template from the template backbone (*e.g.*, ceDNA-plasmid, ceDNA-bacmid, ceDNA-baculovirus genome etc.) via Rep proteins, and second, Rep mediated replication of the excised ceDNA vector.

[00711] An exemplary method to produce ceDNA vectors in a method using insect cell is from a ceDNA-plasmid as described herein.

EXAMPLE 2: Synthetic ceDNA production via excision from a double-stranded DNA molecule

[00712] Synthetic production of the ceDNA vectors is described in Examples 2-6 of International Application PCT/US19/14122, filed January 18, 2019, which is incorporated herein in its entirety by reference. One exemplary method of producing a ceDNA vector using a synthetic method that involves the excision of a double-stranded DNA molecule. In brief, a ceDNA vector can be generated using a double stranded DNA construct, *e.g.*, see FIGS. 7A-8E of PCT/US19/14122. In some embodiments, the double stranded DNA construct is a ceDNA plasmid, *e.g.*, see, *e.g.*, FIG. 6 in International patent application PCT/US2018/064242, filed December 6, 2018).

[00713] In some embodiments, a construct to make a ceDNA vector comprises a regulatory switch as described herein.

[00714] For illustrative purposes, Example 2 describes producing ceDNA vectors as exemplary closed-ended DNA vectors generated using this method. However, while ceDNA vectors are exemplified in this Example to illustrate *in vitro* synthetic production methods to generate a closed-ended DNA vector by excision of a double-stranded polynucleotide comprising the ITRs and expression cassette (*e.g.*, nucleic acid sequence, *e.g.*, heterologous nucleic acid sequence) followed by ligation of the free 3' and 5' ends as described herein, one of ordinary skill in the art is aware that one can, as illustrated above, modify the double stranded DNA polynucleotide molecule such that any desired closed-ended DNA vector is generated, including but not limited to, doggybone DNA, dumbbell DNA and the like. Exemplary ceDNA vectors for production of antibodies or fusion proteins that can be produced by the synthetic production method described in Example 2 are discussed in the sections entitled “III ceDNA vectors in general”. Exemplary antibodies and fusion proteins expressed by the ceDNA vectors are described in the section entitled “IIC Exemplary antibodies and fusion proteins expressed by the ceDNA vectors”.

[00715] The method involves (i) excising a sequence encoding the expression cassette from a double-stranded DNA construct and (ii) forming hairpin structures at one or more of the ITRs and (iii) joining the free 5' and 3' ends by ligation, *e.g.*, by T4 DNA ligase.

[00716] The double-stranded DNA construct comprises, in 5' to 3' order: a first restriction endonuclease site; an upstream ITR; an expression cassette; a downstream ITR; and a second restriction endonuclease site. The double-stranded DNA construct is then contacted with one or more restriction endonucleases to generate double-stranded breaks at both of the restriction endonuclease sites. One endonuclease can target both sites, or each site can be targeted by a different endonuclease as long as the restriction sites are not present in the ceDNA vector template. This excises the sequence between the restriction endonuclease sites from the rest of the double-stranded DNA construct (see Fig. 9 of PCT/US19/14122). Upon ligation a closed-ended DNA vector is formed.

[00717] One or both of the ITRs used in the method may be wild-type ITRs. Modified ITRs may also be used, where the modification can include deletion, insertion, or substitution of one or more nucleotides from the wild-type ITR in the sequences forming B and B' arm and/or C and C' arm (see, *e.g.*, Figs. 6-8 and 10 FIG. 11B of PCT/US19/14122), and may have two or more hairpin loops (see, *e.g.*, Figs. 6-8 FIG. 11B of PCT/US19/14122) or a single hairpin loop (see, *e.g.*, Fig. 10A-10B FIG. 11B of PCT/US19/14122). The hairpin loop modified ITR can be generated by genetic modification of an existing oligo or by de novo biological and/or chemical synthesis.

[00718] In a non-limiting example, ITR-6 Left and Right (SEQ ID NOS: 111 and 112), include 40 nucleotide deletions in the B-B' and C-C' arms from the wild-type ITR of AAV2. Nucleotides remaining in the modified ITR are predicted to form a single hairpin structure. Gibbs free energy of unfolding the structure is about -54.4 kcal/mol. Other modifications to the ITR may also be made, including optional deletion of a functional Rep binding site or a TRS site.

EXAMPLE 3: ceDNA Production via Oligonucleotide Construction

[00719] Another exemplary method of producing a ceDNA vector using a synthetic method that involves assembly of various oligonucleotides, is provided in Example 3 of PCT/US19/14122, where a ceDNA vector is produced by synthesizing a 5' oligonucleotide and a 3' ITR oligonucleotide and ligating the ITR oligonucleotides to a double-stranded polynucleotide comprising an expression cassette. FIG. 11B of PCT/US19/14122 shows an exemplary method of ligating a 5' ITR oligonucleotide and a 3' ITR oligonucleotide to a double stranded polynucleotide comprising an expression cassette.

[00720] As disclosed herein, the ITR oligonucleotides can comprise WT-ITRs (*e.g.*, see **FIG. 2A**, **FIG. 2C**), or modified ITRs (*e.g.*, see, **FIG. 2B** and **FIG. 2D**). (See also, *e.g.*, FIGS. 6A, 6B, 7A and 7B of PCT/US19/14122, which is incorporated herein in its entirety). Exemplary ITR oligonucleotides include, but are not limited to SEQ ID NOS: 134-145 (*e.g.*, see Table 7 in of PCT/US19/14122). Modified ITRs can include deletion, insertion, or substitution of one or more nucleotides from the

wild-type ITR in the sequences forming B and B' arm and/or C and C' arm. ITR oligonucleotides, comprising WT-ITRs or mod-ITRs as described herein, to be used in the cell-free synthesis, can be generated by genetic modification or biological and/or chemical synthesis. As discussed herein, the ITR oligonucleotides in Examples 2 and 3 can comprise WT-ITRs, or modified ITRs (mod-ITRs) in symmetrical or asymmetrical configurations, as discussed herein.

EXAMPLE 4: ceDNA Production via a Single-Stranded DNA Molecule

[00721] Another exemplary method of producing a ceDNA vector using a synthetic method is provided in Example 4 of PCT/US19/14122, and uses a single-stranded linear DNA comprising two sense ITRs which flank a sense expression cassette sequence and are attached covalently to two antisense ITRs which flank an antisense expression cassette, the ends of which single stranded linear DNA are then ligated to form a closed-ended single-stranded molecule. One non-limiting example comprises synthesizing and/or producing a single-stranded DNA molecule, annealing portions of the molecule to form a single linear DNA molecule which has one or more base-paired regions of secondary structure, and then ligating the free 5' and 3' ends to each other to form a closed single-stranded molecule.

[00722] An exemplary single-stranded DNA molecule for production of a ceDNA vector comprises, from 5' to 3': a sense first ITR; a sense expression cassette sequence; a sense second ITR; an antisense second ITR; an antisense expression cassette sequence; and an antisense first ITR.

[00723] A single-stranded DNA molecule for use in the exemplary method of Example 4 can be formed by any DNA synthesis methodology described herein, *e.g.*, *in vitro* DNA synthesis, or provided by cleaving a DNA construct (*e.g.*, a plasmid) with nucleases and melting the resulting dsDNA fragments to provide ssDNA fragments.

[00724] Annealing can be accomplished by lowering the temperature below the calculated melting temperatures of the sense and antisense sequence pairs. The melting temperature is dependent upon the specific nucleotide base content and the characteristics of the solution being used, *e.g.*, the salt concentration. Melting temperatures for any given sequence and solution combination are readily calculated by one of ordinary skill in the art.

[00725] The free 5' and 3' ends of the annealed molecule can be ligated to each other, or ligated to a hairpin molecule to form the ceDNA vector. Suitable exemplary ligation methodologies and hairpin molecules are described in Examples 2 and 3.

EXAMPLE 5: Purifying and/or Confirming Production of ceDNA

[00726] Any of the DNA vector products produced by the methods described herein, *e.g.*, including the insect cell based production methods described in Example 1, or synthetic production methods described in Examples 2-4 can be purified, *e.g.*, to remove impurities, unused components, or byproducts using methods commonly known by a skilled artisan; and/or can be analyzed to confirm that DNA vector produced, (in this instance, a ceDNA vector) is the desired molecule. An exemplary

method for purification of the DNA vector, *e.g.*, ceDNA is using Qiagen Midi Plus purification protocol (Qiagen) and/or by gel purification.

[00727] The following is an exemplary method for confirming the identity of ceDNA vectors.

[00728] ceDNA vectors can be assessed by identified by agarose gel electrophoresis under native or denaturing conditions as illustrated in **FIG. 3D**, where (a) the presence of characteristic bands migrating at twice the size on denaturing gels versus native gels after restriction endonuclease cleavage and gel electrophoretic analysis and (b) the presence of monomer and dimer (2x) bands on denaturing gels for uncleaved material is characteristic of the presence of ceDNA vector.

[00729] Structures of the isolated ceDNA vectors were further analyzed by digesting the purified DNA with restriction endonucleases selected for a) the presence of only a single cut site within the ceDNA vectors, and b) resulting fragments that were large enough to be seen clearly when fractionated on a 0.8% denaturing agarose gel (>800 bp). As illustrated in **FIGS. 3C and 3D**, linear DNA vectors with a non-continuous structure and ceDNA vector with the linear and continuous structure can be distinguished by sizes of their reaction products— for example, a DNA vector with a non-continuous structure is expected to produce 1kb and 2kb fragments, while a ceDNA vector with the continuous structure is expected to produce 2kb and 4kb fragments.

[00730] Therefore, to demonstrate in a qualitative fashion that isolated ceDNA vectors are covalently closed-ended as is required by definition, the samples were digested with a restriction endonuclease identified in the context of the specific DNA vector sequence as having a single restriction site, preferably resulting in two cleavage products of unequal size (*e.g.*, 1000 bp and 2000 bp). Following digestion and electrophoresis on a denaturing gel (which separates the two complementary DNA strands), a linear, non-covalently closed DNA will resolve at sizes 1000 bp and 2000 bp, while a covalently closed DNA (*i.e.*, a ceDNA vector) will resolve at 2x sizes (2000 bp and 4000 bp), as the two DNA strands are linked and are now unfolded and twice the length (though single stranded). Furthermore, digestion of monomeric, dimeric, and *n*-meric forms of the DNA vectors will all resolve as the same size fragments due to the end-to-end linking of the multimeric DNA vectors (see **FIG. 3E**).

[00731] As used herein, the phrase “assay for the Identification of DNA vectors by agarose gel electrophoresis under native gel and denaturing conditions” refers to an assay to assess the close-endedness of the ceDNA by performing restriction endonuclease digestion followed by electrophoretic assessment of the digest products. One such exemplary assay follows, though one of ordinary skill in the art will appreciate that many art-known variations on this example are possible. The restriction endonuclease is selected to be a single cut enzyme for the ceDNA vector of interest that will generate products of approximately 1/3x and 2/3x of the DNA vector length. This resolves the bands on both native and denaturing gels. Before denaturation, it is important to remove the buffer from the sample. The Qiagen PCR clean-up kit or desalting “spin columns,” *e.g.*, GE HEALTHCARE ILUSTRA™

MICROSPIN™ G-25 columns are some art-known options for the endonuclease digestion. The assay includes for example, i) digest DNA with appropriate restriction endonuclease(s), 2) apply to *e.g.*, a Qiagen PCR clean-up kit, elute with distilled water, iii) adding 10x denaturing solution (10x = 0.5 M NaOH, 10mM EDTA), add 10X dye, not buffered, and analyzing, together with DNA ladders prepared by adding 10X denaturing solution to 4x, on a 0.8 – 1.0 % gel previously incubated with 1mM EDTA and 200mM NaOH to ensure that the NaOH concentration is uniform in the gel and gel box, and running the gel in the presence of 1x denaturing solution (50 mM NaOH, 1mM EDTA). One of ordinary skill in the art will appreciate what voltage to use to run the electrophoresis based on size and desired timing of results. After electrophoresis, the gels are drained and neutralized in 1x TBE or TAE and transferred to distilled water or 1x TBE/TAE with 1x SYBR Gold. Bands can then be visualized with *e.g.*, Thermo Fisher, SYBR® Gold Nucleic Acid Gel Stain (10,000X Concentrate in DMSO) and epifluorescent light (blue) or UV (312nm). The foregoing gel-based method can be adapted to purification purposes by isolating the ceDNA vector from the gel band and permitting it to renature.

[00732] The purity of the generated ceDNA vector can be assessed using any art-known method. As one exemplary and non-limiting method, contribution of ceDNA-plasmid to the overall UV absorbance of a sample can be estimated by comparing the fluorescent intensity of ceDNA vector to a standard. For example, if based on UV absorbance 4μg of ceDNA vector was loaded on the gel, and the ceDNA vector fluorescent intensity is equivalent to a 2kb band which is known to be 1μg, then there is 1μg of ceDNA vector, and the ceDNA vector is 25% of the total UV absorbing material. Band intensity on the gel is then plotted against the calculated input that band represents – for example, if the total ceDNA vector is 8kb, and the excised comparative band is 2kb, then the band intensity would be plotted as 25% of the total input, which in this case would be .25μg for 1.0μg input. Using the ceDNA vector plasmid titration to plot a standard curve, a regression line equation is then used to calculate the quantity of the ceDNA vector band, which can then be used to determine the percent of total input represented by the ceDNA vector, or percent purity.

EXAMPLE 6: ceDNA FVIII Constructs and Methods

[00733] Full-length, unmodified FVIII poses a number of challenges in its application in gene therapy. FVIII does not perform well in heterologous systems, and shows poor expression compared to similarly sized proteins. It has been shown that inefficient secretion of FVIII can lead to cellular stress, both inactive and active forms of FVIII have a short half-life, and FVIII does not behave well in circulation. Further, FVIII has been shown to be highly immunogenic. A schematic of FVIII domains, as processed through active FVIIIa is shown in **FIG. 9**.

[00734] The following Examples describe preparation and testing of ceDNA FVIII constructs that show expression and activity following both hydrodynamic and lipid nanoparticle administration.

[00735] FIG. 5 is an annotated schematic of the ceDNA 1638 construct. FIG. 6 is an annotated schematic of the ceDNA 1652 construct. FIG. 7 is an annotated schematic of the ceDNA 1923 construct. FIG. 8 is an annotated schematic of the ceDNA 1373 intron.

[00736] The following ceDNA FVIII constructs were employed in the studies described in Example 7 – Example 16.

Table 20: ceDNA Construct Summary

ceDNA construct identifier	Description
692	B-domain deleted SQ codon optimized (Biomarin)
1362	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-Wt-Afstyla BDD PacI_site WPRE_3pUTR bGH
1368	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1374	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1918	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_0CpG_1_ORF PacI_site WPRE_3pUTR bGH
1919	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_0CpG_6_ORF PacI_site WPRE_3pUTR bGH
1920	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_0CpG_8_ORF PacI_site WPRE_3pUTR bGH
1922	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_5k_wt3_3_ORF PacI_site WPRE_3pUTR bGH
1923	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_5k_wt3_5_ORF PacI_site WPRE_3pUTR bGH
1367	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1373	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1632	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site HBBv3_3pUTR SV40_polyA
1637	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309S PacI_site HBBv3_3pUTR SV40_polyA
1638	CpGmin_hAAT_Promoter_Set hFVIII-F309S-BD226seq124-Afstyla-BDD-F309S PacI_site HBBv3_3pUTR SV40_polyA

1645	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site SV40_polyA
1646	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site HBBv3_3pUTR
1648	3x hSerpEnh_VD_TTRe_PromoterSet Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1657	3x hSerpEnh_VD_PromoterSet (5'UTR variant) PmeI_site Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1922	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_5k_wt3_3_ORF PacI_site WPRE_3pUTR bGH
1923	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_5k_wt3_5_ORF PacI_site WPRE_3pUTR bGH
1368	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1374	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1649	3x SerpEnh_VD_TTRe_PromoterSet Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1651	3x SerpEnh_VD_TTRe_PromoterSet Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1652	3x SerpEnh_VD_TTRe_PromoterSet (5'UTR variant) Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1655	3x SerpEnh_VD_PromoterSet Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1668	3x SerpEnh_VD_TTRe_PromoterSet_v2 PmeI_site Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1367	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1373	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1700	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak ceDNA1367_ORF_exon1_33bpflanks_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD miniF8_50/100 ceDNA1367_ORF_exon2-26_33bpflanks_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1701	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak ceDNA1367_ORF_exon1_33bpflanks_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD miniF8_200/200 ceDNA1367_ORF_exon2-26_33bpflanks_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD PacI_site WPRE_3pUTR bGH

1708	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak ceDNA1373_ORF_exon1_hFVIII-F309S-BD226seq124-Afstyla-BDD miniF8_500/500 ceDNA1373_ORF_exon2-26_hFVIII-F309S-BD226seq124- Afstyla-BDD PacI_site WPRE_3pUTR bGH
1712	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak ceDNA1373_ORF_exon1_hFVIII-F309S-BD226seq124-Afstyla-BDD miniF8_200_5p miniF8_200_3p ceDNA1373_ORF_exon2-26_hFVIII-F309S- BD226seq124-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1725	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak ceDNA1373_ORF_exon1_33bpflanks_hFVIII-F309S-BD226seq124-Afstyla-BDD miniF8_50/100 ceDNA1373_ORF_exon2-26_33bpflanks_hFVIII-F309S- BD226seq124-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1368	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226-Codop-run4-seq102-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1374	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226seq124-Afstyla-BDD-F309 PacI_site WPRE_3pUTR bGH
1579	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1368ORF_ALB-SSv1 PacI_site WPRE_3pUTR bGH
1582	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1368ORF_GAUS-SSv1 PacI_site WPRE_3pUTR bGH
1585	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1368ORF_Secrecon-SSv1 PacI_site WPRE_3pUTR bGH
1598	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1368ORF_Gaus-NS-CAI-v2 PacI_site WPRE_3pUTR bGH
1611	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1374ORF_ALB-SSv1 PacI_site WPRE_3pUTR bGH
1612	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1374ORF_CHY-SSv1 PacI_site WPRE_3pUTR bGH
1615	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1374ORF_LONZ-SSv2 PacI_site WPRE_3pUTR bGH
1616	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- 1374ORF_Secrecon-SSv1 PacI_site WPRE_3pUTR bGH
1270	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226seq124 PacI_site WPRE_3pUTR bGH
1391	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226-Codop-run4-seq102 PacI_site WPRE_3pUTR bGH
1738	1x hSerpEnh_VD_PromoterSet PmeI_site 5pUTR-constant 5pUTR-325243 hFVIII-F309S-BD226seq124 PacI_site WPRE_3pUTR bGH
1740	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226-Codop-run4-seq102 PacI_site WPRE_3pUTR bGH 5'DTS_primer_pad 5x_kB_mesika_DTS 3'DTS_primer_pad
1741	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226-Codop-run4-seq102 PacI_site WPRE_3pUTR bGH CpGfree20mer_1

	SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_2 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_3 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_4 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_5 SV40DNA_DTS_72bpTandemRepeat
1742	5'DTS_primer_pad 5x_kB_mesika_DTS 3'DTS_primer_pad 1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S- BD226-Codop-run4-seq102 PacI_site WPRE_3pUTR bGH
1743	CpGfree20mer_1 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_2 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_3 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_4 SV40DNA_DTS_72bpTandemRepeat CpGfree20mer_5 SV40DNA_DTS_72bpTandemRepeat 1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102 PacI_site WPRE_3pUTR bGH
1744	1x hSerpEnh_VD_PromoterSet PmeI_site 5pUTR-constant 5pUTR-325243 hFVIII-F309S-BD226seq124 PacI_site WPRE_3pUTR bGH AflII_site CpGfree20mer_1, CBX3(674mut1) 20mer_16
694	B domain deleted SQ condon optimized (Sangamo)
1572	CpGfree20mer_1 5xHNF1_ProEnh_10mer 3x hSerpEnh_VD _TTR_PromoterSet_v2 PmeI_site Consensus_Kozak hFVIII-F309S-BD226- Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1664	3x hSerpEnh_VD_TTR_PromoterSet_v2* PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1838	3x hSerpEnh_VD_TTR_PromoterSet 5pUTR-constant, 5pUTR-325243 FVIII_SC_F309_codop_1b PacI_site WPRE_3pUTR bGH
1840	3x hSerpEnh_VD_TTR_PromoterSet 5pUTR-constant, 5pUTR-325243 FVIII_SC_F309_codop_3b PacI_site WPRE_3pUTR bGH
1841	3x hSerpEnh_VD_TTR_PromoterSet 5pUTR-constant, 5pUTR-325243 FVIII_SC_F309S_codop_3b PacI_site WPRE_3pUTR bGH
1886	3x hSerpEnh_VD_TTR_PromoterSet_v2 PmeI_site Consensus_Kozak hFVIII- F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1921	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII-SC_5_ORF PacI_site WPRE_3pUTR bGH
1922	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- SC_5k_wt3_3_ORF PacI_site WPRE_3pUTR bGH
1930	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- SC_5_F309S PacI_site WPRE_3pUTR bGH
1931	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak FVIII- SC_5k_wt3_3_F309S PacI_site WPRE_3pUTR bGH

1574	Minimum_Consensus_Kozak, hFIX_Promoter, PmeI_site, Consensus_Kozak, hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD, PacI_site, WPRE_3pUTR, bGH
1628	CpGmin_hAAT_Promoter_Set, hFVIII-F309S-BD226seq124-Afstyla-BDD, PacI_site, WPRE_3pUTR, bGH,
1593	1x hSerpEnh_VD_PromoterSet, PmeI_site, Consensus_Kozak, FVIII-1368ORF_CD33-NS-struct-v2, PacI_site, WPRE_3pUTR, bGH,
1602	1x hSerpEnh_VD_PromoterSet, PmeI_site, Consensus_Kozak, FVIII_1368ORF_Lonz-NS-CAI-v2, PacI_site, WPRE_3pUTR, bGH,
1367	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1620	CpGmin_hAAT_Promoter_Set PmeI_site Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1622	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1627	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1636	CpGmin_hAAT_Promoter_Set PmeI_site Mod_Minimum_Consensus_Kozak hFVIII-F309S-BD226seq124-Afstyla-BDD PacI_site HBBv3_3pUTR SV40_polyA
1648	3x SerpEnh_VD_TTRe_PromoterSet Consensus_Kozak hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD-F309S PacI_site WPRE_3pUTR bGH
1695	CRM8_SERP_enhancer TTR_liver_specific_Promoter MVM_intron_post_splice PmeI_site Consensus_Kozak ceDNA1367_ORF_exon1_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD HBB_intron1 ceDNA1367_ORF_exon2-26_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1696	CRM8_SERP_enhancer TTR_liver_specific_Promoter MVM_intron_post_splice PmeI_site Consensus_Kozak ceDNA1367_ORF_exon1_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD F8_intron8 ceDNA1367_ORF_exon2-26_hFVIII-F309S-BD226-Codop-run4-seq102-Afstyla-BDD PacI_site WPRE_3pUTR bGH
1710	1x hSerpEnh_VD_PromoterSet PmeI_site Consensus_Kozak ceDNA1373_ORF_exon1_hFVIII-F309S-BD226seq124-Afstyla-BDD miniF8_200_5p Minimum_Consensus_Kozak miniF8_200_3p ceDNA1373_ORF_exon2-26_hFVIII-F309S-BD226seq124-Afstyla-BDD PacI_site WPRE_3pUTR bGH

[00737] FIG. 10 is a schematic detailing a method of insertion of introns into FVIII ORF. Chimeric FVIII intron a with functional splice donor and acceptor sites is inserted at native position of intron 1 into codon optimized FVIII ORF. Intron flanking regions (33bp) derived from FVIII Wt cDNA sequence were substituted for codon optimized sequence in FVIII CDS.

[00738] **FIG. 11** is a schematic detailing a method of insertion of introns into FVIII ORF cDNA 1373. Chimeric FVIII intron with functional splice donor and acceptor sites inserted at native position of intron 1 into codon optimized FVIII ORF. Enhancer element inserted in between 5p and 3p regions of chimeric intron.

[00739] **FIGs. 12A-12B** are schematics detailing method of substituting heterologous secretion signal sequences for the native FVIII signal sequence. **FIG. 12A** shows substitution of native FVIII signal sequence for signal sequence from chymotrypsinogen (CHY-SSv1) ORF. FVIII mature peptide is shown. **FIG. 12B** shows the sequence of FVIII N-terminus showing signal sequence and mature peptide cleavage site.

[00740] Screening was carried out to determine FVIII activity using the following assays:

In vitro screening assay:

[00741] Using Lipofectamine p3000 (Thermofisher cat no: L3000001), 24 hours prior to transfection: HepG2 cells were plated in a 96 well collagen coated plate at a density of 20,000 cells/well (100uL in each well = 200,000 cells/mL). On the day of transfection, the media was changed in all cell-containing wells.

[00742] Lipofectamine dilution was prepared as follows: 0.3uL lipofectamine3000 reagent+10uL Opti-MEM (per well)

[00743] P3000 dilutions was prepared as follows: 10uL Opti-MEM + 0.4uL p3000 (per well)

[00744] 800ng DNA was plated into single wells of a 96 well prep-plate.

[00745] 21uL of the L3000 dilution and 21uL of the P3000 dilutions were added to each DNA-containing well, and gently mixed, followed by incubation at room temperature (RT) for 15 minutes. 10uL/well of the L3000 and P3000 mixture was added to the cells in triplicate, followed by incubation for 72 hours at 37C, 5% CO₂, humidified air.

[00746] 72 hours after transfection, supernatant media was collected into equal volume aliquots into 2X 96W storage plates and either frozen immediately or used in the Chromogenix FVIII Activity assay.
Chromogenix FVIII Activity assay:

[00747] The chromogenic assay to determine FVIII activity was carried out as follows: Kit components were allowed to acclimate to room temperature from 4C before use. The lyophilized kit components were reconstituted with sterile water: 3mL per Factor Reagent (green cap) and 6mL to the S-2765 + I-2581 Reagent (white cap). The Technoclone Coagulation Reference was reconstituted with 1mL sterile water and allow to mix slowly on a rocker for 15min before use. Samples are diluted as follows: 5uL sample + 400uL buffer in a 96W block.

[00748] Standard (coagulation reference) was prepared in the 96W block as seen on "extended curve" tab. Samples and standards were plated on the 384W plate using the 125uL Voyager Pipette: 10uL each. Reconstituted Factor Reagent (green cap) and S-2765 + I-2581 (white cap) was prewarmed from the kit at 37C. Plate was uncubated at 37°C for 4min.

[00749] Next, 10uL Factor Reagent was added to each well, using the 50uL pipette, leaving 10 seconds between row additions to maintain incubation times. Plate was incubated at 37C for 4min. 10uL S-2765 + I-2581 was added to each well, using the 50uL pipette, leaving 10 seconds between row additions to maintain incubation times. Plate was incubated at 37C for 10min. 10uL acetic acid (20%) was added as a stop solution to each well, using the 50uL pipette, leaving 10 seconds between row additions to maintain incubation times. Plate absorbance was read on M3 at 405nm.

[00750] Analysis was performed as follows: After reading on M3, data was exported to Excel for processing. All raw absorbance values were normalized to the 0 IU/mL standard wells (average the 2 wells, then subtract that averaged value from each other well value). Normalized values were plugged into GraphPad Prism, XY table format. Values of IU/mL for FVIII standards were added with their normalized absorbance value. Unknowns were added-the sample name and the normalized absorbance values.

[00751] Data was processed as follows: “transform concentrations (x)” à transform to log (log(10)); XY analysis à “nonlinear regression (curve fit)” à “asymmetric 5 parameter, X is log(concentration); go to “interpolated X mean values” tab à analyze à transform à standard functions and “transform Y values using: $Y=10^Y$ ” AND check off “create new graph of the results”; this gives the processed and interpolated IU/mL values for the unknowns (samples).

EXAMPLE 7: Study to Determine FVIII Expression after Hydrodynamic ceDNA Delivery in Male FVIII Knockout Mice

[00752] A well-known method of introducing nucleic acid to the liver in rodents is by hydrodynamic tail vein injection. In this system, the pressurized injection in a large volume of non-encapsulated nucleic acid results in a transient increase in cell permeability and delivery directly into tissues and cells. This provides an experimental mechanism to bypass many of the host immune systems, such as macrophage delivery, providing the opportunity to observe delivery and expression in the absence of such activity

[00753] A hydrodynamic delivery system was used to test the effect of various ceDNA vectors expressing FVIII on serum FVIII levels, where detection of FVIII in the serum indicated that the ceDNA vector was able to express FVIII after injection.

[00754] ceDNA vectors as described in Example 6 were employed. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in **Table 20**. Test materials for each study are shown in the **Tables 21-23**, below

Table 21: Study 1

Group No.	Animals per Group	Treatment	Dose Level (µg)	Dose Volume	Treatment Regimen, IV	Terminal Time Point
1	4	PBS	1.0		Once on	Day 7

2	4	ceDNA1362		90 – 100 ml/kg (set volume)	Day 0 by IV Hydrodynamic	
3	4	ceDNA1367				
4	4	ceDNA1368				
5	4	ceDNA1373				
6	4	ceDNA1374				
7	4	ceDNA1361				
8	4	ceDNA1265				
9	4	ceDNA1270				
10	4	ceDNA 692				

Table 22: Study 2

Group No.	Animals per Group	Treatment	Dose Level (µg)	Dose Volume	Treatment Regimen, IV	Terminal Time Point
1	4	PBS	1.0	90 – 100 ml/kg (set volume)	Once on Day 0 by IV Hydrodynamic	Day 7
2	4	ceDNA694				
3	4	ceDNA1320				
4	4	ceDNA704				
5	4	ceDNA1260				
6	4	ceDNA1258				
7	4	ceDNA933				
8	4	ceDNA1259				
9	4	ceDNA1270				
10	4	ceDNA1257				

Table 23: Study 3

Group No.	No. of Animals	Strain	Test Material	Dose Levels (µg/an)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	4	CD-1	PBS	NA	90 – 100 ml/kg (set volume)	Once on Day 0 by IV Hydrodynamic	Day 3
2	4		ceDNA692	5			
3	4		ceDNA1362	5			
4	4		ceDNA1368	5			
5	4		ceDNA1374	5			
6	4		ceDNA1918	5			
7	4		ceDNA1919	5			
8	4		ceDNA1920	5			
9	4		ceDNA1922	5			

10	4		ceDNA1923	5			
----	---	--	-----------	---	--	--	--

[00755] Test articles were supplied in a concentrated stock, and stored at nominally 4°C.

Formulations were not vortexed or centrifuged. Groups were housed in clear polycarbonate cages with contact bedding on a ventilated rack in a procedure room. Food and filtered tap water acidified with 1N HCl to a targeted pH of 2.5 - 3.0 were provided to the animals ad libitum. Blood was collected at interim and terminal time points as set forth below in **Tables 24-26**.

Table 24: Study 1 and 2 Interim and terminal collection

Group Number	Sample Collection Times	
	Whole Blood (orbital)	Terminal Whole Blood (cardiac)
	Sodium Citrate Plasma	
1 - 10	Day 3 72 hours $\pm$ 50% post dose	Day 7
Volume / Portion	120 μ L whole blood	MOV
Processing / Storage	120 μ L whole blood was added to tube pre-coated with 13.33 μ L of 3.2% sodium citrate and kept ambient until processed <u>One (1) aliquot</u> of plasma Frozen at nominally -70°C	600 μ L whole blood was added to tube pre-coated with 66.6 μ L of 3.2% sodium citrate and kept ambient until processed <u>Three (3) aliquots</u> of plasma Frozen at nominally -70°C

Table 25: Study 3 Blood Collection (Interim): All animals in Groups 1 – 10 had interim blood collected on Day 1; 24 hours post Test Material dose ($\pm$ 5%)

Group Number	Sample Collection Times	
	Whole Blood (orbital only)	
	Sodium Citrate Plasma	
1 – 10	Day 1 24 hours post Test Material dose ($\pm$ 5%)	
Volume / Portion	120 μ L whole blood	
Processing / Storage	120 μ L whole blood was added to tube pre-coated with 13.33 μ L of 3.2% sodium citrate and kept ambient until processed <u>Two (2) aliquots</u> of plasma Frozen at nominally -70°C	

Table 26: Study 3 Terminal Collection

Group Number	Sample Collection Times
	Terminal Whole Blood (cardiac)
	Sodium Citrate Plasma
1 – 10	Day 3
Volume / Portion	MOV
Processing	600 µL whole blood was added to tube pre-coated with 66.6 µL of 3.2% sodium citrate and kept ambient until processed Four (4) aliquots processed plasma
Storage	Frozen samples at nominally -70°C

[00756] MOV = maximum obtainable volume **Study details are provided as follows:**

[00757] *Species (number, sex, age):* FVIII KO (B6;129S-F8^{tm1Kaz}/J) mice (N = 40 + 4 spare, male, ~4 weeks of age at arrival) from Jackson Laboratories.

[00758] *Cage Side Observations:* Cage side observations were performed daily.

[00759] *Clinical Observations:* Clinical observations were performed ~1, ~5-6 and ~24 hours post the Day 0 Test Material dose.

[00760] *Body Weights:* Body weight for all animals was recorded on Days 0, 3 and 7, including prior to euthanasia.

[00761] *Dose Formulation:* Test articles were supplied in a concentration stock. Stock was diluted with PBS immediately prior to use. Prepared materials were stored at ~4°C (or on wet ice) if dosing was not performed immediately.

[00762] *Dose Administration:* Test Materials were dosed on Day 0 by hydrodynamic IV administration, at a set volume per animal, 90 – 100 ml / kg (dependent on the lightest animal in the group) via lateral tail vein (dosed within 5 seconds). *After each collection, animals received 0.5 – 1.0 mL lactated Ringer's, subcutaneously.* For plasma collections, whole blood was collected into non-coated Eppendorf style tubes via orbital sinus puncture under anesthesia per facility SOPs.

Immediately 120µL was withdrawn and placed into tubes containing 13.33 µL of 3.2% sodium citrate. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack. One (1) aliquot was made and any clotting in the whole blood sample or hemolysis in the plasma was noted. Samples were stored at nominally -70°C until analysis.

[00763] *Anesthesia Recovery:* Animals were monitored continuously while under anesthesia, during recovery and until mobile.

[00764] *Euthanasia & Terminal Blood Collection:* On Day 7, animals were euthanized by CO₂ asphyxiation followed by thoracotomy and exsanguination. Maximum obtainable blood volume was collected by cardiac puncture and processed to plasma. No other tissues were be collected.

[00765] For plasma collections, whole blood was collected by syringe and 600 μ L placed immediately tubes containing 66.66 μ L of 3.2% sodium citrate. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack and three (3) aliquots made. Any clotting in the whole blood sample or hemolysis in the plasma were noted. All plasma samples were stored at nominally -70°C shipped until analysis.

[00766] **Results:** FIG. 13 shows a schematic of B-domain selection for the constructs described herein. Briefly, selection of FVIII protein sequences in clinical use was prioritized to minimize immunogenicity risk. Through ELISA and chromagenic assay analysis (data not shown), FVIII-SC was found to be a favored FVIII protein sequence. In FVIII-SC, the heavy and light chains are covalently linked, and this construct shows increased affinity to von Willbrand factor (VWF), which reduces binding to antigen presenting cells (APCs), improving stability and immunogenicity *in vitro*.

[00767] A comparison was done between the ELISA assay method and the chromogenic assay method to determine if one method produced more reliable results than another in determining FVIII activity. In particular, it was found that the ELISA used to measure plasma human FVIII in WT mice underpredicted FVIII activity for constructs with a short or deleted B domain (SQ and SC - 1373[SC/F309S]). However, good concordance was found between the ELISA and activity only v226 constructs (1270 [v226/F309S]). Therefore, it was concluded that comparisons can only be made between constructs with the same B-domain in studies that used the ELISA assay (hydrodynamic studies in CD-1 or C57bl/6 mice), but among the constructs with different type of B-domain or different optimized sequence. The chromogenic assay appeared to provide more consistent results. Exemplary results are shown in FIG. 14.

EXAMPLE 8: Study to Determine FVIII Expression after Hydrodynamic ceDNA delivery in Male CD-1 and FVIII KO Mice

[00768] A hydrodynamic delivery system was used to test the effect of various ceDNA vectors expressing FVIII on serum FVIII levels, where detection of FVIII in the serum indicated that the ceDNA vector was able to express FVIII after injection.

[00769] ceDNA vectors as described in Example 6 were employed. SEQ ID NOs for the ceDNA constructs are shown in Table 18, and a description of the constructs is provided in Table 20. Test materials for the study are shown in Table 27 below.

Table 27: Study 4

Group No.	No. of Animals	Strain	Test Material	Dose Levels (μ g/an)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	3	CD-1	PBS	NA	90 – 100 ml/kg (set volume)	Once on Day 0 by IV Hydrodynamic	Day 3
2	3		ceDNA1373	0.01			
3	3		ceDNA1373	0.1			

4	3		ceDNA1373	1.0			
5	3		ceDNA1374	0.01			
6	3		ceDNA1374	0.1			
7	3		ceDNA1374	1.0			
8	3	FVIII KO	PBS	NA			
9	3		ceDNA1270	0.01			
10	3		ceDNA1270	0.1			
11	3		ceDNA1270	1.0			
12	3		ceDNA1373	0.01			
13	3		ceDNA1373	0.1			
14	3		ceDNA1373	1.0			
15	1	CD-1	ceDNA1373	1.0			Day 1

No. = Number; IV = intravenous; ROA = route of administration; min = minute; hr = hour

[00770] Test articles were supplied in a concentrated stock, and stored at nominally 4°C.

Formulations were not vortexed or centrifuged. Groups were housed in clear polycarbonate cages with contact bedding on a ventilated rack in a procedure room. Food and filtered tap water acidified with 1N HCl to a targeted pH of 2.5 - 3.0 were provided to the animals ad libitum. Blood was collected at interim and terminal time points as set forth in **Table 28** below.

Table 28: Study 4 Terminal collection

Group Number	Sample Collection Times		
	Terminal Whole Blood (cardiac)	Liver	Liver
	Sodium Citrate Plasma		
1 – 14	Day 3		
15			Day 1
Volume / Portion	MOV	Whole organ, weighed then divided 4 x ~20-30 mg pieces weighed	Whole organ
Processing	600 µL whole blood was added to tube pre-coated with 66.6 µL of 3.2% sodium citrate and kept ambient until processed Three (3) aliquots processed plasma	Snap frozen individually (Lake Pharma)	Placed in cold PBS No processing
Storage	Frozen samples at nominally -70°C		Send Same Day on WET ICE

MOV = maximum obtainable volume

[00771] Study details are provided as follows:

[00772] *Species (number, sex, age)*: FVIII KO (B6;129S-F8^{tm1Kaz}/J) mice (N = 40 + 4 spare, male, ~4 weeks of age at arrival) from Jackson Laboratories. CD-1, 22 plus 1 spare. 4 weeks at age of arrival.

[00773] *Cage Side Observations:* Cage side observations were performed daily.

[00774] *Dose Formulation:* Test articles were supplied in a concentration stock. Stock was diluted with PBS immediately prior to use. Prepared materials were stored at ~4°C (or on wet ice) if dosing was not performed immediately.

[00775] *Dose Administration:* Test Materials were dosed on Day 0 by hydrodynamic IV administration, at a set volume per animal, 90 – 100 ml / kg (dependent on the lightest animal in the group) via lateral tail vein (dosed within 5 seconds).

[00776] Whole blood from Groups 1 – 14 only was collected by syringe and 600 µL placed immediately tubes containing 66.66 µL of 3.2% sodium citrate. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack and three (3) aliquots made. Any clotting in the whole blood sample or hemolysis in the plasma was noted.

[00777] All plasma samples were stored at nominally -70°C until analysis.

[00778] *Perfusion:* Following exsanguination, all animals (including Group 15) underwent cardiac perfusion with saline. In brief, whole body intracardiac perfusion was performed by inserting 23/21-gauge needle attached to 10 mL syringe containing saline into the lumen of the left ventricle for perfusion. The right atrium was incised to provide a drainage outlet for perfusate. Gentle and steady pressure was applied to the plunger to perfuse the animal after the needle has been positioned in the heart. Adequate flow of the flushing solution was ensured until the exiting perfusate flows clear (free of visible blood) indicating that the flushing solution has saturated the body and the procedure was complete.

[00779] *Tissue Collection:* After euthanasia, exsanguination and perfusion, the liver was harvested and whole organ weights were recorded. No whole organ weight was needed for Group 15.

[00780] Groups 1 – 14 Tissue specifications - From the liver: 4 x ~20-30 mg sections (≤ 30 mg) were collected and weighed. Any remaining liver was discarded. Weighed sections were snap frozen individually, stored at nominally -70°C until shipped.

[00781] Group 15 Tissue specifications: The whole liver was placed in cold PBS. Sample were stored on wet ice.

[00782] Similar experiments were conducted and repeated using the protocol shown above. Test articles were B domain (SQ) deleted like 692, 693, 694; or v226/F309S like 1270 and 1391; single chain F309S like 1367 and 1373; and single chain FVIII like 1368 and 1374, as described in Tables 18 and 20.

[00783] Result: Various B-domain and secretion mutant combinations of FVIII ceDNA constructs were tested for their ability to express functional FVIII protein. As shown in **FIG. 15**, FVIII constructs having SC optionally with F309S showed consistently high expression *in vitro* and *in vivo* (see, e.g., ceDNA1368, ceDNA1373 and ceDNA1374).

EXAMPLE 9: A Study to Determine FVIII Expression after Hydrodynamic ceDNA delivery in Male CD-1 Mice

[00784] A hydrodynamic delivery system was used to determine FVIII expression after ceDNA delivery using FVIII ceDNA constructs with various elements (e.g., testing different 3'UTRs, promoter-enhancer combinations, introns for effect on FVIII expression). ceDNA vectors as described in Example 6 were employed. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in **Table 20**. Test materials for the study are shown in **Tables 29-30** below.

Table 29: Study 5

Group No.	No. of Animals	Strain	Test Material	Dose Levels (µg/an)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	4	CD-1	PBS	NA	90 – 100 ml/kg (set volume)	Once on Day 0 by IV Hydrodynamic	Day 7
2	4		ceDNA1367	5			
3	4		ceDNA1373	5			
4	4		ceDNA1632	5			
5	4		ceDNA1637	5			
6	4		ceDNA1638	5			
7	4		ceDNA1645	5			
8	4		ceDNA1646	5			
9	4		ceDNA1648	5			
10	4		ceDNA1657	5			

Table 30: Study 6

Group No.	No. of Animals	Strain	Test Material	Dose Levels (µg/an)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	4	CD-1	PBS	NA	90 – 100 ml/kg (set volume)	Once on Day 0 by IV Hydrodynamic	Day 1 24 hours post dose ±5%
2	4		ceDNA1270	5			
3	4		ceDNA1375	5			
4	4		ceDNA1377	5			
5	4		ceDNA1378	5			
6	4		ceDNA1381	5			
7	4		ceDNA1387	5			
8	4		ceDNA1391	5			
9	4		ceDNA1647	5			
10	4		ceDNA1374	5			

[00785] *Species (number, sex, age):* CD-1, 40 plus 4 spares. 4 weeks at age of arrival.

Remaining study details are similar to those provided in Examples 8 and 9 above. Similar experiments were conducted and repeated to test the effect of the various combinations of promoters-enhancers sets, introns, 3'-UTR on FVIII protein expression. The elements that were tested were as follows:

FIG. 20 shows the results of FVIII expression from ceDNA having the following promoter sets:

1x hSerpEnh_VD_PromoterSet (1x SerpEnh)

SC: 1362, 1368, 1374, 1918, 1919, 1920, 1921, 1922, 1923, 1593, 1602

SC/Leader: 1579, 1582, 1585, 1598, 1611, 1612, 1615, 1616

SC/F309S: 1367, 1373, 1700, 1701, 1708, 1712, 1725, 1930, 1931, 1710

v226/F309S: 1270, 1391, 1740, 1741, 1742, 1743, 1744

3x hSerpEnh_VD_PromoterSet

SC: 1655

v226/F309S: 1375, 1381

3x hSerpEnh_VD_PromoterSet (5'UTR variant)

SC: 1652

SC/F309S: 1657

3x hSerpEnh_VD_TTRe_PromoterSet

SC: 1649, 1651, 1838, 1840, 1841

SC/F309S: 1648

v226/F309S: 1647

3x hSerpEnh_VD_TTRe_PromoterSet_v2

SC: 1668

SC/F309S: 1886

3x SerpEnh_VD_TTRe_PromoterSet_v2*

SC/F309S: 1664

CpGmin_hAAT_Promoter_Set

SC/F309S: 1632, 1637, 1638, 1645, 1646, 1620, 1622, 1627, 1636, 1628

3xSerpEnh-TTRm

v226/F309S: 1377, 1378

hAAT(979)_PromoterSet

v226/F309S: 1387

TTR_liver_specific_Promoter

SC/F309S: 1695, 1696

hFIX_Promoter

SC/F309S: 1574

CpGfree20mer_1, 5xHNF1_ProEnh_10mer, 3x hSerpEnh_VD_TTRe_PromoterSet_v2

SC/F309S: 1572

FIG. 21 shows the results of FVIII expression from ceDNA having the following introns:

miniF8_50/100: 1700, 1725

miniF8_200/200: 1701, 1712

miniF8_500/500: 1708

HBB_intron1: 1695

FIG. 19 shows the results of FVIII expression from ceDNA having the following 3'UTRs:

WPRE_3pUTR, bGH: all constructs tested

HBBv3_3pUTR, SV40_polyA:

CpGmin_hAAT, SC/F309S: 1632 (1622), 1636 (1627), 1637 (1627), 1638 (1628)

hAAT(979), v226/F309S: 1387 (none)

SV40_polyA:

CpGmin_hAAT, SC/F309S: 1645 (1622)

HBBv3_3pUTR:

CpGmin_hAAT, SC/F309S: 1646 (1622)

3xSerpEnh-TTRm_MVM_intron, v226/F309S: 1377 (none)

bGH:

3x hSerpEnh_VD, v226/F309S: 1375 (1381)

HBBv2_3pUTR, bGH:

3xSerpEnh-TTRm_MVM_intron, v226/F309S: 1378

FIG. 24 shows the results of FVIII expression from ceDNA having the following leader sequences (and their locations):

Albumin: 1611, 1579

Gaussia: 1598, 1582

Secrecon: 1616, 1585

Chymotrypsinogen: 1612

Lonza: 1615, 1602

CD33: 1593

DTS

5'DTS_primer_pad || 5x_kB_mesika_DTS || 3'DTS_primer_pad:

After 3pUTR: 1740

Before promotor: 1742

CpGfree20mer_1 || SV40DNA_DTS_72bpTandemRepeat || CpGfree20mer_2 ||

SV40DNA_DTS_72bpTandemRepeat || CpGfree20mer_3 || SV40DNA_DTS_72bpTandemRepeat ||

CpGfree20mer_4 || SV40DNA_DTS_72bpTandemRepeat || CpGfree20mer_5 ||

SV40DNA_DTS_72bpTandemRepeat:

After 3pUTR: 1741

Before promotor: 1743

CpGfree20mer_1, CBX3(674mut1) || 20mer_16

After 3pUTR: 1744 (also has 5pUTR – 1738 is comparator)

[00786] Results: FIG. 19 shows the results of FVIII expression from ceDNA having various 3pUTRs and the effects on plasma FVIII concentration (IU/ml) in 1622, 1632, 1645, 1646, 1627, 1636, 1637, 1628, 1638, 1382, 1375, 1377, 1378, and 1387. The studies described above were also carried out, in part, to test various promoter and enhancer combinations, and their effects on plasma FVIII concentration. FIG. 20 describes various promoters and promoter/enhancer combinations employed and tested. FIG. 21 shows the results of intron combination in 1367, 1700, 1701, 1695, 1373, 1708, 1725, 1712 *in vitro* and *in vivo*. FIG. 23 shows the results of the effect on FVIII expression from ceDNA having DNA nuclear targeting sequences (DTS) on FVIII expression. FIG. 24 shows the results of the impact of having a leader sequence variation on FVIII expression.

EXAMPLE 10: A Study to Evaluate ceDNA Formulations via IV Delivery in Male C57Bl/6 Mice

[00787] The following study was carried out to determine protein expression after IV injection of LNP formulated ceDNA. ceDNA1270 was formulated in two different LNPs compositions (LNP formulation1: Ionizable lipid: DSPC : Cholesterol : PEG-Lipid + DSPE-PEG-GalNAc4 (47.5 : 10.0 : 39.2 : 3.3) (designated “DP#1”); and LNP formulation 2: Ionizable lipid : DSPC : Cholesterol : PEG-Lipid + DSPE-PEG2000-GalNAc4 (47.3 : 10.0 : 40.5 : 2.3) (designated “DP#2”). Doses of test material were administered on Day 0 by intravenous dosing into the lateral tail vein. Doses were administered at a dose volume of 5 mL/kg. Doses were rounded to the nearest 0.01 mL. Test materials for the study are shown in Tables 31 and 32 below. ceDNA expressing Factor IX (ceDNA-FIX) was used as an independent control.

[00788] Table 31

Group No.	No. of Animals	Test Material	Dose Levels (mg/kg)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	5	PBS	NA	5	Once on Day 0 by IV	Day 14
2	5	ceDNA1270	0.5			
3	5	ceDNA1270	2.0			
4	5	ceDNA-FIX	2.0			
5	5	ceDNA-FIX	2.0			
6	5	ceDNA-FIX	2.0			

Table 32

Group No.	No. of Animals	Test Material	Dose Levels (mg/kg)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
-----------	----------------	---------------	---------------------	---------------------	--------------------	---------------------

1	4	PBS	NA	5	Once on Day 0 by IV	N = 2 on Day 10 and N = 2 on Day 57
2	4	ceDNA1270	1.0			Day 10
3	4	ceDNA1270	0.3			Day 10
4	4		1.0			Day 10
5	4		3.0			Day 10
6	4	ceDNA-FIX	2.0			Day 57

[00789] *Species (number, sex, age):* C57Bl/6,30 plus 3 spares. 6 weeks at age of arrival. Remaining study details are similar to those provided in Examples 8 and 9 above.

[00790] Clinical observations were performed on Day 0: 60 – 120 minutes post dose and at the end of the work day (3 – 6 hours post) and on Day 1: 22 - 26 hours post the Day 0 Test Material dose. Additional observations were made per exception.

[00791] Results: Mice were administered 1 mg/kg ceDNA1270 in LNP formulation 1 (Ionizable lipid: DSPC : Cholesterol : PEG-Lipid + DSPE-PEG-GalNAc4 (47.5 : 10.0 : 39.2 : 3.3) (DP#1) or 2 mg/kg ceDNA 1270 in LNP formulation 2 (Ionizable lipid : DSPC : Cholesterol : PEG-Lipid + DSPE-PEG2000-GalNAc4 (47.3 : 10.0 : 40.5 : 2.3) (DP#2). **FIG. 25** shows that mice treated with ceDNA1270 LNP formulations exhibited increased plasma FVIII as compared to mice treated with vehicles, indicating that ceDNA LNP was successfully targeted to the liver and integrated into cells, resulting in successful expression of FVIII protein.

EXAMPLE 11: A Study to Evaluate ceDNA Hydrodynamically Administered via IV Delivery in Male FVIII KO Mice

[00792] The following studies were carried out to determine protein expression after IV injection of naked ceDNA constructs. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in **Table 20**. Doses of test material were administered on Day 0 by intravenous dosing into the lateral tail vein. Doses were administered at a dose volume of 5 mL/kg. Doses were rounded to the nearest 0.01 mL. Test materials for the study are shown in Tables 33 and 34, below.

Table 33

Group No.	No. of Animals	Strain	Test Material	Dose Levels (mg/kg)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	2	FVIII KO	PBS	NA	5	Once on Day 0 by IV	Day 10
2	5			0.3			

3	5		ceDNA1270	1.0			
4	5			2.0			
5	5		ceDNA1368	1.0			
6	5			2.0			
7	5			3.0			
8	5		ceDNA1923	0.3			
9	5			1.0			
10	5			2.0			
11	5		ceDNA1651	0.3			
12	5			1.0			
13	5			2.0			

No. = Number; IV = intravenous; ROA = route of administration; min = minute; hr = hour

[00793] *Species (number, sex, age):* FVIII KO (B6;129S-F8<tm1Kaz>/J), 62 plus 3 spares. 4-8 weeks at age of arrival. Remaining study details are similar to those provided in Examples 8 and 9 above.

[00794] Clinical observations were performed on Day 0: 60 – 120 minutes post dose and at the end of the work day (3 – 6 hours post) and on Day 1: 22 - 26 hours post the Day 0 Test Material dose.

[00795] Results: As shown in **FIG. 26**, after 10 days, mice administered ceDNA1270, ceDNA1368, ceDNA1923 or ceDNA1651 constructs at all of the doses tested exhibited increased plasma FVIII concentration. Overall, the increased FVIII plasma concentration was dose dependent. These ceDNA constructs showed a dramatic increase in plasma FVIII concentration ranging from the 0.5 mg/kg dose to the 2.0 mg/kg dose.

EXAMPLE 12: A Study to Determine FVIII Transgene Expression after IV LNP:ceDNA delivery in Male CD-1 and FVIII KO Mice

[00796] The objective of this Study was to determine transgene expression after IV administration of formulated ceDNA. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in **Table 20**. Test materials for the study are shown in the **Tables 34-37** below.

Table 34: Kinase Inhibitor Administration

Group No.	No. of Animals	Strain	Inhibitor	Dose Levels (mg/kg)	Dose Volume (mL/kg)	Dosing Regimen ROA
1	4	CD-1	Ruxolitinib	300	10	Day 0 30 min. pre-dose & 5 hrs post-dose of Test Material by PO
2	4					
3	4					
4	4					
5	4					

6	4	FVIII KO				
7	4					
8	4					

Table 35: Test Material Administration

Group No.	No. of Animals	Strain	Test Material	Dose Levels (µg/an)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	4	CD-1	PBS	2	5	Once on Day 0 by IV	Day 14
2	4		LNP ceDNA691				
3	4		LNP ceDNA933				
4	4		LNP ceDNA1270				
5	4	FVIII KO	LNP ceDNA0933	2	5	Once on Day 0 by IV	Day 14
6	4		LNP ceDNA1270				
7	4		LNP ceDNA1367				
8	4		LNP ceDNA1368.				

No. = Number; IV = intravenous; ROA = route of administration; min = minute; hr = hour

Table 36: Blood Collection (Interim):

Group Number	Sample Collection Times
	Whole Blood (orbital only)
	Sodium Citrate Plasma
1 – 8	Days 4, 7, 10
Volume / Portion	120 µL whole blood
Processing	120 µL whole blood was added to tube pre-coated with 13.33 µL of 3.2% sodium citrate and kept ambient until processed Two (2) aliquots processed plasma
Storage	Frozen at nominally -70°C

Table 37: Blood Collection (Terminal)

Group Number	Sample Collection Times
	Terminal Whole Blood (cardiac)
	Sodium Citrate Plasma
1 – 8	Day 14
Volume / Portion	MOV

Group Number	Sample Collection Times
	Terminal Whole Blood (cardiac)
	Sodium Citrate Plasma
Processing	600 μ L whole blood was added to tube pre-coated with 66.6 μ L of 3.2% sodium citrate and kept ambient until processed Three (3) aliquots processed plasma
Storage	Frozen at nominally -70°C

MOV = maximum obtainable volume

[00797] Study details are provided as follows:

[00798] Species (number, sex, age): FVIII KO (B6;129S-F8<tm1Kaz>/J) mice (N = 16 + 2 spare, male, ~4 weeks of age at arrival) from Jackson Laboratories. CD1. 16 + 2 spares, male. 4 weeks at time of arrival.

[00799] Cage Side Observations: Cage side observations were performed daily.

[00800] Clinical Observations: Clinical observations were performed ~1, ~5-6 and ~24 hours post the Day 0 Test Material dose, as applicable for remaining groups.

[00801] Body Weights: Body weights for all animals were recorded on Days 0, 1, 2, 4, 7 & 14. Weights were rounded to the nearest 0.1 g. Additional weights were recorded as requested.

[00802] Dose Formulation: Test articles (ceDNA) were supplied in a concentration stock, at 1.0 mg/mL. Stock was warmed to room temperature and diluted with the provided PBS immediately prior to use. Prepared materials may be stored at ~4°C if dosing was not performed immediately.

[00803] Inhibitor was supplied in daily ready to dose aliquots; formulated in 0.5% methylcellulose. Formulations were mixed (pipetting) and/or sonicated prior to administration to distribute particulates of oral gavage suspension.

[00804] Dose Administration: Inhibitor was dosed on Day 0 per Table 1 above, by PO administration (oral gavage) at 10 mL/kg. Inhibitor was dosed 30 minutes ($\pm$ 5 minutes) prior to, and 5 hours ($\pm$ 10 minutes) post the Day 0 ceDNA administration. Doses of test material was administered on Day 0 by intravenous dosing into the lateral tail vein. Doses were administered at a dose volume of 5 mL/kg. Doses were rounded to the nearest 0.01 mL.

[00805] Blood collection: All animals in Groups 1 – 8, had interim blood collected on Days 4, 7 & 10.

[00806] For plasma collections, whole blood was collected into non-coated Eppendorf style tubes *via* orbital sinus puncture under anesthesia per facility SOPs. Immediately 120 μ L was withdrawn and placed into tubes containing 13.33 μ L of 3.2% sodium citrate. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack. Two (2) aliquots were made and any clotting in the whole blood sample or hemolysis in the plasma was noted.

[00807] *Anesthesia Recovery*: Animals were monitored continuously while under anesthesia, during recovery and until mobile.

[00808] *Euthanasia & Terminal Blood Collection*: On Day 14, animals were euthanized by CO₂ asphyxiation followed by thoracotomy and exsanguination..

[00809] Whole blood was collected by syringe and 600 µL placed immediately tubes containing 66.66 µL of 3.2% sodium citrate. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack and three (3) aliquots made. Any clotting in the whole blood sample or hemolysis in the plasma was noted.

[00810] All plasma samples were stored at nominally -70°C for analysis.

[00811] **Results: FIGs. 16 and 22** show plasma FVIII concentration (IU/mL) at 11 days after administration of the LNP:ceDNAFVIII-vector test articles, as indicated. As shown, FVIII was detected at a much greater level in plasma samples from mice treated with the LNP:ceDNAFVIII-vector 1270, 1367, 1368 test article, compared to the first generation vector 993. FVIII was not observed in mice treated with vehicle only (not shown).

EXAMPLE 13: A Study to Determine FVIII Expression after Hydrodynamic ceDNA delivery in Male FVIII KO Mice

[00812] A hydrodynamic delivery system was used to determine FVIII expression and activity after hydrodynamic injection of ceDNA. ceDNA vectors as described in Example 6 were employed. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in **Table 20**. Test materials for the study are shown in **Table 35**, below.

Table 38

Group No.	No. of Animals	Strain	Test Material	Dose Levels (µg/an)	Dose Volume (mL/kg)	Dosing Regimen ROA	Terminal Time Point
1	4	FVIII KO	PBS	NA	90 – 100 mL/kg (set volume)	Once on Day 0 by IV Hydrodynamic	Day 3
2	4		ceDNA1368	5			
3	4		ceDNA1374	5			
4	4		ceDNA1652	5			
5	4		ceDNA1838	5			
6	4		ceDNA1840	5			
7	4		ceDNA1922	5			
8	4		ceDNA1923	5			

No. = Number; IV = intravenous; ROA = route of administration; min = minute; hr = hour

[00813] *Species (number, sex, age)*: FVIII KO (B6;129S-F8<tm1Kaz>/J). 4-8 weeks at age of arrival.

[00814] Remaining study details are similar to those provided in Examples 7 and 8 above.

[00815] Results: FIGS. 17 and 18 show that codon optimized constructs *without* F309S mutation: *i.e.*, 1368 and its variants such as 1923, 1823, 1840, provides improvements in single chain version of FVIII (“SC”) protein expression. Among these constructs, 1923 demonstrated consistently higher expression over other condon optimized SC FVIII ceDNA constructs.

EXAMPLE 14: Evaluation of LNP in Non-Human Primate Tolerability Study

[00816] The objective of this study was to evaluate the tolerability of a 70-minute intravenous infusion of LNP formulated ceDNA to male *Cynomolgus* monkeys. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in Table 20. Test materials for the study are shown in **Table 39** below. ceDNA containing a Factor IX expression cassette was used as an independent control.

[00817] Table 39

Group No.	No. of Males	Pretreatments	Test Material	Dose Level (mg/kg)	Cocn. (mg/mL)	Necropsy Timepoint	Dose Volume (mL)	Dose Route/Regimen
1	1	Dexamethasone and Diphenhydramine 30 minutes prior to dosing	ceDNA1270	0.3	0.06	24 hr	5	70 min IV infusion on Day 1 Infusion rate for first 15 minutes: 0.42 mL/kg Infusion rate for the remaining 55 minutes: 4.59 mL/kg
2	2			1.0	0.2	Day 14		
3	1		ceDNA1270	0.3	0.06	24 hr		
4	2			1.0	0.2	Day 14		
5	1		ceDNA-FIX	0.3	0.06	24 hr		
6	2			1.0	0.2	Day 15		
7	2			2.0	0.4	Day 15		
8	1		Saline Control	0	NA	Day 15		

[00818] The following study details are provided:

[00819] Animals: Species: *Macaca fascicularis*; Strain: *Cynomolgus* macaque; Number of Males: 12; Age: Adult; Research Status: Non-naïve; Weight: ~2-5 kg; Source: Testing Facility Colony.

[00820] Dose Administration

[00821] Pre-treatment: All animals in Groups 1-8 were administered diphenhydramine (5 mg/kg, IV or IM) and dexamethasone (1 mg/kg, IV or IM) 30 minutes ($\pm$ 3 minutes) prior to the start of dosing.

[00822] *Test Article Administration:* the test materials were administered by IV infusion to restrained animals in Groups 1-8 over an approximate 70-minute period. Doses were administered through either the saphenous or cephalic vein with a temporary IV catheter. The catheter was flushed with with 0.5 mL of saline at the end of dosing. Dose volumes were calculated based on the most recent body weight and rounded to the nearest 0.1 mL. The end time of IV administration was used to determine target times for blood sample and necropsy collection time points. Injection site, dosing start and finish times were recorded in the raw data. The injection site was marked with indelible ink.

[00823] *In-Life Observations and Measurements*

[00824] Animal Health Checks: animal health checks were performed at least twice daily, in which all animals were checked for general health.

[00825] Clinical Observations: clinical observations were performed at least once before dosing (Day-1 or 1) and at least once daily thereafter for the duration of the study.

[00826] Body Weights: body weights were recorded prior to dosing on Day-1 and weekly thereafter. Weights were rounded to the nearest 0.1 kg.

[00827] Body Temperature: body temperature was recorded for all animals at predose and at 1, 2, 4, and 6 hours post dose.

[00828] Sample Collection: blood samples were collected from an appropriate peripheral vein (not the vein used for dosing) as indicated in Table 40 below.

Table 40

Group No.	Cytokines	Complement Analysis	Liver Enzymes (AST, ALT, CK)	Coagulation	Whole Blood for qPCR	FVIII and FIX Expression
1, 3, 5	Pretest, 15 min, 6 hr, 24 hr	Pretest, 15 min, 6 hr, 24 hr	Pretest, 24 hr	Pretest, 24 hr	Pretest, 24 hr	N/A
2, 4, 6-8	Pretest, 15 min, 6 hr, 24 hr	Pretest, 15 min, 6 hr, 24 hr	Pretest, 24 hr, Day 14 or 15	Pretest, 24 hr, Day 14 or 15	Pretest, 24 hr, Day 14 or 15	Day 5, 7 and 14 or 15
Additive	SST	K2EDTA	SST	Sodium Citrate	K2EDTA	Sodium Citrate
~Volume of Whole Blood	0.2 mL	0.2 mL	0.2 mL	1.8 mL	1 mL	1.8 mL
Aliquots	75 μ L	100 μ L	80 μ L	700 μ L	2 ~0.5 mL	FVIII: 6 aliquots of 150uL plasma FIX: Remainder in 2 aliquots

[00829] Blood Collection for FVIII Expression

[00830] Whole blood samples were collected from a peripheral vein via direct needle puncture into sodium citrate tubes. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged as soon as practical at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack. Any clotting in the whole blood sample or hemolysis in the plasma was noted. Plasma samples were stored at nominally -80°C until shipment to the Sponsor for analysis.

[00831] Blood Collection for FIX Expression

[00832] Whole blood samples were collected from a peripheral vein via direct needle puncture into sodium citrate tubes. Blood was gently mixed and maintained ambient until processed. Whole blood samples were centrifuged as soon as practical at 2,000g for 15 minutes under ambient conditions (20-25°C). Plasma samples were withdrawn avoiding the cell pack.

[00833] Any clotting in the whole blood sample or hemolysis in the plasma was noted. Plasma samples were stored at nominally -80°C until shipment for analysis.

[00834] Cytokine Analysis

[00835] Whole blood samples were collected from a peripheral vein via direct needle puncture into SST tubes and were processed for serum according to Testing Facility SOP. Serum samples were stored at -80°C until shipment for analysis.

[00836] Complement Analysis

[00837] Whole blood samples were collected from a peripheral vein via direct needle puncture into K2EDTA tubes were processed for plasma according to Testing Facility SOP. Plasma samples were be stored at -80°C until shipment for analysis.

[00838] Liver Enzyme Analysis

[00839] Whole blood samples were collected from a peripheral vein via direct needle puncture into SST tubes and were processed for serum according to Testing Facility SOP. Serum samples were analyzed by the Testing Facility laboratory for the liver enzymes ALT, AST and CK using an Alfa Wassermann Ace Axcel.

[00840] Coagulation Analysis

[00841] Whole blood samples were collected from a peripheral vein via direct needle puncture into sodium citrate tubes and were processed for plasma according to Testing Facility SOP. Samples were transferred on wet ice if shipped same day or were stored at -80°C until transferred to IDEXX Corp for analysis of PTT, aPTT and fibrinogen.

[00842] Whole Blood for qPCR

[00843] Whole blood samples were collected from a peripheral vein via direct needle puncture into K2EDTA tubes and were stored at 4°C until shipment to LakePharma. Day 14 samples were collected, but not processed unless directed by amendment.

[00844] Necropsy and Tissue Collection**[00845] qPCR:**

[00846] Two sets of six samples (12 samples total per tissue) of the following tissues were collected from all animals for qPCR (collection sites outlined below). Only the 24 hr samples were evaluated for qPCR, the Day 14 samples were collected, but not processed.

[00847] Samples weighed at a minimum 25 mg (50 mg preferred, weights to be recorded) each and were snap frozen in liquid nitrogen and stored at nominally -80°C until analysis.

[00848] Heart: Samples collected from left ventricle.

[00849] Kidney: Both the right and the left kidneys were each be bisected and half was used for histology and the other half were snap frozen for qPCR samples.

[00850] Liver: Samples were collected from a consistent area across animals.

[00851] Lung: The left lobe was processed for histology and the right lobe was snap frozen for qPCR samples.

[00852] Spleen: Samples were collected from a consistent area across animals.

[00853] ISH

[00854] For all animals, the remainder of the liver and spleen were collected and were placed into individually labeled cassettes (size-appropriate to fit cassette), then placed into 10% NBF. Only the 24-hour samples were evaluated for ISH, the Day 14 samples were collected, but not processed.

[00855] Histopathology Tissue Processing

[00856] For animals euthanized at Day 14 only, the remainder of the liver and spleen were processed to the slide stage for paraffin embedded, H&E staining. Slides were processed and then shipped for ISH staining and microscopic evaluation.

EXAMPLE 15: A 14-Day Single Dose Intravenous Infusion Toxicity Study of a Lipid Nano Particle Formulation in Cynomolgus Monkeys

[00857] The objective of this study was to determine the toxicity effects of a single IV dose of a lipid nanoparticle ceDNA transgene expression after IV administration of LNP formulated ceDNA to male Cynomolgus monkeys. SEQ ID NOs for the ceDNA constructs are shown in **Table 18**, and a description of the constructs is provided in Table 20. Test materials for the study are shown in Table 41 below. Dosing was by intravenous infusion (70 minutes± 10 minutes) to the saphenous vein (cephalic or tail vein was used, if necessary) dosed at 0.42 mL/kg/hr for 15 min and then escalating to 4.59 mL/kg/hr for 55 min. Prolonged infusion with escalating dosing rate design was necessary to prevent/mitigate infusion reactions. The first day of dosing was designated as day 1. Dosing was performed once on day 1 and was carried out for 15 days.

[00858] Prior to the start of infusion, the catheters were flushed with approximately 2 mL of sterile saline. Next the dosing formulations were administered at 0.42 mL/kg/hr for the first 15 minutes (target time). The infusion pump was stopped, reprogrammed to infuse the remaining dose for an

infusion rate of 4.59 mL/kg/hr, for the remaining 55 minutes (target time) of the infusion. An approximate 1.0 mL flush of sterile saline was administered via the catheter after dose administration.

Table 41.

Group No.	Test Material	Dose Level (mg/kg/dose)	Dose Volume ^a (mL/kg)	Dose Concentration (mg/mL)	No. of Animals
					Males ^b
1	Vehicle	0	4.31	0	2
2	ceDNA-FIX	2.0	4.31	0.46	2
3	ceDNA-FIX	2.0	4.31	0.46	2
4	ceDNA-FIX	2.0	4.31	0.46	2
5	ceDNA1270	1.0	4.31	0.23	1
6	ceDNA1270	2.0	4.31	0.46	2

^a Based on the most recent body weight measurement. The first day of dosing was based on Day 1 body weights.

To mitigate potential infusion reactions, all animals were pretreated approximately 30 ± 5 minutes prior to start of infusion with diphenhydramine and dexamethasone. In addition, all animals received a second dose of diphenhydramine and dexamethasone approximately 4 hours $\pm$ 10 minutes post infusion. Diphenhydramine was administered as an intramuscular injection at a dose volume of 0.1 mL/kg to achieve a dose level of 5 mg/kg/dose. Dexamethasone was administered as an intramuscular injection at a dose volume of 0.25 mL/kg to achieve a dose level of 1 mg/kg/dose.

[00859] : **FIG. 25** shows the results from *in vivo* studies in mice and non-human primates (NHP) using various ceDNA vectors disclosed herein to express FVIII protein as described in Examples 10, 15 and 16. Non human primates (NHPs) were administered with 1 mg/kg ceDNA 1270 in LNP formulation 1 (Ionizable lipid: DSPC : Cholesterol : PEG-Lipid + DSPE-PEG-GalNAc4 (47.5 : 10.0 : 39.2 : 3.3) (DP#1) or 2mg/kg ceDNA 1270 in LNP formulation 2 (Ionizable lipid : DSPC : Cholesterol : PEG-Lipid + DSPE-PEG2000-GalNAc4 (47.3 : 10.0 : 40.5 : 2.3) (DP#2). As shown in **FIG. 25**, it was observed that plasma FVIII concentration (IU/mL) was increased in NHP in the studies described in both Examples 14 (for DP#1) and 15 (for DP#2) as compared to control (vehicle), suggesting that the LNP formulated FVIII ceDNA constructs disclosed herein could be effectively delivered and expressed to increase plasma FVIII protein levels even in non-human primates that may exhibit heightened levels of neutralizing antibodies responses against human FVIII.

[00860] **FIG. 27** depicts a chart showing FVIII expression levels using various spacer variants of 3x hSerpEnh (2-mer and 11-mer) and Serpin enhancer sequence variants (*e.g.*, bushbaby Serpin enhancer and Chinese tree shrew Serpin enhancer) as compared to 3x human serpin enhancer as in ceDNA construct 1651 whose FVIII expression is driven by 3x VD promoter set). These constructs are identical except the spacers for hSerpEnh (spacer variants) or the SerpEnh sequence (SerpEnh variants from bushbaby and Chinese tree shrew). One dose of 50ng plasmid containing FVIII ceDNA sequence was hydrodynamically injected into the tail vein of Rag2 mice on day 0 with a single blood collection performed at day 3 (~72hr post dose) followed by FVIII activity measurements. As shown in **FIG. 27**, FVIII construct having 3x hSerpEnh enhancers with a spacer of two nucleotides ("2mer" spacers) placed inbetween each hSerpEnh showed higher FVIII expression levels as compared the

control construct having 3x VD promoter set with a single nucleotide spacer. Surprisingly, the construct having an 11-nucleotide spacer (3xhSerpEnh_11mer_spacers_v3) exhibited an increased level of FVIII expression as compared to 1 nucleotide spacers or 5 nucleotide spacers (data not shown). Further, three repeats of the bushbaby serpin enhancer sequence as well as Chinese tree shrew Serpin enhancer sequence drove higher levels of FVIII expression as compared to 3x human Serpin enhancer (*i.e.*, 3x VD promoter set), suggesting that these conserved homologous enhancer sequences may have a positive impact on FVIII transcription in the liver.

[00861] FIG. 28 depicts a chart showing the results from an *in vivo* study in which C57BL/6J mice were hydrodynamically injected with synthetically made FVIII-ceDNA molecules, and FVIII activity was measured at Day 3 in the serum of the treated mice. The ceDNA constructs were: (1) ceDNA construct 10 (wild-type left ITR : left ITR spacer : 3x hSerpEnh VD promoter set : Mouse TTR 5'UTR : MVM Intron: hFVIII-F309S_BD226seq124-BDD-F309 ORF which is identical to the ORF sequence of ceDNA 1651 : WPRE_3pUTR : bGH : right ITR Spacer : wild-type right ITR; (2) ceDNA construct 60 which is essentially identical to ceDNA construct 10 except that it contains 3x_hSerpEnh-2mer spacer v17; (3) ceDNA construct 61 which is essentially identical to ceDNA construct 10 except that it contains 3x_SerpEnh_11-mer_spacers_v3; (4) ceDNA construct 62 which is essentially identical to ceDNA construct 10 except it has 3x_Bushbaby SerpEnh with adenine (A) spacers ("Aspacers"); and (5) ceDNA construct 39 which is essentially identical to ceDNA construct 10 except that it contains a truncated right ITR. Consistent with the observations in **FIG. 27**, ceDNA constructs having the 3x human serpin enhancer with 11mer spacers (3xhSerpEnh_11mer_spacers_v3) and 3x bushbaby serpin enhancers (3xBushbaby_Aspacers) exhibited equivalent or superior expression profiles in the ceDNA platform as compared to that of 3x VD driving FVIII expression (*see*, **FIG. 27**).

[00862] ceDNA construct 10 contains wild-type left ITR : left ITR spacer : 3x hSerpEnh VD promoter set : mouse TTR 5'UTR : MVM Intron: hFVIII-F309S_BD226seq124-BDD-F309 ORF identical to the ORF sequence of ceDNA 1651) :

(1) **WPRE_3pUTR : bGH : right ITR Spacer : wild-type right ITR** as shown below:

TGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTGTAG
TTAATGATTAACCCGCCATGCTACTTATCGCGGCCGCGGGGAGGCTGCTGGTGAATATT
AACCAAGGTCACCCAGTTATCGGAGGAGCAAACAGGGGCTAAGTCCACCGGGGAGGC
TGCTGGTGAATATTAACCAAGGTCACCCAGTTATCGGAGGAGCAAACAGGGGCTAAGTC
CACCGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCAGTTATCGGAGGAGCAA
ACAGGGGCTAAGTCCACGGTACCCACTGGGAGGATGTTGAGTAAGATGGAAACTACTG
ATGACCCTTGCAGAGACAGAGTATTAGGACATGTTTGAACAGGGGCCGGGCGATCAGCA
GGTAGCTCTAGAGGATCCCCGTCTGTCTGCACATTTTCGTAGAGCGAGTGTTCCGATACTCT
AATCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGTC

AATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTTGGA
AGGAGGGGGTATAAAAGCCCCTTACCAGGAGAAGCCGTCACACAGATCCACAAGCTCC
TGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGG
AGCACCTGCCTGAAATCACTTTTTTTCAGGTTGGTTTAAACGCCGCCACCATGCAGATTGA
GCTGAGCACCTGCTTCTTCCTGTGCCTGCTGAGGTTCTGCTTCTCTGCCACCAGGAGATAC
TACCTGGGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTCTGACCTGGGGGAGCTGCCT
GTGGATGCCAGGTTCCCCCCCAGAGTGCCCAAGAGCTTCCCCTTCAACACCTCTGTGGTGT
ACAAGAAGACCCGTGTTTGTGGAGTTCAGTACCACCTGTTCAACATTGCCAAGCCCAGGC
CCCCCTGGATGGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACTGTGGTGA
TCACCCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGGGTGAGCTACT
GGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAGACCAGCCAGAGGGAGAAGGAGGAT
GACAAGGTGTTCCCTGGGGGCAGCCACACCTATGTGTGGCAGGTGCTGAAGGAGAATGG
CCCCATGGCCTCTGACCCCTGTGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTG
AAGGACCTGAACTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGCCTGGCC
AAGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTTTGATGAGGGC
AAGAGCTGGCACTCTGAAACCAAGAACAGCCTGATGCAGGACAGGGATGCTGCCTCTGC
CAGGGCCTGGCCCAAGATGCACACTGTGAATGGCTATGTGAACAGGAGCCTGCCTGGCCT
GATTGGCTGCCACAGGAAGTCTGTGTACTGGCATGTGATTGGCATGGGCACCACCCCTGA
GGTGCACAGCATCTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAGGCCAG
CCTGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGGACCTGGGCCA
GTTCTCTGCTGTTCTGCCACATCAGCAGCCACCAGCATGATGGCATGGAGGCCTATGTGAA
GGTGGACAGCTGCCCTGAGGAGCCCCAGCTGAGGATGAAGAACAATGAGGAGGCTGAGG
ACTATGATGATGACCTGACTGACTCTGAGATGGATGTGGTGAGGTTTGATGATGACAACA
GCCCCAGCTTCATCCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTGCACT
ACATTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCTGGTGCTGGCCCCCTGATGACA
GGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGATTGGCAGGAAGTACAAG
AAGGTCAGGTTTCATGGCCTACACTGATGAAACCTTCAAGACCAGGGAGGCCATCCAGCAT
GAGTCTGGCATCCTGGGCCCCCTGCTGTATGGGGAGGTGGGGGACACCCTGCTGATCATC
TTCAAGAACCAGGCCAGCAGGCCCTACAACATCTACCCCCATGGCATCACTGATGTGAGG
CCCCTGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGACTTCCCCATCCTG
CCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGATGGCCCCACCAAGTCT
GACCCCAGGTGCCTGACCAGATACTACAGCAGCTTTGTGAACATGGAGAGGGACCTGGCC
TCTGGCCTGATTGGCCCCCTGCTGATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAAC
CAGATCATGTCTGACAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGGAGC
TGGTACCTGACTGAGAACATCCAGAGGTTCTGCCCAACCCTGCTGGGGTGCAGCTGGAG
GACCCTGAGTTCAGGCCAGCAACATCATGCACAGCATCAATGGCTATGTGTTTGACAGC

CTGCAGCTGTCTGTGTGCCTGCATGAGGTGGCCTACTGGTACATCCTGAGCATTGGGGCC
CAGACTGACTTCCTGTCTGTGTTCTTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATG
AGGACACCCTGACCCTGTTCCCTTCTCTGGGGAGACTGTGTTTCATGAGCATGGAGAACC
CTGGCCTGTGGATTCTGGGCTGCCACAACCTCTGACTTCAGGAACAGGGGCATGACTGCCC
TGCTGAAAGTCTCCAGCTGTGACAAGAACAACACTGGGGACTACTATGAGGACAGCTATGAG
GACATCTCTGCCTACCTGCTGAGCAAGAACAATGCCATTGAGCCCAGGAGCTTCAGCCAG
AATAGCAGGCACCCCAGCACCAGGCAGGAAGCAGTTCAATGCCACCACCATCCCAGAGAA
TACCACCCTGCAGTCTGACCAGGAGGAGATTGACTATGATGACACCATCTCTGTGGAGAT
GAAGAAGGAGGACTTTGACATCTACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCC
AGAAGAAGACCAGGCACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCATGA
GCAGCAGCCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTGCCCCAGTTCAAGA
AGGTGGTGTTCAGGAGTTCACTGATGGCAGCTTCACCCAGCCCCTGTACAGAGGGGAGC
TGAATGAGCACCTGGGCCTGCTGGGCCCCCTACATCAGGGCTGAGGTGGAGGACAACATC
ATGGTGACCTTCAGGAACCAGGCCAGCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGC
TATGAGGAGGACCAGAGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATGA
AACCAAGACCTACTTCTGGAAGGTGCAGCACCATGGCCCCCACCAGGATGAGTTTGA
CTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGATGTGCACTCTGGCCT
GATTGGCCCCCTGCTGGTGTGCCACACCAACACCCTGAACCCTGCCCATGGCAGGCAGGT
GACTGTGCAGGAGTTTGCCCTGTTCTTACCATCTTTGATGAAACCAAGAGCTGGTACTTC
ACTGAGAACATGGAGAGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCAC
CTTCAAGGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGACACCCTGCCTGG
CCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGCATGGGCAGCAATG
AGAACATCCACAGCATCCACTTCTCTGGCCATGTGTTCACTGTGAGGAAGAAGGAGGAGT
ACAAGATGGCCCTGTACAACCTGTACCCTGGGGTGTGTTGAGACTGTGGAGATGCTGCCCA
GCAAGGCTGGCATCTGGAGGGTGGAGTGCCTGATTGGGGAGCACCTGCATGCTGGCATG
AGCACCTGTTCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATGGCCTCTGGC
CACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGGGCCCCCAAGCTG
GCCAGGCTGCACTACTCTGGCAGCATCAATGCCTGGAGCACCAAGGAGCCCTTCAGCTGG
ATCAAGGTGGACCTGCTGGCCCCCATGATCATCCATGGCATCAAGACCCAGGGGGCCAGG
CAGAAGTTCAGCAGCCTGTACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAG
AAGTGGCAGACCTACAGGGGCAACAGCACTGGCACCCCTGATGGTGTCTTTGGCAATGTG
GACAGCTCTGGCATCAAGCACAACATCTTCAACCCCCCATCATTGCCAGATACATCAGG
CTGCACCCACCCACTACAGCATCAGGAGCACCCCTGAGGATGGAGCTGATGGGCTGTGAC
CTGAACAGCTGCAGCATGCCCTGGGCATGGAGAGCAAGGCCATCTCTGATGCCAGATC
ACTGCCAGCAGCTACTTCACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTG
CACCTGCAGGGCAGGAGCAATGCCTGGAGGGCCCCAGGTCAACAACCCCAAGGAGTGGCT

GCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAGGGGGTGAAGA
GCCTGCTGACCAGCATGTATGTGAAGGAGTTCCTGATCAGCAGCAGCCAGGATGGCCACC
AGTGGACCCTGTTCTTCCAGAATGGCAAGGTGAAGGTGTTCCAGGGCAACCAGGACAGCT
TCACCCCTGTGGTGAACAGCCTGGACCCCCCCTGCTGACCAGATACCTGAGGATTCACC
CCCAGAGCTGGGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAGGCCAG
GACCTGTACTGATTAATTAAGAGCATCTTACCGCCATTTATTCCCATATTTGTTCTGTTTTT
CTTGATTTGGGTATACATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATT
TTTAGGGATATGTAATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAAC
TTCCCGTTATTTACGCTCTGTTCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAG
ATTGACTGATATTCTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGC
CTCTGTATCTAGCTATTGCTTCCCGTACGGCTTTTCGTTTTCTCCTCCTTGATAAAATCCTGG
TTGCTGTCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTG
TGTTTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGG
GACTTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCTGCCTTGCCCCG
TGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTGTCTGTGCCTTCTA
GTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCGTGCCTTCCTTGACCTGGAAGGTGCCAC
TCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCAT
TCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAG
CAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTCTAGAGCATGGCTACGTAGATAAGTA
GCATGGCGGGTTAATCATTAATACTACACCTGCAGGAGGAACCCCTAGTGATGGAGTTGGCC
ACTCCCTCTCTGCGCGCTCGCTCGCTCA

(SEQ ID NO: 642)

(2) ceDNA construct 60 contains 3x_hSerpEnh-2mer spacer v17

[00863] TGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTC
TTGTAGTTAATGATTAACCCGCCATGCTACTTATCGCGGCCGCGGGGGAGGCTGCTGGTG
AATATTAACCAAGGTCACCCCAGTTATCGGAGGAGCAAACAGGGGCTAAGTCCACCTGG
GGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCCAGTTATCGGAGGAGCAAACAGGG
GCTAAGTCCACAAGGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCCAGTTATCGG
AGGAGCAAACAGGGGGCTAAGTCCACGGTACCCACTGGGAGGATGTTGAGTAAGATGGAA
AACTACTGATGACCCTTGCAGAGACAGAGTATTAGGACATGTTTGAACAGGGGCCGGGC
GATCAGCAGGTAGCTCTAGAGGATCCCCGTCTGTCTGCACATTTCTAGAGCGAGTGTTT
CGATACTCTAATCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGT
GACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCT
GGGTTGGAAGGAGGGGGTATAAAAGCCCCTTACCAGGAGAAGCCGTCACACAGATCCA
CAAGCTCCTGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTAA

TTACCTGGAGCACCTGCCTGAAATCACTTTTTTTCAGGTTGGTTTAAACGCCGCCACCATG
CAGATAGAGCTCAGCACCTGCTTCTTCCTGTGCCTCCTCAGGTTCTGCTTCTCTGCCACCA
GGAGATACTACCTGGGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTCTGACCTGGGG
GAGCTGCCTGTGGACGCCAGGTTCCCCCCCAGAGTGCCCAAGAGCTTCCCCTTCAACACC
TCTGTGGTGTACAAGAAGACCCTGTTTGTGGAGTTCACTGACCACCTGTTCAACATTGCCA
AGCCCAGGCCCCCTGGATGGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACA
CTGTGGTGATCACCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGGG
TGAGCTACTGGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAGACCAGCCAGAGGGAG
AAGGAGGATGACAAGGTGTTCCCTGGGGGCAGCCACACCTATGTGTGGCAGGTGCTGAA
GGAGAATGGCCCCATGGCCTCTGACCCCCTGTGCCTGACCTACAGCTACCTGAGCCATGT
GGACCTGGTGAAGGACCTGAACTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGG
CAGCCTGGCCAAGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTT
TGATGAGGGCAAGAGCTGGCACTCTGAAACCAAGAAGCAGCCTGATGCAGGACAGGGATG
CTGCCTCTGCCAGGGCCTGGCCCAAGATGCACACTGTGAATGGCTATGTGAACAGGAGCC
TGCCTGGCCTGATTGGCTGCCACAGGAAGTCTGTGTACTGGCATGTGATTGGCATGGGCA
CCACCCCTGAGGTGCACAGCATCTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACA
GGCAGGCCAGCCTGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGG
ACCTGGGCCAGTTCCCTGCTGTTCTGCCACATCAGCAGCCACCAGCATGATGGCATGGAGG
CCTATGTGAAGGTGGACAGCTGCCCTGAGGAGCCCCAGCTGAGGATGAAGAACAATGAG
GAGGCTGAGGACTATGATGATGACCTGACTGACTCTGAGATGGATGTGGTGAGGTTTGAT
GATGACAACAGCCCCAGCTTCATCCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACC
TGGGTGCACTACATTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCTGGTGCTGGCC
CCTGATGACAGGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGATTGGCAG
GAAGTACAAGAAGGTCAGGTTTCATGGCCTACACTGATGAAACCTTCAAGACCAGGGAGG
CCATCCAGCATGAGTCTGGCATCCTGGGCCCCCTGCTGTATGGGGAGGTGGGGGACACCC
TGCTGATCATCTTCAAGAACCAGGCCAGCAGGCCCTACAACATCTACCCCCACGGCATCA
CTGATGTGAGGCCCCTGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGAC
TTCCCCATCCTGCCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGATGGC
CCCACCAAGTCTGACCCCAGGTGCCTGACCAGATACTACAGCAGCTTTGTGAACATGGAG
AGGGACCTGGCCTCTGGCCTGATTGGCCCCCTGCTGATCTGCTACAAGGAGTCTGTGGAC
CAGAGGGGCAACCAGATCATGTCTGACAAGAGGAATGTGATCCTGTTCTCTGTGTTTGAT
GAGAACAGGAGCTGGTACCTGACTGAGAACATCCAGAGGTTTCCTGCCCCAACCTGCTGGG
GTGCAGCTGGAGGACCCTGAGTTCCAGGCCAGCAACATCATGCACAGCATCAATGGCTAT
GTGTTTGACAGCCTGCAGCTGTCTGTGTGCCTGCATGAGGTGGCCTACTGGTACATCCTGA
GCATTGGGGCCCAGACTGACTTCCTGTCTGTGTTCTTCTCTGGCTACACCTTCAAGCACAA
GATGGTGTATGAGGACACCCTGACCCTGTTCCCCTTCTCTGGGGAGACTGTGTTTCATGAGC

ATGGAGAACCCTGGCCTGTGGATTCTGGGCTGCCACAACCTCTGACTTCAGGAACAGGGGC
ATGACTGCCCTGCTGAAAAGTCTCCAGCTGTGACAAGAACAACCTGGGGACTACTACGAGGAC
AGCTATGAGGACATCTCTGCCTACCTGCTGAGCAAGAACAATGCCATTGAGCCCAGGAGC
TTCAGCCAGAATAGCAGGCACCCCAGCACCAGGCAGAAGCAGTTCAATGCCACCACCAT
CCCAGAGAATACCACCCTGCAGTCTGACCAGGAGGAGATTGACTATGATGACACCATCTC
TGTGGAGATGAAGAAGGAGGACTTTGACATCTACGACGAGGACGAGAACCAGAGCCCCA
GGAGCTTCCAGAAGAAGACCAGGCACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACT
ATGGCATGAGCAGCAGCCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTGCCCC
AGTTCAAGAAGGTGGTGTTCAGGAGTTCACTGATGGCAGCTTCACCCAGCCCCCTGTACA
GAGGGGAGCTGAATGAGCACCTGGGCCTGCTGGGCCCCCTACATCAGGGCTGAGGTGGAG
GACAACATCATGGTGACCTTCAGGAACCAGGCCAGCAGGCCCTACAGCTTCTACAGCAGC
CTGATCAGCTATGAGGAGGACCAGAGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAA
GCCCAATGAAACCAAGACCTACTTCTGGAAGGTGCAGCACCATGGCCCCCACCAGG
ATGAGTTTGACTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGATGTGC
ACTCTGGCCTGATTGGCCCCCTGCTGGTGTGCCACACCAACACCCTGAACCCTGCCCATG
GCAGGCAGGTGACTGTGCAGGAGTTTGCCCTGTTCTTCACCATCTTTGATGAAACCAAGA
GCTGGTACTTCACTGAGAACATGGAGAGGAACTGCAGGGCCCCCTGCAACATCCAGATG
GAGGACCCACCTTCAAGGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGAC
ACCCTGCCTGGCCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGCATG
GGCAGCAATGAGAACATCCACAGCATCCACTTCTCTGGCCATGTGTTCCTGTGAGGAAG
AAGGAGGAGTACAAGATGGCCCTGTACAACCTGTACCCTGGGGTGTTTGAGACTGTGGAG
ATGCTGCCCAGCAAGGCTGGCATCTGGAGGGTGGAGTGCCTGATTGGGGAGCACCTGCAT
GCTGGCATGAGCACCTGTTCCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATG
GCCTCTGGCCACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGGGCC
CCCAAGCTGGCCAGGCTGCACTACTCTGGCAGCATCAATGCCTGGAGCACCAAGGAGCCC
TTCAGCTGGATCAAGGTGGACCTGCTGGCCCCCATGATCATCCATGGCATCAAGACCCAG
GGGGCCAGGCAGAAGTTCAGCAGCCTGTACATCAGCCAGTTCATCATCATGTACAGCCTG
GATGGCAAGAAGTGGCAGACCTACAGGGGCAACAGCACTGGCACCCCTGATGGTGTCTTT
GGCAATGTGGACAGCTCTGGCATCAAGCACAACTCTTCAACCCCCCATCATTTGCCAGA
TACATCAGGCTGCACCCACCCACTACAGCATCAGGAGCACCCCTGAGGATGGAGCTGATG
GGCTGTGACCTGAACAGCTGCAGCATGCCCTGGGCATGGAGAGCAAGGCCATCTCTGAT
GCCCAGATCACTGCCAGCAGCTACTTCACCAACATGTTTGCCACCTGGAGCCCCAGCAAG
GCCAGGCTGCACCTGCAGGGCAGGAGCAATGCCTGGAGGGCCCCAGGTCAACAACCCCAA
GGAGTGGCTGCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAGG
GGGTGAAGAGCCTGCTGACCAGCATGTATGTGAAGGAGTTCCTGATCAGCAGCAGCCAG
GATGGCCACCAGTGGACCCTGTTCTTCCAGAATGGCAAGGTGAAGGTGTTCCAGGGCAAC

CAGGACAGCTTCACCCCTGTGGTGAACAGCCTGGACCCCCCTGCTGACCAGATACCTG
AGGATTCACCCCCAGAGCTGGGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGT
GAGGCCCAGGACCTGTACTGATTAATTAAGAGCATCTTACCGCCATTTATTCCCATATTTG
TTCTGTTTTTCTTGATTTGGGTATACATTTAAATGTTAATAAAACAAAATGGTGGGGCAAT
CATTTACATTTTTAGGGATATGTAATTACTAGTTCAGGTGTATTGCCACAAGACAAACATG
TTAAGAACTTTCCCGTTATTTACGCTCTGTTCTGTTAATCAACCTCTGGATTACAAAAT
TTGTGAAAGATTGACTGATATTCTTAACTATGTTGCTCCTTTTACGCTGTGTGGATATGCT
GCTTTATAGCCTCTGTATCTAGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTA
TAAATCCTGGTTGCTGTCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTG
GTGTGCTCTGTGTTTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAAC
TCCTTTCTGGGACTTTTCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTG
CCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTGTCT
GTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCTCCCCCGTGCCTTCCTTGACCCTGGA
AGGTGCCACTCCCCTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGT
AGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGA
AGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTCTAGAGCATGGCTACGT
AGATAAGTAGCATGGCGGGTTAATCATTAACTACACCTGCAGGAGGAACCCCTAGTGATG
GAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCA

(SEQ ID NO: 643)

(3) ceDNA construct 61 contains 3x_SerpEnh_11-mer_spacers_v3

[00864] TGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCC
TTGTAGTTAATGATTAACCCGCCATGCTACTTATCGCGGCCGCGGGGGAGGCTGCTGGTG
AATATTAACCAAGGTCACCCCAGTTATCGGAGGAGCAAACAGGGGCTAAGTCCACTGCA
AAGTCCTGGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCCAGTTATCGGAGGAGC
AAACAGGGGCTAAGTCCACAGTGTTTACAAGGGGGAGGCTGCTGGTGAATATTAACCAA
GGTCACCCCAGTTATCGGAGGAGCAAACAGGGGCTAAGTCCACGGTACCCACTGGGAGG
ATGTTGAGTAAGATGGAAAATACTGATGACCCTTGACAGAGACAGAGTATTAGGACATGT
TTGAACAGGGGCCGGGCGATCAGCAGGTAGCTCTAGAGGATCCCCGTCTGTCTGCACATT
TCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTT
ACTTATTCTCCTTTTGTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTG
GCAGGGATCAGCAGCCTGGGTTGGAAGGAGGGGGTATAAAAGCCCCCTTACCAGGAGAA
GCCGTCACACAGATCCACAAGCTCCTGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGT
GGGGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTTTTCAGGTTGGTT
TAAACGCCGCCACCATGCAGATAGAGCTCAGCACCTGCTTCTTCTGTGCCTCCTCAGGTT
CTGCTTCTCTGCCACCAGGAGATACTACCTGGGGGCTGTGGAGCTGAGCTGGGACTACAT

GCAGTCTGACCTGGGGGAGCTGCCTGTGGACGCCAGGTTCCCCCCCAGAGTGCCCAAGAG
CTTCCCCCTTCAACACCTCTGTGGTGTACAAGAAGACCCTGTTTGTGGAGTTCACTGACCAC
CTGTTCAACATTGCCAAGCCCAGGCCCCCTGGATGGGCCTGCTGGGCCCCACCATCCAG
GCTGAGGTGTATGACACTGTGGTGATCACCTGAAGAACATGGCCAGCCACCCTGTGAGC
CTGCATGCTGTGGGGGTGAGCTACTGGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAG
ACCAGCCAGAGGGAGAAGGAGGATGACAAGGTGTTCCCTGGGGGCAGCCACACCTATGT
GTGGCAGGTGCTGAAGGAGAATGGCCCCATGGCCTCTGACCCCCTGTGCCTGACCTACAG
CTACCTGAGCCATGTGGACCTGGTGAAGGACCTGAACTCTGGCCTGATTGGGGCCCTGCT
GGTGTGCAGGGAGGGCAGCCTGGCCAAGGAGAAGACCCAGACCCTGCACAAGTTCATCC
TGCTGTTTGCTGTGTTTGATGAGGGCAAGAGCTGGCACTCTGAAACCAAGAACAGCCTGA
TGCAGGACAGGGATGCTGCCTCTGCCAGGGCCTGGCCCAAGATGCACACTGTGAATGGCT
ATGTGAACAGGAGCCTGCCTGGCCTGATTGGCTGCCACAGGAAGTCTGTGTACTGGCATG
TGATTGGCATGGGCACCACCCCTGAGGTGCACAGCATCTTCCTGGAGGGCCACACCTTCC
TGGTCAGGAACCACAGGCAGGCCAGCCTGGAGATCAGCCCCATCACCTTCCTGACTGCCC
AGACCCTGCTGATGGACCTGGGCCAGTTCCCTGCTGTTCTGCCACATCAGCAGCCACCAGC
ATGATGGCATGGAGGCCTATGTGAAGGTGGACAGCTGCCCTGAGGAGCCCCAGCTGAGG
ATGAAGAACAATGAGGAGGCTGAGGACTATGATGATGACCTGACTGACTCTGAGATGGA
TGTGGTGAGGTTTGATGATGACAACAGCCCCAGCTTCATCCAGATCAGGTCTGTGGCCAA
GAAGCACCCCCAAGACCTGGGTGCACTACATTGCTGCTGAGGAGGAGGACTGGGACTATG
CCCCCTGGTGCTGGCCCCTGATGACAGGAGCTACAAGAGCCAGTACCTGAACAATGGCC
CCCAGAGGATTGGCAGGAAGTACAAGAAGGTGAGGTTTCATGGCCTACACTGATGAAACC
TTCAAGACCAGGGAGGCCATCCAGCATGAGTCTGGCATCCTGGGCCCCCTGCTGTATGGG
GAGGTGGGGGACACCCTGCTGATCATCTTCAAGAACCAGGCCAGCAGGCCCTACAACATC
TACCCCCACGGCATCACTGATGTGAGGCCCCTGTACAGCAGGAGGCTGCCCAAGGGGGTG
AAGCACCTGAAGGACTTCCCCATCCTGCCTGGGGAGATCTTCAAGTACAAGTGGACTGTG
ACTGTGGAGGATGGCCCCACCAAGTCTGACCCAGGTGCCTGACCAGATACTACAGCAGC
TTTGTGAACATGGAGAGGGACCTGGCCTCTGGCCTGATTGGCCCCCTGCTGATCTGCTAC
AAGGAGTCTGTGGACCAGAGGGGCAACCAGATCATGTCTGACAAGAGGAATGTGATCCT
GTTCTCTGTGTTTGATGAGAACAGGAGCTGGTACCTGACTGAGAACATCCAGAGGTTCCCT
GCCCAACCCTGCTGGGGTGCAGCTGGAGGACCCTGAGTTCCAGGCCAGCAACATCATGCA
CAGCATCAATGGCTATGTGTTTGACAGCCTGCAGCTGTCTGTGTGCCTGCATGAGGTGGC
CTACTGGTACATCCTGAGCATTGGGGCCCAGACTGACTTCCTGTCTGTGTTCTTCTCTGGC
TACACCTTCAAGCACAAGATGGTGTATGAGGACACCCTGACCCTGTTCCCCTTCTCTGGG
GAGACTGTGTTTCATGAGCATGGAGAACCCTGGCCTGTGGATTCTGGGCTGCCACAACCTCT
GACTTCAGGAACAGGGGCATGACTGCCCTGCTGAAAGTCTCCAGCTGTGACAAGAACA
GGGGACTACTACGAGGACAGCTATGAGGACATCTCTGCCTACCTGCTGAGCAAGAACAAT

GCCATTGAGCCCAGGAGCTTCAGCCAGAATAGCAGGCACCCCAGCACCAGGCAGAAGCA
GTTCAATGCCACCACCATCCCAGAGAATACCACCCTGCAGTCTGACCAGGAGGAGATTGA
CTATGATGACACCATCTCTGTGGAGATGAAGAAGGAGGACTTTGACATCTACGACGAGGA
CGAGAACCAGAGCCCCAGGAGCTTCCAGAAGAAGACCAGGCACTACTTCATTGCTGCTGT
GGAGAGGCTGTGGGACTATGGCATGAGCAGCAGCCCCATGTGCTGAGGAACAGGGCCC
AGTCTGGCTCTGTGCCCCAGTTCAAGAAGGTGGTGTTCAGGAGTTCACTGATGGCAGCT
TCACCCAGCCCCTGTACAGAGGGGAGCTGAATGAGCACCTGGGCCTGCTGGGCCCCTACA
TCAGGGCTGAGGTGGAGGACAACATCATGGTGACCTTCAGGAACCAGGCCAGCAGGCCC
TACAGCTTCTACAGCAGCCTGATCAGCTATGAGGAGGACCAGAGGCAGGGGGCTGAGCC
CAGGAAGAACTTTGTGAAGCCCAATGAAACCAAGACCTACTTCTGGAAGGTGCAGCACC
ACATGGCCCCCACCAGGATGAGTTTGACTGCAAGGCCTGGGCCTACTTCTCTGATGTGG
ACCTGGAGAAGGATGTGCACTCTGGCCTGATTGGCCCCCTGCTGGTGTGCCACACCAACA
CCCTGAACCCTGCCCATGGCAGGCAGGTGACTGTGCAGGAGTTTGCCCTGTTCTTCACCAT
CTTTGATGAAACCAAGAGCTGGTACTTCACTGAGAACATGGAGAGGAACTGCAGGGCCC
CCTGCAACATCCAGATGGAGGACCCACCTTCAAGGAGAACTACAGGTTCCATGCCATCA
ATGGCTACATCATGGACACCCTGCCTGGCCTGGTGTATGGCCCAGGACCAGAGGATCAGGT
GGTACCTGCTGAGCATGGGCAGCAATGAGAACATCCACAGCATCCACTTCTCTGGCCATG
TGTTCACTGTGAGGAAGAAGGAGGAGTACAAGATGGCCCTGTACAACCTGTACCCTGGG
GTGTTTGAGACTGTGGAGATGCTGCCAGCAAGGCTGGCATCTGGAGGGTGGAGTGCCTG
ATTGGGGAGCACCTGCATGCTGGCATGAGCACCTGTTCTTGGTGTACAGCAACAAGTGC
CAGACCCCCCTGGGCATGGCCTCTGGCCACATCAGGGACTTCCAGATCACTGCCTCTGGC
CAGTATGGCCAGTGGGCCCCCAAGCTGGCCAGGCTGCACTACTCTGGCAGCATCAATGCC
TGGAGCACCAAGGAGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCCCCCATGATCATC
CATGGCATCAAGACCCAGGGGGCCAGGCAGAAGTTCAGCAGCCTGTACATCAGCCAGTT
CATCATCATGTACAGCCTGGATGGCAAGAAGTGGCAGACCTACAGGGGCAACAGCACTG
GCACCCTGATGGTGTCTTTGGCAATGTGGACAGCTCTGGCATCAAGCACAACATCTTCA
ACCCCCCATCATTGCCAGATACATCAGGCTGCACCCACCCACTACAGCATCAGGAGCA
CCCTGAGGATGGAGCTGATGGGCTGTGACCTGAACAGCTGCAGCATGCCCCCTGGGCATGG
AGAGCAAGGCCATCTCTGATGCCAGATCACTGCCAGCAGCTACTTCACCAACATGTTTG
CCACCTGGAGCCCCAGCAAGGCCAGGCTGCACCTGCAGGGCAGGAGCAATGCCTGGAGG
CCCCAGGTCAACAACCCCAAGGAGTGGCTGCAGGTGGACTTCCAGAAGACCATGAAGGT
GACTGGGGTGACCACCCAGGGGGTGAAGAGCCTGCTGACCAGCATGTATGTGAAGGAGT
TCCTGATCAGCAGCAGCCAGGATGGCCACCAGTGGACCCTGTTCTTCCAGAATGGCAAGG
TGAAGGTGTTCCAGGGCAACCAGGACAGCTTCACCCCTGTGGTGAACAGCCTGGACCCCC
CCCTGCTGACCAGATACCTGAGGATTCACCCCCAGAGCTGGGTGCACCAGATTGCCCTGA
GGATGGAGGTGCTGGGCTGTGAGGCCAGGACCTGTACTGATTAATTAAGAGCATCTTAC

CGCCATTTATTCCCATATTTGTTCTGTTTTTCTTGATTGGGTATACATTTAAATGTTAATA
AAACAAAATGGTGGGGCAATCATTTACATTTTTAGGGATATGTAATTACTAGTTCAGGTG
TATTGCCACAAGACAAACATGTAAAGAACTTTCCCGTTATTTACGCTCTGTTCCTGTAA
TCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCTTAACCTATGTTGCTCCT
TTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTGTATCTAGCTATTGCTTCCCGTACGGC
TTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTTAGAGGAGTTGTGGCCCCG
TTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGTTTGCTGACGCAACCCCCACTGGCTGGGG
CATTGCCACCACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCCCCCTCCCGATCGCCACG
GCAGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTAGGTTGCTGGGCACT
GATAATTCCGTGGTGTGTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCC
CGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAA
ATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGAC
AGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTAT
GGCTCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATCATTAACCTACACCTG
CAGGAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCA

(SEQ ID NO: 644)

**(4) ceDNA construct 62 contains 3x_Bushbaby SerpEnh with adenine (A) spacers
("3xBushbaby_ Aspacers").**

TGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTTGTAG
TTAATGATTAACCCGCCATGCTACTTATCGCGGCCGAGGGGAAGCTACTGGTGAATATT
AACCAAGGTCACCCAGTTATCAGGGAGCAAACAGGAGCTAAGTCCATAGGGGGAAGCTA
CTGGTGAATATTAACCAAGGTCACCCAGTTATCAGGGAGCAAACAGGAGCTAAGTCCATA
GGGGGAAGCTACTGGTGAATATTAACCAAGGTCACCCAGTTATCAGGGAGCAAACAGGA
GCTAAGTCCATGGTACCCACTGGGAGGATGTTGAGTAAGATGGAAAACCTACTGATGACCC
TTGCAGAGACAGAGTATTAGGACATGTTTGAACAGGGGCCGGGCGATCAGCAGGTAGCT
CTAGAGGATCCCCGTCTGTCTGCACATTTCTAGAGCGAGTGTTCCGATACTCTAATCTCC
CTAGGCAAGGTTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTTGACTAAGTCAATAAT
CAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGG
GGGTATAAAAGCCCCCTTACCAGGAGAAGCCGTCACACAGATCCACAAGCTCCTGAAGA
GGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGGAGCACC
TGCCTGAAATCACTTTTTTTTTCAGGTTGGTTTAAACGCCGCCACCATGCAGATAGAGCTCAG
CACCTGCTTCTTCCTGTGCCTCCTCAGGTTCTGCTTCTCTGCCACCAGGAGATACTACCTG
GGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTCTGACCTGGGGGAGCTGCCTGTGGAC
GCCAGGTTCCCCCCCAGAGTGCCCAAGAGCTTCCCCCTCAACACCTCTGTGGTGTACAAG
AAGACCTGTTTGTGGAGTTCACTGACCACCTGTTCAACATTGCCAAGCCCAGGCCCCCT

GGATGGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACTGTGGTGATCACCC
TGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGGGTGAGCTACTGGAAG
GCCTCTGAGGGGGCTGAGTATGATGACCAGACCAGCCAGAGGGAGAAGGAGGATGACAA
GGTGTTCCTGGGGGCAGCCACACCTATGTGTGGCAGGTGCTGAAGGAGAATGGCCCCAT
GGCCTCTGACCCCTGTGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTGAAGGA
CCTGAACTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGCCTGGCCAAGGA
GAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTTTGATGAGGGCAAGAG
CTGGCACTCTGAAACCAAGAACAGCCTGATGCAGGACAGGGATGCTGCCTCTGCCAGGG
CCTGGCCCAAGATGCACACTGTGAATGGCTATGTGAACAGGAGCCTGCCTGGCCTGATTG
GCTGCCACAGGAAGTCTGTGTACTGGCATGTGATTGGCATGGGCACCCCTGAGGTGC
ACAGCATCTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAGGCCAGCCTGG
AGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGGACCTGGGCCAGTTCCT
GCTGTTCTGCCACATCAGCAGCCACCAGCATGATGGCATGGAGGCCTATGTGAAGGTGGA
CAGCTGCCCTGAGGAGCCCCAGCTGAGGATGAAGAACAATGAGGAGGCTGAGGACTATG
ATGATGACCTGACTGACTCTGAGATGGATGTGGTGAGGTTTGATGATGACAACAGCCCCA
GTTTCATCCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTGCACTACATTG
CTGCTGAGGAGGAGGACTGGGACTATGCCCCCTGGTGCTGGCCCCTGATGACAGGAGCT
ACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGATTGGCAGGAAGTACAAGAAGGTC
AGGTTTCATGGCCTACACTGATGAAACCTTCAAGACCAGGGAGGCCATCCAGCATGAGTCT
GGCATCCTGGGCCCCCTGCTGTATGGGGAGGTGGGGGACACCCTGCTGATCATCTTCAAG
AACCAGGCCAGCAGGCCCTACAACATCTACCCCCACGGCATCACTGATGTGAGGCCCTG
TACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGACTTCCCCATCCTGCCTGG
GGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGATGGCCCCACCAAGTCTGACCC
CAGGTGCCTGACCAGATACTACAGCAGCTTTGTGAACATGGAGAGGGACCTGGCCTCTGG
CCTGATTGGCCCCCTGCTGATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAACCAGAT
CATGTCTGACAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGGAGCTGGTA
CCTGACTGAGAACATCCAGAGGTTTCCTGCCCAACCCTGCTGGGGTGCAGCTGGAGGACCC
TGAGTTCCAGGCCAGCAACATCATGCACAGCATCAATGGCTATGTGTTTGACAGCCTGCA
GCTGTCTGTGTGCCTGCATGAGGTGGCCTACTGGTACATCCTGAGCATTGGGGCCCAGAC
TGACTTCCTGTCTGTGTTCTTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATGAGGAC
ACCCTGACCCTGTTCCCTTCTCTGGGGAGACTGTGTTTCATGAGCATGGAGAACCCTGGCC
TGTGGATTCTGGGCTGCCACAACCTCTGACTTCAGGAACAGGGGCATGACTGCCCTGCTGA
AAGTCTCCAGCTGTGACAAGAACAACCTGGGGACTACTACGAGGACAGCTATGAGGACATC
TCTGCCTACCTGCTGAGCAAGAACAATGCCATTGAGCCCAGGAGCTTCAGCCAGAATAGC
AGGCACCCAGCACCAGGCAGAAGCAGTTCAATGCCACCACCATCCCAGAGAATACCAC
CCTGCAGTCTGACCAGGAGGAGATTGACTATGATGACACCATCTCTGTGGAGATGAAGAA

GGAGGACTTTGACATCTACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCCAGAAGA
AGACCAGGCACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCATGAGCAGCA
GCCCCCATGTGCTGAGGAACAGGGCCCCAGTCTGGCTCTGTGCCCCAGTTCAAGAAGGTGG
TGTTCCAGGAGTTCACTGATGGCAGCTTCACCCAGCCCCTGTACAGAGGGGAGCTGAATG
AGCACCTGGGCTGCTGGGCCCCCTACATCAGGGCTGAGGTGGAGGACAACATCATGGTG
ACCTTCAGGAACCAGGCCAGCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGCTATGAG
GAGGACCAGAGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATGAAACCAA
GACCTACTTCTGGAAGGTGCAGCACCACATGGCCCCCACCAGGATGAGTTTGAAGTCAA
GGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGATGTGCACTCTGGCCTGATTGG
CCCCCTGCTGGTGTGCCACACCAACACCCCTGAACCCCTGCCATGGCAGGCAGGTGACTGT
GCAGGAGTTTGCCCTGTTCTTCACCATCTTTGATGAAACCAAGAGCTGGTACTTCACTGAG
AACATGGAGAGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCACCTTCAA
GGAGAATAACAGGTTCCATGCCATCAATGGCTACATCATGGACACCCTGCCTGGCCTGGT
GATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGCATGGGCAGCAATGAGAACA
TCCACAGCATCCACTTCTCTGGCCATGTGTTCACTGTGAGGAAGAAGGAGGAGTACAAGA
TGGCCCTGTACAACCTGTACCCTGGGGTGTGTTGAGACTGTGGAGATGCTGCCAGCAAGG
CTGGCATCTGGAGGGTGGAGTGCCTGATTGGGGAGCACCTGCATGCTGGCATGAGCACCC
TGTTCCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATGGCCTCTGGCCACATCA
GGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGGGCCCCCAAGCTGGCCAGGC
TGCACTACTCTGGCAGCATCAATGCCTGGAGCACCAAGGAGCCCTTCAGCTGGATCAAGG
TGGACCTGCTGGCCCCCATGATCATCCATGGCATCAAGACCCAGGGGGGCCAGGCAGAAGT
TCAGCAGCCTGTACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAGAAGTGGC
AGACCTACAGGGGCAACAGCACTGGCACCCCTGATGGTGTCTTTGGCAATGTGGACAGCT
CTGGCATCAAGCACAAATCTTCAACCCCCCATCATTTGCCAGATACATCAGGCTGCACC
CCACCCACTACAGCATCAGGAGCACCCCTGAGGATGGAGCTGATGGGCTGTGACCTGAAC
AGCTGCAGCATGCCCCCTGGGCATGGAGAGCAAGGCCATCTCTGATGCCAGATCACTGCC
AGCAGCTACTTCACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTGCACCTG
CAGGGCAGGAGCAATGCCTGGAGGCCCCAGGTCAACAACCCCAAGGAGTGGCTGCAGGT
GGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAGGGGGTGAAGAGCCTGC
TGACCAGCATGTATGTGAAGGAGTTCCTGATCAGCAGCAGCCAGGATGGCCACCAGTGG
ACCCTGTTCTTCCAGAATGGCAAGGTGAAGGTGTTCCAGGGCAACCAGGACAGCTTACC
CCTGTGGTGAACAGCCTGGACCCCCCTGCTGACCAGATACCTGAGGATTACCCCCAG
AGCTGGGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAGGCCCAGGACCT
GTACTGATTAATTAAGAGCATCTTACCGCCATTTATTCCCATATTTGTTCTGTTTTCTTGA
TTTGGGTATACATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATTTTAG
GGATATGTAATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAACTTTCC

CGTTATTTACGCTCTGTTCCCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGA
CTGATATTCTTAACCTATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGCCTCTG
TATCTAGCTATTGCTTCCCGTACGGCTTTTCGTTTTCTCCTCCTTGTATAAATCCTGGTTGCT
GTCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTGTGTTT
GCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGGGACTT
TCGCTTTCCCCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCCGCTGCTG
GACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTGTCTGTGCCTTCTAGTTGC
CAGCCATCTGTTGTTTGGCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCA
CTGTCCTTTCTAATAAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTAT
TCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGG
CATGCTGGGGATGCGGTGGGCTCTATGGCTCTAGAGCATGGCTACGTAGATAAGTAGCAT
GGCGGGTTAATCATTAACCTACACCTGCAGGAGGAACCCCTAGTGATGGAGTTGGCCACTC
CCTCTCTGCGCGCTCGCTCGCTCACTCA

(SEQ ID NO: 645)

(5) **ceDNA construct 39** which has the essentially identical sequence to ceDNA construct 10 except that it contains a truncated right ITR.

TGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCCTTGTAG
TTAATGATTAACCCACCATGCTACTTATGGCCTGCAGGGGGGGAGGCTGCTGGTGAATAT
TAACCAAGGTCACCCAGTTATCGGAGGAGCAAACAGGGGGCTAAGTCCACCGGGGGAGG
CTGCTGGTGAATATTAACCAAGGTCACCCAGTTATCGGAGGAGCAAACAGGGGCTAAGT
CCACCGGGGGAGGCTGCTGGTGAATATTAACCAAGGTCACCCAGTTATCGGAGGAGCA
AACAGGGGGCTAAGTCCACGGTACCCACTGGGAGGATGTTGAGTAAGATGGAAAACCTACT
GATGACCCTTGACAGAGACAGAGTATTAGGACATGTTTGAACAGGGGGCCGGGCGATCAGC
AGGTAGCTCTAGAGGATCCCCGTCTGTCTGCACATTTTCGTAGAGCGAGTGTTCCGATACTC
TAATCTCCCTAGGCAAGGTTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTGACTAAGT
CAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTTGGA
AGGAGGGGGTATAAAAGCCCCTTACCAGGAGAAGCCGTCACACAGATCCACAAGCTCC
TGAAGAGGTAAGGGTTTAAGGGATGGTTGGTTGGTGGGGTATTAATGTTTAATTACCTGG
AGCACCTGCCTGAAATCACTTTTTTTTTCAGGTTGGTTTAAACGCCGCCACCATGCAGATTGA
GCTGAGCACCTGCTTCTTCTGTGCCTGCTGAGGTTCTGCTTCTCTGCCACCAGGAGATAC
TACCTGGGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTCTGACCTGGGGGAGCTGCCT
GTGGATGCCAGGTTCCCCCCCAGAGTGCCCAAGAGCTTCCCCTTCAACACCTCTGTGGTGT
ACAAGAAGACCTGTTTGTGGAGTTCACTGACCACCTGTTCAACATTGCCAAGCCCAGGC
CCCCCTGGATGGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACTGTGGTGA
TCACCCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGGGTGAGCTACT

GGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAGACCAGCCAGAGGGAGAAGGAGGAT
GACAAGGTGTTCCCTGGGGGCAGCCACACCTATGTGTGGCAGGTGCTGAAGGAGAATGG
CCCCATGGCCTCTGACCCCCTGTGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTG
AAGGACCTGAACCTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGCCTGGCC
AAGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTTTGATGAGGGC
AAGAGCTGGCACTCTGAAACCAAGAACAGCCTGATGCAGGACAGGGATGCTGCCTCTGC
CAGGGCCTGGCCCAAGATGCACACTGTGAATGGCTATGTGAACAGGAGCCTGCCTGGCCT
GATTGGCTGCCACAGGAAGTCTGTGTACTGGCATGTGATTGGCATGGGCACCACCCCTGA
GGTGCACAGCATCTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAGGCCAG
CCTGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGGACCTGGGCCA
GTTCTGCTGTTCTGCCACATCAGCAGCCACCAGCATGATGGCATGGAGGCCTATGTGAA
GGTGGACAGCTGCCCTGAGGAGCCCCAGCTGAGGATGAAGAACAATGAGGAGGCTGAGG
ACTATGATGATGACCTGACTGACTCTGAGATGGATGTGGTGAGGTTTGATGATGACAACA
GCCCCAGCTTCATCCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTGCACT
ACATTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCTGGTGCTGGCCCCCTGATGACA
GGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGATTGGCAGGAAGTACAAG
AAGGTCAGGTTTCATGGCCTACACTGATGAAACCTTCAAGACCAGGGAGGCCATCCAGCAT
GAGTCTGGCATCCTGGGCCCCCTGCTGTATGGGGAGGTGGGGGACACCCTGCTGATCATC
TTCAAGAACCAGGCCAGCAGGCCCTACAACATCTACCCCCATGGCATCACTGATGTGAGG
CCCCTGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGACTTCCCCATCCTG
CCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGATGGCCCCACCAAGTCT
GACCCCAGGTGCCTGACCAGATACTACAGCAGCTTTGTGAACATGGAGAGGGACCTGGCC
TCTGGCCTGATTGGCCCCCTGCTGATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAAC
CAGATCATGTCTGACAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGGAGC
TGGTACCTGACTGAGAACATCCAGAGGTTTCTGCCCAACCCTGCTGGGGTGCAGCTGGAG
GACCCTGAGTTCCAGGCCAGCAACATCATGCACAGCATCAATGGCTATGTGTTTGACAGC
CTGCAGCTGTCTGTGTGCCTGCATGAGGTGGCCTACTGGTACATCCTGAGCATTGGGGCC
CAGACTGACTTCCTGTCTGTGTTCTTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATG
AGGACACCCTGACCCTGTTCCCTTCTCTGGGGAGACTGTGTTTCATGAGCATGGAGAACC
CTGGCCTGTGGATTCTGGGCTGCCACAACCTCTGACTTCAGGAACAGGGGCATGACTGCCC
TGCTGAAAGTCTCCAGCTGTGACAAGAACAACACTGGGGACTACTATGAGGACAGCTATGAG
GACATCTCTGCCTACCTGCTGAGCAAGAACAATGCCATTGAGCCCAGGAGCTTCAGCCAG
AATAGCAGGCACCCAGCACCAGGCAGAAGCAGTTCAATGCCACCACCATCCCAGAGAA
TACCACCCTGCAGTCTGACCAGGAGGAGATTGACTATGATGACACCATCTCTGTGGAGAT
GAAGAAGGAGGACTTTGACATCTACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCC
AGAAGAAGACCAGGCACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCATGA

GCAGCAGCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTGCCCCAGTTCAAGA
AGGTGGTGTTCAGGAGTTCACTGATGGCAGCTTCACCCAGCCCCTGTACAGAGGGGAGC
TGAATGAGCACCTGGGCCTGCTGGGCCCCTACATCAGGGCTGAGGTGGAGGACAACATC
ATGGTGACCTTCAGGAACCAGGCCAGCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGC
TATGAGGAGGACCAGAGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATGA
AACCAAGACCTACTTCTGGAAGGTGCAGCACCACATGGCCCCCACCAGGATGAGTTTGA
CTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGATGTGCACTCTGGCCT
GATTGGCCCCCTGCTGGTGTGCCACACCAACACCCTGAACCCTGCCCATGGCAGGCAGGT
GACTGTGCAGGAGTTTGCCCTGTTCTTCACCATCTTTGATGAAACCAAGAGCTGGTACTTC
ACTGAGAACATGGAGAGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCAC
CTTCAAGGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGACACCCTGCCTGG
CCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGCATGGGCAGCAATG
AGAACATCCACAGCATCCACTTCTCTGGCCATGTGTTCACTGTGAGGAAGAAGGAGGAGT
ACAAGATGGCCCTGTACAACCTGTACCCTGGGGTGTGTTGAGACTGTGGAGATGCTGCCCA
GCAAGGCTGGCATCTGGAGGGTGGAGTGCTGATTGGGGAGCACCTGCATGCTGGCATG
AGCACCTGTTCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATGGCCTCTGGC
CACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGGGCCCCCAAGCTG
GCCAGGCTGCACTACTCTGGCAGCATCAATGCCTGGAGCACCAAGGAGCCCTTCAGCTGG
ATCAAGGTGGACCTGCTGGCCCCCATGATCATCCATGGCATCAAGACCCAGGGGGGCCAGG
CAGAAGTTCAGCAGCCTGTACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAG
AAGTGGCAGACCTACAGGGGCAACAGCACTGGCACCCCTGATGGTGTCTTTGGCAATGTG
GACAGCTCTGGCATCAAGCACAAACATCTTCAACCCCCCATCATTGCCAGATACATCAGG
CTGCACCCCACTACTACAGCATCAGGAGCACCTGAGGATGGAGCTGATGGGCTGTGAC
CTGAACAGCTGCAGCATGCCCTGGGCATGGAGAGCAAGGCCATCTCTGATGCCAGATC
ACTGCCAGCAGCTACTTCACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTG
CACCTGCAGGGCAGGAGCAATGCCTGGAGGGCCCCAGGTCAACAACCCCAAGGAGTGGCT
GCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAGGGGGTGAAGA
GCCTGCTGACCAGCATGTATGTGAAGGAGTTCCTGATCAGCAGCAGCCAGGATGGCCACC
AGTGGACCCTGTTCTTCCAGAATGGCAAGGTGAAGGTGTTCCAGGGCAACCAGGACAGCT
TCACCCCTGTGGTGAACAGCCTGGACCCCCCCTGCTGACCAGATACCTGAGGATTCACC
CCCAGAGCTGGGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAGGCCAG
GACCTGTACTGATTAATTAAGAGCATCTTACCGCCATTTATTCCCATATTTGTTCTGTTTTT
CTTGATTTGGGTATACATTTAAATGTTAATAAAACAAAATGGTGGGGCAATCATTTACATT
TTTAGGGATATGTAATTACTAGTTCAGGTGTATTGCCACAAGACAAACATGTTAAGAAAC
TTTCCCGTTATTTACGCTCTGTTCTGTTAATCAACCTCTGGATTACAAAATTTGTGAAAG
ATTGACTGATATTCTTAACATATGTTGCTCCTTTTACGCTGTGTGGATATGCTGCTTTATAGC

CTCTGTATCTAGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTTGTATAAAATCCTGG
TTGCTGTCTCTTTTAGAGGAGTTGTGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCTG
TGTTTGCTGACGCAACCCCCACTGGCTGGGGCATTGCCACCACCTGTCAACTCCTTTCTGG
GACTTTCGCTTTCCTCCCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCCGC
TGCTGGACAGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTGTCTGTGCCTTCTA
GTTGCCAGCCATCTGTTGTTGCCCCCTCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCAC
TCCCACTGTCCTTTCCTAATAAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCAT
TCTATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAG
CAGGCATGCTGGGGATGCGGTGGGCTCTATGGCGCTAGCCCACAATCTGCCTCCCAGTAG
TACATGACATTAGTTTATTAATAGCCTAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTC
TCTGCGCGCTCGCTCGCTCA

(SEQ ID NO: 646)

REFERENCES

[00865] All publications and references, including but not limited to patents and patent applications, cited in this specification and Examples herein are incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in the manner described above for publications and references.

CLAIMS

1. A capsid-free close-ended DNA (ceDNA) vector comprising:
at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs),
wherein at least one nucleic acid sequence encodes at least one FVIII protein, wherein the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from a sequence having at least 85% identity to any nucleic acid sequence set forth in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633).
2. The ceDNA vector of claim 1, wherein the ceDNA vector comprises a promoter or promoter set operatively linked to the least one nucleic acid sequence that encodes at least one FVIII protein.
3. The ceDNA vector of claim 2, wherein the promoter is selected from the group consisting of: human α 1 antitrypsin (hAAT) promoter, minimal transthyretin promoter (TTRm), hAAT_core_C06, hAAT_core_C07, hAAT_core_08, hAAT_core_C09, hAAT_core_C10, and hAAT_core_truncated.
4. The ceDNA vector of claim 2, wherein the promoter is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 210-217.
5. The ceDNA vector of claim 2, wherein the promoter set comprises a synthetic liver specific promoter set including enhancers and core promoter, without 5pUTR.
6. The ceDNA vector of claim 2, wherein the promoter set is selected from a nucleic acid sequence having at least 85 % identity to any one of SEQ ID NOs: 184-197, 400, 401, and 484.
7. The ceDNA vector of any of claims 1-6, wherein the ceDNA vector comprises an enhancer.
8. The ceDNA vector of claim 7, wherein the enhancer is selected from the group consisting of: a Serpin enhancer (SerpEnh), the transthyretin (TTRe) gene enhancer (TTRe), the Hepatic Nuclear Factor 1 binding site (HNF1), Hepatic Nuclear Factor 4 binding site (HNF4), Human apolipoprotein E/C-I liver specific enhancer (ApoE_Enh), the enhancer region from Pro-albumin gene (ProEnh), a CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer) (ApoE_Enh_C03, ApoE_Enh_C04, ApoE_Enh_C09, and ApoE_Enh_C10), and Hepatic nuclear factor enhancer array embedded in GE-856 (Embedded_enhancer_HNF_array).
9. The ceDNA vector of claim 8, wherein the Serpin enhancer comprises a nucleic acid sequence at least 85% identical to SEQ ID NO: 198.
10. The ceDNA vector of claim 7, wherein the enhancer is selected from a nucleic acid sequence having at least 85 % identity to any one of SEQ ID NOs: 198-209, 485 and 557-616.
11. The ceDNA vector of claim 1, wherein the ceDNA vector comprises a 5' UTR sequence.
12. The ceDNA vector of claim 11, wherein the 5' UTR sequence is selected from a

sequence having at least 85% identity to any sequence in **Table 10**.

13. The ceDNA vector of claim 1, wherein the ceDNA vector comprises an intron sequence.

14. The ceDNA vector of claim 13, wherein the intron sequence is selected from a sequence having at least 85% identity to any sequence in **Table 11**.

15. The ceDNA vector of claim 1, wherein the ceDNA vector comprises an exon sequence.

16. The ceDNA vector of claim 15, wherein the exon sequence is selected from a sequence having at least 85% identity to any sequence in **Table 12**.

17. The ceDNA vector of any of claims 1, wherein the ceDNA vector comprises a 3' UTR sequence.

18. The ceDNA vector of claim 17, wherein the exon sequence is selected from a sequence having at least 85% identity to any sequence in **Table 13**.

19. The ceDNA vector of claim 1, wherein the ceDNA vector comprises at least one poly A sequence.

20. The ceDNA vector of claim 1, wherein the ceDNA vector comprises one or more DNA nuclear targeting sequences (DTS).

21. The ceDNA vector of claim 20, wherein the DTS is selected from a sequence having at least 85% identity to any sequence in **Table 14**.

22. The ceDNA vector of claim 1, wherein the ceDNA vector comprises one or more of the following: Ubiquitous Chromatin-opening Elements (UCOE), Kozak sequences, spacer sequences or leader sequences.

23. The ceDNA vector of any one of claims 1-22, wherein at least one nucleic acid sequence is cDNA.

24. The ceDNA vector of any one of claims 1-22, wherein at least one ITR comprises a functional terminal resolution site and a Rep binding site.

25. The ceDNA vector of any one of claims 1-24, wherein one or both of the ITRs are from a virus selected from a parvovirus, a dependovirus, and an adeno-associated virus (AAV).

26. The ceDNA vector of any one of claims 1-22, wherein the flanking ITRs are symmetric or asymmetric.

27. The ceDNA vector of claim 26, wherein the flanking ITRs are symmetrical or substantially symmetrical.

28. The ceDNA vector of claim 26, wherein the flanking ITRs are asymmetric.

29. The ceDNA vector of any one of claims 1-28, wherein one or both of the ITRs are wild-type, or wherein both of the ITRs are wild-type.

30. The ceDNA vector of any one of claims 1-29, wherein the flanking ITRs are from different viral serotypes.

31. The ceDNA vector of any one of claims 1-29, wherein the flanking ITRs are from the same

viral serotypes.

32. The ceDNA vector of any one of claims 1-31, wherein one or both of the ITRs comprises a sequence selected from the sequences in **Table 2, Table 4A, Table 4B, and Table 5.**

33. The ceDNA vector of any one of claims 1-32, wherein at least one of the ITRs is altered from a wild-type AAV ITR sequence by a deletion, addition, or substitution that affects the overall three-dimensional conformation of the ITR.

34. The ceDNA vector of any one of claims 1-33, wherein one or both of the ITRs are derived from an AAV serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12.

35. The ceDNA vector of any one of claims 1-34, wherein one or both of the ITRs are synthetic.

36. The ceDNA vector of any one of claims 1-35, wherein one or both of the ITRs is not a wild-type ITR, or wherein both of the ITRs are not wild-type.

37. The ceDNA vector of any one of claims 1-36, wherein one or both of the ITRs is modified by a deletion, insertion, and/or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D, and D'.

38. The ceDNA vector of claim 37, wherein the deletion, insertion, and/or substitution results in the deletion of all or part of a stem-loop structure normally formed by the A, A', B, B' C, or C' regions.

39. The ceDNA vector of any one of claims 1-37, wherein one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of all or part of a stem-loop structure normally formed by the B and B' regions.

40. The ceDNA vector of any one of claims 1-37, wherein one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of all or part of a stem-loop structure normally formed by the C and C' regions.

41. The ceDNA vector of any one of claims 1-37, wherein one or both of the ITRs are modified by a deletion, insertion, and/or substitution that results in the deletion of part of a stem-loop structure normally formed by the B and B' regions and/or part of a stem-loop structure normally formed by the C and C' regions.

42. The ceDNA vector of any one of claims 1-41, wherein one or both of the ITRs comprise a single stem-loop structure in the region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.

43. The ceDNA vector of any one of claims 1-42, wherein one or both of the ITRs comprise a single stem and two loops in the region that normally comprises a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.

44. The ceDNA vector of any one of claims 1-43, wherein one or both of the ITRs comprise a single stem and a single loop in the region that normally comprises a first stem-loop structure formed

by the B and B' regions and a second stem-loop structure formed by the C and C' regions.

45. The ceDNA vector of any one of claims 1-44, wherein both ITRs are altered in a manner that results in an overall three-dimensional symmetry when the ITRs are inverted relative to each other.

46. The ceDNA vector of any one of claims 1-45, wherein one or both of the ITRs comprises a sequence selected from the sequences in **Tables 2, Table 4A, Table 4B, and Table 5.**

47. The ceDNA vector of claim 1, wherein the ceDNA vector comprises a nucleic acid sequence selected from a sequence having at least 85% identity with a sequence in **Table 18.**

48. A method of expressing an FVIII protein in a cell comprising contacting the cell with the ceDNA vector of any one of claims 1-47 or 72-79.

49. The method of claim 48, wherein the cell is a photoreceptor or a RPE cell.

50. The method of claim 48 or 49, wherein the cell is *in vitro* or *in vivo*.

51. The method of any one of claims 48-50, wherein the at least one nucleic acid sequence is codon optimized for expression in the eukaryotic cell.

52. The method of any one of claims 48-51, wherein the at least one nucleic acid sequence is a sequence having at least 85% identity to any one of the sequences set forth in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633).

53. A method of treating a subject with hemophilia A, comprising administering to the subject a ceDNA vector of any one of claims 1-47 or 72-79, wherein at least one nucleic acid sequence encodes at least one FVIII protein.

54. A method of treating a subject with hemophilia A, comprising administering to the subject a nucleic acid sequence selected from a sequence having at least 85% identity with a sequence in **Table 18.**

55. The method of claim 53 or claim 54, wherein a level of FVIII in the plasma of the subject is increased in the subject after administration.

56. The method of claim 55, wherein the level of FVIII in the plasma of the subject is increased by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold or 1,000-fold after administration.

57. The method of claim 53 or 54, wherein a level of FVIII in the serum of the subject is increased the subject administered the ceDNA vector as compared to a control.

58. The method of claim 57, wherein the increase in the level of FVIII in the serum of the subject is greater than about 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 5-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-

fold or 1,000-fold compared to the control.

59. The method of any one of claims 57-58, wherein the control is a level of FVIII in the serum of the subject prior to administration, wherein the control is a level of FVIII in the serum of a subject having hemophilia A who did not receive the administration or wherein the control is a level of FVIII in a subject not having hemophilia A.

60. The method of any one of claims 53-59, wherein the administration restores a plasma level of FVIII in the subject to at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of a FVIII plasma level of a healthy individual not affected by hemophilia A.

61. The method of any one of claims 53-60, wherein the ceDNA vector is administered at a dose of about 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 3.5 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, or 10 mg/kg.

62. The method of claim 54, wherein the at least one nucleic acid sequence is a sequence having at least 85% identity to any sequence set forth in **Table 1A** (SEQ ID NOs: 71-183, 556 and 626-633).

63. The method of any of claims 54-62, wherein the ceDNA vector is administered to a photoreceptor cell, or an RPE cell, or both.

64. The method of any of claims 54-63, wherein the ceDNA vector expresses the FVIII protein in a photoreceptor cell, or an RPE cell, or both.

65. The method of any of claims 54-64, wherein the ceDNA vector is administered by any one or more of: subretinal injection, suprachoroidal injection or intravitreal injection.

66. A pharmaceutical composition comprising the ceDNA vector of any one of claims 1-47.

67. A cell containing a ceDNA vector of any of claims 1-47 or 72-79.

68. The cell of claim 67, wherein the cell is a photoreceptor cell, or an RPE cell, or both.

69. A composition comprising a ceDNA vector of any of claims 1-47 and a lipid.

70. The composition of claim 69, wherein the lipid is a lipid nanoparticle (LNP).

71. A kit comprising the ceDNA vector of any one of claims 1-47 or 72-79, the pharmaceutical composition of claim 66, the cell of claim 67 or claim 68, or the composition of claim 69 or claim 70.

72. A capsid-free close-ended DNA (ceDNA) vector comprising:

at least one nucleic acid sequence between flanking inverted terminal repeats (ITRs),
wherein at least one nucleic acid sequence encodes at least one protein,

wherein the ceDNA vector comprises a promoter or promoter set operatively linked to the least one nucleic acid sequence that encodes the at least one protein, and wherein the promoter is selected from the group consisting of: human $\alpha 1$ antitrypsin (hAAT) promoter,

minimal transthyretin promoter (TTRm), hAAT_core_C06, hAAT_core_C07, hAAT_core_08, hAAT_core_C09, hAAT_core_C10, and hAAT_core_truncated.

73. The ceDNA vector of claim 72, wherein the promoter is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 210-217.

74. The ceDNA vector of claim 72, wherein the promoter set comprises a synthetic liver specific promoter set including enhancers and core promoter, without 5pUTR.

75. The ceDNA vector of claim 72, wherein the promoter set is selected from a nucleic acid sequence having at least 85 % identity to any one of SEQ ID NOs: 184-197, 400, 401, and 484.

76. The ceDNA vector of any of claims 72-75, wherein the ceDNA vector comprises an enhancer.

77. The ceDNA vector of claim 76, wherein the enhancer is selected from the group consisting of: a Serpin enhancer (SerpEnh), the transthyretin (TTRe) gene enhancer (TTRe), the Hepatic Nuclear Factor 1 binding site (HNF1), Hepatic Nuclear Factor 4 binding site (HNF4), Human apolipoprotein E/C-I liver specific enhancer (ApoE_Enh), the enhancer region from Pro-albumin gene (ProEnh), a CpG minimized version of the ApoE_Enh (Human apolipoprotein E/C-I liver specific enhancer) (ApoE_Enh_C03, ApoE_Enh_C04, ApoE_Enh_C09, and ApoE_Enh_C10), and Hepatic nuclear factor enhancer array embedded in GE-856 (Embedded_enhancer_HNF_array).

78. The ceDNA vector of claim 77, wherein the Serpin enhancer comprises a nucleic acid sequence at least 85% identical to SEQ ID NO: 198.

79. The ceDNA vector of claim 76, wherein the enhancer is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 198-209, 485 and 557-616.

80. A method of expressing a protein in a cell comprising contacting the cell with the ceDNA vector of any one of claims 72-79.

81. The method of claim 80, wherein the cell is a photoreceptor or a RPE cell.

82. The method of claim 80 or 81, wherein the cell is *in vitro* or *in vivo*.

83. The method of any one of claims 80-82, wherein the at least one nucleic acid sequence is codon optimized for expression in the eukaryotic cell.

84. The ceDNA vector of any one of claims 1-46, wherein the at least one nucleic acid sequence that encodes at least one FVIII protein is selected from a nucleic acid sequence having at least 85% identity to any one of SEQ ID NOs: 556 and 626-633, and wherein the ceDNA vector comprises an enhancer, wherein the enhancer is selected from a nucleic acid sequence having at least 85 % identity to any one of SEQ ID NOs: 557-616.

85. A DNA vector comprising a nucleic acid sequence at least 85% identical to SEQ ID NOs: 71-183, 556 and 626-633.

86. The DNA vector of claim 85, wherein the DNA vector comprises an enhancer sequence

having at least 95% identity to any one of SEQ ID NOs: 198-209, 485, 557-616.

87. The DNA vector of claim 86, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 198 and 557-616.

88. The DNA vector of claim 87, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 557-616.

89. The DNA vector of claim 88, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 557-568.

90. The DNA vector of claim 88, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NOs: 569 and 570.

91. The DNA vector of claim 88, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 571.

92. The DNA vector of claim 88, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 572.

93. The DNA vector of claim 88, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 611.

94. The DNA vector of claim 88, wherein the DNA vector comprises a SerpEnh sequence having at least 95% identity to any one of SEQ ID NO: 603.

95. The DNA vector of any one of claims 85-94, wherein the DNA vector comprises a TTRe sequence.

96. The DNA vector of claim 95, wherein the TTRe sequence is set forth in SEQ ID NO: 199 or a sequence having at least 95% identity thereof.

97. The DNA vector of claim 95, wherein the DNA vector comprises a TTR promoter.

98. The DNA vector of claim 95, wherein the TTR promoter is set forth in SEQ ID NO: 211 or a sequence having 95% identity thereof.

99. The DNA vector of claim 97, wherein the DNA vector comprises a 5' untranslated region (5' UTR) sequence selected from the group consisting of SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO: 417, SEQ ID NO: 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, and SEQ ID NO: 436.

100. The DNA vector of claim 97, wherein the DNA vector comprises an intron sequence selected from the group consisting of SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, and SEQ ID NO: 248.

101. The DNA vector of claim 97, wherein the DNA vector further comprises an intron

sequence having at least 95% identity to SEQ ID NO: 235.

102. The DNA vector of claim 97, wherein the DNA vector comprises a 3'UTR sequence.

103. The DNA vector of claim 102, wherein the 3'UTR sequence comprises a WPRE element and/or bGH poly A signal sequence or a sequence having at least 95% identity to any one of SEQ ID NOs: 283-291 and 634.

104. The DNA vector of claim 102, wherein the DNA vector comprises a microRNA (mir) sequence set forth in SEQ ID NO: 543 or a sequence having at least 95% identity thereof.

105. The DNA vector of claim 97, wherein the DNA vector comprises a spacer sequence selected from a sequence having at least 85% identity to any sequence set forth in **Table 15** (SEQ ID NOs: 318-332 and 635-641).

106. The DNA vector of claim 85, wherein the DNA vector comprises at least one ITR flanking 5' and/or 3' end of the nucleic acid sequence at least 95% identical to SEQ ID NO: 556.

107. The DNA vector of claim 106, wherein the at least one ITR flanking 5' and/or 3' is a wild-type AAV ITR(s).

108. The DNA vector of claim 85, wherein the DNA vector is a closed-ended DNA (ceDNA).

109. The DNA vector of claim 85, wherein the DNA vector is a plasmid.

110. The DNA vector of claim 85, wherein the DNA vector comprises a nucleic acid sequence encoding a single chain (SC) FVIII.

111. The DNA vector of claim 110, wherein the nucleic acid sequence is set forth in SEQ ID NO: 556 or a sequence having at least 99% identity thereto.

112. A ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 42 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 42.

113. A ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 642 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 642.

114. A ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 643 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 643.

115. A ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 644 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 644.

116. A ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 645 or a nucleic acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 645.

117. A ceDNA vector comprising a nucleic acid sequence of SEQ ID NO: 646 or a nucleic

acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 646.